<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<a href="#coll0">6-ary drug combinations: found 4</a><br/><a href="#coll1">5-ary drug combinations: found 5</a><br/><a href="#coll2">4-ary drug combinations: found 14</a><br/><a href="#coll3">3-ary drug combinations: found 54</a><br/><a href="#coll4">2-ary drug combinations: found 213</a><br/><button type="button" class="collapsible" id="coll0">6-ary drug combinations: found 4</button><div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Recent comparative studies suggest that  <span class="marker" data-anno-id="0" data-anno-label="P1">atenolol</span>  ( 200 mg daily ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">metoprolol</span>  ( 200 mg daily ) ;  <span class="marker" data-anno-id="2" data-anno-label="P1">acebutolol</span>  ( 400 mg daily ) ,  <span class="marker" data-anno-id="3" data-anno-label="P1">oxprenolol</span>  ( 160 mg daily ) ,  <span class="marker" data-anno-id="4" data-anno-label="P1">nadolol</span>  ( 80 mg daily ) and  <span class="marker" data-anno-id="5" data-anno-label="P1">timolol</span>  ( 20 mg daily ) produce a beneficial clinical response equal to that seen with propranolol ( 160 mg daily ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Use of beta-adrenoceptor blocking drugs in hyperthyroidism.</u></h4>There is an increasing use and variety of beta-adrenoceptor blocking agents (beta-blockers) available for the treatment of hyperthyroidism. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>atenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metoprolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>acebutolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxprenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nadolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>timolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>equal</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most beta-blockers reduce resting heart rate by approximately 25 to 30 beats/min, although a lesser reduction is seen with those possessing intrinsic sympathomimetic activity such as <b style='color:Tomato;'><i>oxprenolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b>. While earlier studies employing large doses of intravenous <b style='color:Tomato;'><i>propranolol</i></b> concluded that beta-blockade reduced myocardial contractility, more recent non-invasive studies suggest that the predominant cardiac effect is on heart rate. In patients with cardiac failure, beta-blockers may, however, produce a profound fall in cardiac output. Nevertheless, in combination with <b style='color:Tomato;'><i>digoxin</i></b> they may be useful in controlling the atrial fibrillation of thyrocardiac disease. beta-Blockers improve nervousness and tremor (although to a lesser extent with cardioselective agents) and severe myopathy, and they also reduce the frequency of paralysis in patients with thyrotoxic periodic paralysis. There is often subjective improvement in sweating but usually no major effect on eye signs. Recent studies show a 10% reduction in oxygen consumption/basal metabolic rate with long term oral use of selective or nonselective beta-blockers. In addition, many agents (<b style='color:Tomato;'><i>propranolol</i></b>, <b style='color:Tomato;'><i>metoprolol</i></b>, <b style='color:Tomato;'><i>nadolol</i></b> and <b style='color:Tomato;'><i>sotalol</i></b> but not <b style='color:Tomato;'><i>acebutolol</i></b>, <b style='color:Tomato;'><i>atenolol</i></b> or <b style='color:Tomato;'><i>oxprenolol</i></b>) reduce circulating tri-iodothyronine (T3) concentration by between 10 and 40%, although the clinical significance of this effect (if any) is not established. beta-Blockers may also have endocrinological effects on gastrin, cyclic AMP, catecholamines and other hormone levels. Given in adequate dosage, <b style='color:Tomato;'><i>propranolol</i></b> has been shown to control thyrotoxic hypercalcaemia. Minor side effects (nausea, headaches, tiredness, etc.) are quite common but overall beta-blockers are well tolerated by the thyrotoxic patient. The major use of these drugs is in symptomatic control while awaiting definitive diagnosis or treatment. As an adjunct to antithyroid drugs or radioactive iodine, beta-blockers will produce a satisfactory clinical response in the weeks to months before these forms of therapy produce a euthyroid state. beta-Blockers are more convenient than antithyroid drugs in the control of patients receiving therapeutic radioiodine, in that continuous therapy and assessment of biochemical response is possible.(ABSTRACT TRUNCATED AT 400 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The effects of multiple combination chemotherapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  ( Endoxan ) ,  <span class="marker" data-anno-id="2" data-anno-label="P1">methotrexate</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P1">5-fluorouracil</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="P1">adriamycin</span>  and  <span class="marker" data-anno-id="5" data-anno-label="P1">prednisolone</span>  ( VEMFAH ) for advanced breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Endoxan</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VEMFAH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of <b style='color:Tomato;'><i>vincristine</i></b> (V), <b style='color:Tomato;'><i>cyclophosphamide</i></b> (Endoxan; E), <b style='color:Tomato;'><i>methotrexate</i></b> (M), 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (F), adriamycin (A), and <b style='color:Tomato;'><i>prednisolone</i></b> (H). Disease response was evaluated by the UICC criteria. Among the 35 evaluable cases, 4 complete responses (CR), 23 partial responses (PR), 2 cases of no change (NC), and 6 of progressive disease (PD) were observed. The response rate (CR + PR) was 77.1%. The median duration of response was 52 weeks (8-192 weeks) or 12 months. In 32 patients who received more than two courses of therapy the 50% survival time of responders was 27.0 months, which was significantly longer than the 10.3 months of nonresponders (P less than 0.05). Except for 2 patients who developed myocardial damage, the therapy was never terminated because of side effects. Cumulative cardiotoxicity was not apparent in this study. This multiple-drug combination chemotherapy with 'VEMFAH' is concluded to be an effective treatment for advanced and disseminated breast cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  All patients were treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">doxorubicin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C1">actinomycin-D</span>  , alternating with  <span class="marker" data-anno-id="4" data-anno-label="C1">ifosfamide</span>  and  <span class="marker" data-anno-id="5" data-anno-label="C1">etoposide</span>  every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.</u></h4>The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with extraskeletal Ewing's sarcoma. ### methods Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed. ### results The median age of 27 patients was 24 years (range, 16-54 years). The median follow-up was 31.8 months (range, 6-144 months). Tumor size was between 1.5 and 14 cm (median: 8 cm). Eighty-five percent of patients had localized disease at presentation and 15% had metastatic disease. Local therapy was surgery alone in 16% of patients, surgery combined with radiotherapy in 42% and radiotherapy alone in 27%. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients with localized disease at presentation, the 5-year event-free survival and overall survival were 59.7 and 64.5%, respectively. At univariate analysis, patients with tumor size ≥ 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size 8 ≥ cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ### conclusions Prognostic factors were similar to primary osseous Ewing's sarcomas. Adequate surgical resection, aggressive chemotherapy (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and actinomycin-D alternating with <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b>) and radiotherapy if indicated are the recommended therapy for patients with extraskeletal Ewing's sarcoma.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Twenty-seven received  <span class="marker" data-anno-id="0" data-anno-label="C1">rituximab</span>  mainly in addition to high-dose  <span class="marker" data-anno-id="1" data-anno-label="C1">cytarabine</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">etoposide</span>  ( n = 18 ) and/or  <span class="marker" data-anno-id="3" data-anno-label="C1">ifosfamide</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="C1">carboplatin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="C1">etoposide</span>  ( n = 7 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.</u></h4>In order to describe relapsed B-cell non-Hodgkin lymphoma and mature acute leukemia in children/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the <b style='color:Tomato;'><i>rituximab</i></b> era, relapses in the French LMB2001 study were reviewed. ### methods Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B-cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C. ### results Median time to relapse after diagnosis was 4.5 months (range 2.4-13.6). Thirty-two patients received salvage therapy. <b style='color:DodgerBlue;'><i>Twenty-seven</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> First-line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty-one patients received high-dose chemotherapy (HDC) followed by autologous (n = 13) or allogeneic (n = 8) transplant. With a median follow-up of 6.8 years, the 5-year survival rate after relapse was 36.4% (95% confidence interval [CI] 22-53%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5-year survival rate of 75% (95% CI 46.8-91.1%) for patients in CR before HDC, 33% (95% CI 9.7-70%) for patients in partial remission, and 0% for nonresponders (P = .033). ### conclusion Survival of children/adolescents with mature B-cell lymphoma/leukemia remains poor after relapse with no apparent improvement with <b style='color:Tomato;'><i>rituximab</i></b>. Response rates to salvage chemo-immunotherapies are insufficient and new drugs are urgently needed to improve disease control.</div></div></div></div><button type="button" class="collapsible" id="coll1">5-ary drug combinations: found 5</button><div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Drug therapy included  <span class="marker" data-anno-id="0" data-anno-label="P1">omega-3</span>  fish oil , extended-release  <span class="marker" data-anno-id="1" data-anno-label="P1">niacin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">colesevelam hydrochloride</span>  , and a fixed combination of 10-mg  <span class="marker" data-anno-id="3" data-anno-label="P1">ezetimibe</span>  and 40-mg  <span class="marker" data-anno-id="4" data-anno-label="P1">simvastatin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.</u></h4>Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) mass is a novel inflammatory biomarker. In human blood, Lp-PLA(2) is predominately associated with low-density lipoprotein (LDL). This study examines the ability of lifestyle modification (diet and exercise) and combination lipid therapy to reduce Lp-PLA(2) levels while also determining the relationship between changes in LDL cholesterol and Lp-PLA(2). Thirty dyslipidemic patients who received lifestyle intervention and combination lipid therapy for an average of 6 months were included in these analyses (mean age, 60.9 years); 40% had stable angiographically established coronary artery disease, 40% had the metabolic syndrome, and 70% were men. <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>omega-3</i></b> <b style='color:DodgerBlue;'><i>fish</i></b> <b style='color:DodgerBlue;'><i>oil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>extended-release</i></b> <b style='color:DodgerBlue;'><i>niacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>colesevelam</i></b> <b style='color:DodgerBlue;'><i>hydrochloride</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>10-mg</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>40-mg</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study revealed a 33% reduction in mean Lp-PLA(2) values (baseline 224.9+/-47.5 vs posttreatment 149.5+/-35.5 ng/mL; P<.001). Significant changes in mean LDL cholesterol from baseline (127.9+/-49.3 vs posttreatment 65.2+/-32.1 mg/dL; P<.001) were also observed. However, regression analysis revealed only a weak positive relationship between changes in LDL cholesterol and Lp-PLA(2) mass (R(2)=0.29; P<.01). Thus, Lp-PLA(2) mass is significantly reduced with lifestyle and combination lipid therapy. Changes in Lp-PLA(2) were only partially explained by the changes observed for LDL cholesterol.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI ( bolus  <span class="marker" data-anno-id="0" data-anno-label="C1">irinotecan</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">folinic acid</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">fluorouracil</span>  followed by 46-hour  <span class="marker" data-anno-id="3" data-anno-label="C1">fluorouracil</span>  infusion ) followed by  <span class="marker" data-anno-id="4" data-anno-label="C1">bevacizumab</span>  ( 5 mg/kg ) in Cycle 1 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.</u></h4>Previous reports of the influence of UGT1A1 gene polymorphisms on the pharmacokinetics of <b style='color:Tomato;'><i>irinotecan</i></b> metabolism have not assessed Asian patients treated with FOLFIRI plus <b style='color:Tomato;'><i>bevacizumab</i></b> for advanced and recurrent colorectal cancer. <b style='color:DodgerBlue;'><i>Twenty-one</i></b> <b style='color:DodgerBlue;'><i>Japanese</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>FOLFIRI</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>folinic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>46-hour</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Cycle</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Cycle 2, patients received <b style='color:Tomato;'><i>bevacizumab</i></b> followed by FOLFIRI. The regimen was in 2-week cycles. The area under-the-curves ratio (AUC0-last) (Cycle 2/Cycle 1) was determined from plasma concentrations of <b style='color:Tomato;'><i>irinotecan</i></b> and metabolites (SN-38, SN-38G). Safety, efficacy, and drug-drug interactions were analyzed. Median observation period was 7.8 months; median number of cycles 15. Drug-drug interactions were evaluated in eight patients without <b style='color:Tomato;'><i>irinotecan</i></b> dose reduction. Mean AUC0-last ratios (with/without <b style='color:Tomato;'><i>bevacizumab</i></b>) of <b style='color:Tomato;'><i>irinotecan</i></b>, SN-38, and SN-38G were 0.959, 0.927, and 0.931 respectively. Response rate was 65%; median progression-free survival 16.4 months. Response occurred in four patients with, and nine without, UGT1A1 polymorphism. No significant differences occurred between efficacy, safety, or polymorphism status. This cohort showed no differences in safety or efficacy compared to previous reports. <b style='color:Tomato;'><i>bevacizumab</i></b> did not affect the pharmacokinetics of <b style='color:Tomato;'><i>irinotecan</i></b> and its metabolites, irrespective of UGT1A1 polymorphism status. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  The patient received chemotherapy comprising  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">actinomycin</span>  D ,  <span class="marker" data-anno-id="2" data-anno-label="C1">doxorubicin</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="C1">cisplatin</span>  , and  <span class="marker" data-anno-id="4" data-anno-label="C1">cyclophosphamide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Autologous peripheral blood stem cell transplantation in a patient with relapsed pleuropulmonary blastoma.</u></h4>Pleuropulmonary blastoma (PPB) is a rare and aggressive primary intrathoracic neoplasma of children. The prognosis is extremely poor with frequent metastasis to the brain and bone. We present a 4-year-old girl with a tumor mass in the right hemithorax initially diagnosed as pneumoniae. Tumor resection was performed and the histologic report indicated the diagnosis of PPB. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>comprising</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Irradiation was performed with total 45 Gy at the right lower pulmonary lobe. She relapsed 29 months later at the pleura between the right middle and lower pulmonary lobe. Tumor resection and total 45 Gy of irradiation were performed again. High-dose chemotherapy comprising cisplatin, adriamycin, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> was performed followed by autologous peripheral blood stem cell transplantation (PBSCT). The patient achieved complete hematologic recovery. Thirty-one months after PBSCT, no signs of relapse have been observed. Although it might be that the patient could have been cured with second surgery alone or by the surgery and subsequent chemotherapy, high-dose chemotherapy and PBSCT should be considered for the treatment of relapsed PPB.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  First-line chemotherapy was either R-CHOP (  <span class="marker" data-anno-id="0" data-anno-label="P1">rituximab</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P1">vincristine</span>  and  <span class="marker" data-anno-id="4" data-anno-label="P1">prednisolone</span>  ) or CHOP-like-based regimen . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].</u></h4>To explore the clinical characteristics and prognosis of patients with primary testicular non-Hodgkin's lymphoma. ### methods The clinical profiles and prognostic factors of 21 cases newly diagnosed as primary testicular non-Hodgkin's lymphoma at Peking University Cancer Hospital from January 2005 to December 2012 were retrospectively analyzed. ### results Their median age was 59 (34-86) years. And they were classified as Ann Arbor stage I (n = 8), stage II (n = 2) and stage IV (n = 11). There were B symptoms (n = 4), extranodal involvement outside testis (n = 12) and elevated lactate dehydrogenase (LDH) at diagnosis (n = 6). The scores of international prognostic index (IPI) were 0-1 point (n = 10), 3 points (n = 10) and 4 points (n = 1). The regimens included orchidectomy as the initial treatment (n = 15), chemotherapy followed by radiotherapy (n = 7) and CNS prophylaxis during treatment (n = 15). All patients were pathologically diagnosed as diffuse large B-cell lymphoma. And 11 cases belonged to the non-germinal center B cell-like subgroup. <b style='color:DodgerBlue;'><i>First-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CHOP-like-based</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Complete response was achieved in 85.7% of patients. The median follow-up period was 18 (6-58) months. The 1, 2 and 3-year survival rates were 100%, 80% and 60% respectively. Statistical analysis showed that the first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> was a prognostic factor (P = 0.038).Other factors included stage (P = 0.275), LDH level (P = 0.179) , β2-microglobulin level (P = 0.229) and IPI (P = 0.275) . ### conclusions The prognosis of primary testicular non-Hodgkin's lymphoma is usually poor. The first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> is a prognostic factor.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Those who test positive are treated with combinations of the following agents :  <span class="marker" data-anno-id="0" data-anno-label="C1">omeprazole</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">clarithromycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">amoxicillin</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="C1">tetracycline</span>  , and  <span class="marker" data-anno-id="4" data-anno-label="C1">metronidazole</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacist-managed Helicobacter pylori clinic.</u></h4>A pharmacist-managed Helicobacter pylori assessment clinic for ambulatory patients is described. The pharmacy service at a 400-bed Veterans Affairs Medical Center established a pharmacist-managed clinic to assess patients who were receiving long-term acid-suppressive medications (histamine H2-receptor antagonists, <b style='color:Tomato;'><i>sucralfate</i></b>, or <b style='color:Tomato;'><i>omeprazole</i></b>). Patients with active ulcer disease and those receiving ulcer prophylaxis are screened for the presence of H. pylori. <b style='color:DodgerBlue;'><i>Those</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tetracycline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pharmacist also may adjust or discontinue acid-suppressive drug regimens. The pharmacist is responsible for ordering all appropriate laboratory tests, monitoring patients for adverse effects, collecting data on patient outcomes, and providing patient education. The clinic provides opportunities for pharmacists to study the clinical effectiveness and pharmacoeconomics of various regimens for treating H. pylori-associated disease and for pharmacy students and residents to interact with patients. As of fall 1994, 20 patients had been evaluated at the clinic: 12 tested positive for H. pylori and were treated with antimicrobials and all were pain-free without medication at the end of treatment. An H. pylori assessment clinic enabled pharmacists to assume a primary care role, document improvement in patient outcomes, and study the effectiveness of various antimicrobial regimens.</div></div></div></div><button type="button" class="collapsible" id="coll2">4-ary drug combinations: found 14</button><div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF ( P ) , which included  <span class="marker" data-anno-id="0" data-anno-label="P1">methotrexate</span>  , 60 mg/m2 , and  <span class="marker" data-anno-id="1" data-anno-label="P1">5-fluorouracil</span>  , 700 mg/m2 intravenously on the first and eighth days , in addition to  <span class="marker" data-anno-id="2" data-anno-label="P1">cyclophosphamide</span>  , 100 mg/m2 , and  <span class="marker" data-anno-id="3" data-anno-label="P1">prednisone</span>  , 40 mg/m2 , by mouth daily from the first to the fourteenth day of a 28-day cycle . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combination chemotherapy for advanced breast cancer: response and effect on survival.</u></h4> <b style='color:DodgerBlue;'><i>Forty</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>program</i></b> <b style='color:DodgerBlue;'><i>CMF</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>700</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>eighth</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>mouth</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fourteenth</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>28-day</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Only 2 of 25 patients responded to hormonal therapy or endocrine ablation. Twenty-seven of the 40 patients (68%) had a complete response (8 patients) or partial response (19 patients). Lung, soft tissue, and nodal metastases were the most responsive sites. The median survival of 18 months for the responding group. The nonresponders had a median survival of 4 months. The toxicity was primarily hematologic and was especially severe in patients with functional liver impairment due to metastatic disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">adriamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">vincristine</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C1">prednisolone</span>  every three months . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission].</u></h4>A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received <b style='color:Tomato;'><i>prednisolone</i></b> and the lung lesions disappeared. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>he</i></b> <b style='color:DodgerBlue;'><i>started</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  All patients were treated by surgical debridement followed by a combination of antibiotics ; (  <span class="marker" data-anno-id="0" data-anno-label="P1">ceftazidime</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">amoxy-clavulanic</span>  acid ,  <span class="marker" data-anno-id="2" data-anno-label="P1">co-trimoxazole</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">doxycycline</span>  ) for six months except for one who died due to fulminant septicemia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Burkholderia pseudomallei musculoskeletal infections (melioidosis) in India.</u></h4>Melioidosis, an infection due to gram negative Burkholderia pseudomallei, is an important cause of sepsis in east Asia especially Thailand and northern Australia. It usually causes abscesses in lung, liver, spleen, skeletal muscle and parotids especially in patients with diabetes, chronic renal failure and thalassemia. Musculoskeletal melioidosis is not common in India even though sporadic cases have been reported mostly involving soft tissues. During a two-year-period, we had five patients with musculoskeletal melioidosis. All patients presented with multifocal osteomyelitis, recurrent osteomyelitis or septic arthritis. One patient died early because of septicemia and multi-organ failure. All patients were diagnosed on the basis of positive pus culture. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>surgical</i></b> <b style='color:DodgerBlue;'><i>debridement</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>amoxy-clavulanic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>co-trimoxazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxycycline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>except</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>died</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>fulminant</i></b> <b style='color:DodgerBlue;'><i>septicemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All other patients recovered completely with no recurrences. With increasing awareness and better diagnostic facilities, probably musculoskeletal melioidosis will be increasingly diagnosed in future.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We conducted a double-blind cross-over study in ten volunteers aged from 19 to 30 years , to compare the pain control effects of a single oral dose of two analgesic compounds ( drug A : propyphenazone mg 250 , ethylmorphine mg 5 , caffeine mg 5 ; drug B :  <span class="marker" data-anno-id="0" data-anno-label="C1">dipyrone</span>  mg 500 ,  <span class="marker" data-anno-id="1" data-anno-label="C1">diphenhydramine</span>  mg 12.5 ,  <span class="marker" data-anno-id="2" data-anno-label="C1">adiphenine</span>  mg 5 , ethyl  <span class="marker" data-anno-id="3" data-anno-label="C1">aminobenzoate</span>  mg 2.5 ) in an experimental pain model using stimulation of dental pulp . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Electric stimulation of the dental pulp in the evaluation of the central effect of analgesics].</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ten</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>aged</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>propyphenazone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethylmorphine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>caffeine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>dipyrone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>adiphenine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethyl</i></b> <b style='color:DodgerBlue;'><i>aminobenzoate</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>pulp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Constant voltage stimuli were delivered through silver chloride electrodes placed in contact with the vestibular surface of the upper medial incisor. At the beginning of the session, the pain input was graded by asking the subject to identify the weakest stimulus perceived (threshold level) and the strongest stimulus endurable (tolerance level). The range between threshold and tolerance level was divided in nine steps plus a subliminal step. The ten steps were delivered randomly, and each series of steps was repeated eight times. The subjects were instructed to rate the pain sensation in an arbitrary scale of 5 degrees. The procedure was repeated at 60 min and 180 min after drug administration. Each subject received two tablets of drug A or drug B in two different sessions at weekly intervals. Statistical analysis of the procedures showed that neither drug A nor drug B significantly affected the pain threshold. Drug A significantly reduced the total pain score (P less than 0.01) and its action peaked 60 min after administration.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  54 patients without distant metastases ( T2-T3b , N0-X , M0 ) received 3 cycles of neoadjuvant chemotherapy according to the MVAC protocol (  <span class="marker" data-anno-id="0" data-anno-label="P1">methotrexate</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vinblastine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">cisplatin</span>  ) after transurethral resection ( TUR ) followed by cystectomy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.</u></h4>In order to evaluate the efficacy of neoadjuvant chemotherapy in invasive urothelial carcinoma of the bladder a retrospective analysis was performed. <b style='color:DodgerBlue;'><i>54</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>distant</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>T2-T3b</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>N0-X</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>transurethral</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TUR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>cystectomy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 52 patients had previously undergone cystectomy immediately after TUR. Complete histopathological remission was observed in 9 patients (17.3%) after TUR and in 17 patients (31.5%) after TUR+MVAC. Neoadjuvant MVAC resulted, therefore, in a 14% higher rate of complete remissions. The overall response to TUR was significantly improved by MVAC therapy. Downstaging by neoadjuvant chemotherapy was more readily achieved in initially low-stage tumours (T2: 44.4% and 30.8%, T3a: 47.1% and 19%, T3b: 5.3% and 5.5% in patients receiving TUR+MVAC and TUR alone, respectively). Overall survival did not differ significantly between both groups. Patients who were successfully downstaged to pT0 had a significantly better prognosis, and patients resistant to chemotherapy had the poorest prognosis, showing the shortest survival. In conclusion, histopathological response at cystectomy was improved by neoadjuvant MVAC chemotherapy after TUR and can be expected to be prognostically relevant in those patients who can be downstaged to T0, although overall survival failed to be significantly increased in this relatively small patient sample.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Trials have demonstrated decreased relapse with perioperative  <span class="marker" data-anno-id="0" data-anno-label="P1">methotrexate</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vinblastine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">cisplatin</span>  ( M-VAC ) chemotherapy in patients with muscle invasive bladder cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.</u></h4> <b style='color:DodgerBlue;'><i>Trials</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>relapse</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>perioperative</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M-VAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>muscle</i></b> <b style='color:DodgerBlue;'><i>invasive</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We evaluated whether the benefit of chemotherapy correlates with its effects on distant or pelvic relapse. ### Materials And Methods We retrospectively evaluated the records of all 107 patients who underwent cystectomy for muscle invasive bladder cancer at our institution between 1988 and 1994. Factors predicting relapse were identified and used to group patients at high or low risk. The outcome in each group with and without M-VAC chemotherapy was then analyzed in terms of overall, metastatic and pelvic relapse. Univariate analysis was performed using the Kaplan-Meier method and log rank statistic, and multivariate analysis was done using the Cox proportional hazards model. Median survival was 29 months for patients free of disease. ### results Pathological stage T3 or greater according to the American Joint Committee on Cancer, tumor greater than 3 cm. and creatinine greater than 1.5-fold normal were independent poor prognostic factors in patients treated with cystectomy only. Patients with any of these factors or metastatic involvement of the pelvic lymph nodes were considered at high risk. All 35 low risk patients were treated with cystectomy only and had an excellent outcome with a 3-year relapse-free survival plus or minus standard error of 93% +/- 5%. The 3-year rates in 52 and 20 high risk patients treated without and with chemotherapy, respectively, were 42% +/- 8% versus 57% +/- 13% for relapse-free survival (p = 0.17), 38% +/- 9% versus 8% +/- 8% for pelvic failure (p = 0.02) and 39% +/- 9% versus 38% +/- 13% for distant metastases (not significant). Multivariate analysis of patients who underwent pelvic lymphadenectomy revealed that perioperative chemotherapy improved relapse-free survival and pelvic control but not metastatic control (p = 0.03, 0.02 and 0.31, respectively). ### conclusions Low risk patients have excellent disease control when treated with cystectomy only. Those with high risk features are at substantial risk for pelvic failure (38% at 3 years) after cystectomy only. Perioperative M-VAC chemotherapy has a profound impact on pelvic but not on metastatic failure.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  To assess plasma steady-state pharmacokinetics ( PK ) of  <span class="marker" data-anno-id="0" data-anno-label="C1">rifampicin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">isoniazid</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">saquinavir</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C1">ritonavir</span>  in HIV and tuberculosis ( TB ) co-infected patients , and investigate potential interactions between TB drugs and protease inhibitors ( PIs ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.</u></h4> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>steady-state</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetics</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rifampicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>saquinavir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>HIV</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>co-infected</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>TB</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>protease</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PIs</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Open-label, single-arm, sequential PK study including 22 patients with HIV infection and TB. During the first 2 months, patients received rifampicin, <b style='color:Tomato;'><i>isoniazid</i></b> and <b style='color:Tomato;'><i>pyrazinamide</i></b>, with or without <b style='color:Tomato;'><i>ethambutol</i></b> (first PK study, n = 22). Then patients stopped <b style='color:Tomato;'><i>pyrazinamide</i></b> and <b style='color:Tomato;'><i>ethambutol</i></b> and started once-daily antiretroviral therapy (ART) with <b style='color:Tomato;'><i>didanosine</i></b>, <b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b> (200 mg) and <b style='color:Tomato;'><i>saquinavir</i></b> (1600 mg) (second PK study, n = 18). Patients stopped all TB drugs after 9 months continuing the same ART (third PK study, n = 15). Differences between TB drug parameters in the first and second PK studies, and between PI parameters in the second and third PK studies were used to assess interactions. ### results Rifampicin and <b style='color:Tomato;'><i>isoniazid</i></b> pharmacokinetics did not change substantially with <b style='color:Tomato;'><i>saquinavir</i></b> and <b style='color:Tomato;'><i>ritonavir</i></b>. A significant 39.5%, 34.9% and 48.7% reduction in median <b style='color:Tomato;'><i>saquinavir</i></b> AUC(0-24), C(max) and C(trough), respectively, was seen with rifampicin and <b style='color:Tomato;'><i>isoniazid</i></b>. <b style='color:Tomato;'><i>ritonavir</i></b> AUC(0-24), C(max) and C(trough) decreased 42.5%, 49.6% and 64.3%, respectively, with rifampicin and <b style='color:Tomato;'><i>isoniazid</i></b>. ### conclusions There was a significant interaction between <b style='color:Tomato;'><i>saquinavir</i></b>, <b style='color:Tomato;'><i>ritonavir</i></b> and rifampicin, with reduction in median plasma concentrations of <b style='color:Tomato;'><i>saquinavir</i></b> and <b style='color:Tomato;'><i>ritonavir</i></b>. <b style='color:Tomato;'><i>saquinavir</i></b> should be given with caution in patients receiving rifampicin. Twice-daily dosing or higher <b style='color:Tomato;'><i>saquinavir</i></b> doses in once-daily administration should be tested to obtain more appropriate plasma levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Blood was sampled immediately prior to premedication (  <span class="marker" data-anno-id="0" data-anno-label="C1">temazepam</span>  ) , after induction of anaesthesia (  <span class="marker" data-anno-id="1" data-anno-label="C1">fentanyl</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">thiopentone</span>  ) and at 10-minute intervals until the end of the procedure ( N2O maintenance ,  <span class="marker" data-anno-id="3" data-anno-label="C1">vecuronium</span>  relaxation ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The plasma ACTH, AVP, CRH and catecholamine responses to conventional and laparoscopic cholecystectomy.</u></h4>We compared the responses of the stress hormones, cortisol, ACTH, <b style='color:Tomato;'><i>vasopressin</i></b> (AVP), corticotrophin releasing hormone (CRH) and catecholamines to elective conventional and laparoscopic cholecystectomy. ### design A right upper quadrant transverse incision was used for conventional cholecystectomy, and four 1-2-cm incisions for the laparoscopic procedure (for insertion of surgical instruments, diathermy, fibreoptic telescope and light source, and carbon dioxide insufflation). <b style='color:DodgerBlue;'><i>Blood</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>sampled</i></b> <b style='color:DodgerBlue;'><i>immediately</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>premedication</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>temazepam</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>anaesthesia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>fentanyl</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>thiopentone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-minute</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>end</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>procedure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>N2O</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vecuronium</i></b> <b style='color:DodgerBlue;'><i>relaxation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A blood sample was taken after reversal, and then at 10-minute intervals for 50 minutes. Plasma sodium and blood pressure were measured at similar intervals. Results are expressed as mean +/- standard error. ### patients Twelve patients were studied (six in each group). ### measurements Peptide hormones were measured by radioimmunoassay, cortisol by ELISA and catecholamines by HPLC. ### results The mean premedication hormone values for the conventional and laparoscopic procedures did not increase significantly after induction of anaesthesia. Within 10 minutes of the first incision, however, there was a marked concordant rise in mean plasma ACTH and AVP levels for both procedures (conventional: ACTH, from a premedication value of 10.2 +/- 1.7 to 80.1 +/- 14.3 pmol/l, AVP from 1.2 +/- 0.4 to 117 +/- 24 pmol/l, P < 0.01 for both hormones; laparoscopic: ACTH from 5.8 +/- 2.6 to 55.1 +/- 26.0 pmol/l, AVP from 1.6 +/- 0.11 to 49.2 +/- 27.09 pmol/l). At the end of both types of operation mean levels of ACTH and AVP were still elevated, although the ACTH: AVP ratio had increased. Greater variability in ACTH and AVP responses was seen in the laparoscopic than in the conventional procedure, three patients showing a relatively small response to surgery. Total secretion of ACTH during both types of surgery was not significantly less both during (P < 0.05), and after (P < 0.01) laparoscopic surgery. For both procedures, the timing of AVP and ACTH peaks was significantly related (P < 0.002). A small but significant rise in CRH was observed 30 minutes after the start of surgery for both procedures P < 0.05). The timing of CRH and ACTH peaks was unrelated. The maximum mean plasma cortisol level for the conventional procedure (1268 +/- 147 nmol/l) was reached 20 minutes after reversal of anaesthesia and remained at this level until the end of sampling. The cortisol response was comparable during the laparoscopic procedure but was beginning to fall at 60 minutes post-operatively. Plasma adrenaline responses to the two types of surgery were not significantly different, but the plasma total noradrenaline response to laparoscopic surgery as indicated by the response area during the first 20 minutes was significantly increased (P < 0.02). Plasma sodium, renin activity and initial systolic blood pressure fall were not significantly different during the two procedures. ### conclusions For both procedures, the peak of ACTH secretion after incision is likely to be AVP dependent, and the timing of peak levels of these two hormones was significantly related. Subsequent ACTH secretion may be the result of an interaction between AVP and CRH. Laparoscopic cholecystectomy results in a smaller AVP rise than does the conventional procedure, and plasma AVP falls more rapidly post-operatively. During the period of observation, ACTH, CRH, cortisol and adrenaline responses were not significantly lessened by the laparoscopic approach, but there was a significant increase in the noradrenaline response. Stress hormone monitoring may assist further improvements in surgical technique.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The other received chemotherapy including  <span class="marker" data-anno-id="0" data-anno-label="P1">prednisone</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cytarabine</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">L-asparaginase</span>  , combined with intrathecal injections of methotrexate , dexamethasone and Ara-C and supporting treatment . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Renal tubular acidosis as an initial manifestation in children with malignant lymphoma].</u></h4>Primary renal lymphoma is one of the malignant lymphomas that initially presents in the extra lymphonode, which is rarely seen in children. This study reported two cases of primary renal lymphoma in children who were definitively diagnosed by renal biopsy. Renal tubular acidosis was the initial manifestation in both cases. They were referred to the hospital with chief complaints of polydipsia, polyuria, debilitation, vomiting and anemia. Imaging and laboratory examinations showed bilateral renomegaly, hypocalcemia, hypophosphatemia, and metabolic acidosis. One of the patients discontinued therapy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>L-asparaginase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Ara-C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>supporting</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-three days after treatment, polydipsia and polyuria were relieved, and acidosis, kaliopenia and anemia were improved in the patient. There were no abnormal findings in the renal B-ultrasound re-examination. It was concluded that when a patient is suspected of renal lymphoma, diagnostic puncture and renal biopsy should be performed early. Early combined therapeutics including chemotherapy, radiation therapy, surgery and supporting treatments may result in a favorable prognosis in patients with this disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Then , neoadjuvant chemotherapy ( NAC ) consisting of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">5-fluorouracil</span>  ( 5-FU ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">oxaliplatin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">irinotecan</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P1">leucovorin</span>  ( FOLFOXIRI ) was planned , followed by primary tumor resection . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A pathological complete response after neoadjuvant triplet chemotherapy for locally advanced transverse colon cancer.</u></h4>Perioperative chemotherapy could improve oncological outcomes for patients with advanced colon cancer. However, the effectiveness of triplet chemotherapy in the neoadjuvant setting is still unknown. ### Presentation Of Case A 61-year-old man was referred to our hospital due to abdominal distention. Abdominal computed tomography showed a huge, 18-cm mass in the right upper abdomen. Biopsy showed well-differentiated adenocarcinoma. Locally advanced transverse colon cancer T4b N2a M0 Stage IIIC was diagnosed. Considering the extensive invasion to surrounding organs and difficulties in achieving margin-negative surgery, an emergency ileostomy was performed first. <b style='color:DodgerBlue;'><i>Then</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FOLFOXIRI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>planned</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After 6 courses of treatment, the primary tumor shrank remarkably. Finally, laparoscopic radical extended right hemi-colectomy was performed. There were no residual tumor cells in resected specimens, including the primary tumor and surrounding lymph nodes. The pathological diagnosis was complete response. ### conclusion A case of pathological complete response after neoadjuvant treatment followed by radical resection was reported. Further research is needed to confirm the appropriate indications for neoadjuvant FOLFOXIRI therapy for patients with LACC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Increased dose density is feasible : a pilot study of adjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  , at 10- or 11-day intervals with  <span class="marker" data-anno-id="3" data-anno-label="P1">filgrastim</span>  support in women with breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Increased</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>11-day</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics. ### Experimental Design Thirty-nine women with early-stage breast carcinoma were accrued from April 2004 to October 2004. Median age was 47 years (range, 26-67 years). Patients received therapy with 100 mg/m(2) <b style='color:Tomato;'><i>epirubicin</i></b> and 600 mg/m(2) <b style='color:Tomato;'><i>cyclophosphamide</i></b> (EC) q 10 to 11 days for four cycles followed by 175 mg/m(2) <b style='color:Tomato;'><i>paclitaxel</i></b> q 10 to 11 days for four cycles, all with <b style='color:Tomato;'><i>filgrastim</i></b> support (300 microg s.c. daily) from day 2 to 24 h before the next treatment. ### results Thirty-five (90%) patients completed all planned therapy. The median intertreatment interval was 10 days (range, 8-28 days). Cycles (80.7%) were delivered at no more than 10- to 11-day intervals. There were five dose reductions of 25% for grade 3 nonhematologic toxicity in five patients. Six (16%) patients developed febrile neutropenia defined as temperature >38 degrees C with absolute neutrophil count <1,000/microL. All febrile neutropenia was during therapy with EC. Other grade 3 toxicities included bone pain, hand and foot syndrome, neuropathy, mucositis, nausea, and vomiting. ### conclusions Therapy with EC for four cycles followed by <b style='color:Tomato;'><i>paclitaxel</i></b> for four cycles at 10- to 11-day intervals is feasible. The approximately 30% reduction in intertreatment interval compared with every 14-day treatment could increase the efficacy of adjuvant chemotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The systemic treatment in both studies consisted of a four-drug-regimen ( VACA =  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">actinomycin</span>  D ,  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C1">adriamycin</span>  ; or VAIA =  <span class="marker" data-anno-id="4" data-anno-label="C2">vincristine</span>  ,  <span class="marker" data-anno-id="5" data-anno-label="C2">actinomycin</span>  D ,  <span class="marker" data-anno-id="6" data-anno-label="C2">ifosfamide</span>  , and  <span class="marker" data-anno-id="7" data-anno-label="C2">adriamycin</span>  ) and a total number of four courses , each lasting nine weeks , was recommended by the protocol . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.</u></h4>During recent years, more intensified systemic and local treatment regimens have increased the 5-year survival figures in localized Ewing's sarcoma to more than 60%. There is, however, concern about the risk of second malignancies (SM) in long-term survivors. We have analyzed the second malignancies in patients treated in the German Ewing's Sarcoma Studies CESS 81 and CESS 86. ### Materials And Methods From January 1981 through June 1991, 674 patients were registered in the two sequential multicentric Ewing's sarcoma trials CESS 81 (recruitment period 1981-1985) and CESS 86 (1986-1991). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>four-drug-regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VACA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>VAIA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lasting</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Local therapy in curative patients was either complete surgery (n = 162), surgery plus postoperative radiotherapy with 36-46Gy (n = 274), or definitive radiotherapy with 46-60Gy (n = 212). The median follow-up at the time of this analysis was 5.1 years, the maximum follow-up 16.5 years. ### results The overall survival of all patients including metastatic patients was 55% after 5 years, 48% after 10 years, and 37% after 15 years. Eight out of 674 patients (1.2%) developed a SM. Five of these were acute myelogenic leukemias (n = 4) or MDS (n = 1), and three were sarcomas. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas. The cumulative risk of an SM was 0.7% after 5 years, 2.9% after 10 years, and 4.7% after 15 years. Out of five patients with AML/MDS, three died of rapid AML-progression, and two are living with disease. Local therapy (surgery vs. surgery plus postoperative irradiation vs. definitive radiotherapy) had no impact on the frequency of AML/MDS, but local therapy did influence the risk of secondary sarcomas. All three patients with secondary sarcomas had received radiotherapy; however, all three sarcomas were salvaged by subsequent treatment and are in clinical remission with a follow-up of 1 month, 4.3 years, and 7.5 years after the diagnosis of the secondary sarcoma. Thus far, SM contributed to less than 1 % (3/328) of all deaths in the CESS-studies. ### conclusions The risk of leukemia after treatment for Ewing's sarcoma is probably in the range of 2%. The risk of solid tumors also seems to be low within the first 10 years after treatment and remains in the range of 5 % after 15 years. In the CESS-studies, less than 1% of all deaths within the first 10 years after diagnosis were caused by SM. Effective salvage therapy for secondary sarcomas is feasible.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA , omeprazole , clarithromycin and amoxicillin ; ( ii ) triple OLA , omeprazole , levofloxacin and amoxicillin ; ( iii ) sequential OACM ,  <span class="marker" data-anno-id="0" data-anno-label="P3">omeprazole</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P3">amoxicillin</span>  for 5 days , followed by omeprazole plus  <span class="marker" data-anno-id="2" data-anno-label="P3">clarithromycin</span>  plus  <span class="marker" data-anno-id="3" data-anno-label="P3">metronidazole</span>  for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h4>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We designed this phase II trial to evaluate the safety , tolerability , and efficacy of the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">carboplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cetuximab</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P1">bevacizumab</span>  in chemotherapy-naive patients with advanced , nonsquamous NSCLC . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.</u></h4><b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> have each been demonstrated to prolong survival when added to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). However, the potential benefit of combining <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> together with a platinum-based doublet had not been explored. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>chemotherapy-naive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nonsquamous</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Patients received with up to six cycles of <b style='color:Tomato;'><i>carboplatin</i></b> (area under curve 6), <b style='color:Tomato;'><i>paclitaxel</i></b> (200 mg/m(2)), <b style='color:Tomato;'><i>cetuximab</i></b> (400 mg/m(2) day 1 then 250 mg/m(2) weekly), and <b style='color:Tomato;'><i>bevacizumab</i></b> (15 mg/kg) every 21 days. Patients with an objective response or stable disease received maintenance <b style='color:Tomato;'><i>cetuximab</i></b> (250 mg/m(2) weekly) and <b style='color:Tomato;'><i>bevacizumab</i></b> (15 mg/kg every 21 days) until disease progression. The primary endpoint was safety as defined by the frequency and severity of hemorrhagic toxicities. Secondary endpoints included response rate, progression-free survival, overall survival, and toxicity. Molecular biomarkers were assessed in an exploratory manner. ### results The primary endpoint of grade 4 or higher hemorrhage of 2% (95% confidence interval: 0%-7%) met prespecified criteria for safety. One hundred ten patients were enrolled. There were four treatment-related deaths including lung hemorrhage (2), infection (1), and unknown (1). Median progression-free survival was 7 months and median overall survival was 15 months. The response rate was 56% with an overall disease control rate of 77%. ### conclusion This regimen was safe, feasible, and effective as a frontline treatment of advanced NSCLC, providing the basis for the ongoing phase III trial S0819.</div></div></div></div><button type="button" class="collapsible" id="coll3">3-ary drug combinations: found 54</button><div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Canine leishmaniosis is most frequently treated with the drugs meglumine  <span class="marker" data-anno-id="0" data-anno-label="P2">antimoniate</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P2">allopurinol</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">amphotericin</span>  B , or a combination of meglumine antimoniate and allopurinol . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Chemotherapy of canine leishmaniosis.</u></h4>Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. <b style='color:DodgerBlue;'><i>Canine</i></b> <b style='color:DodgerBlue;'><i>leishmaniosis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>frequently</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Thirteen patients with interstitial cystitis diagnosed by the NIH criteria were treated with intravesical electromotive administration of  <span class="marker" data-anno-id="0" data-anno-label="P1">lidocaine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">dexamethasone</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P1">cystodistention</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis.</u></h4> <b style='color:DodgerBlue;'><i>Thirteen</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>interstitial</i></b> <b style='color:DodgerBlue;'><i>cystitis</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIH</i></b> <b style='color:DodgerBlue;'><i>criteria</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravesical</i></b> <b style='color:DodgerBlue;'><i>electromotive</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>cystodistention</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After a mean follow-up of 10 (range 3-22) months, 8/13 (62%) of the patients reported complete resolution of bladder symptoms lasting an average 4.5 (range 0.75-17) months. Partial or short-term improvement of bladder symptoms was observed in three patients, while two patients reported aggravation of pain for several days after therapy. A significant increase in bladder capacity, to an average 166% of the pretreatment capacity, was observed in all patients. Whenever symptoms recurred after initially effective therapy, retreatments were performed with equal efficacy in 11 patients. This promising new therapeutic approach, performed on an outpatient basis, may become first-line treatment for patients with interstitial cystitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  This study evaluated the safety and efficacy of  <span class="marker" data-anno-id="0" data-anno-label="C1">inotuzumab</span>  ozogamicin ( INO ) , a targeted humanized anti-CD22 antibody conjugated to calicheamicin , plus  <span class="marker" data-anno-id="1" data-anno-label="C1">rituximab</span>  ( R-INO ) every 3 weeks , up to six cycles , followed by high dose therapy and autologous stem cell transplant (  <span class="marker" data-anno-id="2" data-anno-label="C1">HDT-aSCT</span>  ) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.</u></h4> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>inotuzumab</i></b> <b style='color:MediumOrchid;'><i>ozogamicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>INO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>humanized</i></b> <b style='color:DodgerBlue;'><i>anti-CD22</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>conjugated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>calicheamicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>R-INO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDT-aSCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>diffuse</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLBCL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary endpoint was overall response (OR) rate after three cycles of R-INO. Sixty-three patients were enrolled. Common grade 3/4 adverse events during R-INO treatment were thrombocytopenia, lymphopenia and neutropenia. OR rate after three cycles of R-INO was 28.6% (95% confidence interval: 17.9-41.4). Eighteen patients underwent HDT-aSCT; 2-year progression-free survival (PFS) for these patients was 61.1%. Serious infections and hepatic toxicity following aSCT occurred in 33% and 22%, respectively. One- and 2-year PFS rates for all enrolled patients were 28.9% and 25.3%, respectively (median, 3.0 months). R-INO had lower than expected activity as a salvage regimen for transplant eligible patients with DLBCL. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  These are the first 2 reports of successful treatment of this condition by use of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P2">methylprednisolone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">mycophenolate</span>  mofetil , and , in 1 of the cases , additional medication with intravenous  <span class="marker" data-anno-id="2" data-anno-label="P2">immunoglobulin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.</u></h4><b style='color:Tomato;'><i>ipilimumab</i></b> binds and blocks cytotoxic T-lymphocyte-associated antigen-4, causing enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma. Patients treated with <b style='color:Tomato;'><i>ipilimumab</i></b> can develop immune-related adverse effects, primarily dermatitis, colitis, hepatitis, and hypophysitis. Although, in phase I-III studies, 64.2% of all patients suffered from immune-related adverse effects, ocular adverse effects occurred in 1.3% only. In the cases reported below, 2 patients with metastatic melanoma developed severe ocular myositis after treatment with <b style='color:Tomato;'><i>ipilimumab</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>condition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>additional</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  A 70-year-old Asian man was diagnosed with PVT two months after initiating  <span class="marker" data-anno-id="0" data-anno-label="C1">5-fluorouracil/leucovorin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">irinotecan</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">bevacizumab</span>  therapy for rectal cancer with liver metastases . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.</u></h4>Portal vein thrombosis (PVT) while using an angiogenesis inhibitor is relatively rare. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>70-year-old</i></b> <b style='color:DodgerBlue;'><i>Asian</i></b> <b style='color:DodgerBlue;'><i>man</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PVT</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initiating</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil/leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>rectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Because the metastases were small and shrinking, we suspected that the thrombosis might have been caused by <b style='color:Tomato;'><i>bevacizumab</i></b>-containing chemotherapy. We stopped <b style='color:Tomato;'><i>bevacizumab</i></b> and started <b style='color:Tomato;'><i>apixaban</i></b>, a direct oral anticoagulant (DOAC). Eight months later, the complete dissolution of the thrombus and recanalization of the portal vein were attained. Our case suggests that PVT can occur during <b style='color:Tomato;'><i>bevacizumab</i></b>-containing chemotherapy, and DOAC therapy might be beneficial for treating PVT in patients with cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Utilizing this data , we suggest that  <span class="marker" data-anno-id="0" data-anno-label="P1">nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">ipilimumab</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">cabozantinib</span>  may be favored for first-line treatment of specific populations of older patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.</u></h4>Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age, is limited. This is further complicated by clinical trials not commonly reporting adverse events by age. Thus, recommendations on treatment of older patients with mRCC are generally extrapolated from data on younger patients enrolled in these trials, which may not be ideal as many older patients are frail, have age-related organ dysfunction, or have multiple medical co-morbidities. In the last decade, the treatment landscape for mRCC has drastically changed with the approval of more than ten targeted therapies, as well as immune checkpoint inhibitors. Thus, treatment selection and sequencing of treatments can be especially challenging for clinicians. We begin this review by analyzing the available efficacy and toxicity data of these treatments in younger and older patients. We also discuss a network meta-analysis that compares the efficacy of these agents in older patients with mRCC. <b style='color:DodgerBlue;'><i>Utilizing</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cabozantinib</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>favored</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>specific</i></b> <b style='color:DodgerBlue;'><i>populations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>older</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For salvage treatment, we suggest that <b style='color:Tomato;'><i>cabozantinib</i></b> may be the preferred agent for older patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Rats were subchronically primed with  <span class="marker" data-anno-id="0" data-anno-label="C1">nicotine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">clozapine</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C1">saline</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Nicotine and clozapine cross-prime the locus coeruleus noradrenergic system to induce long-lasting potentiation in the rat hippocampus.</u></h4>A priming-challenge schedule of <b style='color:Tomato;'><i>nicotine</i></b> treatment causes long-lasting potentiation (LLP), a form of synaptic plasticity closely associated with the nor<b style='color:Tomato;'><i>epinephrine</i></b> (NE) neurotransmitter system, at the medial perforant path (MPP)-dentate gyrus (DG) synapse in the rat hippocampus. Previous reports revealed that <b style='color:Tomato;'><i>nicotine</i></b> activates the locus coeruleus (LC) noradrenergic (NAergic) system and this mechanism may underlie its beta-adrenoceptor sensitive LLP effects. <b style='color:Tomato;'><i>clozapine</i></b>, an atypical antipsychotic, is also known to activate the LC. Interactions between <b style='color:Tomato;'><i>nicotine</i></b> and <b style='color:Tomato;'><i>clozapine</i></b> are of interest because of the prevalence of smoking in patients with schizophrenia and increasing interest in the use of nicotinic receptor ligands as cognitive enhancers. <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>subchronically</i></b> <b style='color:DodgerBlue;'><i>primed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clozapine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>saline</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-one to twenty-eight days later, the effects of the <b style='color:Tomato;'><i>nicotine</i></b>, <b style='color:Tomato;'><i>clozapine</i></b> or saline challenge on the evoked field excitatory postsynaptic potentials (fEPSP) at the MPP-DG monosynaptic pathway were recorded as a measure of LLP. We confirmed the hypothesis that a challenge dose of either <b style='color:Tomato;'><i>nicotine</i></b> or <b style='color:Tomato;'><i>clozapine</i></b> induces LLP exclusively in <b style='color:Tomato;'><i>nicotine</i></b>- and <b style='color:Tomato;'><i>clozapine</i></b>-primed rats, and not in saline-primed rats, thus indicating a cross-priming effect. Moreover, unilateral suppression of LC using <b style='color:Tomato;'><i>lidocaine</i></b> abolished the LLP induced by <b style='color:Tomato;'><i>nicotine</i></b> in <b style='color:Tomato;'><i>clozapine</i></b>-primed rats. Furthermore, systemic treatment with <b style='color:Tomato;'><i>clonidine</i></b> (an α2 adrenoceptor agonist that reduces NAergic activity via autoreceptors) prior to the challenge doses blocked the <b style='color:Tomato;'><i>nicotine</i></b>/<b style='color:Tomato;'><i>clozapine</i></b>-induced LLP in <b style='color:Tomato;'><i>nicotine</i></b>- and <b style='color:Tomato;'><i>clozapine</i></b>-primed rats. These findings may add to understanding of the cognitive enhancing effects of <b style='color:Tomato;'><i>nicotine</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  New agents , such as  <span class="marker" data-anno-id="0" data-anno-label="C1">taxane</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C2">irinotecan</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C3">oxaliplatin</span>  , combined with old agents , such as  <span class="marker" data-anno-id="3" data-anno-label="C1/C2/C3">cisplatin</span>  and  <span class="marker" data-anno-id="4" data-anno-label="C1/C2/C3">5-FU</span>  , are currently under evaluation to further improve treatment outcomes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Chemotherapy for advanced gastric cancer: slow but further progress.</u></h4>Gastric cancer remains a significant problem in terms of global health, and is the most common cancer in Korea. Surgery is the only potentially curative treatment for localized gastric cancer, but most cases present at an advanced stage. Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves the quality of life and extends survival, by 4 approximately 6 months, compared with best supportive care alone. Single agents with a proven activity in a first-line setting include 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU), <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>mitomycin</i></b> C, cisplatin, taxanes (<b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>) and oral fluoropyrimidines (<b style='color:Tomato;'><i>capecitabine</i></b> and TS-1). Based on the results from several large scale randomized trials, FP (5-FU/cisplatin) and ECF (<b style='color:Tomato;'><i>epirubicin</i></b>/cisplatin/5-FU) combinations are the most widely used regimen against advanced gastric cancer. Phase II studies of the FP and ECF combination reported a 40~51% response rate in previously untreated patients, and this regimen also produced a significantly higher response rate than the FAM (5-FU/<b style='color:Tomato;'><i>doxorubicin</i></b>/<b style='color:Tomato;'><i>mitomycin</i></b>) and FAMTX (5-FU/<b style='color:Tomato;'><i>doxorubicin</i></b>/<b style='color:Tomato;'><i>methotrexate</i></b>) regimens, respectively. However, significant treatment related-toxicities and discomfort were reported from ECF, which prevents this combination from becoming the standard treatment regimen. While no one combination chemotherapy regimen is accepted as the standard for advanced gastric cancer, FP is currently considered a suitable reference regimen worldwide. <b style='color:DodgerBlue;'><i>New</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>taxane</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Also, oral 5-FU prodrugs are replacing the cumbersome 5-FU long-term infusion due to its convenience and superior toxicity profile. However, the low complete response rate and short response duration are still the main obstacles in the chemotherapy for gastric cancer. Only large scale comparative clinical trials will give clues to improve the results of gastric cancer treatments.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">mitomycin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">tamoxifen</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">UFT</span>  proved to be an effective postoperative chemoendocrine therapy for stage II , ER-positive breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.</u></h4>A trial was designed to examine the combination of UFT and <b style='color:Tomato;'><i>mitomycin</i></b> (Mutamycin) plus <b style='color:Tomato;'><i>tamoxifen</i></b> (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer. <b style='color:Tomato;'><i>mitomycin</i></b> was administered intravenously at 13 mg/m2 on the day of surgery. Patients judged to be ER-positive were randomly allocated to either group A, which received oral <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg/day 14 days after surgery for 2 years, or group B, receiving oral UFT 400 mg/day plus <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg/day. A total of 219 patients were enrolled in group A, of which 213 (97.3%) were determined to be eligible; 225 patients enrolled in group B and 223 (99.1%) were eligible. The 5-year survival rates were 93.0% for group A and 95.4% for group B, with no significant difference between groups. The 5-year relapse-free survival rates were 83.1% for group A and 90.7% for group B, a significant advantage (P = .020) for the UFT plus <b style='color:Tomato;'><i>tamoxifen</i></b> group. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>UFT</i></b> <b style='color:DodgerBlue;'><i>proved</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemoendocrine</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ER-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  He was initially treated with combination chemotherapy regimen of  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">actinomycin-D</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  ( VAC therapy ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Rhabdomyosarcoma of the bladder: a case report].</u></h4>A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VAC</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We used MCF-7 and MDA-MB231 breast cancer cells incubated with  <span class="marker" data-anno-id="0" data-anno-label="C1">Curcumin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Quercetin</span>  for 24h , in the absence and presence of  <span class="marker" data-anno-id="2" data-anno-label="C1">Somatostatin</span>  , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDA-MB231</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Curcumin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Quercetin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24h</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Somatostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>EC50</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>fatty</i></b> <b style='color:DodgerBlue;'><i>acid-based</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>lipidomics</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MAPK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ( CTX ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">mitoxantrone</span>  ( MXT ) , with dose escalation of  <span class="marker" data-anno-id="2" data-anno-label="C1">paclitaxel</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.</u></h4>This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. <b style='color:DodgerBlue;'><i>Thirty-three</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MXT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">rituximab</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">vincristine</span>  and 5-day  <span class="marker" data-anno-id="2" data-anno-label="P1">cyclophosphamide</span>  is able to produce CR in patients with advanced follicular lymphoma , even in patients resistant to third-generation regimens . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.</u></h4>Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy, immunotherapy and, for selected patients, autotransplant. Because of the different mechanisms of action and non-overlapping toxicities, combination of <b style='color:Tomato;'><i>rituximab</i></b> with chemotherapy is a rational approach. ### methods 30 patients with follicular non-Hodgkin's lymphoma with advanced-stage disease were treated with four cycles of immunochemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> 375 mg/m2 on day 1, <b style='color:Tomato;'><i>vincristine</i></b> 2 mg i.v. on day 2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 400 mg/m2 i.v. from days 2 to 6, repeated at 3-week intervals. All patients had received multiple lines of therapy (median 3); 9 (30%) had relapses (2 after high-dose therapy with autologous transplant), and 21 (70%) were in relapse and refractory to salvage treatment (with an anthracycline-containing regimen in 19). ### results Of 29 patients evaluable for response, 16 (55 %) obtained a complete response (CR) and 3 (10%) a partial response (PR), with an overall response rate of 65% (19/29); 10 patients (35%) achieved less than PR. The median event-free survival was 16.1 months for all patients, being 22.8 months for responders. After a median follow-up of 2 years from the start of therapy (range 6 months to 3.8 years), of 16 patients who achieved CR, 10 remain free of disease. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-day</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>CR</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>third-generation</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The regimen designed on the basis of pharmacokinetics of the chimeric antibody seemed important for the clinical efficacy of the combination.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  [ Rhabdomyosarcoma of the urinary bladder : complete remission induced by  <span class="marker" data-anno-id="0" data-anno-label="P1">vinblastine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cis-platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">bleomycin</span>  ] . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Rhabdomyosarcoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cis-platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Combination therapy consisting of <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with or without adriamycin is the most common chemotherapy for rhabdomyosarcoma in childhood. But the effective chemotherapy for rhabdomyosarcoma resistant to these four drugs has not been established. We report a case with rhabdomyosarcoma, which was resistant to these four drugs but responded completely to three drug combination chemotherapy consisting of <b style='color:Tomato;'><i>vinblastine</i></b>, cis-platinum, and <b style='color:Tomato;'><i>bleomycin</i></b> (VPB therapy). A 11-months-old boy was referred to us because of giant abdominal tumor. Postoperative diagnosis was Group III embryonal rhabdomyosarcoma of the urinary bladder. Partial resection was followed by <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and adriamycin, but his residual tumor was growing. Then VPB therapy was administered and the first course of the chemotherapy reduced the size of tumor. After three courses of VPB therapy the second-look operation was performed. At operation no residual tumor was found and a complete remission was confirmed. During the course of VPB therapy no severe adverse effect was detectable.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Association of rash with outcomes in a randomized phase II trial evaluating  <span class="marker" data-anno-id="0" data-anno-label="N1">cetuximab</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="N1">mitoxantrone</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="N1">prednisone</span>  after docetaxel for metastatic castration-resistant prostate cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Association</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rash</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>cetuximab</i></b> (C), a chimeric monoclonal antibody that binds epidermal growth factor receptor (EGFR), is active against androgen-independent prostate cancer cell lines and might enhance the activity of chemotherapy. The efficacy of combining <b style='color:Tomato;'><i>cetuximab</i></b> with <b style='color:Tomato;'><i>mitoxantrone</i></b> (M) plus <b style='color:Tomato;'><i>prednisone</i></b> (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) after receiving <b style='color:Tomato;'><i>docetaxel</i></b>. ### Materials And Methods Patients with progression after receiving <b style='color:Tomato;'><i>docetaxel</i></b> were eligible and randomized 2:1 to CMP or MP. Therapy was <b style='color:Tomato;'><i>mitoxantrone</i></b> 12 mg/m(2) intravenously (I.V.) on day 1, oral <b style='color:Tomato;'><i>prednisone</i></b> 10 mg daily in both arms, and <b style='color:Tomato;'><i>cetuximab</i></b> 250 mg/m(2) I.V. (400 mg/m(2) day 1, cycle 1) on days 1, 8, and 15 in the CMP arm. Cycles were repeated every 21 days. Radiologic assessments of disease and PSA (prostate-specific antigen) occurred every 4 cycles. The primary endpoint was time to progression (TTP). ### results A total of 115 patients were enrolled, 75 in the CMP and 40 in the MP arm: the median TTP was 4.9 and 6.6 months, respectively; the measurable disease response rate was 2% and 4%, the PSA response rate 7.7% and 17.6%, and median survival 11.9 and 15.7 months, respectively. Key grade 3-4 toxicities were neutropenia 44% and 25.6%, anemia 6.7% and 7.7%, thrombocytopenia 6.7% and 2.6%, and fatigue 8% in both arms. In an unplanned exploratory analysis, median TTP with (n = 24) and without rash (n = 51) in the CMP arm was 10.3 months vs. 2.8 months (P = .004). On multivariable analysis,rash was significantly associated with TTP (hazard ratio [HR] = 0.43; P = .01). ### conclusions The treatment with CMP is not recommended in unselected men with <b style='color:Tomato;'><i>docetaxel</i></b>-treated CRPC, although rash might help develop tailored therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  In addition , stimulation of erythropoiesis with recombinant human  <span class="marker" data-anno-id="0" data-anno-label="P1">erythropoietin</span>  , supplemental  <span class="marker" data-anno-id="1" data-anno-label="P1">iron</span>  therapy , and improving haemostasis by  <span class="marker" data-anno-id="2" data-anno-label="P1">aprotinin</span>  may further reduce homologous blood requirements . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Reduction in the use of donated blood in surgical medicine].</u></h4>After rapid changes in transfusion practice over the past few years, blood conservation techniques have become standard in modern perioperative management. As a result, the amount of homologous blood products transfused has been markedly reduced in some types of surgical procedures. Provided that skillful surgical technique is applied and the use of blood products is restricted, autologous transfusion techniques (predonation of autologous blood, preoperative plasmapheresis, acute normovolaemic haemodilution, and intra- and postoperative blood salvage) can be performed with an acceptable risk for patients. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>erythropoiesis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>erythropoietin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>supplemental</i></b> <b style='color:DodgerBlue;'><i>iron</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>haemostasis</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>aprotinin</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>reduce</i></b> <b style='color:DodgerBlue;'><i>homologous</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>requirements</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients undergoing elective surgery have to be informed about the side effects of transfusion of homologous blood products and the possibility of blood-saving methods. An individual blood conservation plan, based on the patient's status and surgery, the equipment available, and personal experience should be worked out by the responsible anaesthesiologist, whereby a combination of different methods may be most effective. If storage is necessary, autologous blood products should be preparated like homologous products. The feasibility of predonation and retransfusion of autologous blood in patients with infectious diseases like hepatitis or acquired immune deficiency syndrome and the amount of labaratomy testing are still under discussion. Although blood conservation programs are time-consuming and more expensive, they reduce the various risks of using homologous blood products.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with  <span class="marker" data-anno-id="0" data-anno-label="C1">bevacizumab</span>  +  <span class="marker" data-anno-id="1" data-anno-label="C1">capecitabine</span>  +  <span class="marker" data-anno-id="2" data-anno-label="C1">oxaliplatin</span>  ( XELOX ) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer ( mCRC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.</u></h4> <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>XELOX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>XELOX</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Patients received either <b style='color:Tomato;'><i>bevacizumab</i></b> (7.5 mg/kg) + XELOX (<b style='color:Tomato;'><i>capecitabine</i></b> 1,000 mg/m(2) twice daily on days 1-14 + <b style='color:Tomato;'><i>oxaliplatin</i></b> 130 mg/m(2) on day 1 every 3 weeks) until disease progression (arm A) or the same doses of <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX for 6 cycles followed by <b style='color:Tomato;'><i>bevacizumab</i></b> + <b style='color:Tomato;'><i>capecitabine</i></b> until disease progression (arm B). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. ### results One hundred and twenty-three patients were randomized. Treatment compliance was similar in both groups. Median PFS was significantly longer for arm B than for arm A (11.0 vs. 8.3 months; p = 0.002). There was no significant difference between the two arms for ORR (66.7 vs. 59.0%; p = 0.861) or median OS (23.8 vs. 20.2 months; p = 0.100). Tolerability was acceptable in both treatment arms; the most frequent grade 3/4 treatment-related adverse events (arm B vs. arm A) were fatigue (6.6 vs. 16.1%), diarrhoea (3.3 vs. 11.3%), anorexia (3.3 vs. 11.3%), and neuropathy (1.6 vs. 8.1%). ### conclusions Maintenance therapy with <b style='color:Tomato;'><i>bevacizumab</i></b> + <b style='color:Tomato;'><i>capecitabine</i></b> can be considered an appropriate option following induction <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX in patients with mCRC instead of continuation of <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  This 40-week open-label extension of the 12-week double-blind Triple Therapy With  <span class="marker" data-anno-id="0" data-anno-label="P1">Olmesartan</span>  Medoxomil ,  <span class="marker" data-anno-id="1" data-anno-label="P1">Amlodipine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">Hydrochlorothiazide</span>  in Hypertensive Patients Study ( TRINITY ) evaluated the efficacy and safety of triple-combination treatments with olmesartan medoxomil , amlodipine besylate , and hydrochlorothiazide ( OM/AML/HCTZ ) in 2112 participants with moderate to severe hypertension . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.</u></h4>J Clin Hypertens (Greenwich). 2012;14:149-157. ©2012 Wiley Periodicals, Inc. Most patients with hypertension require combination therapy in order to achieve blood pressure (BP) goals. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>40-week</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>extension</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>12-week</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>Triple</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Olmesartan</i></b> <b style='color:DodgerBlue;'><i>Medoxomil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Amlodipine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Hydrochlorothiazide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Hypertensive</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TRINITY</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>triple-combination</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>olmesartan</i></b> <b style='color:DodgerBlue;'><i>medoxomil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>besylate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydrochlorothiazide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>OM/AML/HCTZ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2112</i></b> <b style='color:DodgerBlue;'><i>participants</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>moderate</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following 2 weeks of initial treatment with OM 40/AML 5/HCTZ 12.5 mg, participants not achieving BP goal were titrated to OM 40/AML 5/HCTZ 25 mg or OM 40/AML 10/HCTZ 12.5 mg on a randomized basis. At week 16, participants who did not achieve BP goal were further titrated to OM 40/AML 10/HCTZ 25 mg. At the end of the study, 44.5% to 79.8% of participants reached BP goal and the mean BP decreased from 168.6/100.7 mm Hg (baseline BP at randomization) to 125.0 to 136.8 mm Hg/77.8 to 82.5 mm Hg, depending on treatment. Long-term treatment with OM/AML/HCTZ was well tolerated and effective with no new safety concerns.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Nithiamide and  <span class="marker" data-anno-id="0" data-anno-label="N1">chlortetracycline</span>  +  <span class="marker" data-anno-id="1" data-anno-label="N1">sulfamethazine</span>  +  <span class="marker" data-anno-id="2" data-anno-label="N1">penicillin</span>  were least effective in preventing SD during the infection + medication and postmedication periods . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A swine dysentery model for evaluation of drug prophylaxis: efficacy of various drugs in the control of swine dysentery.</u></h4>A swine dysentery (SD) model that produces consistent, homogeneous, and severe SD was used in 2 experiments to compare the prophylactic effectiveness of 5 commercially available swine feed additive products. Under the conditions of these studies, <b style='color:Tomato;'><i>carbadox</i></b> and <b style='color:Tomato;'><i>carbadox</i></b> + <b style='color:Tomato;'><i>sulfamethazine</i></b> proved to be the most effective agents in preventing SD during the infection + medication and postmedication periods. Olaquindox was effective in preventing SD in the infection + medication period; however, SD recurrence was high during the postmedication period. <b style='color:DodgerBlue;'><i>Nithiamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chlortetracycline</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>sulfamethazine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>SD</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>postmedication</i></b> <b style='color:DodgerBlue;'><i>periods</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Initial treatment with either neoadjuvant chemoradiation ( CRT ) or induction FOLFOX (  <span class="marker" data-anno-id="0" data-anno-label="P1">5-Fluorouracil</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">leucovorin</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">oxaliplatin</span>  ) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.</u></h4> <b style='color:DodgerBlue;'><i>Initial</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemoradiation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CRT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>FOLFOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-Fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>CRT</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>rectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We compared patient-reported outcomes (PRO) during CRT in patients who had received induction chemotherapy versus those who did not. ### Patients And Methods We reviewed records of patients with locally advanced rectal cancer who were treated with CRT between September 2009 and October 2014, and who had completed ≥ 4 PRO assessments during treatment. Clinician- and patient-reported toxicities were collected each week during treatment. We fit binomial generalized linear models to maximum toxicity scores across all patients' visits. ### results Of 123 patients with ≥ 4 PRO assessments, 87 (71%) patients reported a clinically meaningful PRO score of 3 or higher for diarrhea, and 91 (74%) patients reported a PRO score of ≥ 3 for urgency, during 1 or more weeks of treatment, corresponding to 'very frequent' or worse. Of 116 patients who had also completed ≥ 4 clinician-reported assessments for descriptive analysis, clinically significant diarrhea (Common Terminology Criteria for Adverse Events grade ≥ 2) was reported in 9% of patients, and grade 2 proctitis and cystitis were reported in 20% and 4%, respectively. Eighty-four (68%) patients had undergone induction chemotherapy prior to CRT. Patients who received induction chemotherapy had 68% lower odds of experiencing significant urgency (odds ratio [OR], 0.32; 95% confidence interval [CI], 0.11-0.95; P = .04), 76% lower odds of bleeding (OR, 0.24; 95% CI, 0.1-0.62; P < .01), and 75% lower odds of tenesmus (OR, 0.25; 95% CI, 0.11-0.6; P < .01) versus those treated with upfront CRT. ### conclusion Based on PROs, a high proportion of patients experienced clinically significant symptoms during pelvic CRT, with diarrhea and urgency being most commonly reported. This appears to be under-reported on clinician-reported assessments. Delivery of induction chemotherapy was associated with lower odds of experiencing urgency, bleeding, and tenesmus on PROs during subsequent CRT, with no significant impact on diarrhea and rectal pain.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Prior to the procedure , the child was administered a dental cocktail containing  <span class="marker" data-anno-id="0" data-anno-label="N1">chloral hydrate</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="N1">hydroxyzine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="N1">methadone</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A fatality due to an accidental methadone substitution in a dental cocktail.</u></h4>A 6-year-old male child was scheduled for a dental procedure requiring conscious sedation. <b style='color:DodgerBlue;'><i>Prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>procedure</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>child</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>cocktail</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>chloral</i></b> <b style='color:DodgerBlue;'><i>hydrate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>hydroxyzine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methadone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After returning from the dentist, the child appeared groggy and was allowed to sleep. A few hours later, he was found unresponsive, and following resuscitation attempts at a local medical center, he was pronounced dead. Toxicological analyses of femoral blood indicated the presence of <b style='color:Tomato;'><i>hydroxyzine</i></b> at less than 0.54 μg/mL, trichloroethanol (TCE) at 8.3 μg/mL, and <b style='color:Tomato;'><i>methadone</i></b> at 0.51 μg/mL. No meperidine was detected. The cause of death was reported to be due to the toxic effects of <b style='color:Tomato;'><i>methadone</i></b>. The toxicological analysis was corroborated by the analysis of the contents of the dental cocktail, which revealed the presence of <b style='color:Tomato;'><i>hydroxyzine</i></b>, <b style='color:Tomato;'><i>chloral hydrate</i></b>, and <b style='color:Tomato;'><i>methadone</i></b>. Residue from a control sample obtained from the same pharmacy, but administered to a different subject, was found to contain <b style='color:Tomato;'><i>hydroxyzine</i></b>, <b style='color:Tomato;'><i>chloral hydrate</i></b>, and meperidine. This report represents the first known fatality due to accidental substitution of <b style='color:Tomato;'><i>methadone</i></b> in a dental cocktail.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  This study evaluated the response rate of the combination therapy of  <span class="marker" data-anno-id="0" data-anno-label="N1">aprinocarsen</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="N1">gemcitabine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="N1">carboplatin</span>  in previously untreated patients with advanced non-small cell lung cancer ( NSCLC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.</u></h4>The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>aprinocarsen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Secondary objectives included the measurement of time-to-event efficacy parameters and toxicity. Patients with stage IV or stage IIIB disease (N(3) and/or pleural/pericardial effusion) were treated with <b style='color:Tomato;'><i>gemcitabine</i></b> 1,250 mg/m(2) on days 1 and 8 and <b style='color:Tomato;'><i>carboplatin</i></b> AUC 5 on day 1 every 21 days. Aprinocarsen was administered as 2mg/kg/day continuous iv infusion on the first 14 days of each cycle, following the <b style='color:Tomato;'><i>carboplatin</i></b> treatment. A total of 36 patients received a median of 3 treatment cycles, with 10 patients completing 6 cycles. No complete response was observed, while partial response was seen in 25% of patients. Stable disease and progressive disease was observed in 36.1% and 22.2% of patients. The median overall survival was 8.3 months, and the median duration of progression-free survival was 5.7 months (95% CI, 3.2-7.1 months). Thrombocytopenia (78%) and neutropenia (50%) were the major grade 3/4 toxicities. Enrollment for this study was stopped and the study was terminated in March 2003 due to the results of a large phase III study, which suggested that aprinocarsen did not improve response or add survival benefit to chemotherapy in advanced NSCLC. The addition of aprinocarsen to <b style='color:Tomato;'><i>gemcitabine</i></b>+<b style='color:Tomato;'><i>carboplatin</i></b> therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Nal-IRI</span>  with  <span class="marker" data-anno-id="1" data-anno-label="C1">5-fluorouracil</span>  ( 5-FU ) and  <span class="marker" data-anno-id="2" data-anno-label="C1">leucovorin</span>  or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 ) </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h4>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7 months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus cisplatin. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2 × 46 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We conducted a double-blind cross-over study in ten volunteers aged from 19 to 30 years , to compare the pain control effects of a single oral dose of two analgesic compounds ( drug A :  <span class="marker" data-anno-id="0" data-anno-label="P1">propyphenazone</span>  mg 250 ,  <span class="marker" data-anno-id="1" data-anno-label="P1">ethylmorphine</span>  mg 5 ,  <span class="marker" data-anno-id="2" data-anno-label="P1">caffeine</span>  mg 5 ; drug B : dipyrone mg 500 , diphenhydramine mg 12.5 , adiphenine mg 5 , ethyl aminobenzoate mg 2.5 ) in an experimental pain model using stimulation of dental pulp . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Electric stimulation of the dental pulp in the evaluation of the central effect of analgesics].</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ten</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>aged</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>propyphenazone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethylmorphine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>caffeine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>dipyrone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>adiphenine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethyl</i></b> <b style='color:DodgerBlue;'><i>aminobenzoate</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>pulp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Constant voltage stimuli were delivered through silver chloride electrodes placed in contact with the vestibular surface of the upper medial incisor. At the beginning of the session, the pain input was graded by asking the subject to identify the weakest stimulus perceived (threshold level) and the strongest stimulus endurable (tolerance level). The range between threshold and tolerance level was divided in nine steps plus a subliminal step. The ten steps were delivered randomly, and each series of steps was repeated eight times. The subjects were instructed to rate the pain sensation in an arbitrary scale of 5 degrees. The procedure was repeated at 60 min and 180 min after drug administration. Each subject received two tablets of drug A or drug B in two different sessions at weekly intervals. Statistical analysis of the procedures showed that neither drug A nor drug B significantly affected the pain threshold. Drug A significantly reduced the total pain score (P less than 0.01) and its action peaked 60 min after administration.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Furthermore , 11 AML patients at primary diagnosis , including five AML patients with P-gp overexpression , who were treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">idarubicin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vepesid</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">cytarabine</span>  V ( ara-C ) showed a complete remission . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.</u></h4>P-glycoprotein (P-gp) expression in mononuclear bone marrow cells was analyzed in 119 patients, including 60 with chronic myelogenous leukemia (CML), 48 with myelodysplastic syndromes (MDS), and 11 with acute myelogenous leukemia (AML). For P-gp measurement an immunocytological method using monoclonal antibodies C219, 4E3, and MRK 16 and the reverse transcription-polymerase chain reaction technique were applied. According to our results obtained in healthy volunteers using the immunocytological method, the limit for P-gp overexpression was set at > or = 10% P-gp-positive mononuclear bone marrow cells and at > or = 30% P-gp-positive mononuclear peripheral blood cells. All 42 CML patients in chronic phase had normal P-gp expression. P-gp overexpression was demonstrated in four of six patients in accelerated myelogenous blast cell phase and in four of 12 CML-BC patients. Of eight CML patients in blast crisis (BC) with normal P-gp expression, partial remission was achieved in three and minor response in five after <b style='color:Tomato;'><i>prednisone</i></b>/vindesine therapy. All four of the 12 CML-BC patients with P-gp overexpression did not respond to this therapy. Normal P-gp expression was seen in 41 (85.4%) of 48 untreated MDS patients. While P-gp overexpression did not develop during therapy in any of the myelodysplastic syndrome patients treated with low-dose ara-C alone, four of eight treated with low-dose ara-C plus GM-CSF and four of 11 treated with low-dose ara-C and IL-3 developed P-gp overexpression after therapy. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>P-gp</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>idarubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vepesid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>V</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ara-C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Additionally, one <b style='color:Tomato;'><i>daunorubicin</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months. Our results suggest that in CML patients in BC, P-gp expression influences outcome after therapy. Further more, studies in a larger series of patients are necessary to prove the efficacy and toxicity of <b style='color:Tomato;'><i>idarubicin</i></b>/vepesid and cytardbine--or dexniguldipine-containing--therapy in relation to P-gp expression of AML patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Such therapy has included weekly  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="C1">carboplatin/cisplatin</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="C1">topotecan</span>  , and carboplatin plus doxorubicin . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h4>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The cost-minimisation analysis showed that treatment costs for a 12-week course of  <span class="marker" data-anno-id="0" data-anno-label="C1">capecitabine</span>  ( Pounds 2132 ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">tegafur</span>  with  <span class="marker" data-anno-id="2" data-anno-label="C1">uracil</span>  ( Pounds 3385 ) were lower than costs for the intravenous Mayo regimen ( Pounds 3593 ) and infusional regimens on the de Gramont ( Pounds 6255 ) and Modified de Gramont ( Pounds 3485 ) schedules over the same treatment period . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.</u></h4>Two oral fluoropyrimidine therapies have been introduced for metastatic colorectal cancer. One is a 5-<b style='color:Tomato;'><i>fluorouracil</i></b> pro-drug, <b style='color:Tomato;'><i>capecitabine</i></b>; the other is a combination of <b style='color:Tomato;'><i>tegafur</i></b> and uracil administered together with <b style='color:Tomato;'><i>leucovorin</i></b>. The purpose of this study was to compare the clinical effectiveness and cost-effectiveness of these oral therapies against standard intravenous 5-<b style='color:Tomato;'><i>fluorouracil</i></b> regimens. A systematic literature review was conducted to assess the clinical effectiveness of the therapies and costs were calculated from the UK National Health Service perspective for drug acquisition, drug administration, and the treatment of adverse events. A cost-minimisation analysis was used; this assumes that the treatments are of equal efficacy, although direct randomised controlled trial (RCT) comparisons of the oral therapies with infusional 5-<b style='color:Tomato;'><i>fluorouracil</i></b> schedules were not available. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>cost-minimisation</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>costs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>12-week</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pounds</i></b> <b style='color:DodgerBlue;'><i>2132</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tegafur</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>uracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pounds</i></b> <b style='color:DodgerBlue;'><i>3385</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>costs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>Mayo</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pounds</i></b> <b style='color:DodgerBlue;'><i>3593</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>infusional</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>de</i></b> <b style='color:DodgerBlue;'><i>Gramont</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pounds</i></b> <b style='color:DodgerBlue;'><i>6255</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Modified</i></b> <b style='color:DodgerBlue;'><i>de</i></b> <b style='color:DodgerBlue;'><i>Gramont</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pounds</i></b> <b style='color:DodgerBlue;'><i>3485</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>schedules</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Oral therapies result in lower costs to the health service than intravenous therapies. Further research is needed to determine the relative clinical effectiveness of oral therapies vs infusional regimens.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We investigated the maximum tolerated dose , dose-limiting toxicities , and response rate when the selective cyclooxygenase-2 inhibitor  <span class="marker" data-anno-id="0" data-anno-label="P1">celecoxib</span>  is added to concurrent  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cisplatin</span>  , and radiation therapy for patients with inoperable stage II-III non-small cell lung cancer ( NSCLC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.</u></h4>Preclinical findings suggest that adding targeted therapies to combination radiation-chemotherapy can enhance treatment efficacy; however, this approach may enhance normal tissue toxicity. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dose-limiting</i></b> <b style='color:DodgerBlue;'><i>toxicities</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>cyclooxygenase-2</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>radiation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>inoperable</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>II-III</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Methods And Materials Eighteen patients were analyzed in a phase I clinical dose-escalation trial. <b style='color:Tomato;'><i>celecoxib</i></b> was given daily beginning 5 days before radiation followed by maintenance doses for 12 weeks. Toxicity was graded with the Common Terminology Criteria for Adverse Events V3.0 and response with the World Health Organization system. Primary endpoints were maximum tolerated dose of <b style='color:Tomato;'><i>celecoxib</i></b> and treatment toxicity; secondary endpoints were response and survival rates. ### results The maximum tolerated dose of <b style='color:Tomato;'><i>celecoxib</i></b> was not reached, in part owing to discontinuation of the drug supply. At doses of 200 or 400 mg/day, no patients experienced any dose-limiting toxicity (acute grade ≥4 esophagitis or pneumonitis, neutropenic fever or thrombocytopenia requiring transfusion, or acute grade ≥3 diarrhea). Grade 3 toxicities were leukopenia (five patients), fatigue (3), pneumonitis (2), dyspnea (1), pain (1), and esophageal stricture (1). Interestingly, pulmonary fibrosis (a late toxicity) was no more severe in the higher-dose (400-mg) group and may have been less common than in the lower-dose group. The clinical response rate was 100% (8 complete, 10 partial). Two-year rates were: overall survival 65%; local-regional control 69%; distant metastasis-free survival 71%; and disease-free survival 64%. ### conclusion Although preliminary, our results suggest that adding <b style='color:Tomato;'><i>celecoxib</i></b> to concurrent chemoradiation for inoperable NSCLC is safe and can improve outcome without increasing normal tissue toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel ( control group ) or  <span class="marker" data-anno-id="0" data-anno-label="P1">pertuzumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="P1">docetaxel</span>  ( pertuzumab group ) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.</u></h4>The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody <b style='color:Tomato;'><i>trastuzumab</i></b> improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. <b style='color:Tomato;'><i>pertuzumab</i></b>, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of <b style='color:Tomato;'><i>trastuzumab</i></b>, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>808</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>toxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>effectively</i></b> <b style='color:DodgerBlue;'><i>managed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. ### results The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the <b style='color:Tomato;'><i>pertuzumab</i></b> group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of <b style='color:Tomato;'><i>pertuzumab</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the <b style='color:Tomato;'><i>pertuzumab</i></b> group than in the control group. ### conclusions The combination of <b style='color:Tomato;'><i>pertuzumab</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, as compared with placebo plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  To compare efficacy and toxicity of bolus application of chemotherapy protocol ,  <span class="marker" data-anno-id="0" data-anno-label="C1">oxaliplatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">fluorouracil</span>  ( bolus ) ,  <span class="marker" data-anno-id="2" data-anno-label="C1">leucovorin</span>  ( folfox ) between two groups of patients in the therapy of metastatic colorectal carcinoma ( mCRC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer.</u></h4> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>application</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>folfox</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 63 patients were treated for mCRC in the period January 2009 - January 2010 at the Department of Oncology of the Cantonal Hospital Zenica, Bosnia and Herzegovina (first group, 30 patients) and at the Department of Oncology of the Clinical Hospital Centre Bežanijska kosa in Belgrade, Serbia, in the period January 2005 - January 2006 (second group, 33 patients). The patients were treated according the same protocol, i.v. bolus infusion, but in different day intervals (D), 1, 8, 15/28 days or D1-D5/28 days, respectively. In all patients the following factors were analyzed: tumor response, overall survival (OS), progression free survival, hematological and non-hematological toxicity . ### results Colon was the primary localization in almost two thirds of patients. There was no statistically significant difference between the groups according to the age, hematological and non-hematological toxicity, as well as in achieved OS. Progression free survival expressed in months was in average 5 months though with a large range between minimal and maximal survival time. ### conclusion Both groups have shown equivalent efficacy to applied chemotherapy protocols. Overall survival in the two groups matched data from the literature. Further research should confirm success of the combination of chemotherapy protocols and their combination with the biological therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The study objectives were to evaluate the safety , tolerability , and preliminary efficacy of multiple doses of  <span class="marker" data-anno-id="0" data-anno-label="P1">dulanermin</span>  in combination with modified  <span class="marker" data-anno-id="1" data-anno-label="P1">FOLFOX6</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">bevacizumab</span>  in previously untreated patients with locally advanced , recurrent , or metastatic colorectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>objectives</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dulanermin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>FOLFOX6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods A total of 23 patients received <b style='color:Tomato;'><i>dulanermin</i></b> at dosages of 4.5 or 9 mg/kg/d given on days 1 to 3 of each 14-day cycle along with standard dosing of modified FOLFOX6 plus <b style='color:Tomato;'><i>bevacizumab</i></b>. Dose-limiting toxicities, adverse events (AEs), maximum tolerated dose, and response according to Response Evaluation Criteria in Solid Tumors were assessed. ### results In the first cohort (3 patients given <b style='color:Tomato;'><i>dulanermin</i></b> at 4.5 mg/kg/d) and second cohort (6 patients given <b style='color:Tomato;'><i>dulanermin</i></b> at 9 mg/kg/day), no dose-limiting toxicities were observed. The subsequent 14 patients were treated with a <b style='color:Tomato;'><i>dulanermin</i></b> dosage of 9 mg/kg/d. Patients (N = 23) received 2 to 42 cycles of <b style='color:Tomato;'><i>dulanermin</i></b> (median 15). The most common grade 3 or 4 AEs were neutropenia (39%), hypertension (17%), peripheral neuropathy (17%), hand-foot syndrome (13%), and pulmonary embolism (13%). Three patients (13%) discontinued the study because of serious AEs. Overall, a best response of partial response was observed in 13 patients (57%) (9 confirmed, 4 unconfirmed), stable disease was observed in 7 patients (30%), and disease progression was observed in 3 patients (13%). The median progression-free survival was 9.9 months (95% confidence interval, 7.0-12.7). ### conclusions Overall, the addition of <b style='color:Tomato;'><i>dulanermin</i></b> to first-line FOLFOX plus <b style='color:Tomato;'><i>bevacizumab</i></b> was well tolerated in patients with advanced colorectal cancer, with similar AEs that would be expected from FOLFOX plus <b style='color:Tomato;'><i>bevacizumab</i></b>. A randomized study is required to assess the clinical efficacy of <b style='color:Tomato;'><i>dulanermin</i></b> in this patient population.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The study was conducted in 90 patients operated on for unilateral breast cancer who were then assigned to receive either 12 intravenous cycles of  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">methotrexate</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( CMF ) every three weeks , or no further treatment . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results.</u></h4>Node-negative breast cancers are considered to comprise a subgroup which is amenable to cure with local-regional therapy alone. However, approximately 30% of affected patients present new disease manifestations within 10 years after surgery. To test the hypothesis that node-negative and estrogen receptor-negative breast cancer patients can benefit from adjuvant chemotherapy, a prospective randomized study was activated at the Istituto Nazionale Tumori of Milan in 1980. ### Patients And Methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>operated</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>unilateral</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CMF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Adjuvant chemotherapy was administered in the outpatient clinic of the Division of Medical Oncology. Patient characteristics were fairly well balanced between the two treatment groups except for primary tumor size: 58% of those with a primary tumor measuring > 2 cm in its largest diameter were randomized in the control group compared with 38% in the CMF regimen (P = 0.06). ### results At 12 years after surgery treatment outcome was significantly superior for patients given adjuvant CMF. The relapse-free survival rate was 71% (95% confidence limits (CL): 56-86) versus 43% (95% CL: 28-58), and total survival was 80% (95% CL: 68-92) versus 50% (95% CL: 34-66), respectively. The benefit from the administration of CMF was evident in all patient subsets and was not influenced by menopausal status. ### conclusions The long-term results of this trial of adjuvant combination chemotherapy confirm our previous observations on the efficacy of adjuvant chemotherapy in node-negative breast cancer patients at high risk of early disease relapse.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Postoperative combination chemotherapy for six cycles with  <span class="marker" data-anno-id="0" data-anno-label="P1">cisplatin</span>  ( 100 mg/m2 per day for 1 day every 3 weeks ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">bleomycin</span>  ( 15 units intravenously weekly for 18 weeks ) and  <span class="marker" data-anno-id="2" data-anno-label="P1">etoposide</span>  ( 100 mg/m2 per day for 3 days every 3 weeks ) were given and the tumor responded dramatically . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Huge retroperitoneal germinoma presenting with pathological fracture of the spine.</u></h4>Primary retroperitoneal germ cell tumors are extremely rare neoplasms. The most common presenting features are abdominal pain and palpable abdominal masses. Pathological fractures of the spine presenting as bilateral lower leg weakness are exceptionally rare. We describe a 16-year-old girl who developed progressive paraplegia after a minor falling injury. Radiological study demonstrated a huge retroperitoneal tumor with invasion of the T12 vertebral body and spinal canal. A posterior surgical approach was used to perform laminectomy (T12, L1), removal of the intraspinal tumor and internal fixation with transpedical screws (T10, T11 to L2,3), and posterolateral fusion. <b style='color:DodgerBlue;'><i>Postoperative</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>units</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>responded</i></b> <b style='color:DodgerBlue;'><i>dramatically</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patient had fully recovered without evidence of sequelae or recurrence at 2 years after operation. To the authors' knowledge, this is the first case in which a huge retroperitoneal germinoma presented as pathological fracture of the spine and spinal cord compression. The effectiveness of the postoperative cisplatin-based chemotherapy against this tumor made major retroperitoneal surgery to remove the main tumor mass unnecessary is also demonstrated.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Interestingly ,  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  not only significantly inhibited the growth of TNBC cells , but also attenuated YAP and β-catenin expression by upregulating the E3 ubiquitin ligase β-TrCP to abolished  <span class="marker" data-anno-id="1" data-anno-label="P1">docetaxel</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">vinorelbine</span>  resistance . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer.</u></h4>The use of <b style='color:Tomato;'><i>aspirin</i></b> has been associated with reduced breast cancer risk, but it is litter known if <b style='color:Tomato;'><i>aspirin</i></b> overcomes chemoresistance in triple-negative breast cancer (TNBC). Herein, we demonstrated that changes in the expression of Yes-associated protein (YAP) and β-catenin might be a promising predictive biomarker for neoadjuvant chemotherapy sensitivity in TNBC patients. Inhibition of YAP or β-catenin enhanced the cytotoxicity of the anti-microtubule agents <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> against drug-resistant TNBC cells as well as the sensitivity of these cells to the agents in vitro and in vivo. <b style='color:DodgerBlue;'><i>Interestingly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>TNBC</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>attenuated</i></b> <b style='color:DodgerBlue;'><i>YAP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>β-catenin</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>upregulating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>E3</i></b> <b style='color:DodgerBlue;'><i>ubiquitin</i></b> <b style='color:DodgerBlue;'><i>ligase</i></b> <b style='color:DodgerBlue;'><i>β-TrCP</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>abolished</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>vinorelbine</i></b> remarkably inhibited the growth of drug-resistant TNBC cells in vitro and in vivo. Moreover, TNBC patients with high YAP and/or β-catenin expression had a higher risk of relapse or mortality than patients with low YAP and/or β-catenin expression. Collectively, our study discovered a novel role of <b style='color:Tomato;'><i>aspirin</i></b> based on its anticancer effect, and put forward some possible mechanisms of chemoresistance in TNBC. The combined use of <b style='color:Tomato;'><i>aspirin</i></b> and anti-microtubule drugs presented several promising therapeutic approaches for TNBC treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  In metastastic patients , the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">methotrexate</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">vinblastine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">doxorubicin</span>  , and cisplatin ( MVAC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].</u></h4>Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>metastastic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For second-line treatment, vinflunine is the only approved therapeutic agent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  A randomized clinical trial of adjuvant chemotherapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">ifosfamide</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">cisplatin</span>  followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas ( SARCGYN study ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>localized</i></b> <b style='color:DodgerBlue;'><i>uterine</i></b> <b style='color:DodgerBlue;'><i>sarcomas</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SARCGYN</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>There is no proven benefit of adjuvant treatment of uterine sarcoma (US). SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic radiotherapy (RT) (arm A) versus RT alone (arm B) conducted to detect an increase ≥ 20% of 3-year PFS. ### methods Patients with FIGO stage ≤ III US, physiological age ≤ 65 years; chemotherapy: four cycles of <b style='color:Tomato;'><i>doxorubicin</i></b> 50 mg/m&sup2; d1, <b style='color:Tomato;'><i>ifosfamide</i></b> 3 g/m&sup2;/day d1-2, cisplatin 75 mg/m&sup2; d3, (API) + G-CSF q 3 weeks. Study was stopped because of lack of recruitment. ### results Eighty-one patients were included: 39 in arm A and 42 in arm B; 52 stage I, 16 stage II, 13 stage III; 53 leiomyosarcomas, 9 undifferenciated sarcomas, 19 carcinosarcomas. Gr 3-4 toxicity during API (/37 patients): thrombopenia (76%), febrile neutropenia (22%) with two toxic deaths; renal gr 3 (1 patient). After a median follow-up of 4.3 years, 41/81 patients recurred, 15 in arm A, 26 in arm B. The 3 years DFS is 55% in arm A, 41% in arm B (P = 0.048). The 3-year overall survival (OS) is 81% in arm A and 69% in arm B (P = 0.41). ### conclusion API adjuvant CT statistically increases the 3 year-DFS of patients with US.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA ,  <span class="marker" data-anno-id="0" data-anno-label="P1">omeprazole</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">clarithromycin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">amoxicillin</span>  ; ( ii ) triple OLA ,  <span class="marker" data-anno-id="3" data-anno-label="P2">omeprazole</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="P2">levofloxacin</span>  and  <span class="marker" data-anno-id="5" data-anno-label="P2">amoxicillin</span>  ; ( iii ) sequential OACM , omeprazole plus amoxicillin for 5 days , followed by omeprazole plus clarithromycin plus metronidazole for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h4>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">irinotecan</span>  ( CPT-11 ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">5-fluorouracil</span>  ( 5-FU ) and  <span class="marker" data-anno-id="2" data-anno-label="P1">leucovorin</span>  is widely used for the treatment of metastatic colorectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.</u></h4> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CPT-11</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, little is known about the safety of chemotherapy of malignancies in hemodialysis (HD) patients. We encountered a patient with colorectal carcinoma on HD. We decided to administer combination chemotherapy while monitoring the pharmacodynamics of the patient. ### Case Report A 74-year-old male received regular HD 3 times a week because of type 1 diabetes mellitus. He was diagnosed with stage IV colorectal cancer in November 2004. After sigmoidectomy, the patient received chemotherapy: a weekly schedule of CPT-11 (50 mg/m(2)) was administered followed by l-<b style='color:Tomato;'><i>leucovorin</i></b> (10 mg/m(2)) and 5-FU (400 mg/m(2)) just after HD. During the course, the plasma concentrations of both SN-38, an active metabolite of CPT-11, and 5-FU were not increased compared with those of patients with normal renal function. Our patient presented with grade III hematological toxicity that was easily recovered by granulocyte colony-stimulating factor. ### conclusion These data suggest that the dose-reduced Saltz regimen can be feasible for colorectal cancer patients receiving dialysis as postoperative adjuvant chemotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Long-term safety and outcome of  <span class="marker" data-anno-id="0" data-anno-label="P1">fludarabine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">mitoxantrone</span>  ( FCM ) regimen in previously untreated patients with advanced follicular lymphoma : 12 years follow-up of a phase 2 trial . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Long-term</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FCM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>fludarabine</i></b> combinations are very affective in follicular lymphoma (FL) with high rates of complete response and prolonged survival. However, late toxicities could be a concern. The aim of the present study was to analyze the long-term impact on survival, relapse and late toxicities of a trial of treatment with <b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>mitoxantrone</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (FCM regimen) for untreated patients with advanced stage FL. One hundred and twenty patients enrolled in a phase 2 trial of treatment with FCM regimen between 2000 and 2003 were evaluated. After a median follow-up of 12 years, 52 patients eventually relapsed/progressed with 10 year progression-free survival (PFS) of 46 %. Ten patients showed histological transformation to aggressive lymphoma with a risk of transformation of 2 and 9 % at 5 and 10 years, respectively. Three patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) and seven solid neoplasms with an overall risk of 3 and 8 % at 5 and 10 years, respectively. Twenty-six patients eventually died during the follow-up. Overall survival at 10 years was 83 %. In conclusion, FCM regimen allows excellent long-lasting response in previously untreated patients with FL. The incidence of late events including histological transformation and secondary neoplasia is low but not negligible.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  27 patients suffering from disseminated carcinoma of the breast with at least two visceral metastases , and two had become resistant to conventional chemotherpy and hormones , received a combination of , in the present trial ,  <span class="marker" data-anno-id="0" data-anno-label="P1">vincristine</span>  followed by  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  with  <span class="marker" data-anno-id="2" data-anno-label="P1">5-fluoro-uracil</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].</u></h4> <b style='color:DodgerBlue;'><i>27</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>suffering</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>disseminated</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>chemotherpy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>hormones</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluoro-uracil</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Chemotherapy was administered intermittently: each cycle of treatment lasted 6 days and was followed by a period without treatment of 25 days. Haematological tolerance was satisfactory. No serious incidents occurred during two years use of the combination. 20 out of 27 patients showed objective tumour regression of more than 50 p.cent lasting for more than 6 months, whilst 9 showed apparent complete regression of the malignant lesions. There was one complete failure. Chemotherapy was continued in all cases after regression of the neoplastic process was obtained.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  The experimental protocol was as follows : ( 1 ) at time zero , intravenous infusion of  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">ritodrine</span>  was begun ; ( 2 ) at 120 min , 2 %  <span class="marker" data-anno-id="1" data-anno-label="P1/P2">lidocaine</span>  was given epidurally to achieve a sensory level of at least T6 ; and ( 3 ) at 135 min , an intravenous bolus of either  <span class="marker" data-anno-id="2" data-anno-label="P1">ephedrine</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P2">phenylephrine</span>  , or normal saline-control was given , followed by a continuous intravenous infusion of the same agent for 30 min . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Ephedrine remains the vasopressor of choice for treatment of hypotension during ritodrine infusion and epidural anesthesia.</u></h4>Historically, ephedrine has been the vasopressor of choice for treatment of most cases of hypotension in obstetric patients. However, the choice of vasopressor in the parturient receiving a beta-adrenergic agent for tocolysis has not been evaluated extensively. The current study evaluated whether ephedrine or <b style='color:Tomato;'><i>phenylephrine</i></b> better restores uterine blood flow and fetal oxygenation during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. ### methods Fourteen chronically instrumented gravid ewes between 0.8 and 0.9 timed gestational age were used. On separate days, each animal underwent the experimental protocol with one of three agents: ephedrine, <b style='color:Tomato;'><i>phenylephrine</i></b>, and normal saline-control. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>follows</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ritodrine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>begun</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>epidurally</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sensory</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>T6</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>saline-control</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> experiments, the rate of infusion was adjusted to maintain maternal mean arterial pressure close to baseline. ### results <b style='color:Tomato;'><i>ritodrine</i></b> infusion alone significantly increased maternal heart rate and cardiac output in all three groups. Epidural anesthesia during <b style='color:Tomato;'><i>ritodrine</i></b> infusion significantly decreased maternal mean arterial pressure, heart rate, cardiac output, uterine blood flow, and fetal arterial oxygen tension for each of the three groups. Both ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> restored maternal mean arterial pressure to baseline, as designed. Ephedrine significantly increased uterine blood flow and fetal arterial oxygen tension when compared with normal saline--control, but <b style='color:Tomato;'><i>phenylephrine</i></b> did not. <b style='color:Tomato;'><i>phenylephrine</i></b> significantly increased uterine vascular resistance when compared with normal saline--control, but ephedrine did not. ### conclusions Although ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> provided similar restoration of maternal mean arterial pressure, ephedrine was superior to <b style='color:Tomato;'><i>phenylephrine</i></b> in restoring uterine blood flow during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. Also, ephedrine, but not <b style='color:Tomato;'><i>phenylephrine</i></b>, significantly improved fetal oxygenation, when compared to normal saline--control.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The aim of this study was to find an experimental model of a donor-recipient rat strain combination that , under triple drug immunosuppressive treatment (  <span class="marker" data-anno-id="0" data-anno-label="P1">methylprednisolone</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclosporine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">azathioprine</span>  ) , would develop chronic rejection within a few weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>An experimental model of chronic renal allograft rejection in the rat using triple drug immunosuppression.</u></h4>Chronic rejection is a major problem in renal transplantation. Various experimental models have been developed to study vasculopathy of chronic rejection. However, animal models resembling the clinical situation of renal transplantation with combination therapy of basic immunosuppression are not available. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>donor-recipient</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>immunosuppressive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>azathioprine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>develop</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>rejection</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>few</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Renal transplantations were performed in strain combinations of DA-->AO, PVG-->BN, and DA-->BN. In each group, 5-8 animals received triple drug treatment of <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> (2 mg/kg), <b style='color:Tomato;'><i>azathioprine</i></b> (2 mg/kg), and <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg) daily, 5-10 animals were left without treatment, and 6 syngenic transplantations were performed. The grafts were monitored with ultrasound-guided fine needle aspiration biopsies to quantify the inflammation in the graft. Graft histology was performed in parallel and quantified by using the chronic allograft damage index (CADI). ### results In nonimmunosuppressed animals, irreversible acute rejection with a high peak of inflammation appeared in every strain combination within 5-8 days. In triple drug-treated rats, the DA-->AO combination demonstrated a prolonged acute rejection but no characteristic chronic changes, and the PVG-->BN combination showed practically no inflammation and did not develop any signs of chronic rejection within 60 days (CADI: 2.7+/-2.1), but the DA-->BN combination showed an early, mild inflammatory response 5-7 days after transplantation and developed chronic rejection within 40-60 days after transplantation (CADI: 7.9+/-3.1). Syngenic animals showed no inflammation or histological alterations (CADI: 1.7+/-2.0). ### conclusions In conclusion, in the DA-->BN combination with triple drug treatment, early mild inflammation was followed by the development of chronic rejection and can be used as an experimental model that resembles the clinical situation in renal transplantation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  In FOLL05 trial , R-CHOP was compared with R-CVP (  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">prednisone</span>  ) and R-FM ( fludarabine , mitoxantrone ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.</u></h4>Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (<b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has been shown to be better than <b style='color:Tomato;'><i>fludarabine</i></b> alone and <b style='color:Tomato;'><i>fludarabine</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> for IL. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>FOLL05</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>R-CVP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>R-FM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (<b style='color:Tomato;'><i>bendamustine</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  All patients underwent 3 cycles of neoadjuvant  <span class="marker" data-anno-id="0" data-anno-label="C1">gemcitabine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">paclitaxel</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">capecitabine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer.</u></h4>Pancreatectomy with portal and/or superior mesenteric vein resection remains a controversial procedure because of high complexity and morbidity. Neoadjuvant chemotherapy has been shown to increase resectability of these locally advanced lesions. We aimed to assess the utility and efficacy of direct percutaneous transhepatic portomesenteric venous stenting (THVS) with neoadjuvant chemotherapy in increasing surgical resectability of locally advanced pancreatic carcinoma. ### methods Forty pancreatic carcinoma patients with tumor thrombus involving the portal vein and superior mesenteric vein were identified. Patients underwent THVS followed by neoadjuvant chemotherapy. Whipple procedure was offered to responders. ### results THVS was attempted in all. The tumor thrombus could not be crossed in 2 patients (95% technical success rate). <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Disease progression was noted in 16 patients and surgery was not offered. Twenty-two patients were explored with intent-to-perform a Whipple procedure. In 7 of these (32%), extensive disease precluding surgical resection was identified and the procedure was abandoned. Whipple procedure without vascular resection was performed successfully in 15 patients (68%). There were no perioperative deaths. Negative vascular margins were noted in 3 patients and negative peripancreatic lymph nodes in 5 patients. Median survival was 17 months (range, 5 to 70 mo). In the stented nonoperative group, median survival was 9 months (range, 3 to 19 mo). The stented and resected group achieved a statistically significant (P=0.0422) survival advantage. ### conclusions THVS in combination with neoadjuvant chemotherapy can increase tumor resectability and survival in a select group of locally advanced pancreatic cancer patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Pegylated liposomal  <span class="marker" data-anno-id="0" data-anno-label="P1">doxorubicin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer : results of the phase II CAPRICE study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>elderly</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cardiotoxicity-prone</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>CAPRICE</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines are not commonly used in elderly patients or those prone to cardiotoxicity. Pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b>, (PLD) has comparable efficacy, but less cardiotoxicity than conventional anthracyclines. We conducted a phase II single-arm trial to assess the efficacy and safety of PCT based on PLD followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) in a HRBC population usually undertreated. Fifty patients with stage II-IIIB breast cancer and at least one risk factor for developing cardiotoxicity initiated PLD 35 mg/m(2) plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600 mg/m(2) every 4 weeks for four cycles, followed by 80 mg/m(2) weekly PTX for 12. Close cardiac monitoring was performed. Primary endpoint was the pathological complete response rate (pCR) in the breast. Treatment delivery and toxicities were assessed. Eighty-four per cent of patients were older than 65 years, 64 % suffered from hypertension, and 10 % had prior cardiac disease. In an intention-to-treat analysis, breast pCR was 32 % (95 % CI 19.5-46.7 %) and pCR in breast and axilla was 24 % (95 % CI 12.1-35.8 %). At diagnosis only, 26 % of patients were candidates for breast conservative surgery, which increased to 58.7 % after PCT. No significant decrease in left ventricular ejection fraction was seen. PLD followed by PTX was feasible in a fragile population of patients who were not candidates for conventional <b style='color:Tomato;'><i>doxorubicin</i></b>. Moreover, it achieved a pCR similar to standard therapy and could therefore be an option for elderly patients or cardiotoxicity-prone who present HRBC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  She underwent rectectomy and adjuvant chemotherapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">fluorouracil</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="C1">oxaliplatin</span>  for stage IIIB rectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature.</u></h4>Esophageal metastasis from colorectal carcinoma is uncommon, and diagnosis of esophageal metastasis is difficult. We report a case of a 54-year-old woman with postoperative recurrence of rectal cancer metastasizing to the esophagus. <b style='color:DodgerBlue;'><i>She</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>rectectomy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIB</i></b> <b style='color:DodgerBlue;'><i>rectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Three years later, she presented with dysphagia and cough. Computed tomography showed thickening of the esophagus wall, enlargement of the lymph nodes in the mediastinum and abdomen, and ground-glass opacities in the right lung. Endoscopy revealed a submucosal tumor of the midthoracic esophagus. Histopathological analysis of the tumor biopsy showed infiltration of adenocarcinoma cells into the stroma of the esophagus; tumor cells were positive for caudal type homeobox 2 and negative for thyroid transcription factor 1. A transbronchial biopsy indicated pulmonary lymphangitic carcinomatosis of rectal adenocarcinoma. Based on those findings, she was diagnosed with recurrent rectal cancer. She received <b style='color:Tomato;'><i>fluorouracil</i></b>-based chemotherapy plus <b style='color:Tomato;'><i>bevacizumab</i></b>, which ameliorated her symptoms and induced a durable response without severe adverse events. Diagnosis of esophageal metastasis from rectal cancer can thus be made by repeated biopsy. Furthermore, aggressive systemic treatment with <b style='color:Tomato;'><i>fluorouracil</i></b>-containing chemotherapy and <b style='color:Tomato;'><i>bevacizumab</i></b> is a treatment option for colorectal cancer patients with esophageal metastasis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We report a case of a 78-year-old white male ( weight , 90 kg ) presented to the Department of Medical Oncology and Hematology , Istituto Clinico Humanitas , Rozzano , Milan , Italy , with refractory MM immunoglobulin G kappa ( IgGkappa ) , Durie-Salmon Stage IIA , with progressive renal failure after an oral  <span class="marker" data-anno-id="0" data-anno-label="N1">melphalan</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="N1">prednisone</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="N1">thalidomide</span>  regimen ( 4 mg/m2.d , 40 mg/m2.d for 7 days every 6 weeks , and 100 mg/d , respectively ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.</u></h4>Multiple myeloma (MM) is a hematologic neoplasia characterized by the monoclonal proliferation of bone marrow plasma cells. Renal failure occurs in 20% to 30% of MM patients at diagnosis and in >50% with an advanced form of the disease. For those with advanced MM, often a high-risk group of patients with poor prognosis, salvage treatment for renal failure needs to avoid nephrotoxic drugs. ### Case Summary <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>78-year-old</i></b> <b style='color:DodgerBlue;'><i>white</i></b> <b style='color:DodgerBlue;'><i>male</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>presented</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Department</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Medical</i></b> <b style='color:DodgerBlue;'><i>Oncology</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Hematology</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Istituto</i></b> <b style='color:DodgerBlue;'><i>Clinico</i></b> <b style='color:DodgerBlue;'><i>Humanitas</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Rozzano</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Milan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Italy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>MM</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>G</i></b> <b style='color:DodgerBlue;'><i>kappa</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IgGkappa</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Durie-Salmon</i></b> <b style='color:DodgerBlue;'><i>Stage</i></b> <b style='color:DodgerBlue;'><i>IIA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>progressive</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>melphalan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg/m2.d</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m2.d</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patient had documented increments of serum monoclonal component (M-protein), anemia, and renal failure with Bence Jones proteinuria (serum creatinine, 2.9 mg/dL; creatinine clearance, 30 mL/min; hemoglobin, 10.9 g/dL; serum IgGkappa M-protein, 3.9 g/dL; proteinuria 3.5 g/d;light-chain level in urine, 1.2 g/L). After 2 cycles with <b style='color:Tomato;'><i>bortezomib</i></b> at a reduced dose (1.0 mg/m2 twice weekly for 2 weeks followed by a 10-day rest period) to evaluate tolerability and renal toxicity, the patient completed another 3 cycles at the standard dose (1.3 mg/m2) in combination with <b style='color:Tomato;'><i>dexamethasone</i></b> (20 mg on the day of <b style='color:Tomato;'><i>bortezomib</i></b> administration and the day after). This led to an improvement of the renal function with a reduction of serum and urinary M-protein (serum creatinine 1.4 mg/dL; serum IgGkappa M-protein, 2.9 g/dL; proteinuria, 2 g/d; kappa light-chain level in urine, 0.7 g/L). The patient developed thrombocytopenia but did not suffer from some of the more severe adverse events associated with <b style='color:Tomato;'><i>bortezomib</i></b>, such as infection or peripheral neuropathy, even at full dose. ### conclusion We report an elderly patient with refractory MM and progression with renal failure who responded to <b style='color:Tomato;'><i>bortezomib</i></b> treatment. <b style='color:Tomato;'><i>bortezomib</i></b> was well tolerated in this patient.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We performed a prospective , preplanned , pooled analysis of six randomized , phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (  <span class="marker" data-anno-id="0" data-anno-label="C1">fluorouracil</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">oxaliplatin</span>  ) or CAPOX ( capecitabine and oxaliplatin ) administered for 3 months , as compared with 6 months . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.</u></h4>Since 2004, a regimen of 6 months of treatment with <b style='color:Tomato;'><i>oxaliplatin</i></b> plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since <b style='color:Tomato;'><i>oxaliplatin</i></b> is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>preplanned</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pooled</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>concurrently</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>noninferiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>FOLFOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CAPOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was the rate of disease-free survival at 3 years. Noninferiority of 3 months versus 6 months of therapy could be claimed if the upper limit of the two-sided 95% confidence interval of the hazard ratio did not exceed 1.12. ### results After 3263 events of disease recurrence or death had been reported in 12,834 patients, the noninferiority of 3 months of treatment versus 6 months was not confirmed in the overall study population (hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15). Noninferiority of the shorter regimen was seen for CAPOX (hazard ratio, 0.95; 95% CI, 0.85 to 1.06) but not for FOLFOX (hazard ratio, 1.16; 95% CI, 1.06 to 1.26). In an exploratory analysis of the combined regimens, among the patients with T1, T2, or T3 and N1 cancers, 3 months of therapy was noninferior to 6 months, with a 3-year rate of disease-free survival of 83.1% and 83.3%, respectively (hazard ratio, 1.01; 95% CI, 0.90 to 1.12). Among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; P=0.01 for superiority). ### conclusions Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  It was shown that the H2 receptor antagonist  <span class="marker" data-anno-id="0" data-anno-label="P1">cimetidine</span>  when combined with N ,  <span class="marker" data-anno-id="1" data-anno-label="P1">N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl</span>  (  <span class="marker" data-anno-id="2" data-anno-label="P1">DPPE</span>  ) , a tamoxifen derivate , inhibits the proliferation of HT168 cells . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line.</u></h4>Histamine is produced by many cells expressing histidine decarboxylase (HDC), the enzyme responsible for the synthesis of histamine. Since melanoma cells and tissue contain relatively large amounts of histamine, the functional significance of histamine was examined using specific antihistamines in vitro and in vivo in the human melanoma cell line HT168 and severe combined immunodeficiency (SCID) mice. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>H2</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>cimetidine</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>N</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DPPE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>derivate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>inhibits</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HT168</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, it is suggested that there is a factor(s) that interferes with the exponential growth of HT168 cells xenografted to immunodeficient mice, and <b style='color:Tomato;'><i>cimetidine</i></b> and DPPE together significantly influence this factor(s). This combination of antihistamines also increases the survival of human melanoma-grafted mice. These changes are accompanied by enhanced infiltration of interferon-gamma- producing mouse macrophages into the tumour tissue. These findings suggest that two different mechanisms are probably acting concordantly: direct inhibition of tumour cell proliferation by the H2 receptor antagonists, and activation of the local immune response characterized by interferon-gamma production. These findings may help to elucidate the possibility of a rationally designed antihistamine strategy in melanoma therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  He received six cycles MOPP-induction therapy followed by a  <span class="marker" data-anno-id="0" data-anno-label="N1">chlorambucil</span>  maintenance therapy with  <span class="marker" data-anno-id="1" data-anno-label="N1">procarbazine</span>  and  <span class="marker" data-anno-id="2" data-anno-label="N1">prednisone</span>  reinforcements . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Acute erythroleukemia following chemotherapy for Hodgkin's disease.</u></h4>A case of erythroleukemia developing in a patient 6.5 years after therapy for Hodgkin's disease (HD) is described. The patient had chemotherapy alone for a stage III B lymphocyte-predominant HD. <b style='color:DodgerBlue;'><i>He</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>MOPP-induction</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:MediumOrchid;'><i>chlorambucil</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>reinforcements</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To our knowledge this is the first case of erythroleukemia following HD treated with chemotherapy alone.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  The introduction of  <span class="marker" data-anno-id="0" data-anno-label="P1">rituximab</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">alemtuzumab</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">bendamustine</span>  has improved the current outlook for patients with CLL . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Standard of care and novel treatments for chronic lymphocytic leukemia.</u></h4>The standard of care and novel treatments for chronic lymphocytic leukemia (CLL) are reviewed. ### summary Recent advances in the treatment of CLL have dramatically changed the therapeutic landscape for both patients and health care professionals. The majority of conventional first-line therapies are noncurative and are only used to treat disease that is symptomatic or progressive and include <b style='color:Tomato;'><i>chlorambucil</i></b>, monotherapy with purine analogues, and combination chemotherapy. Immunotherapeutic agents such as <b style='color:Tomato;'><i>rituximab</i></b> and <b style='color:Tomato;'><i>alemtuzumab</i></b> may be indicated in select patient populations. However, because clinical trials have found that overall survival does not depend on the initial therapy, selection of first-line therapy should be based on patient-specific factors and the patient's goals for therapy with respect to response, survival, and symptom palliation. Progression-free survival time and time to treatment are critical endpoints for CLL treatment. An increasingly important endpoint is minimal residual disease (MRD), as it is considered to be the major cause of relapse in CLL. Finally, comparison of toxicities between different therapies is critical in CLL, as it is in other disease states. Several new agents are currently being evaluated for use in CLL, including alvocidib, oblimersen, and <b style='color:Tomato;'><i>lumiliximab</i></b>. ### conclusion Chemotherapy remains the mainstay of treatment for the majority of patients with CLL. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>introduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bendamustine</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>current</i></b> <b style='color:DodgerBlue;'><i>outlook</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CLL</i></b> <b style='color:DodgerBlue;'><i>.</i></b> As overall survival does not appear to depend on the initial therapy, treatment should be selected based on patient-specific factors and goals. Challenges in CLL include determining when to initiate therapy, eradicating MRD, and managing therapeutic resistance.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  The  <span class="marker" data-anno-id="0" data-anno-label="P1">ifosfamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">etoposide</span>  ( ICE ) regimen was developed to address these challenges . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.</u></h4>Despite advances in the management of aggressive non-Hodgkin's lymphoma, the treatment of relapsed and primary refractory disease remains a major challenge. High-dose chemotherapy or radio-chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) is a potentially curative treatment approach; however, the applicability of this approach is restricted to patients responding to second-line chemotherapy. Thus, second-line therapy must be both efficacious and without stem cell or organ toxicity that would compromise the ability to proceed to SCT. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ICE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>address</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>challenges</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In a series of prospective clinical trials, 222 patients were treated with the ICE regimen. with an overall response rate of 72%. The mobilization of stem cells with this regimen was excellent,with 86% of patients mobilizing at least 2.0 x 10(6) CD34+ cells/kg. The incidence of treatment-related toxicity precluding SCT after ICE is very low. Herein, we report the clinical results of this treatment program for 222 patients with 5-year median follow-up for surviving patients. <b style='color:Tomato;'><i>rituximab</i></b> was subsequently added to the ICE regimen for patients with diffuse large B-cell lymphoma (DLBCL) to improve upon these favorable results. This resulted in an increased complete remission rate. Additional follow-up is necessary to determine if this improvement in the complete remission rate will confer an increase in the overall survival following SCT.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Bevacizumab</span>  , a monoclonal antibody targeting vascular endothelial growth factor , is the first antiangiogenic drug to show improved efficacy when used in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">oxaliplatin</span>  for first- and second-line treatment of CRC . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Targeted agents for adjuvant therapy of colon cancer.</u></h4>Among patients with colorectal cancer (CRC) diagnosed in the United States, 37.2% are diagnosed with stage III and 27.9% with stage II disease. In locoregionally advanced CRC, surgery is the primary treatment modality and has a curative intent. The survival depends on the pathologic stage and varies from 30%-60% for stage III to 60%-80% for stage II. However, as much as 40%-50% of patients will relapse and require additional treatment of the disease. Clinical failure after resection of CRC is predominantly secondary to the clinical progression of previously undetected distant metastatic disease. Until very recently, the absolute benefit for survival obtained with adjuvant therapy compared with control was about 6%. Introduction of <b style='color:Tomato;'><i>oxaliplatin</i></b> in the adjuvant setting has shown a reduction of 23% in the risk of relapse when compared with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> alone (MOSAIC). Recent phase III studies have shown that targeted agents improved survival in patients with advanced-stage CRC. <b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>antiangiogenic</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>first-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CRC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>cetuximab</i></b>, another monoclonal antibody targeting epidermal growth factor receptor, has shown efficacy in third-line therapy and promising results in first-line phase II studies. There is great interest in whether the biologic agents <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b> can improve survival in the adjuvant-therapy setting. This article reviews the adjuvant therapy for colon cancer and discusses the potential role and current trials involving the targeted agents.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  HDC with  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclophosphamide</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">carmustine</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">thiotepa</span>  was given from day -7 to -5 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.</u></h4>Immunomodulation with cytokines was used to improve the result of high-dose chemotherapy (HDC)/autologous hematopoietic stem cell transplantation (AHST). We examined the use of IL-2 and growth factors for mobilization, ex vivo activation of peripheral blood stem cell (PBSC) and maintenance therapy after HDC/AHST in metastatic breast cancer. Eligible patients with metastatic breast cancer for HDC/AHST were assigned to 1 of 3 protocols for PBSC mobilization: G-CSF (group 1); IL-2 + G-CSF (group 2); or IL-2 + G-CSF + GM-CSF (group 3). <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carmustine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thiotepa</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>-7</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>-5</i></b> <b style='color:DodgerBlue;'><i>.</i></b> PBSCs were treated ex vivo with IL-2 for 24 h and reinfused on day 0. Maintenance therapy included low-dose IL-2, followed by 2 courses of intermediate-dose IL-2. GM-CSF was given from day 1 until neutrophil recovery. Thirty-four patients (10 in group 1, 14 in group 2, and 10 in group 3) were included. Comparable numbers of CD34(+) cells were collected from all 3 groups; incremental increases of CD3(+) cells were collected from groups 1 to 2 and to 3 (p = 0.03). Major adverse effects from IL-2 were fever, hypotension and fatigue; no treatment-related mortality was seen. At a median follow-up of 790.5 days (range 150-2,722 days), median progression-free survival was 434 days and median overall survival was 1,432 days. Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates.</div></div></div></div><button type="button" class="collapsible" id="coll4">2-ary drug combinations: found 213</button><div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Caspofungin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">amphotericin</span>  B association has been shown to be synergistic in vitro and effective in murine models . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia].</u></h4>The fungi of the order Mucorales cause mucormycosis, which usually presents as an invasive fungal disease with rapid angioinvasion in immunocompromised patients. Rhinocerebral is the most common presentation. The lipid formulations of <b style='color:Tomato;'><i>amphotericin</i></b> B are used as primary treatment in invasive mucormycosis; the combined use of <b style='color:Tomato;'><i>posaconazole</i></b> could allow a reduction in the dose of <b style='color:Tomato;'><i>amphotericin</i></b> B improving tolerance and adherence to treatment. <b style='color:MediumOrchid;'><i>Caspofungin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>murine</i></b> <b style='color:DodgerBlue;'><i>models</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We present the case of a preschool patient that during the debut of acute lymphoblastic leukemia developed a rhinocerebral mucormycosis successfully responding to antifungal treatment with the combination of liposomal <b style='color:Tomato;'><i>amphotericin</i></b> and <b style='color:Tomato;'><i>caspofungin</i></b>. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate , allopurinol , amphotericin B , or a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">meglumine</span>  antimoniate and  <span class="marker" data-anno-id="1" data-anno-label="P1">allopurinol</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Chemotherapy of canine leishmaniosis.</u></h4>Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. <b style='color:DodgerBlue;'><i>Canine</i></b> <b style='color:DodgerBlue;'><i>leishmaniosis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>frequently</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Haloperidol</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">carbamazepine</span>  and levomepromazine were then discontinued . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pituitary microadenoma treated with antipsychotic drug aripiprazole.</u></h4>Male patient 24 years old with a pituitary microadenoma and mental and behavioural disorders due to multiple drug use and use of other psychoactive substances (cocaine, cannabis and alcohol) were treated with <b style='color:Tomato;'><i>haloperidol</i></b> (dopamine receptor blocker) 10 mg daily. In the last control, the patient presented mammary hypertrophy; laboratory testing and brain magnetic resonance imaging (MRI) was performed, reporting the presence of a pituitary microadenoma syndrome with hormonal alteration (Prolactin levels 28.4 ng/ml). <b style='color:MediumOrchid;'><i>Haloperidol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>levomepromazine</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He was started on <b style='color:Tomato;'><i>aripiprazole</i></b> 15 mg po daily for 4 days; the dosage was then increased to 30 mg po daily, with <b style='color:Tomato;'><i>valproic</i></b> Acid 500 mg po tid. After 3 weeks on <b style='color:Tomato;'><i>aripiprazole</i></b>, the mammary hypertrophy that had increased in the patient had resolved. After 10 weeks follow up of prolactin revealed a normal level, at 4.33 ng/ml. Insomnia, aggressiveness, irritability, visual, tactile and auditory hallucinations remained absent after treatment with <b style='color:Tomato;'><i>aripiprazole</i></b> which is not a first line drug in multiple drug use patient with psychosis. We also consider the correlation of drug use in patient with psychosis, <b style='color:Tomato;'><i>haloperidol</i></b> treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine D2- receptor partial agonist <b style='color:Tomato;'><i>aripiprazole</i></b> treatment. This article also summarizes some relevant patents.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Recent clinical work has questioned the safety of a combined therapy of oral  <span class="marker" data-anno-id="0" data-anno-label="N1">quinidine</span>  and intravenous  <span class="marker" data-anno-id="1" data-anno-label="N1">verapamil</span>  , because some patients were reported to react with severe hypotension probably due to drug interactions with vascular alpha-adrenergic receptors . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Additive competitive interaction of verapamil and quinidine at alpha-adrenergic receptors of isolated cardiac guinea pig myocytes and human platelets.</u></h4> <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>work</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>questioned</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>quinidine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>react</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>hypotension</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>alpha-adrenergic</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In order to obtain further quantitative information on the underlying mechanism, we used the radioligands (3H)-<b style='color:Tomato;'><i>prazosin</i></b> and (3H)-<b style='color:Tomato;'><i>yohimbine</i></b> to perform binding studies on intact cells, with predominantly alpha-1 (isolated myocytes) or alpha-2 subtypes (human platelets) of adrenergic receptors. Our studies confirm that both <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinidine</i></b> possess a distinct alpha-adrenergic receptor blocking activity and do not discriminate between the alpha-1 and alpha-2 subtype (Ki-values were between 0.24-0.28 mumol/l for alpha-1 receptors and 0.49-0.50 mumol/l for alpha-2 receptors). Their interaction was competitive and in the presence of both drugs inhibition of radioligand binding was additive. The alpha-adrenergic blockade by <b style='color:Tomato;'><i>verapamil</i></b> was stereospecific as D-<b style='color:Tomato;'><i>verapamil</i></b> increased the dissociation constant of the radioligand to a much lesser degree than L-<b style='color:Tomato;'><i>verapamil</i></b> (Ki = 1.67 +/- 0.29 mumol/l for D-<b style='color:Tomato;'><i>verapamil</i></b>). The calcium channel blocker <b style='color:Tomato;'><i>nitrendipine</i></b>, a 1,4-dihydropyridine derivative, did not show any competition up to concentrations of 10 mumol/l. Our results thus give evidence that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinidine</i></b> have already at therapeutic blood levels significant alpha-adrenergic blocking activities which may be of clinical interest. In addition our results show that adult cardiac myocytes are very well suited for pharmacological adrenergic interaction studies.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  To increase the dose-intensity of two drugs in metastatic breast cancer , we tested the feasibility , in phase I studies , of two schedules of  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  ( E ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  ( C ) - sequential ( E-- > C ) and alternating ( E/C ) - with respect to the standard combination ( EC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.</u></h4> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dose-intensity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>schedules</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E--</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E/C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>respect</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Drugs were given at three planned-dose levels, plus either G-CSF or GM-CSF. Patients with metastatic (30), inoperable stage IIIb (2) or inflammatory (7) breast cancer were treated. The doses of EC, given every 21 days (4 cycles), were 75/1500, 82.5/2250, 90/3000 mg/m2. In the E/C schedule, <b style='color:Tomato;'><i>epirubicin</i></b> was given at cycles 1, 3 and 5, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> at cycles 2, 4 and 6. In the E--> C schedule, three cycles of <b style='color:Tomato;'><i>epirubicin</i></b> then three cycles of <b style='color:Tomato;'><i>cyclophosphamide</i></b> were administered. In both experimental schedules, drugs were given every 14 days for 6 cycles at doses of 100, 110, 120 mg/m2 (E) and 2000, 3000, 4000 mg/m2 (C). The average relative dose-intensity was 1.2-fold and 2-fold greater with E/C and E--> C, respectively, than with EC. The third level dose was feasible with all schedules. Grade 4 leucopenia occurred in 77% of patients. Thrombocytopenia was absent in 6 cases and grade 4 in 12 (30.8%). Eighty-one percent of patients on experimental schedules required red blood cell support versus 44.4% of patients on EC. At the third level, platelet transfusions were more frequent among patients treated with EC (27. 8%). Non-haematological toxicity was mild: about 20% of patients experienced grade 3 vomiting, irrespective of schedule. Only 2 patients had grade 3 mucositis; no patient developed heart failure. Fever (61% of patients) and bone pain (55.5% of patients) were relevant in the GM-CSF treated groups and 12 patients shifted to G-CSF. The overall response rate was 84.6%: 5/39 (12.8%) complete response and 28/39 (71.8%) partial response. At 30/9/98, median survival was 29.5 months, with no difference between patients with metastatic and stage IIIb/inflammatory breast cancer. Median follow-up of surviving patients was 62 months (range 17-83). The 5-year estimated survival was 19% (95% confidence intervals = 7-31%). Rapidly alternating or sequential cycles of <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with CSF support is a feasible strategy that allows a higher increase of dose-intensity of the single drugs. Hospitalization and anemia were more frequent with the experimental schedules, and thrombocytopenia with the standard schedule. Overall, this intensified therapy was very active.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  On February 3 , 2015 , the FDA granted accelerated approval to  <span class="marker" data-anno-id="0" data-anno-label="P1">palbociclib</span>  ( IBRANCE , Pfizer Inc. ) , an inhibitor of cyclin-dependent kinases 4 and 6 ( CDK4 and CDK6 ) , for use in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">letrozole</span>  for the treatment of postmenopausal women with estrogen receptor (ER)-positive , HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.</u></h4> <b style='color:DodgerBlue;'><i>On</i></b> <b style='color:DodgerBlue;'><i>February</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>granted</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>approval</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IBRANCE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Pfizer</i></b> <b style='color:DodgerBlue;'><i>Inc.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cyclin-dependent</i></b> <b style='color:DodgerBlue;'><i>kinases</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDK4</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>CDK6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>estrogen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(ER)-positive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>HER2-negative</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>endocrine-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to <b style='color:Tomato;'><i>palbociclib</i></b> (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg orally daily) or <b style='color:Tomato;'><i>letrozole</i></b> alone. The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-positive patients. The major efficacy outcome measure was investigator-assessed progression-free survival (PFS). A large magnitude of improvement in PFS was observed in patients receiving <b style='color:Tomato;'><i>palbociclib</i></b> plus <b style='color:Tomato;'><i>letrozole</i></b> compared with patients receiving <b style='color:Tomato;'><i>letrozole</i></b> alone (HR, 0.488; 95% confidence interval, 0.319-0.748). Multiple sensitivity analyses were supportive of clinical benefit. The most common adverse reaction in patients receiving <b style='color:Tomato;'><i>palbociclib</i></b> plus <b style='color:Tomato;'><i>letrozole</i></b> was neutropenia. This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clinical benefit in the ongoing and fully accrued confirmatory trial PALOMA-2.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  a combination treatment :  <span class="marker" data-anno-id="0" data-anno-label="P1">estramustine</span>  phosphate ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyproterone</span>  acetate or  <span class="marker" data-anno-id="2" data-anno-label="P2">estrogens</span>  plus  <span class="marker" data-anno-id="3" data-anno-label="P2">bromocriptine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Current aspects of hormonal therapy in prostate cancer].</u></h4>The following endocrine treatment modalities have been used in advanced prostatic carcinoma: 1. orchiectomy plus estrogens; 2. primary orchiectomy with delayed estrogen employment; 3. initial estrogen therapy with delayed orchiectomy; 4. initial <b style='color:Tomato;'><i>cyproterone</i></b> acetate or <b style='color:Tomato;'><i>medroxyprogesterone</i></b> acetate; 5. <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>phosphate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyproterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>estrogens</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bromocriptine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The application of phase-III studies permits the subsequent conclusions: Simultaneous orchiectomy is to no advantage (exception: urinary stasis). <b style='color:Tomato;'><i>cyproterone</i></b> acetate does neither yield better nor worse results regarding survival than estrogen alone, but has fewer side effects. Estrogens and <b style='color:Tomato;'><i>cyproterone</i></b> acetate produce a rise of serum prolactin justifying the use of <b style='color:Tomato;'><i>bromocriptine</i></b> (or lisuride). <b style='color:Tomato;'><i>estramustine</i></b> phosphate should be reserved for relapsing prostatic cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Hormone induced elevations in temperature and possibly other unidentified factors during thyroid crisis may facilitate the triggering of MH following  <span class="marker" data-anno-id="0" data-anno-label="C1">halothane</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">succinylcholine</span>  challenge . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Differential diagnosis of thyroid crisis and malignant hyperthermia in an anesthetized porcine model.</u></h4>The intra-operative differential diagnosis between thyroid crisis and malignant hyperthermia can be difficult. Also stress alone can trigger MH. The purposes of this study were: 1) to investigate the metabolic and hemodynamic differences between thyroid crisis and MH, 2) determine how thyroid crisis affects the development of MH, and 3) determine if the stress of thyroid crisis can trigger MH in susceptible individuals. We studied MH susceptible and normal swine. Two groups of animals (MH susceptible and normal) were induced into thyroid crisis (critical core hyperthermia, sustained tachycardia and increase in oxygen consumption) by pretreatment with intraperitoneal triiodothyronine (T3) followed by large hourly intravenous injections of T3. Two similar groups were given intravenous T3 but no pretreatment. These animals did not develop thyroid crisis and served as controls. Thyroid crisis did not result in metabolic changes or rigidity characteristic of an acute episode of MH. When the animals were subsequently challenged with MH triggering agents (<b style='color:Tomato;'><i>halothane</i></b> plus <b style='color:Tomato;'><i>succinylcholine</i></b>) dramatic manifestations of fulminant MH episodes (acute serious elevation in exhaled carbon dioxide, arterial CO2, rigidity and acidemia) were noted only in the MH susceptible animals. Although thyroid crisis did not trigger MH in the susceptible animals it did decrease the time to trigger MH (14.1 +/- 7.2 minutes versus 47.2 +/- 17.7 minutes, p < 0.01) in susceptible animals. <b style='color:DodgerBlue;'><i>Hormone</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>elevations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>temperature</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>possibly</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>unidentified</i></b> <b style='color:DodgerBlue;'><i>factors</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>thyroid</i></b> <b style='color:DodgerBlue;'><i>crisis</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>facilitate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>triggering</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MH</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>halothane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>succinylcholine</i></b> <b style='color:DodgerBlue;'><i>challenge</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Mitomycin</span>  C plus  <span class="marker" data-anno-id="1" data-anno-label="P1">vinblastine</span>  is an effective and well-tolerated regimen for anthracycline resistant cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study.</u></h4>The purpose of this phase II study was to evaluate the clinical efficacy of <b style='color:Tomato;'><i>mitomycin</i></b> C and <b style='color:Tomato;'><i>vinblastine</i></b> in patients with anthracycline-resistant metastatic breast cancer. This single-center, non-randomized trial enrolled 39 patients. Eligible patients must have received at least three chemotherapy regimens with <b style='color:Tomato;'><i>epirubicin</i></b> or CAF and had treatment failure while on chemotherapy or within 6 months of completing therapy. Treatment consisted of <b style='color:Tomato;'><i>mitomycin</i></b> C at a starting dose of 8 mg/m2 on day 1 and <b style='color:Tomato;'><i>vinblastine</i></b> (8 mg/m2, days 1 and 28). The regimen was repeated every 6 weeks with a 20% dose escalation of both drugs after the first cycle in the absence of grade III hematologic or other toxicity. On an intent-to-treat basis, 38 patients were eligible for assessment; 9 (23.7%, 95% confidence interval 1.92-2.45%) achieved a partial response and 13 (34.2%) had stable disease. The median time to disease progression was 6.21+/-4.26 months (range, 1-15; 95% confidence interval, 4.81-7.61), and the median survival was 10.76+/-7.6 (range, 1-29; 95% confidence interval 8.0-13.1%). Responsive patients had a significantly better survival than those with stable and progressive disease. Treatment was well tolerated. Anemia and neutropenia (grade I-III) developed in 28.9% and 26.3% of the patients, respectively. One patient with grade III granulocytopenia developed fever and infection that required hospitalization. Moderate neurotoxicity, myalgia, constipation, diarrhea and alopecia were observed. No toxic death occurred. <b style='color:MediumOrchid;'><i>Mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>well-tolerated</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>anthracycline</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  An angiotensin 2 type 1 receptor blocker ,  <span class="marker" data-anno-id="0" data-anno-label="P1">olmesartan</span>  , and a calcium channel blocker ,  <span class="marker" data-anno-id="1" data-anno-label="P1">azelnidipine</span>  , possess not only an antihypertensive effect but also an antioxidative effect and other beneficial effects . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.</u></h4> <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>angiotensin</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>type</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>olmesartan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>calcium</i></b> <b style='color:DodgerBlue;'><i>channel</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>azelnidipine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>possess</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>antihypertensive</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>antioxidative</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the present study, we examined the efficacy of <b style='color:Tomato;'><i>olmesartan</i></b> and <b style='color:Tomato;'><i>azelnidipine</i></b> monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. In comparison with the vehicle group, body weight, regional cerebral blood flow, and motor function were preserved, whereas systolic blood pressure and diastolic blood pressure decreased in the five drug-treatment groups. Spontaneous infarct volume decreased with the low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> and with the high-dose <b style='color:Tomato;'><i>olmesartan</i></b>, with a further decrease in the high-dose <b style='color:Tomato;'><i>azelnidipine</i></b> group. In addition, these drugs dose-dependently reduced oxidative stresses, proinflammatory molecules, and well-preserved components of the neurovascular unit. The low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> showed a better effect than the low-dose <b style='color:Tomato;'><i>olmesartan</i></b> or <b style='color:Tomato;'><i>azelnidipine</i></b> monotherapy. The present study shows that the low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> demonstrates a greater synergistic benefit than monotherapy with a low-dose of <b style='color:Tomato;'><i>olmesartan</i></b> or <b style='color:Tomato;'><i>azelnidipine</i></b> in SHR-SP for preventing spontaneous infarct volume, reducing oxidative stresses and proinflammatory molecules, and imparting neurovascular protection. In addition, a high-dose of <b style='color:Tomato;'><i>olmesartan</i></b> showed a greater benefit without the lowering of blood pressure, probably because of the antioxidative and anti-inflammatory effects. A high dose of <b style='color:Tomato;'><i>azelnidipine</i></b> showed the best benefit, probably because of the two effects mentioned above related to the lowering of blood pressure.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  At present , it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and  <span class="marker" data-anno-id="0" data-anno-label="C1">sorafenib</span>  combined with  <span class="marker" data-anno-id="1" data-anno-label="C1">everolimus</span>  for advanced osteosarcoma , which , in a sense , have become a milestone as a second-line therapy for osteosarcoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Anti-angiogenesis target therapy for advanced osteosarcoma (Review).</u></h4>Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including <b style='color:Tomato;'><i>doxorubicin</i></b>, cisplatin, high-dose <b style='color:Tomato;'><i>methotrexate</i></b>, and, in some regimens, <b style='color:Tomato;'><i>ifosfamide</i></b>, was demonstrated to improve overall survival compared with surgery alone. However, standard chemotherapeutic options have been limited by poor response rates in patients with relapsed or advanced cases. It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. <b style='color:DodgerBlue;'><i>At</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>seems</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>us</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>progress</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>made</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:DodgerBlue;'><i>Grignani</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>cohort</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sense</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>milestone</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although the recognization of muramyltripepetide phosphatidyl-ethanolamine has made some progress based on its combination with standard chemotherapy, its effect on refractory cases is controversial. Personalized comprehensive molecular profiling of high-risk osteosarcoma up to now has not changed the therapeutic prospect of advanced osteosarcoma significantly. Thus, how far have we moved forward and what therapeutic strategy should we prefer for anti-angiogenesis therapy? This review provides an overview of the most updated anti-angiogenesis therapy in OS and discusses some clinical options in order to maintain or even improve progression-free survival.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Patients received  <span class="marker" data-anno-id="0" data-anno-label="P1">vinorelbine</span>  starting at 20 mg/m(2 ) ( to 25 mg/m(2 ) ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  area under the curve ( AUC ) 2.5 in divided-doses , both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer.</u></h4><b style='color:Tomato;'><i>vinorelbine</i></b> administered in a doublet with cisplatin has become a standard treatment in patients with advanced non-small cell lung cancer (NSCLC). However, <b style='color:Tomato;'><i>carboplatin</i></b> appears to provide comparable efficacy with a better nonhematologic safety profile than cisplatin. Herein we report the results of a phase I/II trial of weekly <b style='color:Tomato;'><i>vinorelbine</i></b> and divided-dose <b style='color:Tomato;'><i>carboplatin</i></b> in patients with stage IIIB/IV NSCLC, Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>starting</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>divided-doses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21-day</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Dose-limiting toxicity was defined for Cycles 1 and 2. Tumor response and toxicity were assessed using standard criteria. Twenty-one patients with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 patient were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The <b style='color:Tomato;'><i>vinorelbine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> doublet was well tolerated, with 7 courses interrupted or delayed because of toxicity. Toxicities were generally mild and evenly divided between hematologic (i.e., neutropenia) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic toxicity. There was only one case of grade 2 alopecia, and no cases of > or = grade 2 neurotoxicity. There were 5 (24%) partial responses, and 9 (43%) patients had stable disease. Weekly <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m(2) and divided-dose <b style='color:Tomato;'><i>carboplatin</i></b> AUC 2.5 is a well tolerated regimen with activity in advanced NSCLC patients. Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Dexamethasone</span>  exhibited the highest effect on  <span class="marker" data-anno-id="1" data-anno-label="C1">paclitaxel</span>  anti-tumor activity , in a dose-dependent fashion . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer.</u></h4>The effect of topical co-administration of promoter drugs with <b style='color:Tomato;'><i>paclitaxel</i></b> to increase anti-tumor effects of <b style='color:Tomato;'><i>paclitaxel</i></b> was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with <b style='color:Tomato;'><i>paclitaxel</i></b> and a specific promoter drug. Several promoter drugs were evaluated, including: <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>losartan</i></b>, <b style='color:Tomato;'><i>nicotinamide</i></b>, Azone, and oleic acid. <b style='color:MediumOrchid;'><i>Dexamethasone</i></b> <b style='color:DodgerBlue;'><i>exhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>highest</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>anti-tumor</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>dose-dependent</i></b> <b style='color:DodgerBlue;'><i>fashion</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this effect was accompanied by systemic effects of <b style='color:Tomato;'><i>dexamethasone</i></b>, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We therefore explored the in vitro combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">amphotericin</span>  B with  <span class="marker" data-anno-id="1" data-anno-label="P1">itraconazole</span>  against 14 clinical Aspergillus fumigatus isolates ( 9 itraconazole susceptible and 5 itraconazole resistant ) with a colorimetric broth microdilution checkerboard technique using two drug interaction models able to explore complicated patterns of interactions : the response surface analysis of Bliss independence and the isobolographic analysis of Loewe additivity zero interaction theories . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.</u></h4>The interaction between polyenes and azoles is not well understood. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>explored</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>Aspergillus</i></b> <b style='color:DodgerBlue;'><i>fumigatus</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>susceptible</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>colorimetric</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>microdilution</i></b> <b style='color:DodgerBlue;'><i>checkerboard</i></b> <b style='color:DodgerBlue;'><i>technique</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>models</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>explore</i></b> <b style='color:DodgerBlue;'><i>complicated</i></b> <b style='color:DodgerBlue;'><i>patterns</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>surface</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Bliss</i></b> <b style='color:DodgerBlue;'><i>independence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>isobolographic</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Loewe</i></b> <b style='color:DodgerBlue;'><i>additivity</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>theories</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Synergy was found at combinations with low concentrations of <b style='color:Tomato;'><i>amphotericin</i></b> B (<0.125 mg/L), whereas antagonism was found at combinations with higher concentrations of <b style='color:Tomato;'><i>amphotericin</i></b> B. For <b style='color:Tomato;'><i>itraconazole</i></b>-resistant isolates, synergistic interactions were observed at high concentrations of <b style='color:Tomato;'><i>itraconazole</i></b> (>0.5 mg/L). Synergy was more frequently observed for the <b style='color:Tomato;'><i>itraconazole</i></b>-resistant isolates than for the <b style='color:Tomato;'><i>itraconazole</i></b>-susceptible isolates.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  These are the first 2 reports of successful treatment of this condition by use of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">methylprednisolone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  mofetil , and , in 1 of the cases , additional medication with intravenous immunoglobulin . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.</u></h4><b style='color:Tomato;'><i>ipilimumab</i></b> binds and blocks cytotoxic T-lymphocyte-associated antigen-4, causing enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma. Patients treated with <b style='color:Tomato;'><i>ipilimumab</i></b> can develop immune-related adverse effects, primarily dermatitis, colitis, hepatitis, and hypophysitis. Although, in phase I-III studies, 64.2% of all patients suffered from immune-related adverse effects, ocular adverse effects occurred in 1.3% only. In the cases reported below, 2 patients with metastatic melanoma developed severe ocular myositis after treatment with <b style='color:Tomato;'><i>ipilimumab</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>condition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>additional</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  In conclusion , concurrent introduction of  <span class="marker" data-anno-id="0" data-anno-label="P1">ATGAM</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">tacrolimus</span>  is a promising therapeutic combination for GVHD refractory to steroids and cyclosporine . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.</u></h4>We report our experience with the combination of anti-thymocyte globulin (ATGAM) and <b style='color:Tomato;'><i>tacrolimus</i></b> in the treatment of 20 patients with steroid refractory and dependent acute graft-versus-host disease (GVHD) transplanted between August 1996 and February 2000. All patients received <b style='color:Tomato;'><i>cyclosporin</i></b>e-based GVHD prophylaxis. Thirteen patients developed a maximum of grade IV, five grade III and two grade II acute GVHD, with 15 patients being refractory to steroids and five dependent on steroids. Patients were treated with ATGAM (15 mg/kg for 5 d) and <b style='color:Tomato;'><i>tacrolimus</i></b> (0.025--0.1 mg/kg/d) in addition to continuation of their high-dose steroids and cessation of their <b style='color:Tomato;'><i>cyclosporin</i></b>e. Within 28 d of treatment, we observed eight complete responses (CR), six partial responses (PR) and six with no response. Overall response (CR + PR) was predicted by GVHD severity. Infectious complications occurred in 80% of patients. The median survival was 86.5 d (range, 21--1081 d) with 35% of patients remaining alive. Survival following combination therapy was significantly more likely in men (P < 0.001), skin-only GVHD (P = 0.027), less severe GVHD (P = 0.048), and in responders to <b style='color:Tomato;'><i>tacrolimus</i></b> and ATGAM (P < 0.001). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conclusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:DodgerBlue;'><i>introduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ATGAM</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tacrolimus</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>steroids</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Comparison of geometric least-squares mean PK parameters between arms showed no impact of  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">pertuzumab</span>  on the PK of  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">docetaxel</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.</u></h4><b style='color:Tomato;'><i>pertuzumab</i></b> is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined with <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>pertuzumab</i></b> improved progression-free and overall survival versus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b> in the phase III CLEOPATRA trial (NCT00567190) in first-line HER2-positive metastatic breast cancer. Thirty-seven patients participated in a pharmacokinetic (PK)/corrected QT interval substudy of CLEOPATRA, which evaluated potential PK drug-drug interaction (DDI). PK parameters were calculated using noncompartmental methods, and DDI analyses were carried out. In the presence of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, the mean <b style='color:Tomato;'><i>pertuzumab</i></b> Cmin and Cmax in cycle 3 were 63.6 and 183 µg/ml, respectively. The <b style='color:Tomato;'><i>pertuzumab</i></b> concentrations observed were consistent with simulations from a validated population PK model, indicating that <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> did not alter <b style='color:Tomato;'><i>pertuzumab</i></b> PK. <b style='color:DodgerBlue;'><i>Comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>geometric</i></b> <b style='color:DodgerBlue;'><i>least-squares</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>arms</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In conclusion, no PK DDI was observed when <b style='color:Tomato;'><i>pertuzumab</i></b>, <b style='color:Tomato;'><i>trastuzumab</i></b>, and <b style='color:Tomato;'><i>docetaxel</i></b> were combined for the treatment of HER2-positive metastatic breast cancer. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We proved experimentally the use of ECEEM for multiplex determination of kinetic parameters describing weak ( 3 mM > K(d ) > 80 μM ) and fast ( 0.25 s ≥ τ ≥ 0.9 ms ) noncovalent interactions between four small molecule drugs (  <span class="marker" data-anno-id="0" data-anno-label="C1">ibuprofen</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C2">S-flurbiprofen</span>  , salicylic acid and  <span class="marker" data-anno-id="2" data-anno-label="C3">phenylbutazone</span>  ) and α- and  <span class="marker" data-anno-id="3" data-anno-label="C1/C2/C3">β-cyclodextrins</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Revealing equilibrium and rate constants of weak and fast noncovalent interactions.</u></h4>Rate and equilibrium constants of weak noncovalent molecular interactions are extremely difficult to measure. Here, we introduced a homogeneous approach called equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM) to determine k(on), k(off), and K(d) of weak (K(d) > 1 μM) and fast kinetics (relaxation time, τ < 0.1 s) in quasi-equilibrium for multiple unlabeled ligands simultaneously in one microreactor. Conceptually, an equilibrium mixture (EM) of a ligand (L), target (T), and a complex (C) is prepared. The mixture is introduced into the beginning of a capillary reactor with aspect ratio >1000 filled with T. Afterward, differential mobility of L, T, and C along the reactor is induced by an electric field. The combination of differential mobility of reactants and their interactions leads to a change of the EM peak shape. This change is a function of rate constants, so the rate and equilibrium constants can be directly determined from the analysis of the EM peak shape (width and symmetry) and propagation pattern along the reactor. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>proved</i></b> <b style='color:DodgerBlue;'><i>experimentally</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ECEEM</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>multiplex</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>kinetic</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>describing</i></b> <b style='color:DodgerBlue;'><i>weak</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>mM</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>K(d</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>μM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>fast</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>s</i></b> <b style='color:DodgerBlue;'><i>≥</i></b> <b style='color:DodgerBlue;'><i>τ</i></b> <b style='color:DodgerBlue;'><i>≥</i></b> <b style='color:DodgerBlue;'><i>0.9</i></b> <b style='color:DodgerBlue;'><i>ms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>noncovalent</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>molecule</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ibuprofen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>S-flurbiprofen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>salicylic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>phenylbutazone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>α-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>β-cyclodextrins</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The affinity of the drugs was significantly higher for β-cyclodextrin than α-cyclodextrin and mostly determined by the rate constant of complex formation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We evaluated the stem cell mobilization regimen of high-dose  <span class="marker" data-anno-id="0" data-anno-label="C1">ifosfamide</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">etoposide</span>  in 32 patients with epithelial ovarian cancer , who had a positive second-look laparatomy or recurrent disease . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.</u></h4>High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>mobilization</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>32</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>second-look</i></b> <b style='color:DodgerBlue;'><i>laparatomy</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>ifosfamide</i></b> was given at 10 g/m2 by continuous i.v. from days 1 to 3. <b style='color:Tomato;'><i>etoposide</i></b> was given at 150 mg/m2 every 12 h for six doses on days 1-3. <b style='color:Tomato;'><i>filgrastim</i></b> was given at 10 microg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (>8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose <b style='color:Tomato;'><i>ifosfamide</i></b> plus <b style='color:Tomato;'><i>etoposide</i></b> with <b style='color:Tomato;'><i>filgrastim</i></b> support was well tolerated, lead to successful stem cell harvest and had antitumor activity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Combinations of  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">alkylating agents</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">fludarabine</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">cladribine</span>  are also synergistic in producing significantly enhanced activity against refractory lymphoid malignancies , but at the cost of increased haematological toxicity . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.</u></h4>This review establishes the pharmacokinetic characteristics of the major nucleoside analogues with cytotoxic activity. <b style='color:Tomato;'><i>cytarabine</i></b>, pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cladribine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> are all prodrugs whose plasma pharmacokinetics do not fully reflect their therapeutic activity; after cellular uptake, these compounds undergo phosphorylation by deoxycytidine kinase before their incorporation into DNA results in cell death. <b style='color:Tomato;'><i>cytarabine</i></b> is principally active in the S phase of the cell cycle and is most toxic to replicating cells, whereas pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b> and <b style='color:Tomato;'><i>cladribine</i></b> are incorporated into DNA during the process in which strand breaks are repaired and are therefore cytotoxic to slowly replicating cells (although the action of pentostatin results from its inhibition of adenosine deaminase). <b style='color:Tomato;'><i>gemcitabine</i></b> is unusual in being highly metabolised in solid tumour cells. The cytotoxic activity of pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b> and <b style='color:Tomato;'><i>cladribine</i></b> against the clonal cells of lymphoproliferative disorders is accompanied by damage to normal lymphoid cells, which results in significant and long-lasting immunosuppression. Useful interactions between nucleoside analogues have been defined. Cells that are primed by exposure to <b style='color:Tomato;'><i>fludarabine</i></b> or <b style='color:Tomato;'><i>cladribine</i></b> exhibit enhanced accumulation of <b style='color:Tomato;'><i>cytarabine</i></b> triphosphate (the cytotoxic nucleotide of <b style='color:Tomato;'><i>cytarabine</i></b>) and an improved therapeutic effect against acute myeloid leukaemia and chronic lymphocytic leukaemia can be achieved by clinical schedules that exploit this effect. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>alkylating</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>producing</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>lymphoid</i></b> <b style='color:DodgerBlue;'><i>malignancies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>haematological</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Developments in the clinical administration of <b style='color:Tomato;'><i>gemcitabine</i></b> are concentrating on efforts to extend the duration of exposure to the drug as a means of counteracting its rapid catabolism in the circulation. Future developments with this group of agents will further explore the use of <b style='color:Tomato;'><i>fludarabine</i></b>-based combination therapies to produce a transient period of myelosuppression and immunosuppression that is sufficient to permit the engraftment of allogeneic haemopoietic stem cells and also exploit the immunological benefits of graft-versus-tumour reactions. In addition, the clinical spectrum of activity of <b style='color:Tomato;'><i>gemcitabine</i></b> is also being extended by combining the drug with other active chemotherapeutic agents, such as cisplatin, and by early studies of its role as a radiosensitiser.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The pharmacodynamic effects of single doses of  <span class="marker" data-anno-id="0" data-anno-label="C1">trazodone</span>  ( 100 mg ) ,  <span class="marker" data-anno-id="1" data-anno-label="C2">amitriptyline</span>  ( 50 mg ) or  <span class="marker" data-anno-id="2" data-anno-label="C3">placebo</span>  either alone or with  <span class="marker" data-anno-id="3" data-anno-label="C1/C2/C3">ethanol</span>  ( 0.5 ml/kg ) were investigated in 6 healthy volunteers in a double-blind crossover study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Evaluation of possible interactions between ethanol and trazodone or amitriptyline.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>pharmacodynamic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trazodone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ethanol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>ml/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>crossover</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Plasma concentrations of the drugs and ethanol were also measured. Pharmacodynamic tests were critical flicker fusion frequency threshold (CFF), choice reaction time (CRT), manual dexterity, a digit span test and visual analogue scales. Blood ethanol concentrations were not influenced by the co-administration of either antidepressant. tmax for <b style='color:Tomato;'><i>trazodone</i></b> was prolonged by ethanol but the other pharmacokinetic parameters for <b style='color:Tomato;'><i>trazodone</i></b> and <b style='color:Tomato;'><i>amitriptyline</i></b> were not influenced by ethanol. <b style='color:Tomato;'><i>trazodone</i></b> and <b style='color:Tomato;'><i>amitriptyline</i></b> caused the expected profound depressant effects on CFF, CRT, manual dexterity and on the rating scales for drowsiness, 'clearheadedness', aggression and disinhibition. Ethanol alone impaired manual dexterity, increased drowsiness, reduced 'clearheadedness' and also tended to reduce feelings of aggression. In combination with either <b style='color:Tomato;'><i>trazodone</i></b> or <b style='color:Tomato;'><i>amitriptyline</i></b>, ethanol caused little additional effect except in the case of manual dexterity, which was further impaired. This result may reflect the profound effects of the antidepressants alone and does not suggest that it is safe for patients receiving antidepressant medication to take ethanolic drinks.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Results of cell viability assays revealed that treatment with a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">imatinib</span>  and chemotherapy agents  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  or  <span class="marker" data-anno-id="2" data-anno-label="P2">5‑Fu</span>  synergistically inhibited cell growth , compared with treatment with any of these drugs alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.</u></h4><b style='color:Tomato;'><i>imatinib</i></b> is a powerful tyrosine kinase inhibitor that specifically targets BCR‑ABL, c‑KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of <b style='color:Tomato;'><i>imatinib</i></b> in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of <b style='color:Tomato;'><i>imatinib</i></b> on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that <b style='color:Tomato;'><i>imatinib</i></b> induced mitochondria‑mediated apoptosis of gastric cancer cells by involving endoplasmic reticulum (ER) stress‑associated activation of c‑Jun NH2‑terminal kinase (JNK). We also found that <b style='color:Tomato;'><i>imatinib</i></b> suppressed cell proliferation in a time‑ and dose‑dependent manner. Cell cycle analysis revealed that <b style='color:Tomato;'><i>imatinib</i></b>‑treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, <b style='color:Tomato;'><i>imatinib</i></b>‑treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress‑associated apoptotic molecule. <b style='color:DodgerBlue;'><i>Results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>assays</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5‑Fu</i></b> <b style='color:DodgerBlue;'><i>synergistically</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data indicated that <b style='color:Tomato;'><i>imatinib</i></b> exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress‑associated JNK activation. Furthermore, we revealed that <b style='color:Tomato;'><i>imatinib</i></b> induced the apoptosis of gastric cancer cells by inhibiting platelet‑derived growth factor receptor signaling. Collectively, our results strongly support the use of <b style='color:Tomato;'><i>imatinib</i></b> in the treatment of treating gastric cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The combination of a  <span class="marker" data-anno-id="0" data-anno-label="C2">fluoropyrimidine</span>  ( 5-fluorouracil or  <span class="marker" data-anno-id="1" data-anno-label="C1/C3">capecitabine</span>  ) with either  <span class="marker" data-anno-id="2" data-anno-label="C1">oxaliplatin</span>  or  <span class="marker" data-anno-id="3" data-anno-label="C2/C3">irinotecan</span>  has been widely accepted as standard cytotoxic chemotherapy for either the first- or second-line treatment of mCRC . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Options for Second-Line Treatment in Metastatic Colorectal Cancer.</u></h4>Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most important factors in choosing among treatment options and sequencing regimens. In addition, the choice of first-line systemic therapy will affect the options for second-line treatment. Several newer cytotoxic agents for the treatment of mCRC have been approved during the past 2 decades by the US Food and Drug Administration (FDA), including <b style='color:Tomato;'><i>irinotecan</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b>, and <b style='color:Tomato;'><i>capecitabine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fluoropyrimidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>accepted</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The FDA has approved several pathway-targeting agents for the treatment of mCRC; these include agents that target the vascular endothelial growth factor receptor pathway (<b style='color:Tomato;'><i>bevacizumab</i></b>, ziv-<b style='color:Tomato;'><i>aflibercept</i></b>, and <b style='color:Tomato;'><i>ramucirumab</i></b>) and those that target the epidermal growth factor receptor pathway (<b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>panitumumab</i></b>). Here, we review the current clinical options for the second-line treatment of mCRC and the rationales for their use. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The aim of this study was to evaluate all E. coli positive blood cultures collected during a 4-y period in a haematological department using  <span class="marker" data-anno-id="0" data-anno-label="C1">piperacillin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">netilmicin</span>  for empiric treatment of febrile episodes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.</u></h4>Escherichia coli is a leading cause of bacteraemia. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>E.</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>cultures</i></b> <b style='color:DodgerBlue;'><i>collected</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>4-y</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>haematological</i></b> <b style='color:DodgerBlue;'><i>department</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>piperacillin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>netilmicin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>empiric</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>febrile</i></b> <b style='color:DodgerBlue;'><i>episodes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We measured the incidence of <b style='color:Tomato;'><i>piperacillin</i></b>-resistant E. coli bacteraemia among haematological and non-haematological patients, described the importance of previous antibiotic treatment for resistance development in E. coli and evaluated the impact of <b style='color:Tomato;'><i>piperacillin</i></b> resistance on the clinical outcome of E. coli bacteraemia. 114 episodes of E. coli bacteraemia in 104 patients were recorded and 98 episodes in 88 patients (42 males and 46 females) with a median age of 64 y (range 19-85 y) were evaluated. In 81.6% of the episodes the patients had a haematological disorder, dominated by acute leukaemia (41.3%), chronic leukaemia (16.3%) and lymphoma (10%). The proportion of <b style='color:Tomato;'><i>piperacillin</i></b>-resistant E. coli was higher among haematological patients than non-haematological patients (25% vs 0%, p=0.02) and resistance was associated with <b style='color:Tomato;'><i>piperacillin</i></b> therapy during the previous month (p=0.05). No difference in clinical outcome was found between haematological patients infected with <b style='color:Tomato;'><i>piperacillin</i></b>-susceptible or -resistant E. coli (intensive care 12% vs 15%; mortality 22% vs 25%).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Thirty-five percent ( 6 of 17 ) of the patients receiving docetaxel alone and 53 % ( 19 of 36 ) of those receiving  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">thalidomide</span>  have had a PSA decrease of at least 50 % . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.</u></h4>New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent prostate cancer (AIPC). For several years, researchers at the National Cancer Institute have been interested in elucidating the importance of angiogenesis in the pathogenesis of prostate cancer and in identifying inhibitors of this process. <b style='color:Tomato;'><i>thalidomide</i></b> has been shown to inhibit the ability of tumors to recruit new blood vessels. In a recent phase II trial of <b style='color:Tomato;'><i>thalidomide</i></b> in AIPC, 28% of patients achieved a prostate-specific antigen (PSA) decrease of >40%. The taxane <b style='color:Tomato;'><i>docetaxel</i></b> also produces PSA and measurable disease responses when used as monotherapy or as a component of combination chemotherapy for AIPC. Thus, based on the single-agent activity of <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, we initiated a randomized phase II study of weekly <b style='color:Tomato;'><i>docetaxel</i></b> with or without <b style='color:Tomato;'><i>thalidomide</i></b>, 200 mg at bedtime, in patients with chemotherapy-naive metastatic AIPC. <b style='color:Tomato;'><i>docetaxel</i></b>, 30 mg/m(2) intravenously, was administered every 7 days for 3 weeks, followed by a 1-week rest period. Both regimens have been well tolerated among the first 59 treated patients, with a near absence of grade (3/4) myelosuppression. Fatigue, hyperglycemia, and pulmonary toxicity were seen in both groups. Thrombotic events have been seen in the combination arm. <b style='color:DodgerBlue;'><i>Thirty-five</i></b> <b style='color:DodgerBlue;'><i>percent</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>17</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>53</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>36</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>PSA</i></b> <b style='color:DodgerBlue;'><i>decrease</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids to the pro-apoptotic effects of bortezomib and of  <span class="marker" data-anno-id="0" data-anno-label="P1">cisplatin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">pemetrexed</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.</u></h4>To investigate the underlying causes of chemoresistance in malignant pleural mesothelioma, we have studied mesothelioma cell lines as 3D spheroids, which acquire increased chemoresistance compared to 2D monolayers. We asked whether the gene expression of 3D spheroids would reveal mechanisms of resistance. To address this, we measured gene expression of three mesothelioma cell lines, M28, REN and VAMT, grown as 2D monolayers and 3D spheroids. A total of 209 genes were differentially expressed in common by the three cell lines in 3D (138 upregulated and 71 downregulated), although a clear resistance pathway was not apparent. We then compared the list of 3D genes with two publicly available datasets of gene expression of 56 pleural mesotheliomas compared to normal tissues. Interestingly, only three genes were increased in both 3D spheroids and human tumors: argininosuccinate synthase 1 (ASS1), annexin A4 (ANXA4) and major vault protein (MVP); of these, ASS1 was the only consistently upregulated of the three genes by qRT-PCR. To measure ASS1 protein expression, we stained 2 sets of tissue microarrays (TMA): one with 88 pleural mesothelioma samples and the other with additional 88 pleural mesotheliomas paired with matched normal tissues. Of the 176 tumors represented on the two TMAs, ASS1 was expressed in 87 (50%; staining greater than 1 up to 3+). For the paired samples, ASS1 expression in mesothelioma was significantly greater than in the normal tissues. <b style='color:DodgerBlue;'><i>Reduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ASS1</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>siRNA</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>sensitized</i></b> <b style='color:DodgerBlue;'><i>mesothelioma</i></b> <b style='color:DodgerBlue;'><i>spheroids</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pro-apoptotic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although mesothelioma is considered by many to be an ASS1-deficient tumor, our results show that ASS1 is elevated at the mRNA and protein levels in mesothelioma 3D spheroids and in human pleural mesotheliomas. We also have uncovered a survival role for ASS1, which may be amenable to targeting to undermine mesothelioma multicellular resistance. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  In conclusion , the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">thalidomide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclosporine</span>  in subtherapeutic doses may be useful for the treatment of skin allografts . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits.</u></h4>The present study evaluated the effects of <b style='color:Tomato;'><i>thalidomide</i></b>, <b style='color:Tomato;'><i>cyclosporin</i></b>e, and <b style='color:Tomato;'><i>diclofenac</i></b> on skin allograft survival in 42 rabbits divided into the following groups (n = 6): group 1, autograft control; group 2, allograft control; group 3, allografts under <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d); group 4, allografts under sodium <b style='color:Tomato;'><i>diclofenac</i></b> (2 mg/kg/d); group 5, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (10 mg/kg/d); group 6, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d); group 7, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d) plus <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d). The drugs were given via the orogastric tube the day before transplantation and daily during the postoperative period. Total circular skin grafts from the ear were exchanged between California and White New Zealand rabbits. <b style='color:Tomato;'><i>cyclosporin</i></b>e (10 mg/kg/d) increased allograft survival, an effect that was comparable to <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d) plus <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d). <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>diclofenac</i></b> given alone had minimally significant effects on the mean survival of skin allografts. The number of eosinophils around the necrotic skin was higher in the <b style='color:Tomato;'><i>diclofenac</i></b> group. The group receiving <b style='color:Tomato;'><i>cyclosporin</i></b>e combined with <b style='color:Tomato;'><i>thalidomide</i></b> displayed the lowest number of eosinophils surrounding the allograft. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conclusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subtherapeutic</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>useful</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>skin</i></b> <b style='color:DodgerBlue;'><i>allografts</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  One group was given  <span class="marker" data-anno-id="0" data-anno-label="C3">enalapril</span>  ( EN ) 50 mg/l dissolved in the drinking water ; the second received  <span class="marker" data-anno-id="1" data-anno-label="C3">lovastatin</span>  ( L ) 15 mg/kg given daily by gavage ; the third received both agents ; the fourth was left untreated , and the final group received no puromycin and served as the control group . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The combination of lovastatin and enalapril in a model of progressive renal disease.</u></h4><b style='color:Tomato;'><i>puromycin</i></b>-induced nephrotic syndrome is an animal model of progressive renal disease. Both angiotensin converting enzyme inhibitors and lipid-lowering agents have been used to preserve renal structure and function in this model, although neither completely prevents progression. We tested the hypothesis that the combination of the two agents would be more protective than either alone. Rats were divided into five groups; all were uninephrectomized. Four groups were given <b style='color:Tomato;'><i>puromycin</i></b> at a dose of 10 mg/100 g body weight (BW) with additional doses of 4 mg/100 g BW given intraperitoneally at 4, 5, and 6 weeks thereafter. <b style='color:DodgerBlue;'><i>One</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/l</i></b> <b style='color:DodgerBlue;'><i>dissolved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drinking</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>lovastatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>gavage</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fourth</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>left</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>final</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:MediumOrchid;'><i>puromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>served</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eight weeks after the initial dose of <b style='color:Tomato;'><i>puromycin</i></b>, glomerular filtration rate (GFR), as inulin clearance, and protein excretion were determined and blood was collected for cholesterol and triglycerides. Blood pressure was not different between any of the groups. At the end of the study period, serum cholesterol [mean +/- SD, 252 +/- 185 mg/dl (L), 135 +/- 101 mg/dl (L + EN)] and triglycerides (239 +/- 200, 148 +/- 158 mg/dl) were significantly lower (P < 0.001) in the <b style='color:Tomato;'><i>lovastatin</i></b>-treated groups than in the untreated <b style='color:Tomato;'><i>puromycin</i></b> group (535 +/- 255 mg/dl and 579 +/- 561 mg/dl, cholesterol and triglyceride, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Using the Killing-curve method , we tested the in vitro bactericidal activity of  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">fosfomycin</span>  alone or in combination with  <span class="marker" data-anno-id="1" data-anno-label="C1">vancomycin</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">teicoplanin</span>  at a concentration of 8 microg/mL , that is easily achievable in serum at standard dosing regimens , against seven methicillin-resistant Staphylococcus aureus strains , isolated from patients with well documented device-associated infections unresponsive to or relapsing after glycopeptide therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.</u></h4><b style='color:Tomato;'><i>fosfomycin</i></b> is a molecule that inhibits the early stage of peptidoglycan synthesis and shows a broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. <b style='color:DodgerBlue;'><i>Using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Killing-curve</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>bactericidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>fosfomycin</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vancomycin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>teicoplanin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>microg/mL</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>easily</i></b> <b style='color:DodgerBlue;'><i>achievable</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>dosing</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>methicillin-resistant</i></b> <b style='color:DodgerBlue;'><i>Staphylococcus</i></b> <b style='color:DodgerBlue;'><i>aureus</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>documented</i></b> <b style='color:DodgerBlue;'><i>device-associated</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>unresponsive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>relapsing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>glycopeptide</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> MICs of <b style='color:Tomato;'><i>vancomycin</i></b> ranged from 1 to 4 microg/mL, MICs of <b style='color:Tomato;'><i>teicoplanin</i></b> from 2 to 8 microg/mL; MICs of <b style='color:Tomato;'><i>fosfomycin</i></b> were 8 microg/mL for two strains and >128 microg/mL for the remaining strains. The seven strains proved tolerant when tested for <b style='color:Tomato;'><i>vancomycin</i></b> and <b style='color:Tomato;'><i>teicoplanin</i></b> used alone at 2x MIC concentration. <b style='color:Tomato;'><i>fosfomycin</i></b> was bactericidal (reduction of 2 log of the inoculum) only against the two susceptible strains. In all cases both <b style='color:Tomato;'><i>vancomycin</i></b> and <b style='color:Tomato;'><i>teicoplanin</i></b> in combination with <b style='color:Tomato;'><i>fosfomycin</i></b> developed bactericidal synergism already at a concentration of 1x MIC. If these results are confirmed by in vivo experiments, the combination of <b style='color:Tomato;'><i>fosfomycin</i></b> with glycopeptides might be useful for treating device-associated infections, and in preventing the phenomenon of increasing MICs for glycopeptides.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  The remaining 76 patients did not receive anti-thymocyte globulin but were given  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">cyclosporine</span>  A and  <span class="marker" data-anno-id="1" data-anno-label="C1">methotrexate</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">mycophenolate</span>  mofetil ( group 3 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.</u></h4>The impact of the intensity of graft-versus-host-disease immunoprophylaxis on transplantation outcomes in patients undergoing transplantation following reduced-intensity conditioning is unclear. This study addresses this issue in 228 adult patients above 50 years of age with acute myeloid leukemia in first complete remission given peripheral blood stem cells from HLA-identical siblings after <b style='color:Tomato;'><i>fludarabine</i></b> and 2 days of intravenous <b style='color:Tomato;'><i>busulfan</i></b> reduced-intensity conditioning. A total of 152 patients received anti-thymocyte globulin, either in combination with <b style='color:Tomato;'><i>cyclosporin</i></b>e A in 86 patients (group 1), or with <b style='color:Tomato;'><i>cyclosporin</i></b>e A and <b style='color:Tomato;'><i>mycophenolate</i></b> mofetil or short course <b style='color:Tomato;'><i>methotrexate</i></b> in 66 patients (group 2). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>remaining</i></b> <b style='color:DodgerBlue;'><i>76</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>anti-thymocyte</i></b> <b style='color:DodgerBlue;'><i>globulin</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Incidences of grade II-IV acute graft-versus-host-disease were comparable in the three groups (16.5%, 29.5% and 19.5% in groups 1, 2 and 3, respectively, P=0.15). In multivariate analysis, the absence of anti-thymocyte globulin was the only factor associated with a higher risk of chronic graft-versus-host-disease (P=0.005), while the use of triple immunosuppression (group 3) was associated with an increased risk of relapse (P=0.003). In comparison to anti-thymocyte globulin and <b style='color:Tomato;'><i>cyclosporin</i></b>e A alone, the other two strategies of graft-versus-host-disease prophylaxis were associated with reduced leukemia-free survival and overall survival (P=0.001 for each parameter), independently of the dose of anti-thymocyte globulin. These data suggest that fine tuning of the intensity of this prophylaxis can affect the outcome of transplantation and that anti-thymocyte globulin and <b style='color:Tomato;'><i>cyclosporin</i></b>e A alone should be the preferred combination with the <b style='color:Tomato;'><i>fludarabine</i></b>-<b style='color:Tomato;'><i>busulfan</i></b> reduced-intensity conditioning regimen and sibling donors. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Propranolol</span>  significantly decreased the maximum plasma concentration ( Cmax ) and area under the plasma concentration-time curve ( AUC ) of  <span class="marker" data-anno-id="1" data-anno-label="C1">lacidipine</span>  ( by 38 % and 42 % , respectively ) whereas lacidipine significantly increased the Cmax and AUC of propranolol ( by 35 % and 26 % , respectively ) ; neither the time to maximum plasma concentration ( tmax ) nor the terminal half-life ( t 1/2 ) were affected . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers.</u></h4>The pharmacokinetic and pharmacodynamic profiles of lacidipine, a 1,4-dihydropyridine calcium antagonist, and the beta-adrenoceptor blocker <b style='color:Tomato;'><i>propranolol</i></b> were determined alone and in combination in 24 healthy male volunteers. One group (I) of 12 subjects received a single oral dose of 4 mg lacidipine on two separate occasions, which was taken together with a single oral dose of either 160 mg <b style='color:Tomato;'><i>propranolol</i></b> or placebo; a second group (II) of 12 subjects received <b style='color:Tomato;'><i>propranolol</i></b> on two occasions, taken with either lacidipine or placebo. <b style='color:MediumOrchid;'><i>Propranolol</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Cmax</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>lacidipine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>38</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>42</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>lacidipine</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Cmax</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>neither</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>tmax</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>nor</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>terminal</i></b> <b style='color:DodgerBlue;'><i>half-life</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>t</i></b> <b style='color:DodgerBlue;'><i>1/2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>affected</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With regard to the pharmacodynamics, in Group I, there was a greater reduction in supine systolic blood pressure (6 mm Hg) and diastolic blood pressure (4 mm Hg) compared to the reduction produced by lacidipine alone, and pulse rate was approximately 5 beats/min less. In Group II, a significantly greater reduction (6 mm Hg) in supine systolic blood pressure compared to the reduction produced by <b style='color:Tomato;'><i>propranolol</i></b> alone occurred, but there was no marked difference in supine diastolic blood pressure and pulse rate. In conclusion, a modest pharmacokinetic and pharmacodynamic interaction is evident and should be evaluated further in patients with hypertension.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  For antibiotic treatment , mice were administered a mixture of  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">ciprofloxacin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">metronidazole</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">vancomycin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Dietary soyasaponin attenuates 2,4-dinitrofluorobenzene-induced contact hypersensitivity via gut microbiota in mice.</u></h4>Soyasaponins (SSs) are abundant in soybeans and display inhibitory activity against contact hypersensitivity (CHS), which is often used as a mouse model for allergic contact dermatitis (ACD); however, their therapeutic mechanisms remain unknown. Here, we attempted to clarify the role of gut microbiota in the inhibition of CHS by dietary soyasaponins. <b style='color:DodgerBlue;'><i>For</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vancomycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These antibiotics and SSs were given to mice via drinking water 3-weeks prior to CHS induction with 2,4-dinitrofluorobenzene, and the mice were analysed for ear swelling, tissue oedema, infiltration of Gr-1-positive immune cells, the composition of faecal microbiota and regulatory T (T</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Because gemcitabine has been considered a standard treatment for advanced pancreatic cancer for the past decade , several randomized trials have tested the combination of  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">gemcitabine</span>  plus a second agent , including platinum based agents , topoisomerase inhibitors , taxanes ,  <span class="marker" data-anno-id="1" data-anno-label="C1">bevacizumab</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C2">cetuximab</span>  , as biologically " targeted " agents . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.</u></h4>Pancreatic adenocarcinoma remains a treatment-refractory cancer. Although pancreatic adenocarcinoma is only the 10th most common cause of new cancer in the United States, it is the fourth most common cause of cancer-related death. Most cases are not suitable for resection and a majority is metastatic at presentation. <b style='color:Tomato;'><i>gemcitabine</i></b>, with or without <b style='color:Tomato;'><i>erlotinib</i></b>, has been the standard chemotherapy in this setting but the benefit is only modest. <b style='color:DodgerBlue;'><i>Because</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>past</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>several</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topoisomerase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>taxanes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>biologically</i></b> <b style='color:DodgerBlue;'><i>"</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>"</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> At large this approach has not been successful and novel strategies are clearly needed. In this article, the authors summarizes the data from the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including: Abstract #175 (review of survival data in a large cohort); Abstract #286 (rapid change in prescriber patterns after the suggestion of benefit of a new regimen, FOLFIRINOX); Abstracts #238, #277, #304, and #315 (phase II trials looking at combinations that utilized EGFR blockade); Abstracts #221, #266, and #284 (phase I/II trials including VEGF blockade, anticoagulation, and traditional Chinese medicines).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  No synergism was found against Pneumococci and Meningococci but also no antagonism of the lower MIC and MBC values seen with  <span class="marker" data-anno-id="0" data-anno-label="C1">ampicillin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">penicillin</span>  G. The combination of  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">chloramphenicol</span>  with either  <span class="marker" data-anno-id="3" data-anno-label="P1">penicillin</span>  or  <span class="marker" data-anno-id="4" data-anno-label="P2">ampicillin</span>  constitutes a clinically successful therapeutic regimen which is now also proven by in vitro investigations . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Bactericidal action of chloramphenicol and synergism with beta-lactam antibiotics].</u></h4>Excellent clinical results were observed with the combination therapy of <b style='color:Tomato;'><i>chloramphenicol</i></b> with beta-lactam-antibiotics in the treatment of purulent meningitis. This came as a surprise as bacteriostatic antibiotics like <b style='color:Tomato;'><i>chloramphenicol</i></b> are commonly thought to antagonize the bactericidal action of penicillin or <b style='color:Tomato;'><i>ampicillin</i></b>. We reevaluated the mode of action of <b style='color:Tomato;'><i>chloramphenicol</i></b> against the three most common meningeal pathogens after the newborn period. <b style='color:Tomato;'><i>chloramphenicol</i></b> was found to be bactericidal against H. influenzae, Streptococcus pneumoniae and Neisseria meningitidis at clinically achievable levels in the CSF. In addition <b style='color:Tomato;'><i>chloramphenicol</i></b> showed synergistic action with <b style='color:Tomato;'><i>ampicillin</i></b> against H. influenzae which can possess clinical relevance particularly with the high inoculum of 10(7) organisms/ml which is frequently seen in bacterial meningitis. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>synergism</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Pneumococci</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Meningococci</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>antagonism</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>MIC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MBC</i></b> <b style='color:DodgerBlue;'><i>values</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>G.</i></b> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>chloramphenicol</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>constitutes</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>investigations</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Bendamustine</span>  is effective both with  <span class="marker" data-anno-id="1" data-anno-label="P1">rituximab</span>  and as a monotherapy in rituximab-refractory patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.</u></h4><b style='color:Tomato;'><i>bendamustine</i></b> is a water-soluble, bifunctional chemotherapeutic agent with characteristics of both an alkylator and a purine analog. <b style='color:Tomato;'><i>bendamustine</i></b> combined with <b style='color:Tomato;'><i>rituximab</i></b> in vitro shows synergistic effects against various leukemia and lymphoma cell lines. Clinical trials supporting these results show that <b style='color:Tomato;'><i>bendamustine</i></b> plus <b style='color:Tomato;'><i>rituximab</i></b> is highly effective in relapsed and refractory patients with indolent lymphoma. The results have been found in <b style='color:Tomato;'><i>rituximab</i></b>-naive, <b style='color:Tomato;'><i>rituximab</i></b>-pretreated, and <b style='color:Tomato;'><i>rituximab</i></b>-refractory patients with excellent response rates and toxicity profiles. <b style='color:MediumOrchid;'><i>Bendamustine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rituximab-refractory</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Interim results from a phase III, randomized trial comparing <b style='color:Tomato;'><i>bendamustine</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> to a standard CHOP (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b>) and <b style='color:Tomato;'><i>rituximab</i></b> regimen suggest that combination <b style='color:Tomato;'><i>bendamustine</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> may provide a viable alternative for treatment of many indolent lymphomas.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Following corneal scrapings and culture , topical 0.5 %  <span class="marker" data-anno-id="0" data-anno-label="C1">moxifloxacin</span>  and 0.5 %  <span class="marker" data-anno-id="1" data-anno-label="C1">tobramycin</span>  were administered hourly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.</u></h4>A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>corneal</i></b> <b style='color:DodgerBlue;'><i>scrapings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>culture</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>moxifloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>hourly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% <b style='color:Tomato;'><i>moxifloxacin</i></b> was given every hour and 0.5% <b style='color:Tomato;'><i>tobramycin</i></b> was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Combination treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">cetuximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">nystatin</span>  selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.</u></h4>Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of <b style='color:Tomato;'><i>cetuximab</i></b> endocytosis and its influence on <b style='color:Tomato;'><i>cetuximab</i></b> uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that <b style='color:Tomato;'><i>nystatin</i></b>, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether <b style='color:Tomato;'><i>nystatin</i></b> regulates the uptake and efficacy of <b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-based antibody-drug conjugates (<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs). In vitro and in vivo efficacies of <b style='color:Tomato;'><i>nystatin</i></b> on the uptake and activity of <b style='color:Tomato;'><i>cetuximab</i></b>/<b style='color:Tomato;'><i>cetuximab</i></b>-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by <b style='color:Tomato;'><i>nystatin</i></b> enhanced <b style='color:Tomato;'><i>cetuximab</i></b> internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nystatin</i></b> <b style='color:DodgerBlue;'><i>selectively</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>translating</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>potentiated</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A431</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>A549</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nystatin-enhanced internalization of <b style='color:Tomato;'><i>cetuximab</i></b> further improved the uptake and potency of <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>-<b style='color:Tomato;'><i>methotrexate</i></b> conjugates in EGFR-positive <b style='color:Tomato;'><i>cetuximab</i></b>-resistant tumors. Combination therapy with <b style='color:Tomato;'><i>nystatin</i></b> plus either <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>cetuximab</i></b>-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with <b style='color:Tomato;'><i>nystatin</i></b> can potentiate the delivery and efficacy of these EGFR-targeted agents. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The effects of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">chenodeoxycholic</span>  acid ( CDCA ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin</span>  on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chenodeoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>cholestanol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low-density</i></b> <b style='color:DodgerBlue;'><i>lipoprotein</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LDL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lathosterol</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cerebrotendinous</i></b> <b style='color:DodgerBlue;'><i>xanthomatosis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>CDCA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of <b style='color:Tomato;'><i>simvastatin</i></b> from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg <b style='color:Tomato;'><i>simvastatin</i></b>. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg <b style='color:Tomato;'><i>simvastatin</i></b>). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg <b style='color:Tomato;'><i>simvastatin</i></b> daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">anthracyclines</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and doxorubicin in metastatic breast cancer.</u></h4>For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anthracycline-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fact</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efforts</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>combine</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracyclines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several studies aiming to define the optimal dose and schedule of combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> are reviewed, with special emphasis on the short-infusion trials.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Additivity , synergy , or competition was observed with  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">MIS</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">AzadC</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P3">doxorubicin</span>  , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.</u></h4>Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) downstream of Akt, rhMIS and <b style='color:Tomato;'><i>rapamycin</i></b> combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A <b style='color:Tomato;'><i>paclitaxel</i></b>-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. <b style='color:DodgerBlue;'><i>Additivity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>competition</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>AzadC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>MIS</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  , but also on other modifications and the advisability of adding  <span class="marker" data-anno-id="1" data-anno-label="C1">bevacizumab</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.</u></h4>The <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with <b style='color:Tomato;'><i>carboplatin</i></b> dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/<b style='color:Tomato;'><i>paclitaxel</i></b>. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of <b style='color:Tomato;'><i>paclitaxel</i></b>, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the <b style='color:Tomato;'><i>carboplatin</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> doublet; preventive measures must be considered for patients who would otherwise refuse treatment. <b style='color:DodgerBlue;'><i>Several</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>fueled</i></b> <b style='color:DodgerBlue;'><i>debates</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>optimal</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>q3-weeks</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>modifications</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>advisability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by <b style='color:Tomato;'><i>carboplatin</i></b>, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying <b style='color:Tomato;'><i>paclitaxel</i></b> dose and schedule and the addition of <b style='color:Tomato;'><i>bevacizumab</i></b> are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of  <span class="marker" data-anno-id="0" data-anno-label="C1">cladribine</span>  followed by monitored  <span class="marker" data-anno-id="1" data-anno-label="C1">topotecan</span>  in pediatric patients with recurrent/refractory AML . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.</u></h4>Individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. Topotecan dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the <b style='color:Tomato;'><i>topotecan</i></b> systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the <b style='color:Tomato;'><i>topotecan</i></b> dosing. The aim of the study was to estimate the <b style='color:Tomato;'><i>topotecan</i></b> exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>goal</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>correct</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>monitored</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent/refractory</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total <b style='color:Tomato;'><i>topotecan</i></b> in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the <b style='color:Tomato;'><i>topotecan</i></b> dosing was selected so as to achieve the final AUC value of 140±20 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the <b style='color:Tomato;'><i>topotecan</i></b> dosing in children with AML.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  In patients with NPSLE , the use of high-dose  <span class="marker" data-anno-id="0" data-anno-label="P1/P2/P3">corticosteroids</span>  is recommended in combination with immunosuppressants , such as  <span class="marker" data-anno-id="1" data-anno-label="P1">mycophenolate</span>  <span class="marker" data-anno-id="2" data-anno-label="P3">mofetil</span>  and intravenous  <span class="marker" data-anno-id="3" data-anno-label="P2">cyclophosphamide</span>  pulse therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neuropsychiatric Systemic Lupus Erythematosus].</u></h4>Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NPSLE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>corticosteroids</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>immunosuppressants</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  These studies suggest a slight advantage to the combined approaches that contain  <span class="marker" data-anno-id="0" data-anno-label="P1">flutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">bicalutamide</span>  , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The selection of hormonal therapy in prostate cancer: who, when, and for how long?</u></h4>Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>slight</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>approaches</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>contain</i></b> <b style='color:MediumOrchid;'><i>flutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lack</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dramatic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>outcome</i></b> <b style='color:DodgerBlue;'><i>makes</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>reasonable</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, <b style='color:Tomato;'><i>ketoconazole</i></b>, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We examined the feasibility and safety of using  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>examined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>hematopoietic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AHST</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>carmustine</i></b>, and <b style='color:Tomato;'><i>thiotepa</i></b>. After AHST, patients received weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for 12 doses and <b style='color:Tomato;'><i>trastuzumab</i></b> every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. </div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Dual antiplatelet therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">clopidogrel</span>  ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy.</u></h4>Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (<b style='color:Tomato;'><i>ticlopidine</i></b> or <b style='color:Tomato;'><i>clopidogrel</i></b>) is more effective than <b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>heparin</i></b> and extended <b style='color:Tomato;'><i>warfarin</i></b> therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. <b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>antiplatelet</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>thienopyridine</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>hematologic</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>subacute</i></b> <b style='color:DodgerBlue;'><i>stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bare-metal</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>late-stent</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>drug-eluting</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (<b style='color:Tomato;'><i>aspirin</i></b> plus <b style='color:Tomato;'><i>clopidogrel</i></b>) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens ,  <span class="marker" data-anno-id="0" data-anno-label="P1">apalutamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">enzalutamide</span>  , when used in combination with  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">ADT</span>  , have demonstrated a significant benefit in metastasis-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent trends in the management of advanced prostate cancer.</u></h4>Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or <b style='color:Tomato;'><i>abiraterone</i></b> acetate to ADT results in significant survival advantage as compared with ADT alone. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>non-metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M0</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>second-generation</i></b> <b style='color:DodgerBlue;'><i>anti-androgens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>apalutamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ADT</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastasis-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Phase Ib Study of the Oral Proteasome Inhibitor  <span class="marker" data-anno-id="0" data-anno-label="P1">Ixazomib</span>  ( MLN9708 ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">Fulvestrant</span>  in Advanced ER+ Breast Cancer Progressing on Fulvestrant . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51 days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of  <span class="marker" data-anno-id="0" data-anno-label="P1">alemtuzumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rituximab</span>  , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h4>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Compared with risedronate alone , at 6 months ,  <span class="marker" data-anno-id="0" data-anno-label="P1">risedronate</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">atorvastatin</span>  produced significantly greater increases in the bone mineral density of the lumbar spine ( 1.58 % versus 0.75 % , p < 0.05 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.</u></h4>Recent data suggest that statins used in the treatment of hypercholesterolaemia decrease fracture risk. In this study, we aimed to investigate prospectively whether statins have an additive effect to bisphosphonates (<b style='color:Tomato;'><i>risedronate</i></b>) according to the primary hypothesis that the addition of <b style='color:Tomato;'><i>atorvastatin</i></b> to <b style='color:Tomato;'><i>risedronate</i></b> would produce an increase, from baseline, in lumbar vertebrae and total hip BMD that was greater than that observed with <b style='color:Tomato;'><i>risedronate</i></b> alone. ### methods A total of 120 hypercholesterolaemic postmenopausal women with osteoporosis or osteopenia were randomized to receive <b style='color:Tomato;'><i>risedronate</i></b> (5 mg/day) or <b style='color:Tomato;'><i>risedronate</i></b> (5 mg/day) plus <b style='color:Tomato;'><i>atorvastatin</i></b> (20 mg/day). Changes in bone mineral density in the lumbar spine and hip, and serum lipid and glucose metabolism changes were assessed. ### results <b style='color:DodgerBlue;'><i>Compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>risedronate</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>risedronate</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>increases</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>mineral</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lumbar</i></b> <b style='color:DodgerBlue;'><i>spine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1.58</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>0.75</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We found no difference after therapy in BMD of the total hip (1.2% versus 1.1%). <b style='color:Tomato;'><i>risedronate</i></b> plus <b style='color:Tomato;'><i>atorvastatin</i></b> therapy had favorable effects on the serum lipid profile: LDL and total cholesterol. Serum fasting glucose and HbA1c levels were not affected during the treatments. ### conclusion Statins have modest additive effects to bisphosphonates in improving lumbar spine bone mineral density in hypercholesterolaemic postmenopausal women with established osteoporosis-osteopenia. A long-term study with adequate sample size is necessary to assess the effects of statins -- in combination or alone -- on the bones and prevention of fractures.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="N1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="N1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h4>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Patients who had pathologically been proven to have measurable lesions were treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  ( 200 mg/m(2 ) for 3 h ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h4>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Eligible patients received  <span class="marker" data-anno-id="0" data-anno-label="P1">ramucirumab</span>  ( 10mg/kg ) +  <span class="marker" data-anno-id="1" data-anno-label="P1">dacarbazine</span>  ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h4>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-naïve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="P2">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  , in vitro and in vivo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 μg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 μg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 μg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">Gemcitabine</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclosporine</span>  or with  <span class="marker" data-anno-id="2" data-anno-label="P2">tacrolimus</span>  exerts a synergistic effect and induces tolerance in the rat . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tacrolimus</i></b> <b style='color:DodgerBlue;'><i>exerts</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>induces</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>This study investigated the effect of the antineoplastic agent <b style='color:Tomato;'><i>gemcitabine</i></b> (dFdC) in combination with <b style='color:Tomato;'><i>cyclosporin</i></b>e (CsA) or with FK506 on acute heart allograft rejection in a rat model. ### methods Transplantations were performed in the fully allogeneic Lewis-to-Brown Norway strain combination. dFdC, CsA, and FK506 single-drug therapy and combinations of dFdC with CsA and FK506 were administered at various dosages starting on day 1 to prevent and on day 4 to treat acute rejection until day 20. Animals who did not reject their graft were intraperitoneally injected with 108 splenic donor-type lymphocytes. In addition, Lewis and third-party skin grafts were transplanted to these animals. ### results Mean graft survival times under CsA, FK506, and dFdC monotherapy were 18.3/63.7 days (1 mg/5 mg per kg), 41.7 days, and 24.7/38.7 days (100 microg/150 microg per kg), respectively. CsA and FK506 in combination with dFdC prolonged graft survival to more than 100 days (CsA) and more than 95.2 days (FK506). Graft survival after treatment of an ongoing rejection was 21.5/38.3 days for CsA (1 mg/5 mg per kg) and 17.7/59.2 days for dFdC (100 microg/150 microg per kg). The combination of CsA+dFdC prompted indefinite survival of five of six hearts. Lymphocyte inoculation did not induce graft rejection. Notably, none of the Lewis, but all third-party, skin grafts were rejected immediately. Histomorphologic analysis of grafted hearts, however, demonstrated typical features of chronic rejection. ### conclusions The combination of CsA and FK506 with low-dose dFdC exerts a synergistic effect in the prevention and treatment of acute allograft rejection in this model. Although chronic rejection could not be prevented, strain-specific tolerance was achieved. Therefore, combining standard immunosuppressants with dFdC is a novel, promising strategy for prevention and treatment of acute allograft rejection.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Cardiac events occurred after posaconazole administration , incriminating  <span class="marker" data-anno-id="0" data-anno-label="N1">posaconazole</span>  use , alone or in combination with  <span class="marker" data-anno-id="1" data-anno-label="N1">voriconazole</span>  , as the culpable agent . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report.</u></h4>We present the case of a septic patient with severe immunodeficiency, who developed QT interval prolongation followed by episodes of lethal cardiac arrhythmia. <b style='color:DodgerBlue;'><i>Cardiac</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>incriminating</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>culpable</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Case Report A 26-year-old female patient underwent orthopedic surgery to remove ectopic calcifications in her left hip joint. On the first post-operative day she became septic due to a surgical wound infection. Despite being treated according to the therapeutic protocols for sepsis, no clinical improvement was noticed and further assessment revealed an underlying immunodeficiency. Considering the underlying immunodeficiency and to that point poor clinical response, an antifungal agent was added to the antibiotic regiment. Following discontinuation of multiple antifungal agents due to adverse effects, <b style='color:Tomato;'><i>posaconazole</i></b> was administered. <b style='color:Tomato;'><i>posaconazole</i></b> oral intake was followed by episodes of bradycardia and QT interval prolongation. The patient suffered continuous incidents of cardiac arrest due to polymorphic ventricular tachycardia (torsades des pointes) that degenerated to lethal ventricular fibrillation. <b style='color:Tomato;'><i>posaconazole</i></b> was immediately discontinued and a temporary pacemaker was installed. The patient finally recovered without any neurological deficit, and was discharged in a good clinical status. ### conclusions Close cardiac monitoring is recommended in cases where <b style='color:Tomato;'><i>posaconazole</i></b> administration is combined with coexisting risk factors, as they may lead to severe ECG abnormalities and cardiac arrhythmias such as long QT interval syndrome and torsades de pointes. <b style='color:Tomato;'><i>posaconazole</i></b> interactions with medications metabolized via the CYP3A4 pathway should be considered an additional risk factor for lethal cardiac incidents.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  chemotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Kit67</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p53</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TopoIIa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>GSTP1</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>curatively</i></b> <b style='color:DodgerBlue;'><i>resected</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. ### methodology The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. ### results p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. ### conclusions p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. A favorable effect of <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> might therefore be expected in patients that do not express p53.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The standard adjuvant treatment of colon cancer is  <span class="marker" data-anno-id="0" data-anno-label="C1">fluorouracil</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  ( FL ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>oxaliplatin</i></b> improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> in the postoperative adjuvant setting. ### methods We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with <b style='color:Tomato;'><i>oxaliplatin</i></b> for six months. The primary end point was disease-free survival. ### results A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b>, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). ### conclusions Adding <b style='color:Tomato;'><i>oxaliplatin</i></b> to a regimen of <b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> improves the adjuvant treatment of colon cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Thirty-four patients ( 4 patients with stage IIIb , 30 patients in stage IV ) , with median age 66 and performance status 0 - 1 , were administered  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  , 175 mg/m(2 ) in a 3-h infusion rate on day 1 and  <span class="marker" data-anno-id="1" data-anno-label="P1">vinorelbine</span>  , 25 mg/m(2 ) in a 10-min infusion rate on days 1 , and 8 with G-CSF and EPO support . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.</u></h4><b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study. ### Patients And Methods <b style='color:DodgerBlue;'><i>Thirty-four</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>performance</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>10-min</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>G-CSF</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>EPO</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients). ### conclusion The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Phase I study of  <span class="marker" data-anno-id="0" data-anno-label="N1">decitabine</span>  alone or in combination with  <span class="marker" data-anno-id="1" data-anno-label="N1">valproic</span>  acid in acute myeloid leukemia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To determine an optimal biologic dose (OBD) of <b style='color:Tomato;'><i>decitabine</i></b> as a single agent and then the maximum-tolerated dose (MTD) of <b style='color:Tomato;'><i>valproic</i></b> acid (VA) combined with <b style='color:Tomato;'><i>decitabine</i></b> in acute myeloid leukemia (AML). ### Patients And Methods Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received <b style='color:Tomato;'><i>decitabine</i></b> alone for 10 days. To determine the MTD, 11 patients received <b style='color:Tomato;'><i>decitabine</i></b> (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). ### results The OBD of <b style='color:Tomato;'><i>decitabine</i></b> was 20 mg/m(2)/d intravenously, with limited nonhematologic toxicity. In patients treated with <b style='color:Tomato;'><i>decitabine</i></b> plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P < or = .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for <b style='color:Tomato;'><i>decitabine</i></b> alone or with VA. ### conclusion Low-dose <b style='color:Tomato;'><i>decitabine</i></b> was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of <b style='color:Tomato;'><i>decitabine</i></b> (20 mg/m(2)/d for 10 days) alone or with an alternative deacetylating agent are warranted.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Early discontinuation of clopidogrel results in a transient rebound increase in risk of recurrence in acute coronary syndromes , but there are no published data on any similar rebound effect in patients with TIA or stroke that might inform the design of clinical trials of  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">clopidogrel</span>  in the acute phase . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.</u></h4>The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke. <b style='color:DodgerBlue;'><i>Early</i></b> <b style='color:DodgerBlue;'><i>discontinuation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>transient</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>syndromes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>TIA</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>stroke</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>inform</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> (both 75 mg daily) was given to high-risk patients with TIA or minor ischemic stroke seen acutely in the EXPRESS study clinic from April 1, 2002, to March 31, 2009. <b style='color:Tomato;'><i>clopidogrel</i></b> was stopped after 30 days and <b style='color:Tomato;'><i>aspirin</i></b> continued. Recurrent events were ascertained at face-to-face follow-up. ### results A total of 320 patients were prescribed a 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> acutely after TIA or minor stroke. There were 5 recurrent ischemic strokes and 7 TIAs during the <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> treatment period, but no strokes and 4 TIAs during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b>. A similar temporal trend in stroke risk was seen in the 487 patients prescribed <b style='color:Tomato;'><i>aspirin</i></b> alone in the acute phase, with 12 and 5 strokes in the equivalent time periods. The upper 95% confidence intervals of the observed 0% risk of stroke during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b> was 1.15% overall. ### conclusion Although larger studies are required, our findings suggest there is unlikely to be a large rebound effect after discontinuation of a 30-day course of <b style='color:Tomato;'><i>clopidogrel</i></b> in acute TIA and minor ischemic stroke. However, planned trials of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> in the acute phase after TIA or stroke should still follow-up beyond the cessation of <b style='color:Tomato;'><i>clopidogrel</i></b> treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Patients received  <span class="marker" data-anno-id="0" data-anno-label="N1">docetaxel</span>  35 mg/m(2 ) and  <span class="marker" data-anno-id="1" data-anno-label="N1">irinotecan</span>  60 mg/m(2 ) , intravenously , on Days 1 and 8 , every 21 days , until disease progression . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.</u></h4><b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. ### methods Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. ### results Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were <b style='color:Tomato;'><i>paclitaxel</i></b>-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). ### conclusions <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over <b style='color:Tomato;'><i>docetaxel</i></b> alone or platinum-based regimens.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Most patients with advanced ovarian cancer achieve a clinical complete remission following cytoreductive surgery and chemotherapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Gemcitabine and carboplatin in second-line ovarian cancer.</u></h4> <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>cytoreductive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a majority of these patients will ultimately recur, and second-line treatment for this group of patients is an important aspect of management of this disease as well as an area of active clinical investigation. Until recently, for patients with platinum-sensitive ovarian cancer (more than 6-month disease-free interval), chemotherapy with single-agent <b style='color:Tomato;'><i>carboplatin</i></b> was frequently recommended. However, two recent prospective randomized trials have shown that combination chemotherapy produces higher response rates and improvement in progression-free survival compared with treatment with single-agent <b style='color:Tomato;'><i>carboplatin</i></b>. One trial compared treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> plus a platinum compound with re-treatment with platinum, and a second trial compared <b style='color:Tomato;'><i>carboplatin</i></b> plus <b style='color:Tomato;'><i>gemcitabine</i></b> re-treatment against <b style='color:Tomato;'><i>carboplatin</i></b> in patients with platinum-sensitive recurrent ovarian cancer. Both trials showed a 3-month improvement in progression-free survival in patients treated with the combination, as well as acceptable toxicity. In the absence of a prospective randomized trial comparing these two regimens in patients with platinum-sensitive recurrent ovarian cancer, the choice of which combination to use may depend on toxicity considerations.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Agents in clinical trials for subsets of MDS include  <span class="marker" data-anno-id="0" data-anno-label="P1">luspatercept</span>  , antibodies targeting CD33 , isocitrate dehydrogenase inhibitors , deacetylase inhibitors ,  <span class="marker" data-anno-id="1" data-anno-label="P1">venetoclax</span>  , and immunotherapies designed to overcome immune checkpoint inhibition . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.</u></h4>It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity. At present, treatments for MDS are usually administered as sequential monotherapy, but there is a trend toward clinical trials of combination therapies-in which new agents are added to a DNA hypomethylating agent backbone-for both upfront treatment and the treatment of relapsed/refractory disease. <b style='color:DodgerBlue;'><i>Agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MDS</i></b> <b style='color:DodgerBlue;'><i>include</i></b> <b style='color:MediumOrchid;'><i>luspatercept</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isocitrate</i></b> <b style='color:DodgerBlue;'><i>dehydrogenase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>deacetylase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>venetoclax</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>immunotherapies</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>overcome</i></b> <b style='color:DodgerBlue;'><i>immune</i></b> <b style='color:DodgerBlue;'><i>checkpoint</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Exposure of the saphenous veins to imipenem or  <span class="marker" data-anno-id="0" data-anno-label="N1">imipenem</span>  combined with  <span class="marker" data-anno-id="1" data-anno-label="N1">amphotericin</span>  B had no adverse effects on the viability of the endothelial cells with 12 h exposure . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effects of antibiotics on the endothelium of fresh and cryopreserved canine saphenous veins.</u></h4>To determine if antibiotic solutions for potential use in antimicrobial treatment of tissues were detrimental to cell viability, canine saphenous veins were exposed to three different antibiotic solutions at 37 degrees C for 12 h. Viability was determined by tissue culture, utilizing a limiting dilution assay. The antibiotic series included two formulations currently used for the preservation of heart valves and a new formulation containing <b style='color:Tomato;'><i>imipenem</i></b>, a broad spectrum beta-lactam. Currently used antibiotic regimes and <b style='color:Tomato;'><i>imipenem</i></b> with <b style='color:Tomato;'><i>gentamicin</i></b> resulted in a decrease of 30 to 50% of the viable endothelial cells within 12 h. <b style='color:DodgerBlue;'><i>Exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>saphenous</i></b> <b style='color:DodgerBlue;'><i>veins</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, veins exposed to <b style='color:Tomato;'><i>amphotericin</i></b> B were more susceptible to subsequent damage during freezing and thawing than veins frozen after incubation with either <b style='color:Tomato;'><i>imipenem</i></b> alone or <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b>. These studies indicate that <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b> is suitable for use with vein grafts.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  These results confirm that sequential  <span class="marker" data-anno-id="0" data-anno-label="P1">decitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  requires further investigation as a combination treatment for melanoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.</u></h4>Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the DNA damage detection branch, global genome repair (GGR). The key GGR component XPC does not respond to DNA damage in melanoma, the cause of this lack of response has not been investigated. In this study, we investigated the role of methylation in reduced XPC in melanoma. ### methods To reduce methylation and induce DNA-damage, melanoma cell lines were treated with <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, individually and sequentially. Global DNA methylation levels, XPC mRNA and protein expression and methylation of the XPC promoter were examined. Apoptosis, cell proliferation and senescence were also quantified. XPC siRNA was used to determine that the responses seen were reliant on XPC induction. ### results Treatment with high-dose <b style='color:Tomato;'><i>decitabine</i></b> resulted in global demethylation, including the the shores of the XPC CpG island and significantly increased XPC mRNA expression. Lower, clinically relevant dose of <b style='color:Tomato;'><i>decitabine</i></b> also resulted in global demethylation including the CpG island shores and induced XPC in 50% of cell lines. <b style='color:Tomato;'><i>decitabine</i></b> followed by DNA-damaging <b style='color:Tomato;'><i>carboplatin</i></b> treatment led to significantly higher XPC expression in 75% of melanoma cell lines tested. Combined sequential treatment also resulted in a greater apoptotic response in 75% of cell lines compared to <b style='color:Tomato;'><i>carboplatin</i></b> alone, and significantly slowed cell proliferation, with some melanoma cell lines going into senescence. Inhibiting the increased XPC using siRNA had a small but significant negative effect, indicating that XPC plays a partial role in the response to sequential <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. ### conclusions Demethylation using <b style='color:Tomato;'><i>decitabine</i></b> increased XPC and apoptosis after sequential <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  All the animals in the placebo group had tumors in each lobe compared with only 43 % each in the dorsolateral ( DLP ) and anterior prostate ( AP ) of the animals treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">raloxifene</span>  ( 10 mg/kg/day ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">nimesulide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.</u></h4>The chemopreventive efficacies of <b style='color:Tomato;'><i>raloxifene</i></b> and <b style='color:Tomato;'><i>nimesulide</i></b>, an anti-estrogen but with anti-androgen action and a cyclooxygenase-2 (COX-2) selective inhibitor, respectively, were evaluated in probasin/SV40 T antigen (Tag) transgenic (TG) rats. The treatment groups were placebo, <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m. in basal diet p.o.), <b style='color:Tomato;'><i>raloxifene</i></b> (slow-release pellets implanted s.c., 5 mg/kg/day), <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.), and <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.). Animals were killed at 17 weeks of age, and prostate tissues were harvested and weighed by lobes. Tissues were evaluated by histology, immunohistochemistry, and western blot analyses and blood was collected to measure the testosterone levels. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lobe</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>43</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsolateral</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anterior</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>raloxifene</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nimesulide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The total prostate weights and adenocarcinoma portions were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups, whereas atrophic glands were increased. There were no significant differences between the <b style='color:Tomato;'><i>nimesulide</i></b> alone and placebo groups or between the <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) alone and <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> group, suggesting a lack of cancer preventive effects of the COX-2 inhibitor in this animal model. PCNA positive rates in ventral prostate (VP) and DLP, and androgen receptor (AR) levels in VP were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups. Furthermore, circulating testosterone was decreased after <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> treatment. These results demonstrate that <b style='color:Tomato;'><i>raloxifene</i></b>, but not <b style='color:Tomato;'><i>nimesulide</i></b>, inhibits prostate carcinogenesis in SV40 Tag TG rats associated with a decline in circulating testosterone levels and a loss of AR expression, as well as an inhibition of cell proliferation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Overdose of  <span class="marker" data-anno-id="0" data-anno-label="C1">dolutegravir</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="C1">tenofovir</span>  disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Overdose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dolutegravir</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disaproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate/emtricitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suicide</i></b> <b style='color:DodgerBlue;'><i>attempt</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>21-year</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>A 21 year old MSM patient with newly diagnosed HIV infection was hospitalized in our department after ingestion of an overdose of his antiretroviral therapy (ART) comprising <b style='color:Tomato;'><i>dolutegravir</i></b> (DTG - Tivicay®) and <b style='color:Tomato;'><i>tenofovir</i></b> disaproxil fumarate/<b style='color:Tomato;'><i>emtricitabine</i></b> (Truvada®) in suicidal intention. On admission, the patient did not show any clinical signs of intoxication and laboratory findings were unremarkable. After 6 hours of intensive care monitoring, the patient was referred to a psychiatric clinic. 5 days after the day of intoxication, serum creatinine levels increased to high normal values (1.2 mg/dl). However, levels never exceeded the upper threshold. 8 and 12 weeks later, serum creatinine normalized to levels measured prior to the intoxication. No other adverse events occurred, and the patient does not suffer from permanent impairments.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Abiraterone</span>  acetate and  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Abiraterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pre-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>post-docetaxel</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mono-institutional</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> acetate (AA) and <b style='color:Tomato;'><i>prednisone</i></b> (PDN) outside clinical trials, and their association with survival outcomes. ### methods This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- ### results Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) ⩾ 10 ng/ml ( ### conclusions Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">ipilimumab</span>  combined therapy is among the most effective therapies for advanced melanoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.</u></h4> <b style='color:MediumOrchid;'><i>Nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Cells that were sequentially exposed to  <span class="marker" data-anno-id="0" data-anno-label="P1">rapamycin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">topotecan</span>  had significantly higher levels of cleaved caspase-8 , -3 , and PARP compared to those treated with topotecan alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells.</u></h4>The present study aimed to investigate the antitumor efficacy of combination of <b style='color:Tomato;'><i>topotecan</i></b> with <b style='color:Tomato;'><i>rapamycin</i></b>, a mTOR inhibitor, in cisplatin-resistant ovarian cancer cells A2780cis and COC1/DDP. Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to cisplatin using Western blotting. Cell proliferation was examined using MTT assay in vitro and a nude mouse model in vivo, respectively. Cell apoptosis and the relevant proteins were determined by flow cytometry and Western blotting. We found that the levels of phosphorylated mTOR, p70S6K, and 4E-BP1 were obviously higher in A2780cis and COC1/DDP cells than that in A2780 and COC1 cells. Pretreatment with <b style='color:Tomato;'><i>rapamycin</i></b> significantly enhanced the effects of <b style='color:Tomato;'><i>topotecan</i></b> in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells. <b style='color:DodgerBlue;'><i>Cells</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>sequentially</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cleaved</i></b> <b style='color:DodgerBlue;'><i>caspase-8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>-3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mice co-administered <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>topotecan</i></b> had significantly decreased terminal tumor burden without additional loss of bodyweight compared to the mice received <b style='color:Tomato;'><i>topotecan</i></b> alone. The results suggested that <b style='color:Tomato;'><i>rapamycin</i></b> sensitized A2780cis and COC1/DDP cells to <b style='color:Tomato;'><i>topotecan</i></b>-induced apoptosis and <b style='color:Tomato;'><i>rapamycin</i></b>-<b style='color:Tomato;'><i>topotecan</i></b> combination might have a value in treatment of cisplatin-resistant ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  CDM mice show decreased Homer1a and Homer1b/c mRNA expression in cortex and blood samples , while chronic treatment with  <span class="marker" data-anno-id="0" data-anno-label="C1">imipramine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">fluoxetine</span>  or acute ketamine application increases their level only in the cortex . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Antidepressant treatment is associated with epigenetic alterations of Homer1 promoter in a mouse model of chronic depression.</u></h4>Understanding the neurobiology of depression and the mechanism of action of therapeutic measures is currently a research priority. We have shown that the expression of the synaptic protein Homer1a correlates with depression-like behavior and its induction is a common mechanism of action of different antidepressant treatments. However, the mechanism of Homer1a regulation is still unknown. ### methods We combined the chronic despair mouse model (CDM) of chronic depression with different antidepressant treatments. Depression-like behavior was characterized by forced swim and tail suspension tests, and via automatic measurement of sucrose preference in IntelliCage. The Homer1 mRNA expression and promoter DNA methylation were analyzed in cortex and peripheral blood by qRT-PCR and pyrosequencing. ### results <b style='color:DodgerBlue;'><i>CDM</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>Homer1a</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Homer1b/c</i></b> <b style='color:DodgerBlue;'><i>mRNA</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cortex</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>samples</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluoxetine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>ketamine</i></b> <b style='color:DodgerBlue;'><i>application</i></b> <b style='color:DodgerBlue;'><i>increases</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cortex</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The quantitative analyses of the methylation of 7 CpG sites, located on the Homer1 promoter region containing several CRE binding sites, show a significant increase in DNA methylation in the cortex of CDM mice. In contrast, antidepressant treatments reduce the methylation level. ### limitations Homer1 expression and promotor methylation were not analyzed in different blood cell types. Other CpG sites of Homer1 promoter should be investigated in future studies. Our experimental approach does not distinguish between methylation and hydroxymethylation. ### conclusions We demonstrate that stress-induced depression-like behavior and antidepressant treatments are associated with epigenetic alterations of Homer1 promoter, providing new insights into the mechanism of antidepressant treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  A retrospective analysis was conducted on the clinical data of 122 advanced NSCLC patients with pleural effusion , and among them , 61 received thoracic hyperthermic perfusion with recombinant human  <span class="marker" data-anno-id="0" data-anno-label="P1">endostatin</span>  ( ES ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">nedaplatin</span>  ( Endostatin group ) , while the other 61 underwent thoracic hyperthermic perfusion with cisplatin alone ( Cisplatin group ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.</u></h4>To explore the efficacy and safety of thoracic hyperthermia perfusion with recombinant human <b style='color:Tomato;'><i>endostatin</i></b> plus <b style='color:Tomato;'><i>nedaplatin</i></b> in the treatment of pleural effusion in patients with advanced non-small cell lung cancer (NSCLC). ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>122</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>pleural</i></b> <b style='color:DodgerBlue;'><i>effusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>them</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>61</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>thoracic</i></b> <b style='color:DodgerBlue;'><i>hyperthermic</i></b> <b style='color:DodgerBlue;'><i>perfusion</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>endostatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ES</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nedaplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>Endostatin</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>61</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>thoracic</i></b> <b style='color:DodgerBlue;'><i>hyperthermic</i></b> <b style='color:DodgerBlue;'><i>perfusion</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Cisplatin</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The short-term efficacy, changes in the pleural effusion and serum immunological indicators before and after treatment, quality of life, and incidence of adverse reactions were compared between the two groups of patients. Finally, the progression of pleural effusion in patients were followed up and recorded. ### results After treatment, the overall response rate of patients in <b style='color:Tomato;'><i>endostatin</i></b> group was considerably higher than that in Cisplatin group (p=0.030). At 2 weeks after treatment, the level of alanine transferase (ALT) rose notably, while that of carcinoembryonic antigen (CEA) declined dramatically in both groups of patients, and the patients in <b style='color:Tomato;'><i>endostatin</i></b> group had markedly lower levels of ALT and CEA than those in Cisplatin group (p=0.007, p=0.003). After treatment, the Karnofsky Performance status (KPS) score of patients was prominently raised in the two groups, and <b style='color:Tomato;'><i>endostatin</i></b> group exhibited considerably higher KPS scores than Cisplatin group (p=0.045). The incidence rates of nausea and vomiting as well as diarrhea in <b style='color:Tomato;'><i>endostatin</i></b> group were prominently lower than those in Cisplatin group (p=0.039, p=0.048). According to the follow-up results, the median time to the progression of pleural effusion in <b style='color:Tomato;'><i>endostatin</i></b> group was markedly longer than that in Cisplatin group (p=0.008). ### conclusions Compared with the thoracic hyperthermic perfusion with cisplatin alone, the thoracic hyperthermic perfusion with recombinant human <b style='color:Tomato;'><i>endostatin</i></b> plus <b style='color:Tomato;'><i>nedaplatin</i></b> showed dramatically potential efficacy, decrease of the incidence rate of adverse reactions in the digestive system, improvement of quality of life of patients, and prolongation of progression of pleural effusion.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  In the presence of  <span class="marker" data-anno-id="0" data-anno-label="P1">heparin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cortisone</span>  and of cortisone alone there was a 4.5- and 2.3-fold reduction , respectively , in the growth of the 9L glioma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate.</u></h4>Malignant gliomas are difficult to treat systemically because of exclusion of many chemotherapeutic agents by the blood brain barrier. Furthermore, as opposed to other neoplasms, malignant gliomas recur locally, at the site of original presentation. These tumors are remarkably vascular and hence may be more dependent on angiogenesis for continued growth than other tumors. The inhibition of tumor angiogenesis can control tumor growth by preventing the exponential vascular growth phase. We report the inhibition of the growth of the 9L glioma by the localized, controlled release of known angiogenesis inhibitors administered in a biodegradable polyanhydride polymer matrix. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cortisone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cortisone</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>4.5-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2.3-fold</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>9L</i></b> <b style='color:DodgerBlue;'><i>glioma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We compared these results to the inhibition of tumor neovascularization in the rabbit cornea by the localized delivery of the same agents. In the rabbit cornea model, the local release of <b style='color:Tomato;'><i>heparin</i></b> and <b style='color:Tomato;'><i>cortisone</i></b> and of <b style='color:Tomato;'><i>cortisone</i></b> alone resulted in a 2.5- and 2.0-fold reduction, respectively, in the angiogenesis response evoked by the VX2 carcinoma. This study introduces two new potential therapeutic modalities for the treatment of malignant gliomas: the use of the combination of <b style='color:Tomato;'><i>heparin</i></b> and <b style='color:Tomato;'><i>cortisone</i></b> as antineoplastic agents and the use of polymeric carriers for the local delivery of such agents in the central nervous system.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  It was the aim of this study to evaluate maintenance therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">bevacizumab</span>  +  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  following induction with bevacizumab + capecitabine + oxaliplatin ( XELOX ) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer ( mCRC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.</u></h4> <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>XELOX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>XELOX</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Patients received either <b style='color:Tomato;'><i>bevacizumab</i></b> (7.5 mg/kg) + XELOX (<b style='color:Tomato;'><i>capecitabine</i></b> 1,000 mg/m(2) twice daily on days 1-14 + <b style='color:Tomato;'><i>oxaliplatin</i></b> 130 mg/m(2) on day 1 every 3 weeks) until disease progression (arm A) or the same doses of <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX for 6 cycles followed by <b style='color:Tomato;'><i>bevacizumab</i></b> + <b style='color:Tomato;'><i>capecitabine</i></b> until disease progression (arm B). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. ### results One hundred and twenty-three patients were randomized. Treatment compliance was similar in both groups. Median PFS was significantly longer for arm B than for arm A (11.0 vs. 8.3 months; p = 0.002). There was no significant difference between the two arms for ORR (66.7 vs. 59.0%; p = 0.861) or median OS (23.8 vs. 20.2 months; p = 0.100). Tolerability was acceptable in both treatment arms; the most frequent grade 3/4 treatment-related adverse events (arm B vs. arm A) were fatigue (6.6 vs. 16.1%), diarrhoea (3.3 vs. 11.3%), anorexia (3.3 vs. 11.3%), and neuropathy (1.6 vs. 8.1%). ### conclusions Maintenance therapy with <b style='color:Tomato;'><i>bevacizumab</i></b> + <b style='color:Tomato;'><i>capecitabine</i></b> can be considered an appropriate option following induction <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX in patients with mCRC instead of continuation of <b style='color:Tomato;'><i>bevacizumab</i></b> + XELOX.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Etoposide</span>  ( 25 mg , twice daily ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  ( 5 mg , twice daily ) were administered orally . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer.</u></h4>Treatment options for patients with castration-resistant prostate cancer (CRPC) are limited. The purpose of our study was to investigate the safety and efficacy in terms of prostate-specific antigen (PSA) response of a low-dose oral combination of <b style='color:Tomato;'><i>etoposide</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> in patients with CRPC. Thirty-nine patients with prostate cancer (median age, 77.9 years) with progressive disease after standard hormonal therapy were enrolled. <b style='color:MediumOrchid;'><i>Etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Each cycle comprised 21 consecutive days of treatment followed by a 7-day drug holiday. All patients previously treated with an antiandrogen were required to undergo antiandrogen withdrawal prior to entry into the study. A total of 226 cycles were administered with a median of 6.7 cycles per patient (range, 1-18 cycles). Sixteen of 39 patients (41%) with elevated PSA levels at baseline achieved at least a 50% reduction in PSA levels. Median progression-free survival for all patients was 5.9 months (range, 1-17 months). No Grade 4 toxicities were observed. The predominant toxicities were mucositis, nausea, fatigue, and anemia in twelve, nine, eight, and seven patients, respectively. Hematologic toxicity was infrequent, with no episodes of febrile neutropenia. The combination of low-dose <b style='color:Tomato;'><i>etoposide</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> is an efficacious and reasonably well-tolerated oral regimen in the treatment of elderly patients with CRPC. This regimen can be easily administered in an outpatient setting and does not require frequent patient visits.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Rosuvastatin</span>  +  <span class="marker" data-anno-id="1" data-anno-label="P1">ezetimibe</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P2">simvastatin</span>  +  <span class="marker" data-anno-id="3" data-anno-label="P2">ezetimibe</span>  , and  <span class="marker" data-anno-id="4" data-anno-label="P3">atorvastatin</span>  +  <span class="marker" data-anno-id="5" data-anno-label="P3">ezetimibe</span>  were the most cost-effective combination therapies for reducing LDL-C levels . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.</u></h4>HMG-CoA reductase inhibitors (statins) are the first-line drugs for use in the reduction of low-density lipoprotein cholesterol (LDL-C) levels and prevention of coronary heart disease (CHD) in patients with hypercholesterolemia. Generic statins could change the cost effectiveness of statin therapies in Spain, and more population groups could be included in the recommendations for reduction of cholesterol levels based on cost effectiveness. ### objectives The objectives of this study were: (i) to assess the cost effectiveness of available statins for the reduction of LDL-C levels in Spain in 2010, after the introduction of generics and reference prices; (ii) to assess the cost effectiveness of combination therapy using a statin plus cholestyramine or <b style='color:Tomato;'><i>ezetimibe</i></b>; and (iii) to estimate the mean cost per patient to achieve National Cholesterol Education Program (Adult Treatment Panel-III) therapeutic objectives. ### methods The following treatments were evaluated: <b style='color:Tomato;'><i>rosuvastatin</i></b> 5-20 mg/day; <b style='color:Tomato;'><i>atorvastatin</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>, and <b style='color:Tomato;'><i>pravastatin</i></b> 10-40 mg/day; <b style='color:Tomato;'><i>lovastatin</i></b> and <b style='color:Tomato;'><i>fluvastatin</i></b> 20-80 mg/day; and combination therapy with a statin plus either cholestyramine 12-24 g/day or <b style='color:Tomato;'><i>ezetimibe</i></b> 10 mg/day. The cost effectiveness was evaluated in terms of cost per percentage point reduction in LDL-C, comparing the annual treatment costs with the effectiveness in reducing LDL-C. Treatment costs included those for medications (2010 wholesale prices), control measures, and treatment of adverse drug effects. The effectiveness of statins was estimated by developing a meta-analysis of clinical trials published between 1993 and 2005 that met several inclusion criteria. Average and incremental cost-effectiveness ratios were calculated to assess the efficiency of individual statin and combination therapies in reducing LDL-C levels. ### results The effectiveness in terms of percentage reduction in LDL-C ranged from 19% for <b style='color:Tomato;'><i>pravastatin</i></b> 10 mg/day to 55% for <b style='color:Tomato;'><i>atorvastatin</i></b> 80 mg/day. Annual treatment costs ranged from Euro 189.7 for <b style='color:Tomato;'><i>simvastatin</i></b> 10 mg/day to Euro 759.3 for <b style='color:Tomato;'><i>atorvastatin</i></b> 80 mg/day. The cost-effectiveness ratios, in terms of cost per percentage point reduction in LDL-C, were: Euro 6 for <b style='color:Tomato;'><i>simvastatin</i></b>, Euro 10-12 for <b style='color:Tomato;'><i>rosuvastatin</i></b>, Euro 10 for <b style='color:Tomato;'><i>lovastatin</i></b>, Euro 13-16 for <b style='color:Tomato;'><i>atorvastatin</i></b>, Euro 13-14 for <b style='color:Tomato;'><i>fluvastatin</i></b>, and Euro 14-20 for <b style='color:Tomato;'><i>pravastatin</i></b>. <b style='color:MediumOrchid;'><i>Rosuvastatin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>cost-effective</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>LDL-C</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>rosuvastatin</i></b> was the most cost-effective statin for achieving the LDL-C therapeutic goal in patients at high risk for CHD, with a mean cost per patient of Euro 516. <b style='color:Tomato;'><i>simvastatin</i></b> was the most cost-effective statin to achieve the LDL-C goal in patients with moderate or low CHD risk, with a cost per patient of Euro 217 and Euro 190, respectively. ### conclusion <b style='color:Tomato;'><i>rosuvastatin</i></b> should be the first-choice agent in patients with high CHD risk, while <b style='color:Tomato;'><i>simvastatin</i></b> should be the first choice in patients with moderate or low risk. The addition of <b style='color:Tomato;'><i>ezetimibe</i></b> to <b style='color:Tomato;'><i>rosuvastatin</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>, or <b style='color:Tomato;'><i>atorvastatin</i></b> should be the preferred combination therapies when greater LDL-C reductions are required. The cost effectiveness of all statin therapies has increased in Spain after the introduction of generic statins and reference prices.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  These results suggest that the addition of intravenous  <span class="marker" data-anno-id="0" data-anno-label="N1">ceftriaxone</span>  during the first 3 days of hospitalization does not improve the cost-efficacy of oral  <span class="marker" data-anno-id="1" data-anno-label="N1">norfloxacin</span>  in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding and high risk of infection . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.</u></h4>Selective intestinal decontamination with <b style='color:Tomato;'><i>norfloxacin</i></b> is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. However, bleeding cirrhotic patients with ascites, encephalopathy, or shock are at high risk to develop bacterial infections in spite of prophylactic <b style='color:Tomato;'><i>norfloxacin</i></b>. The aim of this study was to assess whether the addition of intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> could improve the efficacy of prophylaxis with <b style='color:Tomato;'><i>norfloxacin</i></b> in these patients. ### methods Fifty-six cirrhotic patients with gastrointestinal hemorrhage and ascites, encephalopathy, or shock were randomized into two groups: Group 1 (n = 28) received oral <b style='color:Tomato;'><i>norfloxacin</i></b> 400 mg/12 h for 7 days, and group 2 (n = 28) received <b style='color:Tomato;'><i>norfloxacin</i></b> plus intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> 2 g daily during the first 3 days of admission. ### results Ten patients were excluded because of community-acquired infection, surgery, or death within the first 24 h. The incidence of bacterial infections during hospitalization was 18.1% in group 1 and 12.5% in group 2 (p = NS). The incidence of severe infections (spontaneous bacterial peritonitis, bacteremia, or pneumonia) was also similar in both groups: 9% in group 1 versus 8.3% in group 2 (p = NS). There were no statistical differences between the two groups with respect to duration of hospitalization or mortality. The cost of antibiotic therapy (including prophylaxis and treatment of infections) was significantly higher in group 2. ### conclusion <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hospitalization</i></b> <b style='color:DodgerBlue;'><i>does</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost-efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>norfloxacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cirrhotic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We conducted a multicenter , retrospective study to evaluate the efficacy and safety of combination  <span class="marker" data-anno-id="0" data-anno-label="C1">nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">ipilimumab</span>  ( NIVO+IPI ) in 35 patients with advanced or metastatic renal cell carcinoma ( mRCC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NIVO+IPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mRCC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, we focused on patients who received NIVO+IPI and were stratified into intermediate- or poor-risk disease according to the International Metastatic Renal Cell Carcinoma Database Consortium model at five institutions in Japan. The primary endpoint was overall survival (OS). Secondary endpoints were disease control rate (DCR), best overall response (BOR), objective response rate (ORR), and progression-free survival (PFS). In addition, we evaluated the role of inflammatory cell ratios, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as predictive biomarkers in patients with mRCC. The median follow-up period was 1 year, and the 1-year OS rate was 95.8%. The ORR and DCR were 34.3% and 80.0%, respectively. According to BOR, four patients (11.4%) achieved complete response. According to NLR stratification, the 1-year PFS rates were 82.6% and 23.7% when the NLR was ≤4.6 and >4.6, respectively (</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  To evaluate the eradication of Helicobacter pylori by therapy with a combination of 60 mg  <span class="marker" data-anno-id="0" data-anno-label="P1">lansoprazole</span>  and 800 mg  <span class="marker" data-anno-id="1" data-anno-label="P1">clarithromycin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.</u></h4> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>eradication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Helicobacter</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods In an open therapeutic trial, 30 H. pylori-positive patients with active ulcer disease took 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> twice a day and 400 mg <b style='color:Tomato;'><i>clarithromycin</i></b> twice a day for the first 2 weeks, followed by 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> once a day for 4-6 weeks. Endoscopy was performed both before and at the end of therapy, and 4 weeks after the end of the therapy. H. pylori was detected by using a combination of smear, culture and tissue sections. ### results Complete pain relief occurred within 3 days in all patients and all ulcers were healed by the end of the therapy. The H. pylori clearance rate was 83.3% and the eradication rate was 73.3%. A minor side effect (metallic taste) was reported by only one patient (3.3%). ### conclusions Therapy with a combination of 60 mg <b style='color:Tomato;'><i>lansoprazole</i></b> and 800 mg <b style='color:Tomato;'><i>clarithromycin</i></b> is efficacious in the eradication of H. pylori and has the advantage of a low incidence of side effects and quick pain relief for patients with active ulcers.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We studied the combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">pemetrexed</span>  , a multi-targeted antifolate , and  <span class="marker" data-anno-id="1" data-anno-label="C1">cetuximab</span>  , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-targeted</i></b> <b style='color:DodgerBlue;'><i>antifolate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>mAb</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and <b style='color:Tomato;'><i>cetuximab</i></b> in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. ### results Thirty-two patients were enrolled. The maximum tolerated dose of <b style='color:Tomato;'><i>pemetrexed</i></b> was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. ### conclusion The addition of <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m(2) to <b style='color:Tomato;'><i>cetuximab</i></b> and radiotherapy is recommended for further study in not previously irradiated patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Boosting  <span class="marker" data-anno-id="0" data-anno-label="P1">darunavir</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">ritonavir</span>  instead of with cobicistat may be preferred if  <span class="marker" data-anno-id="2" data-anno-label="P2">darunavir</span>  is to be combined with  <span class="marker" data-anno-id="3" data-anno-label="P2">etravirine</span>  in clinical practice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.</u></h4>To determine the effect of <b style='color:Tomato;'><i>etravirine</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> and vice versa. Safety and tolerability of this combination were also evaluated. ### methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> 800/150 mg once daily (DRV cohort; n = 15) or <b style='color:Tomato;'><i>etravirine</i></b> 400 mg once daily (ETR cohort; n = 15). <b style='color:Tomato;'><i>etravirine</i></b> or <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. <b style='color:Tomato;'><i>darunavir</i></b>, <b style='color:Tomato;'><i>cobicistat</i></b> and <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. ### results <b style='color:Tomato;'><i>etravirine</i></b> co-administration decreased <b style='color:Tomato;'><i>cobicistat</i></b> AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although <b style='color:Tomato;'><i>darunavir</i></b> AUC0-24 and Cmax were unchanged by <b style='color:Tomato;'><i>etravirine</i></b>, <b style='color:Tomato;'><i>darunavir</i></b> C24 was 56% lower for <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> co-administered with <b style='color:Tomato;'><i>etravirine</i></b> relative to <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> alone. <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics were unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. ### conclusions Although <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics was unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>, there was a significant decrease in <b style='color:Tomato;'><i>cobicistat</i></b> exposure and in <b style='color:Tomato;'><i>darunavir</i></b> C24 when <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> was co-administered with <b style='color:Tomato;'><i>etravirine</i></b>. <b style='color:DodgerBlue;'><i>Boosting</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cobicistat</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>etravirine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Nal-IRI with 5-fluorouracil ( 5-FU ) and leucovorin or  <span class="marker" data-anno-id="0" data-anno-label="C2">gemcitabine</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C2">cisplatin</span>  in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 ) </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h4>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7 months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus cisplatin. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2 × 46 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan , and  <span class="marker" data-anno-id="0" data-anno-label="C2">carboplatin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C2">doxorubicin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h4>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Addition of  <span class="marker" data-anno-id="0" data-anno-label="P1">verapamil</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">tamoxifen</span>  to the initial chemotherapy of small cell lung cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Based on experimental observations that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>verapamil</i></b> were escalated by 25% and 33%, respectively. The cohort of patients receiving <b style='color:Tomato;'><i>verapamil</i></b> 360 mg/day and <b style='color:Tomato;'><i>tamoxifen</i></b> 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Additive beneficial effects of  <span class="marker" data-anno-id="0" data-anno-label="P1">fenofibrate</span>  combined with  <span class="marker" data-anno-id="1" data-anno-label="P1">atorvastatin</span>  in the treatment of combined hyperlipidemia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Additive</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>fenofibrate</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>hyperlipidemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>We compared vascular and metabolic responses (and adverse responses) to statin and fibrate therapies alone or in combination in patients with combined hyperlipidemia. ### background The mechanisms of action for statins and fibrates are distinct. ### methods Fifty-six patients were given <b style='color:Tomato;'><i>atorvastatin</i></b> 10 mg and placebo, <b style='color:Tomato;'><i>atorvastatin</i></b> 10 mg and <b style='color:Tomato;'><i>fenofibrate</i></b> 200 mg, or <b style='color:Tomato;'><i>fenofibrate</i></b> 200 mg and placebo daily during each two-month treatment period of a randomized, double-blind, placebo-controlled crossover trial with two washout periods of two months' each. ### results Lipoproteins were changed to a greater extent with combined therapy when compared with <b style='color:Tomato;'><i>atorvastatin</i></b> or <b style='color:Tomato;'><i>fenofibrate</i></b> alone. Flow-mediated dilator response to hyperemia and plasma high-sensitivity C-reactive protein and fibrinogen levels were changed to a greater extent with combined therapy when compared with <b style='color:Tomato;'><i>atorvastatin</i></b> or <b style='color:Tomato;'><i>fenofibrate</i></b> alone (p < 0.001, p = 0.182, and p = 0.015 by analysis of variance [ANOVA], respectively). The effects of combined therapy or <b style='color:Tomato;'><i>fenofibrate</i></b> alone on plasma adiponectin levels and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) were significantly greater than those of <b style='color:Tomato;'><i>atorvastatin</i></b> alone (p = 0.022 for adiponectin and p = 0.049 for QUICKI by ANOVA). No patients were withdrawn from the study as the result of serious adverse effects. ### conclusions Combination therapy is safe and has beneficial additive effects on endothelial function in patients with combined hyperlipidemia.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Bevacizumab</span>  with or without  <span class="marker" data-anno-id="1" data-anno-label="P1">erlotinib</span>  as maintenance therapy in patients with metastatic colorectal cancer ( GERCOR DREAM ; OPTIMOX3 ): a randomised , open-label , phase 3 trial . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GERCOR</i></b> <b style='color:DodgerBlue;'><i>DREAM</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>OPTIMOX3</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomised</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies with chemotherapy in first-line treatment resulted in adverse outcomes. We assessed whether the combination of <b style='color:Tomato;'><i>erlotinib</i></b>, an EGFR tyrosine kinase inhibitor, with <b style='color:Tomato;'><i>bevacizumab</i></b> could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer. ### methods This randomised, open-label, phase 3 study was undertaken in 49 centres in France, Austria, and Canada. Eligible patients were aged 18-80 years with histologically confirmed, unresectable metastatic colorectal cancer, WHO performance status 0-2, had received no previous therapy for metastatic disease, and had adequate organ function. Patients without disease progression after <b style='color:Tomato;'><i>bevacizumab</i></b>-based induction therapy were randomly assigned (1:1) by a minimisation technique to <b style='color:Tomato;'><i>bevacizumab</i></b> (7·5 mg/kg every 3 weeks) or <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> (150 mg once daily) as maintenance therapy until progression. All patients were stratified by centre, baseline performance status, age, and number of metastatic sites. The primary endpoint was progression-free survival on maintenance therapy analysed by intention to treat. We report the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00265824. ### findings Between Jan 1, 2007, and Oct 13, 2011, 700 eligible patients were enrolled; following induction treatment, patients without disease progression were randomly assigned to <b style='color:Tomato;'><i>bevacizumab</i></b> (n=228) or <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> (n=224). At the final analysis, median follow-up was 51·0 months (IQR 36·0-60·0) in the <b style='color:Tomato;'><i>bevacizumab</i></b> group and 48·3 months (31·5-61·0) in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> group. In the primary analysis (after 231 progression-free survival events), median progression-free survival from randomisation was 5·1 months (95% CI 4·1-5·9) in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> group compared with 6·0 months (4·6-7·9) in the <b style='color:Tomato;'><i>bevacizumab</i></b> group (stratified hazard ratio [HR] 0·79 [95% CI 0·60-1·06]; p=0·11; unstratified HR 0·76 [0·59-0·99]; p=0·043). In the final analysis, median progression-free survival from randomisation was 5·4 months (95% CI 4·3-6·2) in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> group compared with 4·9 months (4·1-5·7) in the <b style='color:Tomato;'><i>bevacizumab</i></b> group (stratified HR 0·81 [95% CI 0·66-1·01], p=0·059; unstratified HR 0·78 [0·68-0·96], p=0·019). At the final analysis, median overall survival from maintenance was 24·9 months (95% CI 21·4-28·9) in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> group and 22·1 months (19·6-26·7) in the <b style='color:Tomato;'><i>bevacizumab</i></b> group (stratified HR 0·79 [95% CI 0·63-0·99], p=0·036; unstratified HR 0·79 [0·64-0·98], p=0·035). The most frequent grade 3-4 adverse events were skin rash (47 [21%] of 220 patients in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> group vs none of 224 patients in the <b style='color:Tomato;'><i>bevacizumab</i></b> alone group), diarrhoea (21 [10%] vs two [<1%]), and asthenia (12 [5%] vs two [<1%]). ### interpretation Maintenance <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>erlotinib</i></b> might be a new non-chemotherapy-based maintenance option for the first-line treatment of patients with unresectable metastatic colorectal cancer after <b style='color:Tomato;'><i>bevacizumab</i></b>-based induction therapy. ### funding GERCOR and F Hoffmann-La Roche.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Eighteen patients with primary or recurrent ovarian cancer were treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  150 or 110 mg/m2 , respectively , together with  <span class="marker" data-anno-id="1" data-anno-label="C1">gemcitabine</span>  800 mg/m2 and cisplatin 75 mg/m2 , 3 weekly for 6 cycles . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.</u></h4>To evaluate the peripheral neuropathic changes induced by combination chemotherapy including <b style='color:Tomato;'><i>paclitaxel</i></b> (taxol), <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin (TGC regimen). ### Patients And Methods <b style='color:DodgerBlue;'><i>Eighteen</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>110</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neurologic evaluation and quantitative assessment by vibration perception threshold (VPT) and grip strength took place before therapy, after 3 and 6 cycles of chemotherapy, and thereafter when possible. ### results Both neuropathic symptoms and signs developed in all patients (100%), becoming most prominent 3 months after the last course of chemotherapy. Grade 3 peripheral neuropathy developed in one patient during chemotherapy, and in 3 additional patients after cessation of therapy. No significant differences were observed between chemo-naive patients and pretreated patients. ### conclusion This TGC combination is well tolerated in terms of peripheral neuropathy during therapy, although the off-therapy worsening caused by cisplatin remains a problem.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  However , the combination of  <span class="marker" data-anno-id="0" data-anno-label="N1">clindamycin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">ciprofloxacin</span>  increased mortality associated with B. anthracis Sterne infection , particularly in gamma-irradiated animals . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.</u></h4>Sublethal ionizing doses of radiation increase the susceptibility of mice to Bacillus anthracis Sterne infection. In this study, we investigated the efficacy of <b style='color:Tomato;'><i>clindamycin</i></b> in 60Co-gamma-photon-irradiated and sham-irradiated mice after intratracheal challenge with B. anthracis Sterne spores. <b style='color:Tomato;'><i>clindamycin</i></b> has in vitro activity against B. anthracis and inhibits the production of toxin from other species, although no direct evidence exists that production of B. anthracis toxin is inhibited. ### methods Ten-week-old B6D2F1/J female mice were either sham-irradiated or given a sublethal 7 Gy dose of 60Co-gamma-photon radiation 4 days prior to an intratracheal challenge with toxigenic B. anthracis Sterne spores. Mice were treated twice daily with 200 mg/kg <b style='color:Tomato;'><i>clindamycin</i></b> (subcutaneous or oral), 100 mg/kg <b style='color:Tomato;'><i>moxifloxacin</i></b> (oral), 50 mg/kg <b style='color:Tomato;'><i>ciprofloxacin</i></b> (subcutaneous) or a combination therapy (<b style='color:Tomato;'><i>clindamycin</i></b> + <b style='color:Tomato;'><i>ciprofloxacin</i></b>). Bacteria were isolated and identified from lung, liver and heart blood at five timed intervals after irradiation. Survival was recorded twice daily following intratracheal challenge. ### results The use of <b style='color:Tomato;'><i>clindamycin</i></b> increased survival in gamma-irradiated and sham-irradiated animals challenged with B. anthracis Sterne in comparison with control mice (P < 0.001). <b style='color:Tomato;'><i>ciprofloxacin</i></b>-treated animals had higher survival compared with <b style='color:Tomato;'><i>clindamycin</i></b>-treated animals in two experiments, and less survival in a third experiment, although differences were not statistically significant. <b style='color:Tomato;'><i>moxifloxacin</i></b> was just as effective as <b style='color:Tomato;'><i>clindamycin</i></b>. Combination therapy did not improve survival of sham-irradiated animals and significantly decreased survival among gamma-irradiated animals (P = 0.01) in comparison with <b style='color:Tomato;'><i>clindamycin</i></b>-treated animals. B. anthracis Sterne was isolated from lung, liver and heart blood, irrespective of the antimicrobial treatment. ### conclusions Treatment with <b style='color:Tomato;'><i>clindamycin</i></b>, <b style='color:Tomato;'><i>ciprofloxacin</i></b> or <b style='color:Tomato;'><i>moxifloxacin</i></b> increased survival in sham-irradiated and gamma-irradiated animals challenged intratracheally with B. anthracis Sterne spores. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>mortality</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>B.</i></b> <b style='color:DodgerBlue;'><i>anthracis</i></b> <b style='color:DodgerBlue;'><i>Sterne</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>particularly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>gamma-irradiated</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">estramustine</span>  phosphate ( estramustine ) has been reported to be effective for HRPC . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.</u></h4>Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer (HRPC). A recent randomized trial of treatment with <b style='color:Tomato;'><i>docetaxel</i></b> demonstrated improved survival for patients with HRPC. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>phosphate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>HRPC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Low-dose <b style='color:Tomato;'><i>estramustine</i></b> suppresses the pituitary-gonadal axis. <b style='color:Tomato;'><i>docetaxel</i></b> plus 5-fluoro-5'-deoxyuridine (5'-dFUrd) had supra-additive cytotoxic effects on HRPC cells consistent with the molecular mechanism. Therefore, we examined the efficacy of adding 5'-dFUrd on the chemotherapy regimen, which consist <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>estramustine</i></b>. ### methods All of the HRPC patients were treated with <b style='color:Tomato;'><i>estramustine</i></b> 140 mg orally twice 5'-dFUrd 200 mg orally four times daily on days 1-21, and <b style='color:Tomato;'><i>docetaxel</i></b> 60 mg/m(2) was administered on day 1. We evaluated serum prostate-specific antigen (PSA) and measurable responses, the progression-free and overall survival, and the impact on adverse effects and the quality of life (QOL). ### results Of 34 patients with a median age of 72.3 years, 73% showed PSA responses and 70% showed measurable responses. The median progression-free survival was 18.0 and 5.8 months for PSA responders and non-responders and the overall survival was 19.4 months, respectively. There were few serious adverse effects. Grade 3/4 neutropenia occurred in 32.4% of the patients, and was easily managed with granulocyte colony-stimulating factor (G-CSF) injection. There was no significant change in the overall QOL scores serially. ### conclusions This study shows that the combined regimen is tolerable and effective in Japanese HRPC patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  A fixed-dose combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">artesunate</span>  +  <span class="marker" data-anno-id="1" data-anno-label="P1">amodiaquine</span>  ( ASAQ ) was recently developed . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.</u></h4>The use of <b style='color:Tomato;'><i>artemisinin</i></b> derivative-based combination therapy (ACT) such as <b style='color:Tomato;'><i>artesunate</i></b> plus <b style='color:Tomato;'><i>amodiaquine</i></b> is currently recommended for the treatment of uncomplicated Plasmodium falciparum malaria. Fixed-dose combinations are more adapted to patients than regimens involving multiple tablets and improve treatment compliance. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>fixed-dose</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>artesunate</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>amodiaquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ASAQ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To assess the efficacy and safety of this new combination and to define its optimum dosage regimen (once or twice daily) in the treatment of uncomplicated P. falciparum malaria, a multicentre clinical study was conducted. ### methods A multicentre, randomized, controlled, investigator-blinded, parallel-group study was conducted in five African centers in Cameroon, Madagascar, Mali and Senegal from March to December 2006. Efficacy and safety of ASAQ were assessed compared to those of <b style='color:Tomato;'><i>artemether</i></b> + <b style='color:Tomato;'><i>lumefantrine</i></b> (AL). The WHO protocol with a 28-day follow-up for assessing the drug therapeutic efficacy was used. Patients suffering from uncomplicated P. falciparum malaria were randomized to receive ASAQ orally once daily (ASAQ1), ASAQ twice daily (ASAQ2) or AL twice daily (AL) for three days. The primary outcome was PCR-corrected parasitological cure rate and clinical response. ### results Of 941 patients initially randomized and stratified into two age groups (<5 years, and >or=5 years), 936 (99.5%) were retained for the intent to treat (ITT) analysis, and 859 (91.3%) patients for the per protocol (PP) analysis. Among ITT population, up to D28, PCR-corrected adequate parasitological and clinical response rates were 95.2% in the ASAQ1 group, 94.9% in the ASAQ2 group and 95.5% in the AL group. Moreover, the cure rate evaluated among PP population was >or=98.5% in both ASAQ therapeutic arms. Therapeutic response rates did not display any significant differences between age groups or between one geographical site and another. Altogether, this demonstrates the non-inferiority of ASAQ1 regimen compared to both ASAQ2 and AL regimens. During follow-up mild and moderate adverse events including gastrointestinal and/or nervous disorders were reported in 29.3% of patients, with no difference between groups in the nature, frequency or intensity of adverse events. ### conclusion The non-inferiority of ASAQ compared with AL was demonstrated. The fixed-dose combination <b style='color:Tomato;'><i>artesunate</i></b> + <b style='color:Tomato;'><i>amodiaquine</i></b> (ASAQ) is safe and efficacious even in young children under 5 years of age. Whilst administration on a twice-a-day basis does not improve the efficacy of ASAQ significantly, a once-a-day intake of this new combination clearly appears as an effective and safe therapy in the treatment of uncomplicated P. falciparum malaria both in adults and children. Implications of such findings are of primary importance in terms of public health especially in African countries. As most national policies plan to strengthen malaria control to reach the elimination of this disease, anti-malarial drugs such as the <b style='color:Tomato;'><i>artesunate</i></b> + <b style='color:Tomato;'><i>amodiaquine</i></b> fixed-dose ACT will play a pivotal role in this process. ### Trial Registration The protocol was registered with the www.clinicaltrials.gov open clinical trial registry under the identifier number NCT00316329.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  All patients have received a median of four and half cycles ( range , 1 - 10 ) of 3-week ( 60 - 75 mg/m2 )  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  regimens and 5 mg  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  twice per day . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience.</u></h4>Prostate cancer is the most common type of malignancy in elderly men. Although elderly patients are commonly encountered in clinical practice, few studies have focused on the value of chemotherapy in elderly patients. In this study, we reviewed the use of <b style='color:Tomato;'><i>docetaxel</i></b> with <b style='color:Tomato;'><i>prednisolone</i></b> in elderly men (aged ≥80 years) with metastatic castration-resistant prostate cancer (mCRPC) at Ningbo First Hospital with a focus on efficacy and toxicity. ### methods A retrospective study including a series of men aged ≥80 years with mCRPC and received <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> chemotherapy between August 2011 and May 2019. All these cases were selected from the Ningbo First Hospital prostate cancer database located in Zhejiang Province, China. ### results Sixteen patients were identified, with a mean age of 82 years (range, 80 to 87 years). <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>half</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>3-week</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Seven (43.75%) patients completed more than six cycles. Ten (62.50%) patients had a good prostate-specific antigen (PSA) response of ≥50% decline. Eight (50.00%) patients had ostealgia before receiving <b style='color:Tomato;'><i>docetaxel</i></b> treatment and six of them (75.00%) experienced reduced pain after the treatment. Hematologic toxicity was observed in six (37.50%) patients with neutropenia, one of which was diagnosed with agranulocytosis and had to be admitted for the same reason. Other adverse reactions such as fever, debilitation, and alopecia were also observed. ### conclusions Very elderly patients (aged ≥80 years) with mCRPC are easy to be neglected and infrequently involved in clinical trials. Our study demonstrates that <b style='color:Tomato;'><i>docetaxel</i></b> chemotherapy plus <b style='color:Tomato;'><i>prednisone</i></b> is tolerable and effective among Chinese elderly patients (≥80 years) with mCRPC. <b style='color:Tomato;'><i>docetaxel</i></b> chemotherapy may be given under careful surveillance even in frail elderly patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The results of this work encourage the in vivo examination of the therapeutic potential of the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">bortezomib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rapamycin</span>  in Mantle Cell Lymphoma patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma.</u></h4>Mantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Novel therapeutic approaches for treating the disease are aimed at the mechanisms regulating growth signals, cellular proliferation, and survival pathways of the malignant clones. <b style='color:Tomato;'><i>bortezomib</i></b> (Brt), a proteasome inhibitor with pleiotropic activities was shown to be active in MCL and is currently implemented in therapeutic combinations for this disease. Telomerase activity is essential for survival of malignant cells and as such is considered a valid therapeutic target. This study evaluated the effects of <b style='color:Tomato;'><i>bortezomib</i></b> on telomerase activity and its regulation in MCL cells in vitro and ex vivo. Our study shows that <b style='color:Tomato;'><i>bortezomib</i></b> exerts a cytotoxic effect in a dose dependent manner in two MCL cell lines, with differential sensitivity. While the IC50 for HBL-2 cells ranged between 2.5 ng/ml to 1.5 ng/ml during 24-72 h respectively, the IC50 for the NCEB cells was twice. <b style='color:Tomato;'><i>bortezomib</i></b> differentially inhibited telomerase activity (TA): in HBL-2 cells there was a decline of 20%-55% during 24-72 h respectively. However in NCEB cells the decline was much smaller, and did not exceed 25%. Inhibition of telomerase activity is shown to be operated by two separate mechanisms: reduction of the hTERT mRNA expression (controlled by the binding of transcription factors) and reduction in phosphorylation of the catalytic subunit of hTERT by its kinases, AKT and PKCα. A decrease in telomerase activity was demonstrated also in mononuclear cells, isolated from three MCL patients following incubation of the cells in the presence of <b style='color:Tomato;'><i>bortezomib</i></b> for 24-72 h. In one patient the decrease in TA ranged between 17%-37% respectively, in the second patient between 63%-76% and in the third patient between 70-100% for 24-72 h respectively. The current study indicates that a combination of <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>rapamycin</i></b>, (an m-Tor pathway inhibitor used in MCL treatment) induced synergistic inhibition of telomerase activity. In HBL-2 cells, the combined treatment of <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>rapamycin</i></b> decreased TA by 80% compared to the expected value (40%) and for NCEB cells a similar trend was observed. In contrast, there was neither additive nor synergistic effect of this combination on cell proliferation. In the light of the crucial role of telomerase in cancer cells, it was important to characterize the possible relations between telomerase and <b style='color:Tomato;'><i>bortezomib</i></b> and to distinguish the biochemical mechanisms of its regulation and its interactions with other signal transduction inhibitors such as <b style='color:Tomato;'><i>rapamycin</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>work</i></b> <b style='color:DodgerBlue;'><i>encourage</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>examination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Mantle</i></b> <b style='color:DodgerBlue;'><i>Cell</i></b> <b style='color:DodgerBlue;'><i>Lymphoma</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Additive effects of combined  <span class="marker" data-anno-id="0" data-anno-label="P1">valsartan</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">spironolactone</span>  on cardiac aldosterone escape in spontaneously hypertensive rats . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Additive</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>valsartan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>spironolactone</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>aldosterone</i></b> <b style='color:DodgerBlue;'><i>escape</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>spontaneously</i></b> <b style='color:DodgerBlue;'><i>hypertensive</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The additive effects of combined <b style='color:Tomato;'><i>valsartan</i></b> and <b style='color:Tomato;'><i>spironolactone</i></b> on plasma and cardiac aldosterone escape were evaluated in spontaneously hypertensive rats (SHRs). Twenty-four SHRs were treated with <b style='color:Tomato;'><i>valsartan</i></b> (30 mg/kg body weight per day), <b style='color:Tomato;'><i>spironolactone</i></b> (20 mg/kg body weight per day) and a combination of both for 4 months. Blood was collected and plasma aldosterone (PA) was estimated with radioimmunoassay (RIA). Ex vivo heart perfusion was performed, the ex vivo cardiac aldosterone (EXCA) was assessed by RIA after high-performance liquid chromatography separation. PA and EXCA were significantly decreased after one month but increased after 4 months in <b style='color:Tomato;'><i>valsartan</i></b> administration group. The combined <b style='color:Tomato;'><i>valsartan</i></b> and <b style='color:Tomato;'><i>spironolactone</i></b> therapy normalized cardiac aldosterone levels. This study provides the first evidence that the long-term treatment with Angiotensin II type 1 receptor antagonist (AT1A) induces local aldosterone escape in cardiovascular tissue, whereas the combined AT1A and <b style='color:Tomato;'><i>spironolactone</i></b> therapy inhibits the escape in hypertensive rats.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The objective of this study was to compare cycle control , efficacy and tolerance of an oral contraceptive containing 20 microg  <span class="marker" data-anno-id="0" data-anno-label="P1">ethinylestradiol</span>  and 150 microg  <span class="marker" data-anno-id="1" data-anno-label="P1">desogestrel</span>  with a preparation containing 30 microg  <span class="marker" data-anno-id="2" data-anno-label="P2">ethinylestradiol</span>  combined with 75 microg  <span class="marker" data-anno-id="3" data-anno-label="P2">gestodene</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>contraceptive</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>ethinylestradiol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>desogestrel</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>preparation</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>ethinylestradiol</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>gestodene</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study involved 342 women and 4104 cycles use in Argentina, Brazil, Chile, and Mexico. Contraceptive efficacy was good with both formulations. Two pregnancies occurred in the <b style='color:Tomato;'><i>desogestrel</i></b> group but were not due to method failure. With respect to cycle control, the incidence of intermenstrual bleeding was higher during the first 3 cycles in the <b style='color:Tomato;'><i>desogestrel</i></b> group; it was significant (p <0.01) during the first 3 days of the cycle for a normal or heavy bleeding only in the Mexican group. Amenorrhea was not reported for any group, but the incidence of dysmenorrhea was significantly higher (p <0.01) in the Brazilian <b style='color:Tomato;'><i>desogestrel</i></b> group (13.8%) and was significantly lower (p <0.01) in the Mexican <b style='color:Tomato;'><i>gestodene</i></b> group (8.5%). Adverse events were similar in all the countries with headache, breast tension, and nausea, the most frequently reported symptoms. The range of mean increase in body weight varied from 0.2 kg in the Argentine group to 2.6 kg in the Chilean group (95% confidence limit, +/- 2.51) in the <b style='color:Tomato;'><i>gestodene</i></b> group, and 0.2 kg in the Argentine group to 2.5 kg in Brazilian group (95% confidence limit, +/- 2.36) in the <b style='color:Tomato;'><i>desogestrel</i></b> group. Fifteen women discontinued because of headache, but there were no significant differences between the groups regarding discontinuation for this and other medical or non-medical reasons. Both oral contraceptive preparations are reliable and well tolerated, and both have favorable effects on control cycle.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  They were assigned to either receiving a COCP containing 20 mcg  <span class="marker" data-anno-id="0" data-anno-label="P1">ethinyl</span>  estradiol/150 mg  <span class="marker" data-anno-id="1" data-anno-label="P1">desogestrel</span>  for two continuous cycle or NSAID ; mefenamic acid 500 mg TDS for 5 days , 21 days apart for two cycles . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Management of bleeding irregularities among etonogestrel implant users: Is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option?</u></h4>This study is to evaluate whether unacceptable bleeding among the <b style='color:Tomato;'><i>etonogestrel</i></b> implant user could be better alleviated using combined oral contraceptive pills (COCP) or nonsteroidal anti-inflammation drugs (NSAID). ### methods This is a prospective randomized study for evaluation of 84 <b style='color:Tomato;'><i>etonogestrel</i></b> implant (Implanon) users with prolonged or frequent bleeding. <b style='color:DodgerBlue;'><i>They</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>COCP</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mcg</i></b> <b style='color:MediumOrchid;'><i>ethinyl</i></b> <b style='color:DodgerBlue;'><i>estradiol/150</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>desogestrel</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>NSAID</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>mefenamic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>TDS</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>apart</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Bleeding pattern during the treatment was recorded and analyzed. ### results A total of 32 women (76.2%) in COCP group and 15 women (35.7%) in NSAID group stop bleeding within 7 days after the initiation of treatment which was statistically significant (P < 0.05). The mean duration of bleeding and spotting days in women treated with COCP was significantly lesser compared to NSAID group (7.29 ± 3.16 vs 10.57 ± 4.14 days (P < 0.05). ### conclusion We conclude that COCP is more efficient compared to NSAID in managing bleeding irregularities among <b style='color:Tomato;'><i>etonogestrel</i></b> implant users.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Preclinical data suggest that  <span class="marker" data-anno-id="0" data-anno-label="P1">enzastaurin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">bevacizumab</span>  may have complementary effects in inhibiting angiogenesis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.</u></h4>: <b style='color:Tomato;'><i>bevacizumab</i></b> is approved in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC). <b style='color:DodgerBlue;'><i>Preclinical</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>enzastaurin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>complementary</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>angiogenesis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods : ### Eligibility Criteria ≥18 years of age, chemonaïve, stage IIIB/IV nonsquamous NSCLC, and Eastern Cooperative Oncology Group performance status 0 to 1. Patients were randomized to placebo or <b style='color:Tomato;'><i>enzastaurin</i></b> 500 mg orally daily (after a loading dose), plus <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m, <b style='color:Tomato;'><i>carboplatin</i></b> area under the curve 6, and <b style='color:Tomato;'><i>bevacizumab</i></b> 15 mg/kg, intravenously, every 21 days for four cycles. Patients without progression received maintenance therapy with <b style='color:Tomato;'><i>bevacizumab</i></b> and placebo or <b style='color:Tomato;'><i>enzastaurin</i></b>. The primary objective was progression-free survival (PFS). Planned sample size was 90 patients, one-sided alpha of 0.20, with two interim analyses: one for safety and the second for futility, with a PFS hazard ratio of 0.8857. ### results : Forty patients were randomized. No unique safety concerns were noted at the first interim analysis. The early stopping rule for futility was met at the second interim analysis. Median PFS was 3.5 months and 4.3 months (hazard ratio: 1.04, 95% confidence interval: 0.49-2.21), and response rates were 20% and 30% (p = 0.462) for <b style='color:Tomato;'><i>enzastaurin</i></b> and placebo, respectively. Grade 3 or 4 toxicity was similar between the two arms. Two patients died on study because of respiratory arrest and pulmonary embolism. An additional patient died of sepsis secondary to a gastrointestinal perforation >30 days after study treatment discontinuation. ### conclusions : <b style='color:Tomato;'><i>enzastaurin</i></b> does not improve efficacy when combined with <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, and <b style='color:Tomato;'><i>bevacizumab</i></b>. This combination does not warrant further study in NSCLC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  m2 on day 1 ,  <span class="marker" data-anno-id="0" data-anno-label="P1">oxaliplatin</span>  85 mg/m² day 1 and  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  twice-daily dose of 625 mg/ m2 , p.o . for 2 weeks ) every 3 </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer</u></h4>Objective: We aimed to evaluate the effectiveness of an mEOX (modified <b style='color:Tomato;'><i>epirubicin</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>) regimen as second line therapy after failure of mDCF (modified <b style='color:Tomato;'><i>docetaxel</i></b>, cisplatin plus <b style='color:Tomato;'><i>fluorouracil</i></b>). Methods: Gastic cancer patients for whom first-line therapy was unsuccessful and who subsequently received mEOX (<b style='color:Tomato;'><i>epirubicin</i></b> 50 mg/ <b style='color:DodgerBlue;'><i>m2</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>85</i></b> <b style='color:DodgerBlue;'><i>mg/m²</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>twice-daily</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>625</i></b> <b style='color:DodgerBlue;'><i>mg/</i></b> <b style='color:DodgerBlue;'><i>m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p.o</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> weeks until disease progression or unacceptable toxicity, were retrospectively analyzed. Results: The study population comprised 129 cases with a median age of 55 years (range= 27-78), the majority being male (76 %). Most (75.2%) had ≥ 2 sites of metastasis. The median number of chemotherapy courses was five (range= 2–9). Forty-nine achieved a partial response and 33 showed stable disease, resulting in a ORR (overall response rate) of 38% and a DCR (disease control rate) of 63.6%. The most frequent features of grade 3-4 hematological and non-hematological toxicity were neutropenia (8.5%) and nausea/vomiting (5.4%). None of the patients suffered death due to toxicity. The median PFS was 4.7 months (95% CI, 4.1–5.3) and the OS was 7.4 months (95% CI, 6.3–8.5). On multivariate analysis, age ≥ 60 years and ECOG performance status (0-1) were independent prognostic factors affecting PFS and OS. Conslusions: In advanced gastric cancer patients, who progress after first line chemotherapy and have an ECOG performance status of 0-1, mEOX is a well tolerated triple regimen associated with a promising OS and PFS.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  However , two phase III trials demonstrated that incorporation of  <span class="marker" data-anno-id="0" data-anno-label="N1">oxaliplatin</span>  to  <span class="marker" data-anno-id="1" data-anno-label="N1">capecitabine</span>  with RT did not improve early outcomes and , by contrast , increased toxicity . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The role of capecitabine in locally advanced rectal cancer treatment: an update.</u></h4>Preoperative infusional 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) and concurrent radiation therapy (RT) followed by total mesorectal surgery is the current standard of care for locally advanced rectal cancer (LAR). When compared with postoperative 5-FU-based chemoradiation, this strategy is associated with significantly lower rates of local relapse, lower toxicity and better compliance. <b style='color:Tomato;'><i>capecitabine</i></b> is a rationally designed oral prodrug that is converted into 5-FU by intracellular thymidine phosphorylase. Substitution of infusional 5-FU with <b style='color:Tomato;'><i>capecitabine</i></b> is an attractive option that provides a more convenient administration schedule and, possibly, increased efficacy. Indeed, incorporation of <b style='color:Tomato;'><i>capecitabine</i></b> in combined modality neoadjuvant therapy for LAR has been under intense investigation during the last 10 years. Phase I and II clinical trials showed that a regimen consisting of <b style='color:Tomato;'><i>capecitabine</i></b> 825mg/m(2) twice daily for 7 days/week continuous oral administration in combination with RT is an active and well tolerated regimen, thereby being the preferred concurrent regimen. The definitive demonstration that efficacy of <b style='color:Tomato;'><i>capecitabine</i></b>/RT is similar to 5-FU/RT has been provided by the NSABP-R-04 and the German Margit trials. One approach to improve outcomes in rectal cancer is to deliver a second RT-sensitizing drug with effective systemic activity. <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> are therefore good candidates. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>incorporation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>RT</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>early</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>contrast</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>capecitabine</i></b> has also been combined with <b style='color:Tomato;'><i>irinotecan</i></b>. This regimen showed encouraging results in phase I and II clinical trials, which led to an ongoing phase III clinical trial. New strategies with induction chemotherapy with or without chemoradiation prior to surgery are currently under investigation. Whether or not <b style='color:Tomato;'><i>capecitabine</i></b> has a role in this setting is being investigated in ongoing trials. Incorporation of agents directed towards new targets, such as anti-epidermal growth factor receptor (EGFR) antibodies or antiangiogenic agents, in combination preoperative regimens, is being hampered by results of early trials in which efficacy outcomes with <b style='color:Tomato;'><i>cetuximab</i></b> were poor and an excessive rate of surgical complications with <b style='color:Tomato;'><i>bevacizumab</i></b> was observed. The lack of improvements in efficacy with the addition of <b style='color:Tomato;'><i>cetuximab</i></b> or <b style='color:Tomato;'><i>bevacizumab</i></b> in the adjuvant treatment of colon cancer led to concerns about further development of these agents in rectal cancer. The role of <b style='color:Tomato;'><i>capecitabine</i></b> in the postoperative adjuvant setting is the aim of the ongoing Dutch SCRIPT trial. The prediction of response associated with <b style='color:Tomato;'><i>capecitabine</i></b> has been based on expression of thymidylate synthase and dihydropyrimidine dehydrogenase, as well as on gene expression arrays. All these procedures require further validation and should be considered as investigational. In conclusion, <b style='color:Tomato;'><i>capecitabine</i></b> can safely and effectively replace intravenous continuous infusion of 5-FU in the preoperative chemoradiation setting for rectal cancer management. The addition of other new antineoplastic agents to a fluoropyrimidine-based regimen remains investigational.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The addition of  <span class="marker" data-anno-id="0" data-anno-label="P1">everolimus</span>  to  <span class="marker" data-anno-id="1" data-anno-label="P1">bicalutamide</span>  treatment of resistant tumours significantly reduced tumour growth rates and tumour volumes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.</u></h4>To determine the mechanisms associated with loss of androgen dependency and disease progression in prostate cancer (PCa), we investigated the relationship between the androgen receptor (AR) and mTOR pathways and the impact of inhibiting both pathways in androgen-dependent and castration-resistant PCa models. ### Experimental Design Androgen-dependent (LNCaP) and castration-resistant PCa (HP-LNCaP) cells were grown as tumours in SCID mice. Once tumours reached 500 mm(3), animals were grouped and injected subcutaneous with vehicle, our novel anti-androgen/androgen synthesis inhibitor, VN/124-1, <b style='color:Tomato;'><i>bicalutamide</i></b>, and <b style='color:Tomato;'><i>everolimus</i></b>. Tumour volumes were measured biweekly. The PSA and protein analyses were performed after completion of the treatment. ### results <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>bicalutamide</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>tumours</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>volumes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Anti-androgen treatment also increased protein expression of multiple signal transduction pathways earlier than vehicle-treated control xenografts. VN/124-1 plus <b style='color:Tomato;'><i>everolimus</i></b> acted in concert to reduce tumour growth rates in our castration-resistant xenograft model. ### conclusions This study suggests that dual inhibition of AR and mTOR in castration-resistant xenograft models can restore sensitivity of tumours to anti-androgen therapy. Furthermore, after <b style='color:Tomato;'><i>bicalutamide</i></b> failure, dual inhibition with VN/124-1 and <b style='color:Tomato;'><i>everolimus</i></b> was the most effective treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus  <span class="marker" data-anno-id="0" data-anno-label="C1">trastuzumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">docetaxel</span>  ( control group ) or pertuzumab plus trastuzumab plus docetaxel ( pertuzumab group ) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.</u></h4>The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody <b style='color:Tomato;'><i>trastuzumab</i></b> improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. <b style='color:Tomato;'><i>pertuzumab</i></b>, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of <b style='color:Tomato;'><i>trastuzumab</i></b>, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>808</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>toxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>effectively</i></b> <b style='color:DodgerBlue;'><i>managed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. ### results The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the <b style='color:Tomato;'><i>pertuzumab</i></b> group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of <b style='color:Tomato;'><i>pertuzumab</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the <b style='color:Tomato;'><i>pertuzumab</i></b> group than in the control group. ### conclusions The combination of <b style='color:Tomato;'><i>pertuzumab</i></b> plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, as compared with placebo plus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Toxicological studies revealed that the oral LD50 for  <span class="marker" data-anno-id="0" data-anno-label="N1">thiabendazole</span>  in mice was 2200 mg/kg , and when combined with 140 mg/kg of  <span class="marker" data-anno-id="1" data-anno-label="N1">aspirin</span>  , the LD50 was reduced to 900 mg/kg . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of thiabendazole on pain threshold.</u></h4><b style='color:Tomato;'><i>thiabendazole</i></b> significantly increased the reaction time to thermal stimulus. However, in mice treated with morphine, the reaction time was not in any way different from those treated with combined doses of <b style='color:Tomato;'><i>thiabendazole</i></b> and morphine. <b style='color:Tomato;'><i>thiabendazole</i></b> was found to have an antinociceptive action. The protective dose for 50% of animal (ED50) against p-benzoquinone-induced writhing reflex was found to be 310 mg/kg. The ED50 for <b style='color:Tomato;'><i>aspirin</i></b> alone was 140 mg/kg. When the ED50 of <b style='color:Tomato;'><i>aspirin</i></b> was determined in combination with different dose levels of <b style='color:Tomato;'><i>thiabendazole</i></b>, it showed a marked reduction in the values reaching 50 mg/kg, when 300 mg of <b style='color:Tomato;'><i>thiabendazole</i></b> was used in combination. <b style='color:DodgerBlue;'><i>Toxicological</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>LD50</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>thiabendazole</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>2200</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>140</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>LD50</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>900</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These findings indicate that <b style='color:Tomato;'><i>thiabendazole</i></b> possesses an analgesic activity which is potentiated by <b style='color:Tomato;'><i>aspirin</i></b>, though <b style='color:Tomato;'><i>aspirin</i></b> was found to significantly enhance its toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Azacitidine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">enasidenib</span>  are two therapies available for treatment of acute myelogenous leukemia ( AML ) , and the mechanisms of action of these drugs involve alteration of aberrant DNA methylation . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.</u></h4> <b style='color:MediumOrchid;'><i>Azacitidine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>enasidenib</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>available</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myelogenous</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>involve</i></b> <b style='color:DodgerBlue;'><i>alteration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>aberrant</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>methylation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We hypothesized that a combination of these agents could have interactive effects on DNA methylation and enhance differentiation in mIDH2 cells. Combination treatment enhanced cellular differentiation in TF-1 cells overexpressing IDJ2R140Q through increased hemoglobinization and increased hemoglobin γ RNA expression compared with the effects of single agents. Furthermore, in primary AML samples (IDH2R140Q or R172K), combination treatment reduced CD34+ cells and increased CD15+ cells to a greater extent than attained with single agents. To explore the mechanism of enhanced differentiation with combination treatment, the TF-1 epigenome was analyzed by profiling 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) DNA methylation changes. <b style='color:Tomato;'><i>enasidenib</i></b> treatment alone increased 5hmC, consistent with reactivation of ten-eleven-translocation (TET) enzyme activity. Compared with treatment with <b style='color:Tomato;'><i>azacitidine</i></b> alone, combination treatment reduced 5mC levels at greater numbers of sites and these loci were significantly enriched in regions with increased 5hMC (25.8% vs. 7.4%). Results are consistent with a model in which <b style='color:Tomato;'><i>enasidenib</i></b>-mediated reactivation of ten-eleven-translocation enzymes cooperates with <b style='color:Tomato;'><i>azacitidine</i></b>-mediated inhibition of DNA methyltransferase enzymes, leading to greater reductions in DNA methylation and enhanced erythroid differentiation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Good , moderate and mild pain relief were noted in 19 ( 41 % ) , six ( 13 % ) and seven ( 15 % ) patients on  <span class="marker" data-anno-id="0" data-anno-label="N1">lamotrigine</span>  and 13 ( 28 % ) , five ( 11 % ) and 15 ( 33 % ) patients on  <span class="marker" data-anno-id="1" data-anno-label="N1">amitriptyline</span>  , respectively , by patient 's global assessment of efficacy and safety . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy.</u></h4>To compare the efficacy and safety of <b style='color:Tomato;'><i>lamotrigine</i></b> and <b style='color:Tomato;'><i>amitriptyline</i></b> in controlling chronic painful peripheral neuropathy in diabetic patients. ### methods A randomized, double-blind, crossover, active-control, clinical trial with variable dose titration was carried out (n = 53). <b style='color:Tomato;'><i>amitriptyline</i></b> orally, at doses of 10, 25 and 50 mg at night-time, each dose for 2 weeks, and <b style='color:Tomato;'><i>lamotrigine</i></b> orally, at doses of 25, 50 and 100 mg twice daily, each dose for 2 weeks, by optional titration were used. There was a placebo washout period for 2 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out. ### results <b style='color:DodgerBlue;'><i>Good</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>moderate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>mild</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>relief</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>noted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>41</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>13</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>lamotrigine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>13</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>global</i></b> <b style='color:DodgerBlue;'><i>assessment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patient and physicians global assessment, McGill pain questionnaire and Likert pain scale showed no significant difference between the treatments, although improvement with both treatments was seen from 2 weeks. Of the 44 adverse events reported, 33 (75%) were with <b style='color:Tomato;'><i>amitriptyline</i></b>, sedation being the commonest [in 19 (43%) patients]. <b style='color:Tomato;'><i>lamotrigine</i></b> caused adverse events in 11 (25%), of which rash in three (7%) and elevations of creatinine in four (9%) were the most common. The preferred <b style='color:Tomato;'><i>lamotrigine</i></b> dose was 25 mg twice daily. ### conclusions As there are few differences between the two treatments in efficacy, <b style='color:Tomato;'><i>lamotrigine</i></b> 25 mg twice daily might be the first choice as it is associated with fewer adverse effects in our population.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  The majority of the evidence comes from studies of  <span class="marker" data-anno-id="0" data-anno-label="C1">bevacizumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">triamcinolone</span>  used as primary therapy for DMO . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.</u></h4>The combination of steroid and anti-vascular endothelial growth factor (VEGF) intravitreal therapeutic agents could potentially have synergistic effects for treating diabetic macular oedema (DMO). On the one hand, if combined treatment is more effective than monotherapy, there would be significant implications for improving patient outcomes. Conversely, if there is no added benefit of combination therapy, then people could be potentially exposed to unnecessary local or systemic side effects. ### objectives To assess the effects of intravitreal agents that block vascular endothelial growth factor activity (anti-VEGF agents) plus intravitreal steroids versus monotherapy with macular laser, intravitreal steroids or intravitreal anti-VEGF agents for managing DMO. ### Search Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2018, Issue 1); Ovid MEDLINE; Ovid Embase; LILACS; the ISRCTN registry; ClinicalTrials.gov and the ICTRP. The date of the search was 21 February 2018. ### Selection Criteria We included randomised controlled trials (RCTs) of intravitreal anti-VEGF combined with intravitreal steroids versus intravitreal anti-VEGF alone, intravitreal steroids alone or macular laser alone for managing DMO. We included people with DMO of all ages and both sexes. We also included trials where both eyes from one participant received different treatments. ### Data Collection And Analysis We used standard methodological procedures recommended by Cochrane.Two authors independently reviewed all the titles and abstracts identified from the electronic and manual searches against the inclusion criteria. Our primary outcome was change in best corrected visual acuity (BCVA) between baseline and one year. Secondary outcomes included change in central macular thickness (CMT), economic data and quality of life. We considered adverse effects including intraocular inflammation, raised intraocular pressure (IOP) and development of cataract. ### Main Results There were eight RCTs (703 participants, 817 eyes) that met our inclusion criteria with only three studies reporting outcomes at one year. The studies took place in Iran (3), USA (2), Brazil (1), Czech Republic (1) and South Korea (1). Seven studies used the unlicensed anti-VEGF agent <b style='color:Tomato;'><i>bevacizumab</i></b> and one study used licensed <b style='color:Tomato;'><i>ranibizumab</i></b>. The study that used licensed <b style='color:Tomato;'><i>ranibizumab</i></b> had a unique design compared with the other studies in that included eyes had persisting DMO after anti-VEGF monotherapy and received three monthly doses of <b style='color:Tomato;'><i>ranibizumab</i></b> prior to allocation. The anti-VEGF agent was combined with intravitreal <b style='color:Tomato;'><i>triamcinolone</i></b> in six studies and with an intravitreal <b style='color:Tomato;'><i>dexamethasone</i></b> implant in two studies. The comparator group was anti-VEGF alone in all studies; two studies had an additional steroid monotherapy arm, another study had an additional macular laser photocoagulation arm. Whilst we judged these studies to be at low risk of bias for most domains, at least one domain was at unclear risk in all studies.When comparing anti-VEGF/steroid with anti-VEGF monotherapy as primary therapy for DMO, we found no meaningful clinical difference in change in BCVA (mean difference (MD) -2.29 visual acuity (VA) letters, 95% confidence interval (CI) -6.03 to 1.45; 3 RCTs; 188 eyes; low-certainty evidence) or change in CMT (MD 0.20 μm, 95% CI -37.14 to 37.53; 3 RCTs; 188 eyes; low-certainty evidence) at one year. There was very low-certainty evidence on intraocular inflammation from 8 studies, with one event in the anti-VEGF/steroid group (313 eyes) and two events in the anti-VEGF group (322 eyes). There was a greater risk of raised IOP (Peto odds ratio (OR) 8.13, 95% CI 4.67 to 14.16; 635 eyes; 8 RCTs; moderate-certainty evidence) and development of cataract (Peto OR 7.49, 95% CI 2.87 to 19.60; 635 eyes; 8 RCTs; moderate-certainty evidence) in eyes receiving anti-VEGF/steroid compared with anti-VEGF monotherapy. There was low-certainty evidence from one study of an increased risk of systemic adverse events in the anti-VEGF/steroid group compared with the anti-VEGF alone group (Peto OR 1.32, 95% CI 0.61 to 2.86; 103 eyes).One study compared anti-VEGF/steroid versus macular laser therapy. At one year investigators did not report a meaningful difference between the groups in change in BCVA (MD 4.00 VA letters 95% CI -2.70 to 10.70; 80 eyes; low-certainty evidence) or change in CMT (MD -16.00 μm, 95% CI -68.93 to 36.93; 80 eyes; low-certainty evidence). There was very low-certainty evidence suggesting an increased risk of cataract in the anti-VEGF/steroid group compared with the macular laser group (Peto OR 4.58, 95% 0.99 to 21.10, 100 eyes) and an increased risk of elevated IOP in the anti-VEGF/steroid group compared with the macular laser group (Peto OR 9.49, 95% CI 2.86 to 31.51; 100 eyes).One study provided very low-certainty evidence comparing anti-VEGF/steroid versus steroid monotherapy at one year. There was no evidence of a meaningful difference in BCVA between treatments at one year (MD 0 VA letters, 95% CI -6.1 to 6.1, low-certainty evidence). Likewise, there was no meaningful difference in the mean CMT at one year (MD - 9 μm, 95% CI -39.87μm to 21.87μm between the anti-VEGF/steroid group and the steroid group. There was very low-certainty evidence on raised IOP at one year comparing the anti-VEGF/steroid versus steroid groups (Peto OR 0.75, 95% CI 0.16 to 3.55).No included study reported impact of treatment on patients' quality of life or economic data. None of the studies reported any cases of endophthalmitis. ### Authors Conclusions Combination of intravitreal anti-VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>majority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>comes</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>triamcinolone</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>DMO</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There is limited evidence from studies using licensed intravitreal anti-VEGF agents plus licensed intravitreal steroid implants with at least one year follow-up. It is not known whether treatment response is different in eyes that are phakic and pseudophakic at baseline.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Doxorubicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">ifosfamide</span>  are currently the two main drugs for the treatment of soft tissue sarcomas in adults . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.</u></h4> <b style='color:MediumOrchid;'><i>Doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>main</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>soft</i></b> <b style='color:DodgerBlue;'><i>tissue</i></b> <b style='color:DodgerBlue;'><i>sarcomas</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>adults</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Given in combination at full doses, with or without <b style='color:Tomato;'><i>dacarbazine</i></b>, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tailor treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  The skin and oral mucous membrane lesions recurred after effective treatments with methylprednisolone pulse therapy and combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">prednisolone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">cyclosporine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method.</u></h4>A 15-year-old girl with pemphigus vulgaris did not respond to oral administration of <b style='color:Tomato;'><i>prednisolone</i></b> at 45 mg/day. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>skin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>mucous</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>recurred</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>pulse</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The finally successful treatment involved eleven cycles of immunoadsorption using a tryptophan column and administration of a moderate dose of <b style='color:Tomato;'><i>prednisolone</i></b>. Serum gamma-globulin level and anti-intercellular antibody titer decreased from 1.08 g/dl to 0.5 g/dl and 1:320 to 1:20, respectively. She has been well controlled with 21.5 mg/day <b style='color:Tomato;'><i>prednisolone</i></b> for 8 months after the final adsorption. Considering the physical, mental and social situation of adolescent student patients, immunoadsorption is a highly preferable choice among a variety of treatment modalities for pemphigus vulgaris because it makes the term of hospitalization shorter and avoids undesirable side effects from initial high dose corticosteroids.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Incorporation of  <span class="marker" data-anno-id="0" data-anno-label="P1">colistin</span>  significantly accelerated the release of  <span class="marker" data-anno-id="1" data-anno-label="P1">ciprofloxacin</span>  from the DMPG anionic liposomes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.</u></h4>This study aims to develop liposomal formulations containing synergistic antibiotics of <b style='color:Tomato;'><i>colistin</i></b> and <b style='color:Tomato;'><i>ciprofloxacin</i></b> for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa. ### methods <b style='color:Tomato;'><i>colistin</i></b> (Col) and <b style='color:Tomato;'><i>ciprofloxacin</i></b> (Cip) were co-encapsulated in anionic liposomes by ammonium sulfate gradient. Particle size, encapsulation efficiency, in vitro drug release and in vitro antibiotic activities were evaluated. ### results The optimized liposomal formulation has uniform sizes of approximately 100 nm, with encapsulation efficiency of 67.0% (for <b style='color:Tomato;'><i>colistin</i></b>) and 85.2% (for <b style='color:Tomato;'><i>ciprofloxacin</i></b>). Incorporation of anionic lipid (DMPG) markedly increased encapsulation efficiency of <b style='color:Tomato;'><i>colistin</i></b> (from 5.4 to 67.0%); however, the encapsulation efficiency of <b style='color:Tomato;'><i>ciprofloxacin</i></b> was independent of DMPG ratio. <b style='color:DodgerBlue;'><i>Incorporation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>colistin</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>release</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>DMPG</i></b> <b style='color:DodgerBlue;'><i>anionic</i></b> <b style='color:DodgerBlue;'><i>liposomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In vitro release of <b style='color:Tomato;'><i>ciprofloxacin</i></b> and <b style='color:Tomato;'><i>colistin</i></b> in the bovine serum for 2 h were above 70 and 50%. The cytotoxicity study using A549 cells showed the liposomal formulation is as non-toxic as the drug solutions. Liposomal formulations of combinations had enhanced in vitro antimicrobial activities against multidrug resistant P. aeruginosa than the monotherapies. ### conclusions Liposomal formulations of two synergistic antibiotics was promising against multidrug resistant P. aeruginosa infections.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Phase I study of  <span class="marker" data-anno-id="0" data-anno-label="P1">decitabine</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">vorinostat</span>  in patients with advanced solid tumors and non-Hodgkin 's lymphomas . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vorinostat</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>solid</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>lymphomas</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>PURPOSE: This phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of <b style='color:Tomato;'><i>decitabine</i></b> with <b style='color:Tomato;'><i>vorinostat</i></b>.  PATIENTS AND METHODS: Patients with advanced solid tumors or non-Hodgkin's lymphomas were eligible. Sequential and concurrent schedules were studied.  RESULTS: Forty-three patients were studied in 9 different dose levels (6 sequential and 3 concurrent). The maximum tolerated dose (MTD) on the sequential schedule was <b style='color:Tomato;'><i>decitabine</i></b> 10 mg/m(2)/day on days 1-5 and <b style='color:Tomato;'><i>vorinostat</i></b> 200 mg three times a day on days 6-12. The MTD on the concurrent schedule was <b style='color:Tomato;'><i>decitabine</i></b> 10 mg/m(2)/day on days 1-5 with <b style='color:Tomato;'><i>vorinostat</i></b> 200 mg twice a day on days 3-9. However, the sequential schedule of <b style='color:Tomato;'><i>decitabine</i></b> 10 mg/m(2)/day on days 1-5 and <b style='color:Tomato;'><i>vorinostat</i></b> 200 mg twice a day on days 6-12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination. Dose-limiting toxicities during the first cycle consisted of myelosuppression, constitutional and gastrointestinal symptoms and occurred in 12/42 (29%) patients evaluable for toxicity. The most common ≥ grade 3 adverse events were neutropenia (49% of patients), thrombocytopenia (16%), fatigue (16%), lymphopenia (14%), and febrile neutropenia (7%). Disease stabilization for ≥ 4 cycles was observed in 11/38 (29%) evaluable patients.  CONCLUSION: The combination of <b style='color:Tomato;'><i>decitabine</i></b> with <b style='color:Tomato;'><i>vorinostat</i></b> is tolerable on both concurrent schedules in previously treated patients with advanced solid tumors or non-Hodgkin's lymphomas. The sequential schedule was easier to deliver. The combination showed activity with prolonged disease stabilization in different tumor types.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Epirubicin</span>  ( 35 mg/m(2 ) ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  ( 400 mg/m(2 ) ) were administered from day 2 to day 4 , every 4 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer.</u></h4>5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) given by continuous infusion (c.i.) allows higher dose delivery, causes less myelosuppression, and may interfere with repair of DNA damage caused by <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b>. With this rationale, we conducted a phase II study to test the activity and toxicity of 5-FU c.i., <b style='color:Tomato;'><i>epirubicin</i></b>, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> in patients with metastatic breast cancer (MBC). Twenty-eight patients with MBC were entered in the trial. 5-FU (200 mg/m(2)) was administered by c.i. from day 1 to day 20. <b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients were evaluable for response and toxicity. A total of 125 courses of chemotherapy were administered, with a median of 4 per patient (range: 2--6). Toxicity, assessed using World Health Organization criteria, was as follows: nausea and vomiting grade III--IV occurred in 36%, alopecia (grade III) in 86%, neutropenia (grade III--IV) in 50%, and cardiac toxicity grade I--II in 11% of patients. Five patients (17.9%) had a complete response to therapy, and 16 (57.1%) had a partial response (response rate 75%, 95% CI 55--89%). Disease stability and progression occurred in 4 (14.3%) and 3 (10.7%) patients, respectively. Median time to progression was 13.1 months (range: 3.4--66.9+), and median survival time was 27.7 months (range: 5.4--67.1+). Outpatient treatment with combined 5-FU c.i., <b style='color:Tomato;'><i>epirubicin</i></b>, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> shows high activity in advanced breast cancer and gives prolonged remission with acceptable toxicity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Our patient could be weaned from LVAD probably due to the combination management strategy employing mitral valvuloplasty , use of cardiac resynchronization therapy , and taking  <span class="marker" data-anno-id="0" data-anno-label="P1">carvedilol</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">spironolactone</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy.</u></h4>Anthracyclines are effective antineoplastic drugs, but they are known to be cardiotoxic. Recovery of cardiac function is rare. A few studies on implantation of a ventricular assist device (VAD) have been performed for anthracycline-induced cardiomyopathy. Recovery of left ventricular (LV) function with an LVAD is also rare. Recently, several adjunctive therapies were attempted to restore ventricular function. We report a successful bridge to recovery of ventricular function using VAD implantation for anthracycline-induced cardiomyopathy. The patient was a 57-year-old man who had been diagnosed with diffuse large B-cell lymphoma (DLBCL) at age 52. Combination chemotherapy including hydroxy<b style='color:Tomato;'><i>daunorubicin</i></b> was started. Complete remission was achieved after chemotherapy. Heart failure symptoms such as fatigue, dyspnea on exertion, and weight gain appeared 5 months later. A cardiac resynchronization device was implanted. His heart function deteriorated. He underwent implantation of a Toyobo LVAD and mitral annuloplasty. After implantation, he was prescribed <b style='color:Tomato;'><i>carvedilol</i></b> with <b style='color:Tomato;'><i>spironolactone</i></b>. He was weaned from the LVAD on postoperative day (POD) 239 and discharged on POD 37 after weaning. He remained in New York Heart Association classes within the first- to second-degree range, the LV dimention diastolic/systolic ratio was 56/46 mm, ejection fraction 38%, and mitral regurgitation mild at 3 years after weaning from the LVAD. <b style='color:DodgerBlue;'><i>Our</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>weaned</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>LVAD</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>employing</i></b> <b style='color:DodgerBlue;'><i>mitral</i></b> <b style='color:DodgerBlue;'><i>valvuloplasty</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>resynchronization</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>taking</i></b> <b style='color:MediumOrchid;'><i>carvedilol</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>spironolactone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Further studies will be needed to clarify the efficacy of these adjunctive therapies.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Serum  <span class="marker" data-anno-id="0" data-anno-label="N1">hydroxyzine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">cetirizine</span>  concentrations were above the limit of quantitation ( 0.1 ng/ml ) of the assay </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses.</u></h4><b style='color:Tomato;'><i>hydroxyzine</i></b> is a first-generation antihistamine and <b style='color:Tomato;'><i>cetirizine</i></b>, a second-generation antihistamine and active metabolite of <b style='color:Tomato;'><i>hydroxyzine</i></b>. <b style='color:Tomato;'><i>hydroxyzine</i></b> is commonly used in performance horses and as such its use in closely regulated; however, there are no published studies suitable for establishing appropriate regulatory recommendations. In the current study, 12 exercised Thoroughbred research horses received a single oral administration of 500 mg of <b style='color:Tomato;'><i>hydroxyzine</i></b>. Blood and urine samples were collected prior to and up to 96 hr postdrug administration and concentrations of <b style='color:Tomato;'><i>hydroxyzine</i></b> and <b style='color:Tomato;'><i>cetirizine</i></b> determined using liquid chromatography-tandem mass spectrometry. A joint parent/metabolite population 2-compartment pharmacokinetic model with first-order absorption and elimination was utilized to describe the pharmacokinetics of both compounds. <b style='color:DodgerBlue;'><i>Serum</i></b> <b style='color:MediumOrchid;'><i>hydroxyzine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetirizine</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>above</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>limit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>quantitation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.1</i></b> <b style='color:DodgerBlue;'><i>ng/ml</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>assay</i></b> at 96 hr (the last time point sampled). The terminal half-life was 7.41 and 7.13 hr for <b style='color:Tomato;'><i>hydroxyzine</i></b> and <b style='color:Tomato;'><i>cetirizine</i></b>, respectively. Findings from this study suggest that a prolonged withdrawal time should be observed if this compound is used in performance administered to performance horses and is classified as prohibited substance by the applicable regulatory body.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Although well tolerated , the efficacy of  <span class="marker" data-anno-id="0" data-anno-label="N1">everolimus</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">vinorelbine</span>  combination therapy was not superior to vinorelbine monotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.</u></h4>Improving the outcome of patients with HER2-negative metastatic breast cancer experiencing tumour progression following first-line chemotherapy remains an urgent medical need. The purpose of the VicTORia trial was to show superiority of <b style='color:Tomato;'><i>everolimus</i></b> in combination with <b style='color:Tomato;'><i>vinorelbine</i></b> versus <b style='color:Tomato;'><i>vinorelbine</i></b> monotherapy as second-line chemotherapy for patients with advanced HER2 negative breast cancer. ### methods In this randomised phase II trial, 133 patients were recruited in 32 centres in Germany. Patients were randomised 1:1 to second-line chemotherapy either with <b style='color:Tomato;'><i>vinorelbine</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> (arm1) or <b style='color:Tomato;'><i>vinorelbine</i></b> alone (arm2). Primary endpoint was progression-free survival (PFS). Secondary endpoints were PFS rate at 6 months, overall survival (OS), overall response rate (ORR) and safety. Baseline PI3 K mutational status was determined in plasma samples. ### results Median progression-free survival was not different between arms (arm1 vs. arm2: 4.01 months, 95% CI 2.40-6.09 vs. 4.08, 95% CI 2.80-5.33). PFS rate at 6 months (arm1 vs. arm2: 39.4%, 95% CI 27.6-50.9% vs. 36.6%, 95% CI 24.6-48.6%), median OS (arm1 vs. arm2: 16.3 months, 95% CI 11.4-19.0 vs. 13.8 months, 95% CI 10.2-19.1) and ORR were not different between arms. Most frequent grade 3/4 adverse events were neutropenia (50% vs. 40%), gastrointestinal toxicities (19.1% vs. 6.1%), and infections (19.1% vs. 7.7%). PI3 K mutational status was neither associated with PFS nor with OS. ### conclusion <b style='color:DodgerBlue;'><i>Although</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There was no correlation between PI3 K mutational status and efficacy. EudracCT No 2011-001024-38, ClinicalTrials.gov No NCT01520103.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  In addition , biochemical examinations revealed that  <span class="marker" data-anno-id="0" data-anno-label="N1">docetaxel</span>  could induce phosphorylation of both bcl-2 and c-raf-1 , but these changes were inhibited when tumor cells were pretreated or simultaneously treated with  <span class="marker" data-anno-id="1" data-anno-label="N1">doxorubicin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.</u></h4><b style='color:Tomato;'><i>docetaxel</i></b>, a novel member of the taxoid family, has shown greater potency than <b style='color:Tomato;'><i>paclitaxel</i></b> in the treatment of advanced breast cancer and certain other solid tumors. The promising clinical activity of <b style='color:Tomato;'><i>docetaxel</i></b> has also promoted considerable interest in combining this drug with other antitumor agents. In this study, we assessed the cytotoxic interaction between <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> administered at various schedules to human breast and ovarian cancer cells. Through a series of in vitro assays including DNA fragmentation analyses, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and flow cytometric analyses, we found that the antagonistic interaction occurred when tumor cells were exposed to the two drugs simultaneously or exposed to <b style='color:Tomato;'><i>doxorubicin</i></b> before <b style='color:Tomato;'><i>docetaxel</i></b>. However, no antagonism was observed when <b style='color:Tomato;'><i>docetaxel</i></b> was added before <b style='color:Tomato;'><i>doxorubicin</i></b>. Further analyses demonstrated that <b style='color:Tomato;'><i>doxorubicin</i></b> could interfere with the cytotoxic effect of <b style='color:Tomato;'><i>docetaxel</i></b> on both mitotic arrest and apoptotic cell death. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>biochemical</i></b> <b style='color:DodgerBlue;'><i>examinations</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>induce</i></b> <b style='color:DodgerBlue;'><i>phosphorylation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>bcl-2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>c-raf-1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>pretreated</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>simultaneously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These results indicate that the interaction between <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> is highly schedule dependent. Exposure of tumor cells to <b style='color:Tomato;'><i>doxorubicin</i></b> before <b style='color:Tomato;'><i>docetaxel</i></b> could result in pronounced antagonism. The optimal schedule for this combination might be sequential exposure to <b style='color:Tomato;'><i>docetaxel</i></b> followed by <b style='color:Tomato;'><i>doxorubicin</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Enhancement of radiation-induced downstaging of rectal cancer by  <span class="marker" data-anno-id="0" data-anno-label="P1">fluorouracil</span>  and high-dose  <span class="marker" data-anno-id="1" data-anno-label="P1">leucovorin</span>  chemotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Enhancement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>radiation-induced</i></b> <b style='color:DodgerBlue;'><i>downstaging</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To determine if <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) plus high-dose <b style='color:Tomato;'><i>leucovorin</i></b> (LV) enhances local response in patients receiving preoperative radiation therapy (RT) for adenocarcinoma of the rectum, we compared the degree of downstaging in patients receiving preoperative RT with or without chemotherapy. ### Patients And Methods For this comparison, three groups of patients who were treated with identical doses and techniques of preoperative pelvic RT (total dose of 5,040 cGy) were examined. Group 1 included 20 patients with unresectable disease who received combined RT and LV/5-FU. Group 2 included 11 patients with unresectable disease who received preoperative RT. Group 3 included 21 patients with invasive, resectable, primary disease who received preoperative RT. ### results Patients with unresectable disease who received LV/5-FU had a higher rate of pathologic complete response (20% v 0%) and a lower incidence of positive nodes (30% v 64%) compared with those who did not receive chemotherapy. Even when the most favorable group of patients was included (group 3), patients who received LV/5-FU still had a higher complete response rate (20% v 6%) and a lower incidence of positive nodes (30% v 53%) compared with those who received RT without LV/5-FU. Of those patients with initially unresectable disease, the resectability rate was higher in those who received LV/5-FU compared with those who did not receive LV/5-FU (90% v 64%). Patients who received LV/5-FU experienced slightly more grade 1 to 2 fatigue, stomatitis, nausea, and grade 3 diarrhea, tenesmus, and dysuria. ### conclusions Despite the fact that patients who received chemotherapy (group 1) had more advanced disease compared with those with resectable disease (group 3), the addition of LV/5-FU increased the resectability and downstaging rates. The ultimate impact of a complete response as well as a decrease in the incidence of pelvic nodes on local control and survival remains to be determined. However, given the enhancement of down-staging in patients with unresectable rectal cancer, we are encouraged by the combined modality approach.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  Final analysis of a phase II study of  <span class="marker" data-anno-id="0" data-anno-label="N1">nivolumab</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="N1">ipilimumab</span>  for unresectable chemotherapy-naive advanced melanoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Final</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>chemotherapy-naive</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>nivolumab</i></b> plus <b style='color:Tomato;'><i>ipilimumab</i></b> combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines. However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains less robust. This is the final analysis of a multicenter, open-label, uncontrolled phase II study that investigated the long-term efficacy and safety in treatment-naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents. Patients received four doses of <b style='color:Tomato;'><i>nivolumab</i></b> (1 mg/kg i.v.) in combination with <b style='color:Tomato;'><i>ipilimumab</i></b> (3 mg/kg i.v.) at 3-week intervals, followed by doses of <b style='color:Tomato;'><i>nivolumab</i></b> (3 mg/kg i.v.) at 2-week intervals. The median follow-up period was 20.8 months (range, 5.2-35.0). The centrally and locally assessed objective response rates were both 43.3% (13/30; 95% confidence interval [CI], 25.5-62.6). Median progression-free survival was not reached (95% CI, 3.02-not reached), and median overall survival was also not reached (95% CI, 19.52-not reached). The 30-month progression-free survival and overall survival rates were 50.3% and 54.2%, respectively. No new safety concerns were detected. After discontinuation of the investigational agents, 83.3% of patients received some form of subsequent therapy including 43.3% of patients who received <b style='color:Tomato;'><i>nivolumab</i></b> monotherapy and 26.7% of patients who received radiotherapy. Of the four patients who discontinued the investigational agents because of immune-related adverse events, two received subsequent therapy (<b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b>, respectively) and the other two showed long-term treatment-free survival (659 and 590 days, respectively). Long-term survival with <b style='color:Tomato;'><i>nivolumab</i></b> plus <b style='color:Tomato;'><i>ipilimumab</i></b> was observed in Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study. Many patients continued to receive some form of treatment safely after stopping treatment with <b style='color:Tomato;'><i>nivolumab</i></b> plus <b style='color:Tomato;'><i>ipilimumab</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  In some relatively developed regions in China ,  <span class="marker" data-anno-id="0" data-anno-label="P1">infliximab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rituximab</span>  may be a favorable cost-effective alternative for moderate to severe RA . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.</u></h4>To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society. ### Methodology Principal Findings A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and <b style='color:Tomato;'><i>rituximab</i></b> produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, and <b style='color:Tomato;'><i>adalimumab</i></b> without <b style='color:Tomato;'><i>rituximab</i></b> were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, and <b style='color:Tomato;'><i>adalimumab</i></b> with <b style='color:Tomato;'><i>rituximab</i></b>. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, <b style='color:Tomato;'><i>infliximab</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis. ### Conclusions Significance tDMARD was the most cost-effective option in the Chinese healthcare setting. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>relatively</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>regions</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>China</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>favorable</i></b> <b style='color:DodgerBlue;'><i>cost-effective</i></b> <b style='color:DodgerBlue;'><i>alternative</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>moderate</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>RA</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Topiramate</span>  CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">metformin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.</u></h4>This is a randomized, placebo-controlled study of the weight-loss efficacy and safety of a controlled-release (CR) formulation of <b style='color:Tomato;'><i>topiramate</i></b> in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with <b style='color:Tomato;'><i>metformin</i></b>. ### Research Design And Methods Patients with type 2 diabetes, BMI > or =27 kg/m2, A1C >6.5 and <11.0%, treated with diet and exercise alone or in combination with <b style='color:Tomato;'><i>metformin</i></b> monotherapy were enrolled. Patients were randomized to placebo or <b style='color:Tomato;'><i>topiramate</i></b> CR titrated up to 175 mg/day. Treatment consisted of a 7-week titration phase followed by a 9-week maintenance phase. ### results A total of 111 subjects were randomized and analyzed. By the end of week 16, patients in the placebo and <b style='color:Tomato;'><i>topiramate</i></b> groups lost 2.5 and 6.0 kg, which represented 2.3 and 5.8%, respectively, of their baseline body weight (P < 0.001 vs. placebo). A1C improved from a baseline of 7.4% in the placebo and 7.6% in the <b style='color:Tomato;'><i>topiramate</i></b> groups to 7.1 and 6.7%, respectively, representing a 0.4 and 0.9% reduction from baseline, respectively (P < 0.001 vs. placebo). <b style='color:Tomato;'><i>topiramate</i></b> also significantly reduced blood pressure and urinary albumin excretion. Adverse events were predominantly neuropsychiatric or central and peripheral nervous system related. ### conclusions <b style='color:MediumOrchid;'><i>Topiramate</i></b> <b style='color:DodgerBlue;'><i>CR</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>loss</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>meaningful</i></b> <b style='color:DodgerBlue;'><i>improvements</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>A1C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>obese</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>type</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>diabetes</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>diet</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>exercise</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the central nervous system and psychiatric adverse event profile of <b style='color:Tomato;'><i>topiramate</i></b> CR makes it unsuitable for the treatment of obesity and diabetes.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Verapamil</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">quinine</span>  were added in patients with tumors failing to respond or progressing on CVAD alone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.</u></h4>We evaluated the question of whether the chemosensitizers <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinine</i></b> given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed <b style='color:Tomato;'><i>verapamil</i></b> sensitization of Adriamycin resistance in 18.8% of fresh human breast cancer specimens tested. Patients (27) were first treated with <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, Adriamycin and <b style='color:Tomato;'><i>dexamethasone</i></b> (CVAD) alone. <b style='color:MediumOrchid;'><i>Verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>quinine</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>failing</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>respond</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>CVAD</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following treatment with CVAD alone there were no complete remissions and 3 patients (11%) developed partial remissions lasting 5.5, 8, 10.5 months. With the addition of <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinine</i></b> to the CVAD regimen, one patient (4%) developed a complete remission of 11.8 months duration and 4 additional patients (15%) developed partial remissions lasting 2.8, 17.3, 19 and > 40 months. Thus, the overall rate of CVAD sensitization by <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinine</i></b> was 19%. Treatment with CVAD plus <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinine</i></b> was generally well tolerated with observed toxicities including: myelosuppression, neuropathy, Cushingoid symptoms and tinnitus and/or dizziness due to <b style='color:Tomato;'><i>quinine</i></b>. We conclude that addition of the non-cytotoxic chemosensitizers <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinine</i></b> to CVAD in patients failing CVAD alone results in additional clinical responses in a small percentage of patients, some with long term durations. The results of this study lend credence to the notion that non-cytotoxic chemosensitizers can enhance the clinical activity of combination chemotherapy and the search for more effective and less toxic chemosensitizers continues.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  However ,  <span class="marker" data-anno-id="0" data-anno-label="N1">dipyridamole</span>  had no effect on both the influx and efflux of  <span class="marker" data-anno-id="1" data-anno-label="N1">epirubicin</span>  in doxorubicin-sensitive cells . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Studies on reversing effect of multidrug resistance by dipyridamole. II. Inhibition of epirubicin efflux from resistant cells by dipyridamole and its pharmacological effect].</u></h4>We have previously reported that <b style='color:Tomato;'><i>dipyridamole</i></b> increases the cytotoxicity of <b style='color:Tomato;'><i>epirubicin</i></b> and alters the cell cycle in <b style='color:Tomato;'><i>doxorubicin</i></b>-resistant (P388/DOX) cells, increasing the accumulation of G2/M phase by blocking the cell cycle. In cultured cells, <b style='color:Tomato;'><i>dipyridamole</i></b> increased dose-dependently the intracellular accumulation of <b style='color:Tomato;'><i>epirubicin</i></b> in the resistant cells. Simultaneous exposure of the resistant cells to <b style='color:Tomato;'><i>epirubicin</i></b> and 100 microM <b style='color:Tomato;'><i>dipyridamole</i></b> resulted in a 4.2-fold increase in proportion to the control level of <b style='color:Tomato;'><i>epirubicin</i></b> after 60 min. <b style='color:Tomato;'><i>dipyridamole</i></b> inhibited the enhanced efflux of <b style='color:Tomato;'><i>epirubicin</i></b> in <b style='color:Tomato;'><i>doxorubicin</i></b>-resistant cells. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dipyridamole</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>influx</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efflux</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>doxorubicin-sensitive</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In mice, lethal and bone marrow toxicity induced by <b style='color:Tomato;'><i>epirubicin</i></b> were potentiated by administration of high-dose of <b style='color:Tomato;'><i>dipyridamole</i></b>. In addition, in vivo results also demonstrated that <b style='color:Tomato;'><i>dipyridamole</i></b> in combination with <b style='color:Tomato;'><i>epirubicin</i></b> produced a significant reversal of the in vivo antitumor activity of <b style='color:Tomato;'><i>epirubicin</i></b> in mice bearing P388/DOX cells. These data imply the enhancement effects of <b style='color:Tomato;'><i>dipyridamole</i></b> on the efficacy and toxicity of <b style='color:Tomato;'><i>epirubicin</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  This study aims to evaluate the potential role of combination therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">flavopiridol</span>  , or 5-FU in modulating chemosensitivity and better understand how they might be used clinically . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.</u></h4>Clinical treatment of solid tumors with <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>flavopiridol</i></b>, or 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) often encounters undesirable side effects and drug resistance. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aims</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>role</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>flavopiridol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>modulating</i></b> <b style='color:DodgerBlue;'><i>chemosensitivity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>understand</i></b> <b style='color:DodgerBlue;'><i>how</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods HCT116 colon cancer cells were treated with <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>flavopiridol</i></b>, and 5-FU in several different administrative schedules in vitro, either sequentially or simultaneously. Cell survival was measured by MTT assay. The activity of caspase-3 was determined by caspase-3 assays and the soft agar colony assay was used to test the colony formation of HCT116 cells in soft agar. We also established xenograft models to extend in vitro observations to an in vivo system. ### results The maximum cytotoxicity was found when human colon cancer HCT116 cells were treated with <b style='color:Tomato;'><i>docetaxel</i></b> for 1 h followed by <b style='color:Tomato;'><i>flavopiridol</i></b> for 24 h and 5-FU for another 24 h. This sequential combination therapy not only inhibits tumor cell growth more strongly compared to other combination therapies but also significantly reduces colony formation in soft agar and augments apoptosis of HCT116 cells. Sequencing of <b style='color:Tomato;'><i>docetaxel</i></b> followed 1 h later by <b style='color:Tomato;'><i>flavopiridol</i></b>, followed 24 h later by 5-FU in xenograft models, also resulted in delayed tumor growth and higher survival rate. ### conclusion These results highlight the importance of an administrative schedule when combining <b style='color:Tomato;'><i>docetaxel</i></b> with <b style='color:Tomato;'><i>flavopiridol</i></b> and 5-FU, providing a rationale explanation for its development in clinical trials.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Dipyridamole or  <span class="marker" data-anno-id="0" data-anno-label="C1">dipyridamole</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">acetylsalicyclic acid</span>  were used in 22 pregnancies . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The course of pregnancy in patients with artificial heart valves.</u></h4>Twenty-five women with prosthetic heart valves (PHV) became pregnant 28 times. Twenty-six of the pregnancies occurred while the patients were receiving oral anticoagulants and these were continued throughout in 25 pregnancies. <b style='color:MediumOrchid;'><i>Dipyridamole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>dipyridamole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>acetylsalicyclic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>pregnancies</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eighteen infants were delivered, one with a congenital corneal leukoma; none had hemorrhagic complications; their psychomotor development was normal. Nine women aborted 10 times, including patients with two PHV, pelvic trauma and self-induced abortion. We could not detect excess anticoagulation in eight of the nine who had spontaneous losses; excess anticoagulation occurred five weeks before an abortion. There were no maternal deaths despite numerous complications; in two women, brain embolism was related to short interruptions of anticoagulation. The details of management are mentioned. We lack enough evidence to suggest routine sterilization, routine interruption of coumarin therapy during pregnancy or routine interruption of pregnancy in women with certain types and models of PHV; however, pregnancy under such conditions, plus antithrombotic therapy, carries a high risk for the product and a potential teratogenic effect. Women with one or two PHV can have children if their management is closely supervised and if extreme care is taken with the use of oral anticoagulants.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Bevacizumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  are efficacious for treatment of advanced or HER2-positive metastatic breast cancer ; however , few data exist for this regimen in inflammatory breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.</u></h4> <b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>efficacious</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>few</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>exist</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inflammatory</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In our phase 2 trial, we aimed to assess efficacy and safety of neoadjuvant <b style='color:Tomato;'><i>bevacizumab</i></b> combined with <b style='color:Tomato;'><i>trastuzumab</i></b> and chemotherapy in patients with primary HER2-positive inflammatory breast cancer. ### methods In our phase 2, multicentre, open-label, single-arm, non-comparative trial, we enrolled women (aged ≥ 18 years) with histologically confirmed HER2-positive non-metastatic inflammatory breast cancer at private or public oncology centres in France. Before surgery, patients were treated with <b style='color:Tomato;'><i>fluorouracil</i></b>, <b style='color:Tomato;'><i>epirubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and <b style='color:Tomato;'><i>bevacizumab</i></b> (cycles 1-4) and <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>bevacizumab</i></b>, and <b style='color:Tomato;'><i>trastuzumab</i></b> (cycles 5-8) in 3-week cycles. After surgery, patients received adjuvant radiotherapy, <b style='color:Tomato;'><i>trastuzumab</i></b>, and <b style='color:Tomato;'><i>bevacizumab</i></b>. For the primary endpoint, we assessed the proportion of patients who achieved a pathological complete response (defined by central review of surgical specimens according to Sataloff classification, counting missing data as failure) and adverse events in all enrolled patients. This study is registered with ClinicalTrials.gov, number NCT00717405. ### findings Between Oct 23, 2008, and Oct 28, 2009, we enrolled 52 patients at 21 centres. 42 (81%) of 52 patients received all eight cycles of neoadjuvant therapy and 49 (94%) underwent surgery. After neoadjuvant therapy, 33 of 52 patients had a pathological complete response according to central review (63·5%, 95% CI 49·4-77·5). The most common adverse events were asthenia and nausea (both occurred in 36 [69%] of 52 patients). 25 (48%) patients had grade 3-4 neutropenia, which was the most common grade 3-4 adverse event. Only one grade 3 or worse adverse event regarded as related to <b style='color:Tomato;'><i>bevacizumab</i></b> was reported (hypertension, one patient). Four patients (8%) had cardiac failure. ### interpretation Neoadjuvant treatment with <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>trastuzumab</i></b>, and chemotherapy was efficacious and well tolerated in patients with previously untreated primary inflammatory breast cancer. Further confirmation of use of <b style='color:Tomato;'><i>bevacizumab</i></b> in inflammatory breast cancer is needed. ### funding Roche (France).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Rats were distributed into three groups ( n = 5 ) according to the drug studied namely , 50 % enantiomeric excess bupivacaine mixture ( 5 μg/mL ) ; pancuronium ( 2 μg/mL ) ; 50 % enantiomeric excess  <span class="marker" data-anno-id="0" data-anno-label="C1">bupivacaine</span>  mixture +  <span class="marker" data-anno-id="1" data-anno-label="C1">pancuronium</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of 50% enantiomeric excess bupivacaine mixture combined with pancuronium on neuromuscular transmission in rat phrenic nerve-diaphragm preparation; a pilot study.</u></h4>Local anaesthetics are drugs that are widely used in clinical practice. However, the effects of these drugs on the neuromuscular junction and their influence on the blockade produced by non-depolarising neuromuscular blocking drugs are still under investigation. The aim of this study was to evaluate, in vitro, the influence of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on neuromuscular transmission and neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. ### methods <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>distributed</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>μg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>μg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The following parameters were evaluated: (1) Effects of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on membrane potential (MP) and miniature endplate potentials (MEPPs); (2) amplitude of diaphragmatic response before and 60 min after the addition of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture; the degree of neuromuscular block with <b style='color:Tomato;'><i>pancuronium</i></b> and <b style='color:Tomato;'><i>pancuronium</i></b> combined with a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### results A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture did not alter the amplitude of muscle response (MP) but decreased the frequency and amplitude of MEPP. The block produced by <b style='color:Tomato;'><i>pancuronium</i></b> was potentiated by a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### conclusion A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture used alone did not affect neuromuscular transmission, but potentiated the neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. No action was shown on the muscle fibre, and alterations on MEPPs demonstrated a presynaptic action.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The planned concomitant treatment in group B was :  <span class="marker" data-anno-id="0" data-anno-label="P1">bleomycin</span>  5 units twice a week i.m . , total dose 70 units ,  <span class="marker" data-anno-id="1" data-anno-label="P1">mitomycin</span>  C 15 mg/m2 i.v . after delivery of 10 Gy , and 10 mg/m2 i.v . on the last day of radiotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report.</u></h4>To compare the efficacy of concomitant irradiation with <b style='color:Tomato;'><i>mitomycin</i></b> C and <b style='color:Tomato;'><i>bleomycin</i></b> in patients with inoperable head and neck carcinoma with radiotherapy alone. ### Methods And Materials Between March 1991 and December 1993, 64 patients with inoperable head and neck carcinoma (41 with oropharyngeal site) were randomized to radiotherapy alone (group A) or radiotherapy combined with simultaneous application of <b style='color:Tomato;'><i>mitomycin</i></b> C and <b style='color:Tomato;'><i>bleomycin</i></b> (group B). In both groups patients were irradiated five times weekly with 2 Gy to a total dose of 66-70 Gy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>planned</i></b> <b style='color:DodgerBlue;'><i>concomitant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>units</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>week</i></b> <b style='color:DodgerBlue;'><i>i.m</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>units</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>delivery</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>Gy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>last</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To enhance the effect of these two drugs, patients received also <b style='color:Tomato;'><i>nicotinamide</i></b>, <b style='color:Tomato;'><i>chlor<b style='color:Tomato;'><i>promazine</i></b></i></b>, and <b style='color:Tomato;'><i>dicoumarol</i></b>. Because significantly better results were achieved in arm B for patients with inoperable oropharyngeal carcinoma, the study was closed and such patients were after December 1993 routinely treated with the combined therapy (as in arm B). Until October 1996, we treated and followed up 48 such consecutive patients. ### results Median follow-up of our study patients is 42 months. Complete remission (CR) rate in group A was 31% and in group B 59% (p = 0.04); disease-free survival (DFS) in group A was 8% and in group B 37% (P = 0.01); and overall survival (OS) was 7% in group A and 26% in group B (p = 0.08). CR rate for patients with oropharyngeal carcinoma was 29% in group A (N = 21) and 75% in group B (N = 20) (p = 0.007); DFS in group A was 10% and in group B 48% (p = 0.001); and the OS was 10% in group A and 38% in group B (p = 0.019). In patients with inoperable oropharyngeal carcinoma treated after December 1993, complete remission was achieved in 32/48 (67%, 95% CI: 52%-80%). DFS at the median follow-up of 14 months was 60% (95% CI 43-77%) and OS 58% (95% CI 42-74%). ### conclusion From the results of our study it seems that the concomitant treatment significantly improves CR rate, DFS, and OS in patients with inoperable oropharyngeal carcinoma in comparison with radiotherapy alone.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  This study compared the efficacy of topical  <span class="marker" data-anno-id="0" data-anno-label="P1">emedastine</span>  0.05 % ophthalmic solution with that of oral  <span class="marker" data-anno-id="1" data-anno-label="P1">loratadine</span>  10 mg and their combination in the conjunctival allergen challenge model of allergic conjunctivitis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.</u></h4>When selecting treatment for allergic conjunctivitis, a primary concern is whether to choose local or systemic therapy. ### objective <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:MediumOrchid;'><i>emedastine</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>ophthalmic</i></b> <b style='color:DodgerBlue;'><i>solution</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>loratadine</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>conjunctival</i></b> <b style='color:DodgerBlue;'><i>allergen</i></b> <b style='color:DodgerBlue;'><i>challenge</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>allergic</i></b> <b style='color:DodgerBlue;'><i>conjunctivitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This was a single-center, randomized, double-masked, placebo-controlled, parallel-group study. At visit 1, eligible subjects underwent conjunctival allergen challenge to identify the dose required to elicit a positive allergic reaction. After 7 days, subjects returned for visit 2, at which the allergen dose was confirmed. At visit 3, which took place 2 weeks later, subjects were randomized to receive either <b style='color:Tomato;'><i>emedastine</i></b> plus placebo capsules, <b style='color:Tomato;'><i>loratadine</i></b> plus placebo eyedrops, or both <b style='color:Tomato;'><i>emedastine</i></b> and <b style='color:Tomato;'><i>loratadine</i></b>. One hour after receiving study drug, subjects were challenged with allergen in both eyes. Allergic signs and symptoms were graded using standardized 5-point scales. The primary efficacy variables were itching and conjunctival hyperemia. Secondary efficacy variables were ciliary and episcleral hyperemia, chemosis, lid swelling, and tearing. Itching was graded subjectively at 3, 5, and 10 minutes after challenge. All other variables were assessed at 5, 10, and 20 minutes after challenge. ### results Eighty subjects (mean age, 43.68 years) were randomized to receive study treatment. Forty subjects (20 men, 20 women) received <b style='color:Tomato;'><i>emedastine</i></b> plus placebo capsules, 20 (7 men, 13 women) received <b style='color:Tomato;'><i>loratadine</i></b> plus placebo eyedrops, and 20 (12 men, 8 women) received both active treatments. In the between-group efficacy comparison at visit 3, the difference in itching and hyperemia scores between <b style='color:Tomato;'><i>emedastine</i></b> and <b style='color:Tomato;'><i>loratadine</i></b> was statistically significant at all time points (all, P < 0.05). Efficacy scores for the combination of <b style='color:Tomato;'><i>emedastine</i></b> and <b style='color:Tomato;'><i>loratadine</i></b> were significantly better than those for <b style='color:Tomato;'><i>loratadine</i></b> alone at 2 of 3 time points for itching and all time points for hyperemia (P < 0.05). The combination was significantly better than <b style='color:Tomato;'><i>emedastine</i></b> alone at I of 3 time points for itching and 6 of 9 time points for hyperemia (P < 0.05). ### conclusion In this study, <b style='color:Tomato;'><i>emedastine</i></b> was more efficacious than <b style='color:Tomato;'><i>loratadine</i></b> for reducing the itching and redness associated with allergic conjunctivitis in the human conjunctival allergen challenge model.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Mycophenolate mofetil resulted in rapid improvement of steroid-refractory immune-related adverse event hepatitis , induced by  <span class="marker" data-anno-id="0" data-anno-label="C1">nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">ipilimumab</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer.</u></h4> <b style='color:MediumOrchid;'><i>Mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rapid</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>steroid-refractory</i></b> <b style='color:DodgerBlue;'><i>immune-related</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>event</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Resistant isolates emerged quickly and uniformly in all patients administered  <span class="marker" data-anno-id="0" data-anno-label="C1">nevirapine</span>  either as monotherapy or in combination with  <span class="marker" data-anno-id="1" data-anno-label="C1">zidovudine</span>  ( AZT ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.</u></h4>Drug susceptibility and mutations in the reverse transcriptase (RT) gene were analyzed with 167 virus isolates from 38 patients treated with <b style='color:Tomato;'><i>nevirapine</i></b>, a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) RT. <b style='color:DodgerBlue;'><i>Resistant</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>emerged</i></b> <b style='color:DodgerBlue;'><i>quickly</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>uniformly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>nevirapine</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AZT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Resistance developed as early as 1 week, indicating rapid turnover of the virus population. The development of resistance was associated with the loss of antiviral drug activity as measured by CD4 lymphocyte counts and levels of HIV p24 antigen and RNA in serum. In addition to mutations at amino acid residues 103, 106, and 181 that had been identified by selection in cell culture, mutations at residues 108, 188, and 190 were also found in the patient isolates. Sequences from patient clones documented cocirculating mixtures of populations of different mutants. The most common mutation with monotherapy, tyrosine to cysteine at residue 181, was prevented from emerging by coadministration of AZT, which resulted in the selection of alternative mutations. The observations documented that, under selective drug pressure, the circulating virus population can change rapidly, and many alternative mutants can emerge, often in complex mixtures. The addition of a second RT inhibitor, AZT, significantly altered the pattern of mutations in the circulating population of HIV.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  No alterations in  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  or  <span class="marker" data-anno-id="1" data-anno-label="C1">doxorubicin</span>  pharmacokinetics were observed when the drugs were administered alone versus in combination . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.</u></h4><b style='color:Tomato;'><i>paclitaxel</i></b> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a very active agent for the treatment of breast cancer, with associated complete response rates of 12% in patients with minimally pretreated metastatic disease. Simultaneous <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> administration by 72-hour continuous infusion in patients with previously untreated metastatic breast cancer has yielded an overall response rate of 72% with 8% complete responses. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>alterations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetics</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Two phase I studies from the M.D. Anderson Cancer Center (Houston, TX) and the University of Indiana (Indianapolis, IN) have shown that administration of a 24-hour <b style='color:Tomato;'><i>paclitaxel</i></b> infusion prior to <b style='color:Tomato;'><i>doxorubicin</i></b> results in a significantly higher incidence of mucositis than the reverse sequence. Preliminary pharmacokinetic studies from M.D. Anderson suggest that peak plasma concentration and clearance of <b style='color:Tomato;'><i>doxorubicin</i></b> are altered by pretreatment with 24-hour <b style='color:Tomato;'><i>paclitaxel</i></b>. In contrast, in an ongoing phase I study at the Istituto Nazionale Tumori in Milan, Italy, no differences in toxicities have been observed with the combination of intravenous bolus <b style='color:Tomato;'><i>doxorubicin</i></b> and 3-hour infusional <b style='color:Tomato;'><i>paclitaxel</i></b> administered by either sequence. Preclinical in vitro and in vivo studies suggest that the combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> is associated with no or minimal additive antitumor effects. The modest complete response rates that have been observed in patients with metastatic breast cancer to date are in agreement with these observations. A randomized study of <b style='color:Tomato;'><i>paclitaxel</i></b> versus <b style='color:Tomato;'><i>doxorubicin</i></b> versus intravenous bolus <b style='color:Tomato;'><i>doxorubicin</i></b> followed by 24-hour <b style='color:Tomato;'><i>paclitaxel</i></b> is now being conducted by the Eastern Cooperative Oncology Group.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Both mono and combination therapies achieved the primary efficacy parameters : lowered diastolic blood pressure ( at trough ) more than placebo , p < 01 ( except the 120 mg  <span class="marker" data-anno-id="0" data-anno-label="P1">verapamil</span>  SR , NS , 0.5 mg  <span class="marker" data-anno-id="1" data-anno-label="P1">trandolapril</span>  , 0.5/180 and 2/120 combinations , p < 05 ) , yielded a trough to peak ratio of > 0.52 and had higher percentages of responders compared to placebo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group.</u></h4>The Joint National Committee V suggested that combination therapy can provide effective blood pressure control in patients with stage I-IV hypertension. This 4 x 4 factorial trial design assessed the efficacy of monotherapy with <b style='color:Tomato;'><i>trandolapril</i></b>-an ACE inhibitor, and <b style='color:Tomato;'><i>verapamil</i></b> SR-a calcium antagonist, each in a range of 3 doses as monotherapy, and in combination therapy in patients with stage I-III diastolic hypertension. After a 4-week, single-blind placebo treatment period, 746 patients in 39 study centers were randomized to 1 of the 16 double-blind treatments for 6 weeks (placebo, <b style='color:Tomato;'><i>verapamil</i></b> SR monotherapy 120, 180, or 240 mg; <b style='color:Tomato;'><i>trandolapril</i></b> monotherapy 0.5, 2, or 8 mg; and <b style='color:Tomato;'><i>trandolapril</i></b>/<b style='color:Tomato;'><i>verapamil</i></b> SR combinations 0.5/120, 0.5/180, 0.5/240, 2/120, 2/180, 2/240, 8/120, 8/180, or 8/240 mg. <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:DodgerBlue;'><i>mono</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>lowered</i></b> <b style='color:DodgerBlue;'><i>diastolic</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>pressure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>01</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>except</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>SR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NS</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>trandolapril</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.5/180</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2/120</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>yielded</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>peak</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>0.52</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>percentages</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>responders</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combination therapy was more effective than monotherapy for sitting diastolic blood pressure 2/180, p < 01; 2/240 and 8/240, p < 05. There were no differences between active treatment groups and placebo as a percentage of patients having adverse reactions. <b style='color:Tomato;'><i>trandolapril</i></b>, 2 and 8 mg, appeared to have a greater incremental effect on the systolic blood pressure reduction of the combination than <b style='color:Tomato;'><i>verapamil</i></b> SR 180 and 240 mg.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  In metastastic patients , the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">gemcitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cisplatin</span>  has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate , vinblastine , doxorubicin , and cisplatin ( MVAC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].</u></h4>Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>metastastic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For second-line treatment, vinflunine is the only approved therapeutic agent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant  <span class="marker" data-anno-id="0" data-anno-label="C1">lapatinib</span>  and/or  <span class="marker" data-anno-id="1" data-anno-label="C1">trastuzumab</span>  Treatment Optimization Trial . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Long-term</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>Optimization</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Cardiotoxicity is the most significant adverse event associated with <b style='color:Tomato;'><i>trastuzumab</i></b> (T), the main component of HER2-positive breast cancer (BC) treatment. Less is known about the cardiotoxicity of dual HER2 blockade with T plus <b style='color:Tomato;'><i>lapatinib</i></b> (L), although this regimen is used in the metastatic setting. ### methods This is a sub-analysis of the ALTTO trial comparing adjuvant treatment options for patients with early HER2-positive BC. Patients randomised to either T or concomitant T + L were eligible. Cardiac events (CEs) rates were compared according to treatment arm. ### results With 6.9 years of median follow-up (FU) and 4190 patients, CE were observed in 363 (8.6%): 166 (7.9%) of patient in T + L arm vs. 197 (9.3%) in T arm (OR = 0.85 [95% CI, 0.68-1.05]). During anti-HER2 treatment 270 CE (6.4%) occurred while 93 (2.2%) were during FU (median time to onset = 6.6 months [IQR = 3.4-11.7]). While 265 CEs were asymptomatic (73%), 94 were symptomatic (26%) and four were cardiac deaths (1%). Recovery was observed in 301 cases (83.8%). Identified cardiac risk factors were: baseline LVEF < 55% (vs > 64%, OR 3.1 [95% CI 1.54-6.25]), diabetes mellitus (OR 1.85 [95% CI 1.25-2.75]), BMI > 30 kg/m ### conclusions Dual HER2 blockade with T + L is a safe regimen from a cardiac perspective, but cardiac-focused history for proper patient selection is crucial. ### Trial Registration Number ClinicalTrials.gov Identifier: NCT00490139 (registration date: 22/06/2007); EudraCT Number: 2006-000562-36 (registration date: 04/05/2007); Sponsor Protocol Number: BIG2-06 /EGF106708/N063D.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  To determine the current status of ivermectin ,  <span class="marker" data-anno-id="0" data-anno-label="C1">abamectin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">praziquantel</span>  combined , and fenbendazole resistance to Parascaris spp . in horses in Saudi Arabia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A field study on the anthelmintic resistance of Parascaris spp. in Arab foals in the Riyadh region, Saudi Arabia.</u></h4>In the last decade, Parascaris spp. resistance to anthelmintics has been recorded in many countries. In Saudi Arabia, there are limited data available on Parascaris spp. resistance to anthelmintics. ### objective <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>current</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ivermectin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>abamectin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>praziquantel</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>fenbendazole</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>Parascaris</i></b> <b style='color:DodgerBlue;'><i>spp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>horses</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Saudi</i></b> <b style='color:DodgerBlue;'><i>Arabia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Three hundred and forty-one foals from eleven different farms were examined by faecal egg count (FEC). The foals were all Arab horses aged 17.2 ± 4.5 (SD) months. <b style='color:Tomato;'><i>ivermectin</i></b> (n = 46 foals), abamectin and <b style='color:Tomato;'><i>praziquantel</i></b> combined (n = 46), and fenbendazole (n = 46) were administered on day 0 and faeces were collected on day 14. The study comprised 41 untreated foals as controls. Animals that have FEC of ≥100 eggs per gram (EPG) were used to measure anthelmintic efficacy. Parascaris spp. populations were considered susceptible when faecal egg count reduction (FECR) was ≥95% associated with a lower 95% confidence limit (LCL) >90%, suspected resistant when FECR ≤90% or LCL <90% and resistant when FECR <90% and LCL <90%. ### results Prevalence of Parascaris spp. infection was 53% (179/341 horses). Anthelmintic resistance to Parascaris spp. were highest following fenbendazole (55% of farms and 65% of foals) and to a lower extent following <b style='color:Tomato;'><i>ivermectin</i></b> or the combination of abamectin and <b style='color:Tomato;'><i>praziquantel</i></b> which comprised 27% of farms (and 46% of foals) and 18% of farms (and 10% of foals), respectively. ### conclusion These data indicate that anthelmintics-resistant Parascaris spp. populations are present on horse farms in Saudi Arabia.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  To determine the response rate ( RR ) and survival produced by  <span class="marker" data-anno-id="0" data-anno-label="C1">carboplatin</span>  +  <span class="marker" data-anno-id="1" data-anno-label="C1">gemcitabine</span>  therapy in patients with untreated extensive small cell lung cancer ( ESCLC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.</u></h4> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>extensive</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ESCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Treatment consisted of <b style='color:Tomato;'><i>carboplatin</i></b> (AUC = 5) on day 1 and <b style='color:Tomato;'><i>gemcitabine</i></b> (1100 mg/m(2)) on days 1 and 8 of each 21-day cycle for 4 planned cycles (additional cycles allowed as per treating physician). ECOG performance status 0/1/2 was 29, 58, and 13%. Median age was 66.5 years (range: 41.3-83.1), 94% were white, and 50.7% were female. ### results Between August 2000 and February 2002, 69 patients with ESCLC were enrolled. All 69 patients were included in the safety analysis, and 66 patients were evaluable for response. There were 2 CR (3.0%), 26 PR (39.5%), 23 SD (34.8%), and 15 PD (22.7%) resulting in a RR of 42.5%. The median survival was 9.2 months (range: <1-22.6), and the estimated 1-year survival was 33%. The median TTP was 3.9 months (range: <1-12.8), and the estimated 6-month progression free survival was 24%. The median duration of response was 3.8 months (range: 1.0-9.9). Out of 69 patients, 29, 3, and 16 received 4, 5, and 6 cycles of therapy, respectively. The major Grade 3, 4 toxicities included neutropenia (39.1%), thrombocytopenia (31.9%), anemia (13.0%), and fatigue (4.3%). ### conclusion This regimen resulted in survival data that was similar to other regimens for ESCLC and treatment appeared to be well tolerated. <b style='color:Tomato;'><i>gemcitabine</i></b> in combination with <b style='color:Tomato;'><i>carboplatin</i></b> or other active drugs in ESCLC may be worth further investigation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  The interaction of  <span class="marker" data-anno-id="0" data-anno-label="P1">chloroquine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">citalopram</span>  in vitro resulted in a synergistic response in the chloroquine-resistant strain but there was no interaction between the drugs in the chloroquine-sensitive strain -- a pattern found with other reversal agents . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Citalopram enhances the activity of chloroquine in resistant plasmodium in vitro and in vivo.</u></h4><b style='color:Tomato;'><i>citalopram</i></b>, is an extremely potent inhibitor of neuronal serotonin reuptake. It is structurally unrelated to other antidepressants, but it contains the chemical features associated with reversal of drug resistance and exhibits minimal cardiotoxic side effects and fewer of the anticholinergic and adrenolytic side effects associated with other psychotropic agents. Sensitivity tests to <b style='color:Tomato;'><i>citalopram</i></b> alone and in combination with <b style='color:Tomato;'><i>chloroquine</i></b> were performed against <b style='color:Tomato;'><i>chloroquine</i></b>-resistant and <b style='color:Tomato;'><i>chloroquine</i></b>-sensitive strains of Plasmodium falciparum and Plasmodium chabaudi. <b style='color:Tomato;'><i>citalopram</i></b> alone showed intrinsic activity against the <b style='color:Tomato;'><i>chloroquine</i></b>-resistant strains of P. falciparum (IC50 = 1.51 +/- .6 microM) but only limited activity against the <b style='color:Tomato;'><i>chloroquine</i></b>-sensitive strain (IC50 = 33.27 +/- 5.87 microM) and no activity in vivo. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>citalopram</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>chloroquine-resistant</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>chloroquine-sensitive</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>reversal</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>citalopram</i></b> enhanced <b style='color:Tomato;'><i>chloroquine</i></b> susceptibility in both strains of P. chabaudi, however, the potentiating effect was seen at lower doses in the <b style='color:Tomato;'><i>chloroquine</i></b>-resistant strain. The results of this study suggest that <b style='color:Tomato;'><i>citalopram</i></b> may have potential as a chemosensitizer in Plasmodium infections on the basis of the low toxicity of <b style='color:Tomato;'><i>citalopram</i></b> at concentrations potentiating <b style='color:Tomato;'><i>chloroquine</i></b> activity both in vitro and in vivo.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Interfacial Phenomenon Based Biocompatible Alginate-Chitosan Nanoparticles Containing  <span class="marker" data-anno-id="0" data-anno-label="P1">Isoniazid</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">Pyrazinamide</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Interfacial</i></b> <b style='color:DodgerBlue;'><i>Phenomenon</i></b> <b style='color:DodgerBlue;'><i>Based</i></b> <b style='color:DodgerBlue;'><i>Biocompatible</i></b> <b style='color:DodgerBlue;'><i>Alginate-Chitosan</i></b> <b style='color:DodgerBlue;'><i>Nanoparticles</i></b> <b style='color:DodgerBlue;'><i>Containing</i></b> <b style='color:MediumOrchid;'><i>Isoniazid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pyrazinamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Tuberculosis (TB) is one of the major health challenge in the world. The current treatment of TB needs daily administration of combined drug therapy for six or more months. Sometime non-adherence and less bioavailability from current therapy develops multidrug resistance, as a result, high dose requirement and subsequent intolerable toxicity are seen. Therefore, nanotechnology gained special attention as it has potential to improve patient compliance, bioavailability and reduction in dosing frequency. ### objective The aim of this study is to fabricate alginate-chitosan nanoparticles (AL-CS NPs) under appropriate conditions using ionic gelation method. The use of natural polymers in nanoparticle fabrication has a vast application due to their biodegradability, biocompatibility and nontoxic nature. Ionic gelation method involves the interaction between macromolecules with opposite charged ionizable groups forming polyelectrolyte complex. Hence, it is rational to formulate natural polymerbased sustained release nano-particulate matrix to improve patient adherence, reducing dose frequency and drug toxicity. ### method The formulations were based on 32 factorial designs. Nanoparticles of combined drug (<b style='color:Tomato;'><i>isoniazid</i></b>- INH and <b style='color:Tomato;'><i>pyrazinamide</i></b>-PYZ) were fabricated using natural polymer. Formulation process involved the use of pregelated sodium alginate followed by ionic gelation with chitosan. Pregelation of sodium alginate included calcium chloride. The effects of sodium alginate concentration and chitosan concentration on particle size, zeta potential, entrapment efficiency and in vitro drug release were studied. ### results Optimized Batch-3s showed particle size 539.7 ± 2.33 nm, zeta potential -26.4 ± 0.55 mV, and entrapment efficiency is 70.21 ± 0.24% and 73.45 ± 0.21% of INH and PYZ, respectively. Dissolution release study of Batch-3s in 7.4 pH phosphate buffer exhibited the initial burst of 5.04 ±0.45% and 19.68 ± 0.87% at 0.25 hrs followed by slow, sustained release of drug 74.53 ± 2.53 and 57.87 ± 2.04% at 10 hrs of INH and PYZ, respectively. ### conclusion It concluded that chitosan (CS) and sodium alginate (AL) concentration are rate-limiting factors in formulation development. Natural polymer based combined drug nano-particulate system could be an innovative and optimistic approach in the treatment of TB.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  In a 27-day inpatient study , 10 methamphetamine-dependent individuals participated in a double-blind , placebo-controlled , cross-over design , with oral doses of  <span class="marker" data-anno-id="0" data-anno-label="C1">topiramate</span>  ( 0 , 100 , and 200 mg ) administered as a pretreatment before intravenous doses of  <span class="marker" data-anno-id="1" data-anno-label="C1">methamphetamine</span>  ( 0 , 15 , and 30 mg ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals.</u></h4>Previously, we have shown that orally administered <b style='color:Tomato;'><i>topiramate</i></b>, a sulfamate-substituted fructopyranose derivative, appears to accentuate rather than diminish some aspects of <b style='color:Tomato;'><i>methamphetamine</i></b>-induced positive subjective mood and cognitive performance. One possible mechanism by which this might occur would be for <b style='color:Tomato;'><i>topiramate</i></b> to increase plasma <b style='color:Tomato;'><i>methamphetamine</i></b> level. Such an effect also would be expected to enhance <b style='color:Tomato;'><i>methamphetamine</i></b>-induced hemodynamic response. We, therefore, studied -- in the same experiment from which the previous findings originated -- the effects of <b style='color:Tomato;'><i>topiramate</i></b> on the kinetic profile and hemodynamic response to <b style='color:Tomato;'><i>methamphetamine</i></b>. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>27-day</i></b> <b style='color:DodgerBlue;'><i>inpatient</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>methamphetamine-dependent</i></b> <b style='color:DodgerBlue;'><i>individuals</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>placebo-controlled</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>topiramate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>before</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The 3x3 factorial combination of <b style='color:Tomato;'><i>topiramate</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b> resulted in a sequence of the nine treatments administered to each subject in an order determined by a 9x9 Latin Square design. <b style='color:Tomato;'><i>methamphetamine</i></b> alone was associated with prototypical increases in hemodynamic response that were not altered in the presence of <b style='color:Tomato;'><i>topiramate</i></b>. While there was no significant kinetic interaction between <b style='color:Tomato;'><i>topiramate</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b>, there was a non-significant trend for <b style='color:Tomato;'><i>topiramate</i></b> to increase plasma <b style='color:Tomato;'><i>methamphetamine</i></b> level. No significant adverse events were reported. The combination of <b style='color:Tomato;'><i>topiramate</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b> at pharmacologically relevant doses appears to be safe. Larger laboratory studies with chronic dosing regimens are needed to establish whether or not there is a kinetic interaction between <b style='color:Tomato;'><i>topiramate</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi:</b>  Synergism between penicillin ,  <span class="marker" data-anno-id="0" data-anno-label="P1">clindamycin</span>  , or  <span class="marker" data-anno-id="1" data-anno-label="P1">metronidazole</span>  and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Synergism</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>species</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Bacteroides</i></b> <b style='color:DodgerBlue;'><i>melaninogenicus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Bacteroides</i></b> <b style='color:DodgerBlue;'><i>fragilis</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Clinical isolates of the Bacteroides melaninogenicus and Bacteroides fragilis groups were tested for in vitro and in vivo susceptibility to penicillin, <b style='color:Tomato;'><i>clindamycin</i></b>, and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b>, used singly or in combination with <b style='color:Tomato;'><i>gentamicin</i></b>. The in vitro tests consisted of determinations of minimal inhibitory concentrations (MICs) carried out with or without constant amounts of <b style='color:Tomato;'><i>gentamicin</i></b>. When used alone, <b style='color:Tomato;'><i>gentamicin</i></b> had negligible effects on the bacteria but significantly reduced the MICs of penicillin, <b style='color:Tomato;'><i>clindamycin</i></b>, and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> against 11, 10, and 3, of the 15 strains of the B. melaninogenicus group, respectively. The 15 strains of the B. fragilis group were all beta-lactamase producers and were highly resistant to penicillin or the combination of penicillin and <b style='color:Tomato;'><i>gentamicin</i></b>. However, <b style='color:Tomato;'><i>gentamicin</i></b> reduced the MICs of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> against 1 and 7 strains of this group, respectively. The in vivo tests were carried out in mice and consisted of measurements of the effects of the antimicrobial agents on the sizes and bacterial content of abscesses induced by subcutaneous injection of bacterial suspensions. The results of the in vivo tests were generally consistent with those obtained in vitro with strains of the B. melaninogenicus group. Synergism between <b style='color:Tomato;'><i>gentamicin</i></b> and penicillin, <b style='color:Tomato;'><i>clindamycin</i></b>, or <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> was shown in 13, 10, and 3 strains of this group, respectively. In vivo synergism was not clearly demonstrated with the strains of the B. fragilis group, possibly because <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> used alone were highly efficacious. We suggest that the synergistic effect of <b style='color:Tomato;'><i>gentamicin</i></b> is due to its increased transport into the bacterial cell in the presence of penicillin and, possibly, other antimicrobial agents. The newly recognized in vitro and in vivo synergism between penicillin and other antimicrobial agents and an aminoglycoside in B. melaninogenicus may have clinical implications that deserve to be investigated.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The resistance of  <span class="marker" data-anno-id="0" data-anno-label="P1">topotecan</span>  in MDR HL-60 cells was potently reversed by the addition of  <span class="marker" data-anno-id="1" data-anno-label="P1">amlodipine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.</u></h4>Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy as the over-expressed MDR protein acts as an efflux pump, which leads to a reduction in the uptake of the anticancer agent by tumour cells. We combined <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> together into the stealthy liposomes, in which <b style='color:Tomato;'><i>amlodipine</i></b> was applied as a MDR reversing agent to overcome the resistance. ### Materials And Methods Cytotoxicity, apoptosis and the signalling pathway assays were performed on human chronic myelogenous leukaemia K562, promyelocytic leukaemia HL-60 and MDR HL-60 cells, respectively. Pharmacokinetics and antitumour activity studies were performed on normal Kunming mice and female BALB/c nude mice with MDR HL-60 xenografts, respectively. ### results <b style='color:Tomato;'><i>topotecan</i></b> alone was effective in inhibiting the growth of non-resistant leukaemia cells, K562 and HL-60 cells but not the growth of MDR HL-60 cells. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>MDR</i></b> <b style='color:DodgerBlue;'><i>HL-60</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>potently</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Moreover, <b style='color:Tomato;'><i>amlodipine</i></b> enhanced the apoptosis-inducing effect of <b style='color:Tomato;'><i>topotecan</i></b> synergistically. Apoptosis was through activating caspases in a cascade: first, the initiator caspase 8 and then effectors caspase 3/7 (total activity of caspases 3 and 7) were activated. Being encapsulated into the stealthy liposomes with an acidic internal medium, <b style='color:Tomato;'><i>topotecan</i></b> existed dominantly in an active lactone species, which was reversibly changed from an inactive carboxylate form via a pH-dependent reaction. After administration of stealthy liposomes to mice, the blood exposure of the lactone form was evidently increased and extended. The antitumour effects in the MDR HL-60 xenografted tumour were stealthy liposomal <b style='color:Tomato;'><i>topotecan</i></b> (SLT) plus <b style='color:Tomato;'><i>amlodipine</i></b> > SLT > un-encapsulated <b style='color:Tomato;'><i>topotecan</i></b> > blank control. ### conclusions The enhanced antitumour activity in the MDR HL-60 cells by the SLT plus <b style='color:Tomato;'><i>amlodipine</i></b> could be owing to multiple reasons: (a) synergistic apoptosis inducing effect, (b) reversing MDR by <b style='color:Tomato;'><i>amlodipine</i></b> and (c) increasing the availability of active lactone of <b style='color:Tomato;'><i>topotecan</i></b> by the stealthy liposomes. The apoptosis induced by <b style='color:Tomato;'><i>amlodipine</i></b> is through caspase 8 and then the 3/7 signalling pathway.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  [ Clinical evaluation of effects from neoadjuvant chemotherapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  in cases of locally advanced breast cancer -- comparative study of treatment with 2 and 4 cycles ] . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Neoadjuvant chemotherapy of <b style='color:Tomato;'><i>epirubicin</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> was administered to 75 patients (including a 2-cycle group of 39 patients and a 4-cycle group of 36 patients) with locally advanced breast cancer (35 cases of stage IIb, 28 of stage IIIa, 12 of stage IIIb) to compare efficacy and toxicity of 2 cycle and 4 cycle regimens. All patients were female. They were treated with <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m2, on day 1, by i.v., followed by <b style='color:Tomato;'><i>paclitaxel</i></b> 150 mg/m2, by 3 hour continuous infusion on day 2 repeated every 3 weeks. Premedication with <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>ondansetron</i></b>, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>cimetidine</i></b> were administered to prevent gastroenteritic and allergic reactions before chemotherapy. Thirty-nine patients were given 2 cycles and thirty-six were given 4 cycles of this regimen. One of 39 patients had complete response, 28 had partial response and 10 had no change in the 2-cycle group. In addition, 21 of 36 patients had complete response (including 9 who had pathologic complete response), 13 had partial response and 2 had no change. The response rates were 74% (29/39) in the 2-cycle group and 94% (34/36) in the 4-cycle group. There were no progressive disease in these 2 groups. However a higher proportion of PR was observed in stage II patients than in stage III patients. Twelve of 36 patients underwent breast conserving surgery, as tumor size had become smaller and down-staging was realized after neoadjuvant chemotherapy. In addition, axillary lymph nodes were palpable in all 75 patients before neoadjuvant chemotherapy with the ET regimen. But 46% (18/39) in the 2-cycle group and 75% (27/36) in the 4-cycle group became impalpable. Conversely, major toxicities (including leukopenia and gastroenteric reactions) were similar in both groups, but myalgia, arthralgia, neurotoxicity and alopecia were more severe in the 4-cycle group than in the 2-cycle group. In the present study, neoadjuvant chemotherapy with a 4-cycle ET regimen was more effective than with a 2-cycle regimen in down staging locally advanced breast cancer. Although major toxicities were more severe in the 4-cycle group than in the 2-cycle group, the regimen was tolerable and safe.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  When systemically active chemotherapy doses were reached , further dose escalation was discontinued , and a phase II dose-range was established (  <span class="marker" data-anno-id="0" data-anno-label="P1">pemetrexed</span>  500 mg/m(2 ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  AUC = 5 - 6 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.</u></h4>The primary objective of this phase I study was to determine the maximum tolerated dose for <b style='color:Tomato;'><i>pemetrexed</i></b>, alone and in combination with <b style='color:Tomato;'><i>carboplatin</i></b>, with concurrent radiotherapy. ### Experimental Design Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or esophageal cancer were treated every 21 days for two cycles. Regimen 1 was <b style='color:Tomato;'><i>pemetrexed</i></b> (200-600 mg/m(2)); regimen 2 was <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) with escalating <b style='color:Tomato;'><i>carboplatin</i></b> doses (AUC = 4-6). Both regimens included concurrent radiation (40-66 Gy; palliative-intent doses were lower). ### results Thirty patients (18 locally advanced and 12 metastatic with dominant local symptoms) were enrolled, with an Eastern Cooperative Oncology Group performance status of 0/1/2 (n = 8/21/1). All dose levels were tolerable for regimen 1 (n = 18: 15 NSCLC and 3 esophageal cancers) and regimen 2 (n = 12: all NSCLC). In regimen 1, one dose-limiting toxicity (grade 4 esophagitis/anorexia) occurred (500 mg/m(2)). Grade 3 neutropenia (3 of 18 patients) was the main hematologic toxicity. In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity. Four complete responses (2 pathology proven) and eight partial responses were observed. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>systemically</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reached</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>dose-range</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The combination of <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) and <b style='color:Tomato;'><i>carboplatin</i></b> (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity. To further determine efficacy, safety profile, and optimal dosing, the Cancer and Leukemia Group B study 30407 is currently evaluating this regimen in patients with unresectable stage III NSCLC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  The clinical studies provide evidence that combined fluticasone/formoterol is more efficacious than fluticasone or formoterol given alone , and provides similar improvements in lung function to  <span class="marker" data-anno-id="0" data-anno-label="P1">fluticasone</span>  ( Flixotide ( ® ) ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">formoterol</span>  ( Foradil ( ® ) ) administered concurrently . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].</u></h4>The combination of an inhaled corticosteroid and a long acting beta-2 agonist is indicated for the regular treatment of persistent moderate-to-severe asthmatics whose asthma is not controlled by inhaled corticosteroids and the occasional use of a short acting beta-2 agonist. The aim of this review is to give an overview of the rationale of combining <b style='color:Tomato;'><i>formoterol</i></b> and <b style='color:Tomato;'><i>fluticasone</i></b> and to analyze the clinical data concerning a new fixed combination of <b style='color:Tomato;'><i>fluticasone</i></b> and <b style='color:Tomato;'><i>formoterol</i></b> in a pressurised metered-dose inhaler with a dose counter (Flutiform(®)) that was approved for the treatment of asthma in France in 2013. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>fluticasone/formoterol</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>efficacious</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>provides</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>improvements</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Flixotide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>®</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Foradil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>®</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>concurrently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> gave a more rapid bronchodilatation than the combination <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>. As a whole, the combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> had similar efficacy and tolerability profiles to the combinations of either <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>/<b style='color:Tomato;'><i>formoterol</i></b> or <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Rationale , design , and baseline characteristics of a trial of prevention of cardiovascular and renal disease with  <span class="marker" data-anno-id="0" data-anno-label="C1">fosinopril</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">pravastatin</span>  in nonhypertensive , nonhypercholesterolemic subjects with microalbuminuria ( the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [ PREVEND IT ] ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Rationale</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fosinopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pravastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonhypertensive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nonhypercholesterolemic</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>microalbuminuria</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>REnal</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Vascular</i></b> <b style='color:DodgerBlue;'><i>ENdstage</i></b> <b style='color:DodgerBlue;'><i>Disease</i></b> <b style='color:DodgerBlue;'><i>Intervention</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>PREVEND</i></b> <b style='color:DodgerBlue;'><i>IT</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>This study describes the rationale, design, and baseline characteristics of a trial to determine whether treatment with <b style='color:Tomato;'><i>fosinopril</i></b> 20 mg/day and/or <b style='color:Tomato;'><i>pravastatin</i></b> 40 mg/ day will prevent cardiovascular and renal disease in nonhypertensive (RR <160/100 mm Hg and not using antihypertensive medication) and nonhypercholesterolemic (total cholesterol <8.0 or <5.0 mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men and women with persistent microalbuminuria (urinary albumin excretion >10 mg/L once in an early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Phase III , randomized , double-blind , multicenter trial comparing orteronel (  <span class="marker" data-anno-id="0" data-anno-label="P1">TAK-700</span>  ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy : ELM-PC 5 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>orteronel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>TAK-700</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>docetaxel-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>ELM-PC</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Orteronel (<b style='color:Tomato;'><i>tak-700</i></b>) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after <b style='color:Tomato;'><i>docetaxel</i></b> therapy. ### Patients And Methods In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive orteronel 400 mg plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily or placebo plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily, stratified by region (Europe, North America [NA], and non-Europe/NA) and Brief Pain Inventory-Short Form worst pain score. Primary end point was overall survival (OS). Key secondary end points (radiographic progression-free survival [rPFS], ≥ 50% decrease of prostate-specific antigen [PSA50], and pain response at 12 weeks) were to undergo statistical testing only if the primary end point analysis was significant. ### results The study was unblinded after crossing a prespecified OS futility boundary. The median OS was 17.0 months versus 15.2 months with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> versus placebo-<b style='color:Tomato;'><i>prednisone</i></b> (hazard ratio [HR], 0.886; 95% CI, 0.739 to 1.062; P = .190). Improved rPFS was observed with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> (median, 8.3 v 5.7 months; HR, 0.760; 95% CI, 0.653 to 0.885; P < .001). Orteronel-<b style='color:Tomato;'><i>prednisone</i></b> showed advantages over placebo-<b style='color:Tomato;'><i>prednisone</i></b> in PSA50 rate (25% v 10%, P < .001) and time to PSA progression (median, 5.5 v 2.9 months, P < .001) but not pain response rate (12% v 9%; P = .128). Adverse events (all grades) were generally more frequent with orteronel-<b style='color:Tomato;'><i>prednisone</i></b>, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased amylase (14% v 2%). ### conclusion Our study did not meet the primary end point of OS. Longer rPFS and a higher PSA50 rate with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> indicate antitumor activity.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Five clinical trials with  <span class="marker" data-anno-id="0" data-anno-label="C1">temozolomide</span>  or  <span class="marker" data-anno-id="1" data-anno-label="C1">dacarbazine</span>  have been performed in metastatic colorectal cancer ( mCRC ) with selection based on methyl-specific PCR ( MSP ) testing with modest results . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.</u></h4>O(6)-methylguanine-DNA-methyltransferase (MGMT) is a repair protein, and its deficiency makes tumours more susceptible to the cytotoxic effect of alkylating agents. <b style='color:DodgerBlue;'><i>Five</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selection</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>methyl-specific</i></b> <b style='color:DodgerBlue;'><i>PCR</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MSP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modest</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We hypothesised that mitigated results are consequences of unspecific patient selection and that alternative methodologies for MGMT testing such as immunohistochemistry (IHC) and digital polymerase chain reaction (PCR) could enhance patient enrolment. ### Patients And Methods Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of <b style='color:Tomato;'><i>temozolomide</i></b> or <b style='color:Tomato;'><i>dacarbazine</i></b> in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Pooled data were then retrospectively analysed according to objective response rate, progression-free survival (PFS) and overall survival (OS). ### results One hundred and five patients were included in the study. Twelve had achieved partial response (PR) (11.4%), 24 stable disease (SD; 22.9%) and 69 progressive disease (PD; 65.7%). Patients with PR/SD had lower IHC scores and higher MB levels than those with PD. MGMT expression by IHC was negatively and MB levels positively associated with PFS (p < 0.001 and 0.004, respectively), but not with OS. By combining both assays, IHC low/MB high patients displayed an 87% reduction in the hazard of progression (p < 0.001) and a 77% in the hazard for death (p = 0.001). ### conclusion In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents. Their combination could enhance patient selection in this setting.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  <span class="marker" data-anno-id="0" data-anno-label="N1">Fluoxetine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N2">paroxetine</span>  are potent inhibitors of CYP2D6 and administration of these SSRIs reduces the clinical benefit of an anticancer drug , such as  <span class="marker" data-anno-id="2" data-anno-label="N1/N2">tamoxifen</span>  , by decreasing the formation of active metabolites of this drug . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.</u></h4>Different antidepressant drugs are currently used for the treatment of depression in cancer patients, such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective serotonin reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. <b style='color:MediumOrchid;'><i>Fluoxetine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paroxetine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>SSRIs</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>decreasing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>metabolites</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Women with breast cancer who receive <b style='color:Tomato;'><i>paroxetine</i></b> in combination with <b style='color:Tomato;'><i>tamoxifen</i></b> are at increased risk for death. Other SSRIs, including <b style='color:Tomato;'><i>citalopram</i></b>, es<b style='color:Tomato;'><i>citalopram</i></b>, are weak or negligible inhibitors of CYP2D6 and are less likely to interact with anticancer drugs, while <b style='color:Tomato;'><i>sertraline</i></b> causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the CYP3A4 and the P-glycoprotein (P-gp), can reduce the plasma concentrations of different antineoplastic agents such as <b style='color:Tomato;'><i>imatinib</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of <b style='color:Tomato;'><i>fluoxetine</i></b>, <b style='color:Tomato;'><i>paroxetine</i></b> and Hypericum extract should be avoided in cancer patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Captopril</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">HYZ</span>  significantly reduced BP compared with controls but T replacement increased BP and coronary collagen deposition in spite of HYZ and captopril treatment . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Testosterone increases blood pressure and cardiovascular and renal pathology in spontaneously hypertensive rats.</u></h4>The objective of this paper was to test the hypothesis that testosterone (T) raises blood pressure (BP), which is associated with increased coronary adventitial collagen, whereas the hemodynamic force of BP increases the coronary media:lumen ratio. Five treatment groups of spontaneously hypertensive rat (SHR) were established (n = 8-10 per group): controls; <b style='color:Tomato;'><i>hydralazine</i></b> (HYZ); castration; castration + HYZ; and castration + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b>. At 12 weeks of age, the castrate + HYZ group was divided so that the mean BP was the same in both groups (162 mmHg). Both groups continued to receive HYZ treatment; however one group received T implants. Also, at 12 weeks of age the castrate + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b> group received T implants. BP in the HYZ group was reduced compared with controls (192 mmHg vs 218 mmHg, p < 0.01). Castration lowered BP to 170 mmHg (p < 0.01) compared with controls. However, T implants increased BP by 15 mmHg (p < 0.02) in the castrate + HYZ group and by 44 mmHg in the castrate + HYZ + <b style='color:Tomato;'><i>captopril</i></b> group (p < 0.01). <b style='color:MediumOrchid;'><i>Captopril</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>collagen</i></b> <b style='color:DodgerBlue;'><i>deposition</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>spite</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with  <span class="marker" data-anno-id="0" data-anno-label="C1">sirolimus+ crizotinib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C2">abraxane+ celecoxib</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.</u></h4>Despite advances in molecular medicine over recent decades, there has been little advancement in the treatment of osteosarcoma. We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy. ### Patients And Methods Hybridization capture of >300 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer was applied to >50 ng of DNA extracted from tumor samples from two patients with recurrent, metastatic osteosarcoma. The DNA from each sample was sequenced to high, uniform coverage. Immunohistochemical probes and morphoproteomics analysis were performed, in addition to fluorescence in situ hybridization. All analyses were performed in CLIA-certified laboratories. Molecularly targeted therapy based on the resulting profiles was offered to the patients. Biomedical analytics were performed using QIAGEN's Ingenuity® Pathway Analysis. ### results In Patient #1, comprehensive next-generation exome sequencing showed MET amplification, PIK3CA mutation, CCNE1 amplification, and PTPRD mutation. Immunohistochemistry-based morphoproteomic analysis revealed c-Met expression [(p)-c-Met (Tyr1234/1235)] and activation of mTOR/AKT pathway [IGF-1R (Tyr1165/1166), p-mTOR [Ser2448], p-Akt (Ser473)] and expression of SPARC and COX2. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>match</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>P1K3CA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>c-MET</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>SPARC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>COX2</i></b> <b style='color:DodgerBlue;'><i>aberrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>sirolimus+</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>abraxane+</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Patient #2, aberrations included NF2 loss in exons 2-16, PDGFRα amplification, and TP53 mutation. This patient was enrolled on a clinical trial combining targeted agents tem<b style='color:Tomato;'><i>sirolimus</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>, to match NF2, PDGFRα and TP53 aberrations. Both the patients did not benefit from matched therapy. ### conclusions Relapsed osteosarcoma is characterized by complex signaling and drug resistance pathways. Comprehensive molecular profiling holds great promise for tailoring personalized therapies for cancer. Methods for such profiling are evolving and need to be refined to better assist clinicians in making treatment decisions based on the large amount of data that results from this type of testing. Further research in this area is warranted.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  EURAMOS-1 results do not support the addition of  <span class="marker" data-anno-id="0" data-anno-label="N1">ifosfamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">etoposide</span>  to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</u></h4>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. ### methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>methotrexate</i></b> (MAP) or MAP plus <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m ### findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78-1·23]); hazards were non-proportional (p=0·0003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b>). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to <b style='color:Tomato;'><i>methotrexate</i></b>. ### interpretation <b style='color:DodgerBlue;'><i>EURAMOS-1</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>poorly</i></b> <b style='color:DodgerBlue;'><i>responding</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>event-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results define standard of care for this population. New strategies are required to improve outcomes in this setting. ### funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The most effective treatment regimens for advanced nonseminomatous testicular tumors employ  <span class="marker" data-anno-id="0" data-anno-label="P1">vinblastine</span>  , CDDP and  <span class="marker" data-anno-id="1" data-anno-label="P1">bleomycin</span>  and adjunctive surgery . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Preoperative chemotherapy of testicular cancer and Wilm's tumor].</u></h4>Of the various urogenital malignancies, preoperative chemotherapy is most effective for testicular cancer and Wilms' tumor. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>nonseminomatous</i></b> <b style='color:DodgerBlue;'><i>testicular</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>employ</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CDDP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adjunctive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Another effective chemotherapy regimen is combination of <b style='color:Tomato;'><i>vinblastine</i></b>, actinomycin D, <b style='color:Tomato;'><i>bleomycin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and CDDP presented by MSKCC. Available pretreatment with 4 courses of platinum, <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>bleomycin</i></b> before any surgical treatment in those with massive bulk metastatic disease seems to provide the most effective cytoreduction and best survival. Donohue has shown that in a primary chemotherapy group, there is only 20% active carcinoma after primary chemotherapy, whereas in a salvage chemotherapy group there is approximately 50% active carcinoma at surgery. It must therefore be emphasized that complete remission should be obtained by primary chemotherapy and adjunctive surgery. In Wilms' tumor preoperative chemotherapy with <b style='color:Tomato;'><i>vincristine</i></b> and actinomycin D should be given.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">anastrozole</span>  or  <span class="marker" data-anno-id="1" data-anno-label="C1">tamoxifen</span>  : a TransATAC study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Prediction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>distant</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>21-gene</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>score</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>node-negative</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>node-positive</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>TransATAC</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the <b style='color:Tomato;'><i>tamoxifen</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> arms of the Arimidex, <b style='color:Tomato;'><i>tamoxifen</i></b>, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P < .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS > or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in <b style='color:Tomato;'><i>anastrozole</i></b>- and <b style='color:Tomato;'><i>tamoxifen</i></b>-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with <b style='color:Tomato;'><i>tamoxifen</i></b> in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with <b style='color:Tomato;'><i>anastrozole</i></b>, adding value to estimates with standard clinicopathologic features.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Paclitaxel</span>  showed synergistic anti-proliferative impacts with  <span class="marker" data-anno-id="1" data-anno-label="P1">fulvestrant</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.</u></h4>To investigate the prognostic role of the estrogen receptor (ER) in gastric cancer (GC) patients, tumor tissues from 932 patients with advanced GC were assessed for ER expression using immunohistochemistry, and their clinicopathologic features were evaluated. Forty patients (4.3%) had ER expression and they were more frequently associated with diffuse type gastric cancer and shorter disease free survival. Furthermore, we carried out in vitro analysis to evaluate the effect of ER modulation on the proliferation of GC cell lines. Estradiol enhanced proliferation of ER positive GC cells while it did not show any effect on ER negative GC cells. When ER was inhibited by <b style='color:Tomato;'><i>fulvestrant</i></b> and ER siRNA, estradiol-induced proliferation of ER positive GC cell was suppressed. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>anti-proliferative</i></b> <b style='color:DodgerBlue;'><i>impacts</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Suppressing ER by <b style='color:Tomato;'><i>fulvestrant</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b> and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We previously demonstrated that the combination of oral  <span class="marker" data-anno-id="0" data-anno-label="P1">estramustine</span>  ( 15 mg/kg/day ) and oral  <span class="marker" data-anno-id="1" data-anno-label="P1">etoposide</span>  ( 50 mg/m2/day ) is effective first-line therapy for the treatment of hormone refractory prostate cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/m2/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We initiated a new Phase II trial utilizing a lower dose of <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and allowing previous chemotherapy treatment. ### methods <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) were administered orally for 21 of 28 days. Sixty-two patients were enrolled with a minimum of 26 weeks of follow-up. ### results Of 15 patients with measurable soft tissue disease, 8 (53%) had a partial response (PR). Seven of these 8 patients also demonstrated a decrease in baseline prostate-specific antigen (PSA) of more than 50%. The median survival of all patients was 56 weeks. Of 47 patients with disease limited to the bone, 16 (34%) had a PR to therapy based on decrease in pretreatment PSA of more than 50%. Overall, 24 (39%) of 62 patients demonstrated a decrease in pretreatment PSA levels of at least 50% from baseline. Twenty-two patients received previous chemotherapy. There were no differences in survival or disease response in patients treated with previous chemotherapy compared with untreated patients. Pretreatment hemoglobin, PSA, alkaline phosphatase and lactate dehydrogenase levels were not significant prognostic factors, but performance status was an important predictor of survival. ### conclusions We conclude that the combination of oral <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and oral <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) is an active regimen for hormone refractory prostate cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Therapy consisted of  <span class="marker" data-anno-id="0" data-anno-label="P1">bendamustine</span>  ( 70 mg/m(2 ) ) for 2 consecutive days every 28 days , and  <span class="marker" data-anno-id="1" data-anno-label="P1">ofatumumab</span>  300 mg on day 1 and 1000 mg on day 8 during the first cycle , and 1000 mg on day 1 subsequently . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.</u></h4>We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of <b style='color:Tomato;'><i>bendamustine</i></b> in combination with <b style='color:Tomato;'><i>ofatumumab</i></b> (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bendamustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ofatumumab</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>subsequently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57-84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0-95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9-68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade ≥3 neutropenia was observed in 61.7% of patients; however, grade ≥3 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Recent randomized controlled trials ( RCT ) have failed to demonstrate the efficacy of widely used therapies , such as  <span class="marker" data-anno-id="0" data-anno-label="N1/N2">rituximab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="N1">intravenous immunoglobulin</span>  or proteasome inhibition (  <span class="marker" data-anno-id="2" data-anno-label="N2">bortezomib</span>  ) , reinforcing a great need for new therapeutic concepts . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.</u></h4>Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>failed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>demonstrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reinforcing</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>great</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>concepts</i></b> <b style='color:DodgerBlue;'><i>.</i></b> One promising target in this context may be interleukin-6 (IL-6), a pleiotropic cytokine known to play an important role in inflammation and adaptive immunity. ### methods This investigator-driven RCT was designed to assess the safety and efficacy of <b style='color:Tomato;'><i>clazakizumab</i></b>, a genetically engineered humanized monoclonal antibody directed against IL-6. The study will include 20 DSA-positive kidney allograft recipients diagnosed with ABMR ≥ 365 days after transplantation. Participants will be recruited at two study sites in Austria and Germany (Medical University of Vienna; Charité University Medicine Berlin). First, patients will enter a three-month double-blind RCT (1,1 randomization, stratification according to ABMR phenotype and study site) and will receive either <b style='color:Tomato;'><i>clazakizumab</i></b> (subcutaneous administration of 25 mg in monthly intervals) or placebo. In a second open-label part of the trial (months 4-12), all patients will receive <b style='color:Tomato;'><i>clazakizumab</i></b> at 25 mg every month. The primary endpoint is safety and tolerability. Secondary endpoints are the pharmacokinetics and pharmacodynamics of <b style='color:Tomato;'><i>clazakizumab</i></b>, its effect on drug metabolism in the liver, DSA characteristics, morphological ABMR lesions and molecular gene expression patterns in three- and 12-month protocol biopsies, serum/urinary biomarkers of inflammation and endothelial activation/injury, Torque Teno viral load as a measure of overall immunosuppression, kidney function, urinary protein excretion, as well as transplant and patient survival. ### discussion Currently, there is no treatment proven to be effective in halting the progression of late ABMR. Based on the hypothesis that antagonizing the effects of IL-6 improves the outcome of DSA-positive late ABMR by counteracting DSA-triggered inflammation and B cell/plasma cell-driven alloimmunity, we suggest that our trial has the potential to provide proof of concept of a novel treatment of this type of rejection. ### Trial Registration ClinicalTrials.gov, NCT03444103 . Registered on 23 February 2018 (retrospective registration).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  compared to  <span class="marker" data-anno-id="0" data-anno-label="P1">busulfan</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>busulfan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>conditioning</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>allogeneic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>matched</i></b> <b style='color:DodgerBlue;'><i>siblings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>unrelated</i></b> <b style='color:DodgerBlue;'><i>donors</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>busulfan</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo-SCT) for young, fit patients with acute myeloid leukemia (AML). The <b style='color:Tomato;'><i>thiotepa</i></b>-<b style='color:Tomato;'><i>busulfan</i></b>-<b style='color:Tomato;'><i>fludarabine</i></b> (TBF) protocol has recently demonstrated promising outcome in cord blood and haploidentical SCT; however, there is limited evidence about this regimen in transplant from matched siblings (MSD) and unrelated donors (UD). We retrospectively compared outcomes of 2523 patients aged 18-50 with AML in remission, undergoing transplant from MSD or UD prepared with either TBF or BuCy conditioning. A 1:3 pair-matched analysis was performed: 146 patients receiving TBF were compared with 438 patients receiving BuCy. Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P = .02), while NRM did not differ. No significant difference was observed in LFS and OS between the two regimens. TBF was associated with a trend towards higher risk of grades III-IV aGVHD (HR 1.8, P = .06) and inferior cGVHD (HR 0.7, P = .04) when compared with BuCy. In patients undergoing transplant in first remission, the advantage for TBF in terms of relapse was more evident (HR 0.4, P = .02), leading to a trend for better LFS in favor of TBF (HR 0.7, P = .10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid myeloablative conditioning regimen providing significantly lower relapse and similar survival when compared with BuCy. Patients in first remission appear to gain the most from this protocol, as in this subgroup a tendency for better LFS was observed when compared with BuCy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  After clinical improvement under  <span class="marker" data-anno-id="0" data-anno-label="P1">vemurafenib</span>  monotherapy , four cycles of  <span class="marker" data-anno-id="1" data-anno-label="P1">ipilimumab</span>  were additionally administered . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.</u></h4>Sixteen BRAF-mutation positive, metastatic melanoma patients with highly advanced disease received combination therapy of <b style='color:Tomato;'><i>vemurafenib</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> as an individual treatment decision. Our aim was to assess the role of fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (PET/CT) in the evaluation of the clinical benefit (CB) of this combination treatment. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:MediumOrchid;'><i>vemurafenib</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>additionally</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>.</i></b> F-FDG PET/CT was performed before the start, after two cycles and after completion of the combined <b style='color:Tomato;'><i>ipilimumab</i></b>/<b style='color:Tomato;'><i>vemurafenib</i></b> treatment. PET-based patient response evaluation to treatment was based on the European Organization for Research and Treatment of Cancer and the PET Response Evaluation Criteria for Immunotherapy criteria. Progression-free survival (PFS) from the end of combination treatment was calculated. According to their best clinical response at the end of combination treatment, eight patients showed CB and eight patients had no-CB. Two patients revealed extraordinary good clinical outcome with PFS of more than 5 years. Overall, 13 out of 16 patients were correctly classified by the European Organization for Research and Treatment of Cancer and 15 out of 16 by the PET Response Evaluation Criteria for Immunotherapy criteria. Median PFS was 8.8 months among PET-responders and 3.6 months among nonresponders. During immunotherapy administration seven patients developed radiologic signs of immune-related adverse events (irAEs), with colitis and arthritis being the most frequent ones; these patients had a significantly longer PFS than those without irAEs (P=0.036). F-FDG PET/CT is a valuable tool for the evaluation of patients receiving a combination of targeted treatment and immunotherapy. The appearance of irAEs on PET/CT might correlate with benefit to immunotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  In FOLL05 trial , R-CHOP was compared with R-CVP ( cyclophosphamide , vincristine , prednisone ) and R-FM (  <span class="marker" data-anno-id="0" data-anno-label="C2">fludarabine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C2">mitoxantrone</span>  ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.</u></h4>Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (<b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has been shown to be better than <b style='color:Tomato;'><i>fludarabine</i></b> alone and <b style='color:Tomato;'><i>fludarabine</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> for IL. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>FOLL05</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>R-CVP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>R-FM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (<b style='color:Tomato;'><i>bendamustine</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Posttransplant immunosuppression to prevent graft-versus-host disease ( GVHD ) consisted of  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclosporine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  ( CSA/PSE ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.</u></h4>Two novel preparatory regimens for conditioning of patients with leukemia for allogeneic bone marrow transplantation (BMT) from histocompatible sibling donors have been tested in a phase III trial under the auspices of the Southwest Oncology Group (SWOG 8612). These two regimens consisted either of fractionated total body irradiation and <b style='color:Tomato;'><i>etoposide</i></b> (FTBI/VP-16) or high-dose <b style='color:Tomato;'><i>busulfan</i></b> with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BU/CY). Only patients who had failed prior conventional management at least once were study eligible, ie, no patients with acute leukemia in first remission (CR) or in first chronic phase (CP) of chronic myelogenous leukemia (CML) participated. Patients were stratified according to the following risk criteria: "good-risk" patients were those who were in second CR of their acute leukemia or in accelerated phase (AP) of CML; "poor-risk" patients had further advanced stages of leukemia. During a 52-month period, 131 patients were registered of whom 122 (93%) were study eligible. Sixty-one eligible patients were randomized to the FTBI/VP-16 arm and 61 to the BU/CY regimen. Of these 122 patients, 114 (93%) proceeded to BMT according to protocol. <b style='color:DodgerBlue;'><i>Posttransplant</i></b> <b style='color:DodgerBlue;'><i>immunosuppression</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>graft-versus-host</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CSA/PSE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neither overall survival nor disease-free survival (DFS) differed significantly between the two treatment groups (P = .89 and .69, respectively). Estimated DFS for "good-risk" patients who had been prepared with the FTBI/VP-16 regimen was 55% +/- 11%, as compared with patients treated with BU/CY whose DFS figure was 34% +/- 10% (P = .30). For "poor-risk" candidates, the DFS rates at 24 months were 17% +/- 6% (for FTBI/VP-16) and 24% +/- 8% (for BU/CY), respectively (P = .81). These figures do not differ significantly, especially in view of the fact that the "good-risk" patients prepared with the FTBI/VP-16 regimen were younger than those treated with BU/CY. Both regimens were well tolerated with no regimen-related deaths encountered during the 6-week period after BMT. This study also confirmed the efficacy of the CSA/PSE combination in the prevention of GVHD with 23 of 113 (20%) of BMT recipients developing moderate to severe acute GVHD. The leading cause for treatment failure was leukemic relapse (45 of the 114 BMT recipients suffered a recurrence of their leukemia), whereas 38 patients died without evidence of relapse. Thirty-one patients are alive and in continued CR after marrow transplantation; four are alive in relapse.(ABSTRACT TRUNCATED AT 400 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Either 5-fluorouracil (  <span class="marker" data-anno-id="0" data-anno-label="P1">5-FU</span>  ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">leucovorin</span>  for 6 months or  <span class="marker" data-anno-id="2" data-anno-label="P2">5-FU</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P2">levamisole</span>  for 12 months are currently considered standard adjuvant treatment for stage III colorectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>National Cancer Institute Clinical Trials Program in Colorectal Cancer.</u></h4>Colorectal cancer will be diagnosed in approximately 150,000 patients in the USA this year. Chemotherapy has recently been shown to improve survival when given as adjuvant therapy to surgery in patients with stage III colorectal cancer. Demonstration of this benefit required large, randomized controlled trials. <b style='color:DodgerBlue;'><i>Either</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levamisole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, current adjuvant trials are comparing continuous infusion and intravenous bolus 5-FU regimens and oral uracil/Ftorafur with intravenous 5-FU and <b style='color:Tomato;'><i>leucovorin</i></b>, as well as studying the timing of chemotherapy in the adjuvant setting. Subsequent adjuvant trials will examine newer regimens with activity in advanced colorectal cancer, as well as the efficacy of monoclonal antibodies. Other trials will study which type of surgery is optimal and whether adjuvant therapy is helpful in stage II colon cancer. Trials in metastatic disease will focus on combinations of newer agents which may improve survival in this patient group. Studies in rectal cancer will focus on determining which agents are optimal in combination with radiation therapy in the adjuvant setting. Molecular characteristics of tumor cells are being defined, which may guide therapy in the future. Careful, logically designed clinical trials will hopefully provide more efficacious therapy for this common cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Dual Therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">Aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Cilostazol</span>  May Improve Platelet Aggregation in Noncardioembolic Stroke Patients : A Pilot Study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Cilostazol</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>Improve</i></b> <b style='color:DodgerBlue;'><i>Platelet</i></b> <b style='color:DodgerBlue;'><i>Aggregation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Noncardioembolic</i></b> <b style='color:DodgerBlue;'><i>Stroke</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Pilot</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> for prevention of secondary stroke, but the physiological mechanism involved remains unknown. We aimed to clarify the effects of <b style='color:Tomato;'><i>aspirin</i></b>/<b style='color:Tomato;'><i>cilostazol</i></b> therapy on the platelet and endothelial functions of patients with acute noncardioembolic ischemic stroke, in comparison to patients who were treated with <b style='color:Tomato;'><i>aspirin</i></b> alone. Methods The present randomized prospective pilot study enrolled 24 patients within a week after the onset of noncardioembolic ischemic stroke. The patients were randomly allocated to receive <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (A group; 11 patients) or <b style='color:Tomato;'><i>cilostazol</i></b> (200 mg/day) plus <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (CA group; 13 patients). We measured platelet aggregation, platelet activation, and the thrombomodulin (TM), highly sensitive C-reactive protein (hs-CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand (vWF) antigen levels and vWF activity over a 4-week period after enrollment. Results There was no significant difference in the platelet functions of the A and CA groups. However, the platelet aggregation induced by adenosine diphosphate (ADP) was decreased at 2 and 4 weeks (p<0.05) after treatment in comparison to the pre-treatment values in the CA group, but not in the A group. Platelet activation, and the hs-CRP, TM, ICAM-1, VCAM-1 and vWF values did not significantly decrease after treatment in either group. Conclusion Although there were no significant differences in platelet aggregation, platelet activation or the endothelial biomarker levels of the A and CA groups, dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> inhibited platelet aggregation in comparison to the pre-treatment values, similarly to patients who received <b style='color:Tomato;'><i>aspirin</i></b> alone. This may suggest the clinical usefulness of dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> in the treatment of patients with noncardioembolic ischemic stroke.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Efficacy of  <span class="marker" data-anno-id="0" data-anno-label="P1">sorafenib</span>  combined with the pan-CDK inhibitor  <span class="marker" data-anno-id="1" data-anno-label="P1">flavopiridol</span>  was tested both in vitro and in xenograft experiments . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.</u></h4>To clarify the effects of cyclin E1 suppression on antitumor efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma cells and to explore the potential of combining <b style='color:Tomato;'><i>sorafenib</i></b> with cyclin-dependent kinase (CDK) inhibition in therapy. ### Experimental Design The effects of cyclin E1 suppression on <b style='color:Tomato;'><i>sorafenib</i></b>-induced apoptosis were tested in both <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive (Huh-7 and HepG2, IC50 5-6 μmol/L) and <b style='color:Tomato;'><i>sorafenib</i></b>-resistant (Huh-7R and HepG2R, IC50 14-15 μmol/L) hepatocellular carcinoma cells. The activity of pertinent signaling pathways and the expression of cell cycle and apoptosis-related proteins were measured using Western blotting. <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pan-CDK</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>flavopiridol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>experiments</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pertinent downstream mediators of antitumor efficacy were tested in transient transfection and RNA interference experiments. ### results Cyclin E1 mRNA and protein expressions were suppressed after <b style='color:Tomato;'><i>sorafenib</i></b> treatment in <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive but not in <b style='color:Tomato;'><i>sorafenib</i></b>-resistant hepatocellular carcinoma cells. Changes in cyclin E2 or D1 were not correlated with <b style='color:Tomato;'><i>sorafenib</i></b> sensitivity. The knockdown of cyclin E1 expression reversed the resistance of hepatocellular carcinoma cells to <b style='color:Tomato;'><i>sorafenib</i></b> in terms of cell growth and apoptosis induction, whereas the overexpression of cyclin E1 increased the resistance to <b style='color:Tomato;'><i>sorafenib</i></b>. The growth-inhibitory and apoptosis-inducing effects of <b style='color:Tomato;'><i>sorafenib</i></b> were enhanced by <b style='color:Tomato;'><i>flavopiridol</i></b>, and Mcl-1 suppression was determined to play a critical role in mediating this enhancing effect. ### conclusions The cyclin E1 suppression in hepatocellular carcinoma cells may serve as a pharmacodynamic biomarker for predicting <b style='color:Tomato;'><i>sorafenib</i></b> efficacy. The combination of <b style='color:Tomato;'><i>sorafenib</i></b> and CDK inhibitors may improve the efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma. Clin Cancer Res; 22(10); 2555-64. ©2015 AACR.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Gemcitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">vinorelbine</span>  have shown activity in the first-line setting . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.</u></h4><b style='color:Tomato;'><i>pemetrexed</i></b>-cisplatin chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The objective of this study was to evaluate the activity and toxicity of the <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>vinorelbine</i></b> combination in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. ### methods From January 2004 to September 2006, 30 consecutive patients who were pretreated with <b style='color:Tomato;'><i>pemetrexed</i></b> with or without a platinum-derivative were enrolled. <b style='color:Tomato;'><i>gemcitabine</i></b> 1000 mg/m(2) and <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m(2) were administered intravenously on Days 1 and 8 every 3 weeks. Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity. ### results A partial response was observed in 3 patients (10%; 95% confidence interval [CI], 2.1-26.5%), and 10 patients (33.3%; 95% CI, 17.3-52.8%) had stable disease after treatment. Overall, 13 patients (43.3%; 95% CI, 25.5-62.6%) achieved disease control. The median time to progression was 2.8 months (range, 0.6-12.1 months), and the median survival was 10.9 months (range, 0.8-25.3 months). Hematologic toxicity was acceptable, with grade 3 or 4 neutropenia occurring in 11% of patients and thrombocytopenia occurring in 4% of patients; no case of febrile neutropenia was observed. Nonhematologic toxicity generally was mild. ### conclusions The <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination was moderately active and had an acceptable toxicity profile in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  The combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">tenofovir disoproxil fumarate</span>  ( TDF ) plus  <span class="marker" data-anno-id="1" data-anno-label="P1">emtricitabine</span>  ( FTC ) is used extensively to treat HIV infection and also has potent activity against hepatitis B virus ( HBV ) infection . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disoproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TDF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>emtricitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FTC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>extensively</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>treat</i></b> <b style='color:DodgerBlue;'><i>HIV</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HBV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The aim of this study was to assess the efficacy and tolerance of TDF + FTC in patients with chronic hepatitis B (CHB). ### methods Seventy eight consecutive CHB patients from five European centers were included. All started a TDF + FTC combination between October 2005 and March 2010. Virological, biochemical, and clinical data were recorded during follow-up. Tolerance was also monitored. Patients were classified into either treatment simplification (TS), where efficacy of the previous treatment was obtained at TDF + FTC initiation, and treatment intensification (TI), where the previous line of therapy had failed. ### results TDF + FTC was given as a TI to 54 patients (69%) and as a TS to 24 (31%). Among patients with TI, 83% were males. The median baseline HBV-DNA was 4.4 log10 IU/mL, and median alanine-transaminase (ALT) was 1.10 × ULN. Sixty percent were HBeAg positive, 47% had significant fibrosis (≥ F3 Metavir equivalent), and 29% had confirmed cirrhosis. Median treatment duration was 76 weeks (interquartile range 60-116). Kaplan-Meier analysis showed that, 48 weeks after TI, the probability of being HBV-DNA becoming undetectable was 76%, and reached 94% at week 96. No viral breakthrough occurred. Patients with TS (87% males, median baseline HBV-DNA 1.1 log10 IU/mL, median ALT 0.79 × ULN, 33% HBeAg positive, 61% with significant fibrosis) were treated for a median duration of 76 weeks. In this subgroup, all patients but one remained HBV-DNA undetectable and no ALT flare-up occurred during follow-up. Creatinine levels did not show kidney-function deterioration in either group of patients. ### conclusions After a median follow-up of > 76 weeks, the TDF + FTC combination showed encouraging antiviral efficacy and a good safety profile in all patients with CHB. TDF + FTC may represent an interesting clinical option to simplify therapy and increase the barrier to resistance, which should be assessed in the long term.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Codelivery of  <span class="marker" data-anno-id="0" data-anno-label="P1">sorafenib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">curcumin</span>  by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Codelivery</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>directed</i></b> <b style='color:DodgerBlue;'><i>self-assembled</i></b> <b style='color:DodgerBlue;'><i>nanoparticles</i></b> <b style='color:DodgerBlue;'><i>enhances</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>hepatocellular</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Herein, we first reported the codelivery of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> by directed self-assembled nanoparticles (SCN) to enhance the therapeutic effect on HCC. SCN was formed by employing the hydrophobic interactions among the lipophilic structure in <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and similar hydrophobic segments of polyethylene glycol derivative of vitamin E succinate (PEG-VES), which comprised uniform spherical particles with particle size of 84.97 ± 6.03 nm. SCN presented superior effects over <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and their physical mixture (Sora + Cur) on enhancing in vitro cytotoxicity and cell apoptosis in BEL-7402 cells and Hep G2 cells, and antiangiogenesis activities in tube formation and microvessel formation from aortic rings. Moreover, the tissue concentration of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> in gastrointestinal tract and major organs were significantly improved after their coassembly into SCN. In particular, in BEL-7402 cells induced tumor xenograft, SCN treatment displayed the obviously enhanced inhibitory effect on tumor progression over free drug monotherapy or their physical mixture, with significantly increased antiproliferation and antiangiogenesis capability. Thereby, the codelivered nanoassemblies of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> provided a promising strategy to enhance the combinational therapy of HCC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Single treatment of  <span class="marker" data-anno-id="0" data-anno-label="P1">closantel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">albendazole</span>  mixture reduced egg counts in camels by 100 % , 100 % , 98 % and 77 % for Haemonchus longistipes , Ascaris spp . , Monezia expansa and Fasciola hepatica , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of closantel plus albendazole liquid suspension against natural infection of gastrointestinal parasites in camels.</u></h4>Oral administration of <b style='color:Tomato;'><i>closantel</i></b> in a dose of 10 mg/kg plus <b style='color:Tomato;'><i>albendazole</i></b> in a dose of 5 mg/kg liquid suspension was studied in 75 camels naturally infected with various types of gastrointestinal parasites. The camels involved were 15 pregnant she-camels, 20 non-pregnant she-camels and 40 male camels of various ages. Each camel received a single oral dose of <b style='color:Tomato;'><i>closantel</i></b> (10 mg/kg) plus <b style='color:Tomato;'><i>albendazole</i></b> (5 mg/kg) orally. Two weeks later, 20 camels of this group were re-dosed again with the same dose of the anthelmintic. Fecal samples were collected per rectum from all camels at the time of treatment and again 14 and 42 days post treatment. Fecal egg counts and generic determination of third stage larvae was performed. Results indicated that six different species of gastrointestinal tract parasites were identified in camels. <b style='color:DodgerBlue;'><i>Single</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>closantel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>albendazole</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>egg</i></b> <b style='color:DodgerBlue;'><i>counts</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>camels</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>98</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>77</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Haemonchus</i></b> <b style='color:DodgerBlue;'><i>longistipes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Ascaris</i></b> <b style='color:DodgerBlue;'><i>spp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Monezia</i></b> <b style='color:DodgerBlue;'><i>expansa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Fasciola</i></b> <b style='color:DodgerBlue;'><i>hepatica</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, administration of the drug twice on the base of 2 weeks apart significantly raised the efficacy of the drug for clearance of the parasites from 92.5% to 100% in camels infected with various parasites. Camels were not adversely affected by treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Second-line chemotherapy was also ineffective ; therefore , the  <span class="marker" data-anno-id="0" data-anno-label="P1">bevacizumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">irinotecan</span>  were given after a third gross-total resection of the tumor . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.</u></h4>A 5-year-old boy with glioblastoma relapsed soon after postoperative irradiation in combination with <b style='color:Tomato;'><i>temozolomide</i></b>. <b style='color:DodgerBlue;'><i>Second-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>ineffective</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>gross-total</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re-initiated at a lower dose of <b style='color:Tomato;'><i>bevacizumab</i></b> with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> are a promising regimen for pediatric cases of recurrent glioblastoma after gross-total resection, although the optimal treatment schedule must be determined on a patient-by-patient basis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive  <span class="marker" data-anno-id="0" data-anno-label="P1/C1">cisplatin</span>  ( 75 mg per square meter of body-surface area ) with either  <span class="marker" data-anno-id="1" data-anno-label="C1">cyclophosphamide</span>  ( 750 mg per square meter ) or  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  ( 135 mg per square meter over 24 hours ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.</u></h4>Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, cisplatin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> and cisplatin and <b style='color:Tomato;'><i>paclitaxel</i></b>, in women with ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>410</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>masses</i></b> <b style='color:DodgerBlue;'><i>larger</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>cm</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>body-surface</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>750</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group. Among 216 women with measurable disease, 73 percent in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group responded to therapy, as compared with 60 percent in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (P = 0.01). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group than in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (median, 18 vs. 13 months). Survival was also significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group (median, 38 vs. 24 months). ### conclusions Incorporating <b style='color:Tomato;'><i>paclitaxel</i></b> into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">rapamycin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  resulted in decreased phosphorylation of S6 and 4E-BP1 , two critical downstream targets of the mTOR pathway . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.</u></h4>Mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitors modulate signaling pathways involved in cell cycle progression, and recent phase II trials demonstrate activity in patients with endometrial cancer. Our objective was to examine the effects of combination therapy with <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cell lines. <b style='color:Tomato;'><i>paclitaxel</i></b> inhibited proliferation in a dose-dependent manner in both cell lines with IC(50) values of 0.1-0.5 nM and 1-5 nM for Ishikawa and ECC-1 cells, respectively. To assess synergy of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>rapamycin</i></b>, the combination index (CI) was calculated by the method of Chou and Talalay. Simultaneous exposure of cells to various doses of <b style='color:Tomato;'><i>paclitaxel</i></b> in combination with <b style='color:Tomato;'><i>rapamycin</i></b> (1 nM) resulted in a significant synergistic anti-proliferative effect (CI <1, range 0.131-0.920). <b style='color:Tomato;'><i>rapamycin</i></b> alone did not induce apoptosis, but combined treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> increased apoptosis over that of <b style='color:Tomato;'><i>paclitaxel</i></b> alone. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>phosphorylation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>S6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4E-BP1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>critical</i></b> <b style='color:DodgerBlue;'><i>downstream</i></b> <b style='color:DodgerBlue;'><i>targets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>rapamycin</i></b> decreased hTERT mRNA expression by real-time RT-PCR while <b style='color:Tomato;'><i>paclitaxel</i></b> alone had no effect on telomerase activity. <b style='color:Tomato;'><i>paclitaxel</i></b> increased polymerization and acetylation of tubulin, and <b style='color:Tomato;'><i>rapamycin</i></b> appeared to enhance this effect. Thus, in conclusion, we demonstrate that <b style='color:Tomato;'><i>rapamycin</i></b> potentiates the effects of <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cells through inhibition of cell proliferation, induction of apoptosis and potentially increased polymerization and acetylation of tubulin. This suggests that the combination of <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> may be a promising effective targeted therapy for endometrial cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Conversely , the IMbrave150 trial recently showed that , among patients with previously untreated unresectable HCC , treatment with  <span class="marker" data-anno-id="0" data-anno-label="P1">atezolizumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">bevacizumab</span>  resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.</u></h4>Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer worldwide, and the overall survival of patients with unresectable disease is poor. In the last five years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment scenario of several hematological and solid tumors, and these agents have been actively explored in unresectable HCC. Firstly, promising findings of phase I and II clinical studies reporting durable responses and a tolerable safety profile have led to the assessment of ICIs as single agents in phase III clinical studies; however, the latter have provided controversial results, and the activity of ICI monotherapy seems limited to a small subgroup of patients. <b style='color:DodgerBlue;'><i>Conversely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>IMbrave150</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In addition, the activity of several other ICIs is under investigation, as combination immunotherapy as well as combinations of immunotherapy with antiangiogenic agents. Nonetheless, there are currently no validated predictive biomarkers able to guide treatment choice in this setting, where the identification of specific predictors of response to ICIs represents a major challenge. In this review, we aim to provide a critical overview of recent evidence on biochemical predictors of response to ICIs in patients with unresectable HCC, especially focusing on PD-L1, TMB, MSI, and other emerging biomarkers.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Evaluation of  <span class="marker" data-anno-id="0" data-anno-label="P1">tamoxifen</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">letrozole</span>  with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>assessment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of <b style='color:Tomato;'><i>letrozole</i></b> on <b style='color:Tomato;'><i>tamoxifen</i></b> (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus <b style='color:Tomato;'><i>letrozole</i></b>; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or evaluable metastatic breast cancer received TAM (20 mg daily) for 6 weeks, and then <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg daily) was added. To examine for any effect of <b style='color:Tomato;'><i>letrozole</i></b> on the levels of TAM and two metabolites [N-desmethyl-TAM and 4-hydroxy-TAM], serum samples were obtained at 6, 12, 18, and 24 weeks. To examine for aromatase inhibition, serum samples were obtained before treatment and at 6, 12, 18, and 24 weeks for estradiol, <b style='color:Tomato;'><i>estrone</i></b> (E1) E1 sulfate, and sex hormone-binding globulin. A total of 34 patients were entered on this trial, and 23 patients were still on study at week 24, 18 of whom had blood samples available at both week 6 and week 24. The 95% confidence interval for the mean difference between levels at week 24 and levels at week 6 was -34 to 15 ng/ml for TAM, -35 to 45 ng/ml for N-desmethyl-TAM, and -1 to 2 for 4-hydroxy-TAM. For estradiol, a significant decrease (median, 88.5%; range, 73.7-95.2%) was identified after 6 weeks of <b style='color:Tomato;'><i>letrozole</i></b>, which was maintained for an additional 12 weeks. Similar significant reductions were identified for E1. E1 sulfate levels increased after 6 weeks of TAM alone but then decreased significantly after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Sex hormone-binding globulin levels were significantly elevated after 6 weeks of TAM alone and remained elevated after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months. There was no indication of a systematic decrease in TAM, N-desmethyl-TAM, or 4-hydroxy-TAM after the additional of <b style='color:Tomato;'><i>letrozole</i></b>. Estrogen suppression induced by <b style='color:Tomato;'><i>letrozole</i></b> was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus <b style='color:Tomato;'><i>letrozole</i></b> was less than expected.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  The EVERLAR study reports prospective data of  <span class="marker" data-anno-id="0" data-anno-label="P1">somatostatin</span>  analogue in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">everolimus</span>  in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.</u></h4>Antitumor activity of the combination of <b style='color:Tomato;'><i>somatostatin</i></b> analogues (SSAs) and the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitor <b style='color:Tomato;'><i>everolimus</i></b> in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. ### Materials And Methods This prospective, multicenter, single-arm phase II EVERLAR study evaluated <b style='color:Tomato;'><i>everolimus</i></b> 10 mg/day and the SSA <b style='color:Tomato;'><i>octreotide</i></b> 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials.gov NCT01567488). Prior treatment with SSAs and any systemic or locoregional therapy was allowed except for mTOR inhibitors. Patients continued treatment until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS) at 12 months; secondary endpoints included early biochemical response, objective response rate (ORR) by RECIST v1.0, overall survival (OS), AEs, activation of mTOR pathway (insulin-like growth factor 1 receptor [IGF1R] and phosphoS6 [pS6] expression). ### results Forty-three patients were included in the intent-to-treat analyses. After 12 months of treatment, 62.3% (95% confidence interval [CI] 48%-77%) of patients had not progressed or died. The 24-month PFS rate was 43.6% (95% CI 29%-58%). The confirmed ORR was 2.3%, and stable disease was 58.1%. Median OS was not reached after 24 months of median follow-up. Dose reductions and temporary interruptions due to AEs were required in 14 (33%) and 33 (77%) patients, respectively. The most frequent AEs were diarrhea, asthenia, mucositis, rash, and hyperglycemia. No correlation was observed between IGFR1 and pS6 expression and PFS/OS. ### conclusion The <b style='color:Tomato;'><i>everolimus</i></b>-<b style='color:Tomato;'><i>octreotide</i></b> combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting. ### Implications For Practice <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>EVERLAR</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>analogue</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonfunctioning</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>neuroendocrine</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>meaningful</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>favorable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>profile</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>supports</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Synergism between anti-HER2 monoclonal antibody (  <span class="marker" data-anno-id="0" data-anno-label="P1">trastuzumab</span>  ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  has been shown in vitro and in vivo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.</u></h4> <b style='color:DodgerBlue;'><i>Synergism</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>anti-HER2</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In previous experiences, weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity and the toxicity of this weekly regimen in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Between November 1999 and July 2001, 25 patients were treated with <b style='color:Tomato;'><i>trastuzumab</i></b> (4 mg kg(-1) i.v. loading dose followed by 2 mg kg(-1) i.v. week(-1)) and <b style='color:Tomato;'><i>paclitaxel</i></b> (60-90 mg m(-2) h(-1) i.v. infusion week(-1)). The treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, after 6 months of therapy, the decision to stop <b style='color:Tomato;'><i>paclitaxel</i></b> while continuing weekly <b style='color:Tomato;'><i>trastuzumab</i></b> was left to the physicians' judgement. At the median follow-up of 19.6 months (range 9.2-38.1), all patients are evaluable for response and toxicity. We obtained four (16%) complete responses (CR), 10 (40%) partial responses (PR), four (16%) stable diseases and seven (28%) disease progressions. The response rate (CR+PR) was 56% (95% CI, 36.5-75.5%). The median duration of response was 10.4 months (range 4.1-24.2+). Median time to progression was 8.6 months (range 2.5-24.2+). The toxicity was mild; five patients experienced fever and chills during the first infusion of <b style='color:Tomato;'><i>trastuzumab</i></b> (20%); leukopenia grade 2 was recorded in one patient (4%). Two patients (8%) came off study for grade 3 cardiotoxicity (after 9 and 17 weeks of treatment, respectively): both had already received anthracyclines and taxanes. Onycholysis grade 2 was observed in five patients (20%). These results confirm that weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing. Since cardiac disfunctions grade 3 were observed (8%), we recommend that cardiac function should be monitored in these patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Bevacizumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">paclitaxel</span>  versus  <span class="marker" data-anno-id="2" data-anno-label="P1">bevacizumab</span>  plus  <span class="marker" data-anno-id="3" data-anno-label="P1">capecitabine</span>  as first-line treatment for HER2-negative metastatic breast cancer ( TURANDOT ): primary endpoint results of a randomised , open-label , non-inferiority , phase 3 trial . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Bevacizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>HER2-negative</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TURANDOT</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>endpoint</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomised</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>non-inferiority</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The randomised phase 3 TURANDOT trial compared two approved <b style='color:Tomato;'><i>bevacizumab</i></b>-containing regimens for HER2-negative metastatic breast cancer in terms of efficacy, safety, and quality of life. The interim analysis did not confirm non-inferior overall survival (stratified hazard ratio [HR] 1·04; 97·5% repeated CI [RCI] -∞ to 1·69). Here we report final results of our study aiming to show non-inferior overall survival with first-line <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> versus <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> for locally recurrent or metastatic breast cancer. ### methods In this multinational, open-label, randomised phase 3 TURANDOT trial, patients aged 18 years or older who had an Eastern Cooperative Oncology Group performance status 0-2 and measurable or non-measurable HER2-negative locally recurrent or metastatic breast cancer who had received no previous chemotherapy for locally recurrent or metastatic breast cancer were stratified and randomly assigned (1:1) using permuted blocks of size six to either <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> (<b style='color:Tomato;'><i>bevacizumab</i></b> 10 mg/kg on days 1 and 15 plus <b style='color:Tomato;'><i>paclitaxel</i></b> 90 mg/m(2) on days 1, 8, and 15 every 4 weeks) or <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> (<b style='color:Tomato;'><i>bevacizumab</i></b> 15 mg/kg on day 1 plus <b style='color:Tomato;'><i>capecitabine</i></b> 1000 mg/m(2) twice daily on days 1-14 every 3 weeks) until disease progression, unacceptable toxicity, or withdrawal of consent. Stratification factors were oestrogen or progesterone receptor status, country, and menopausal status. The primary objective was to show non-inferior overall survival with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> versus <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the per-protocol population by rejecting the null hypothesis of inferiority (HR ≥1·33) using a stratified Cox proportional hazard model. This trial is registered with ClinicalTrials.gov, number NCT00600340. ### findings Between Sept 10, 2008, and Aug 30, 2010, 564 patients were randomised, representing the intent-to-treat population. The per-protocol population comprised 531 patients (266 in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> group and 265 in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> group). At the final overall survival analysis after 183 deaths (69%) in 266 patients receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> and 201 (76%) in 265 receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> in the per-protocol population, median overall survival was 30·2 months (95% CI 25·6-32·6 months) versus 26·1 months (22·3-29·0), respectively. The stratified HR was 1·02 (97·5% RCI -∞ to 1·26; repeated p=0·0070), indicating non-inferiority. The unstratified Cox model (HR 1·13 [97·5% RCI -∞ to 1·39]; repeated p=0·061) did not support the primary analysis. Intent-to-treat analyses were consistent with the per-protocol results. The most common grade 3 or worse adverse events were neutropenia (54 [19%] of 284 patients in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> group vs 5 [2%] of 277 patients in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> group), hand-foot syndrome (1 [<1%] vs 43 [16%]), peripheral neuropathy (39 [14%] vs 1 [<1%]), leucopenia (20 [7%] vs 1 [<1%]), and hypertension (12 [4%] vs 16 [6%]). Serious adverse events were reported in 65 (23%) of 284 patients receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> and 68 (25%) of 277 receiving <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. Deaths in two (1%) of 284 patients in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> group were deemed by the investigator to be treatment-related. No treatment-related deaths occurred in the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> group. ### interpretation <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> represents a valid first-line treatment option for HER2-negative locally recurrent or metastatic breast cancer, offering good tolerability without compromising overall survival compared with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Although progression-free survival with the <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> combination is inferior to that noted with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>, we suggest that physicians should consider possible predictive risk factors for overall survival, individual's treatment priorities, and the differing safety profiles. ### funding Roche.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  All patients underwent  <span class="marker" data-anno-id="0" data-anno-label="P1">mexiletine</span>  monotherapy ( M-mono ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">propafenone</span>  monotherapy ( P-mono ) , low dose combination therapy ( low M+P ) , and full dose combination therapy ( full M+P ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy.</u></h4>The electrophysiological effects of combination therapy of <b style='color:Tomato;'><i>mexiletine</i></b> and <b style='color:Tomato;'><i>propafenone</i></b> were assessed using standard 12-lead electrocardiogram (standard ECG), signal-averaged ECG (SAECG), and ambulatory ECG in 31 patients with ventricular arrhythmias. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:MediumOrchid;'><i>mexiletine</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>M-mono</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>propafenone</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P-mono</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>M+P</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>full</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>full</i></b> <b style='color:DodgerBlue;'><i>M+P</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Full M+P increased the PQ interval and QRS duration to the same extent as P-mono did. Low M+P increased PQ interval and QRS duration to a lesser extent than P-mono and full M+P did. P-mono and full M+P significantly decreased root mean square (RMS) and increased f-QRS in SAECG, while M-mono and low M+P showed only a weak trend. SAECGs with late potentials increased in number with treatments; 9 in predrug control, 11 on M-mono, 15 on P-mono, 10 on low M+P, and 14 on full M+P. The percent suppression of frequent premature ventricular contractions (PVCs) (> 1,000/day) with M-mono, P-mono, low M+P, and full M+P were 46.4 +/- 9.0, 56.6 +/- 10.4, 64.4 +/- 9.2, and 71.4 +/- 7.1, respectively, and those of frequent couplets (> 10/day) were 58.3 +/- 17.7, 62.6 +/- 23.6, 87.5 +/- 6.2, and 92.1 +/- 4.0, respectively. Thus, full dose combination of <b style='color:Tomato;'><i>mexiletine</i></b> and <b style='color:Tomato;'><i>propafenone</i></b> exhibited the maximum antiarrhythmic efficacy without enhancement of effects on standard ECG and SAECG. Low dose combination therapy showed better antiarrhythmic efficacy in association with lesser effects on standard ECG and SAECG compared with <b style='color:Tomato;'><i>propafenone</i></b> monotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Cephalexin</span>  , 500 mg 4 times daily , plus  <span class="marker" data-anno-id="1" data-anno-label="C1">trimethoprim-sulfamethoxazole</span>  , 320 mg/1600 mg twice daily , for 7 days ( n = 248 participants ) or cephalexin plus placebo for 7 days ( n = 248 participants ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.</u></h4>Emergency department visits for skin infections in the United States have increased with the emergence of methicillin-resistant Staphylococcus aureus (MRSA). For cellulitis without purulent drainage, β-hemolytic streptococci are presumed to be the predominant pathogens. It is unknown if antimicrobial regimens possessing in vitro MRSA activity provide improved outcomes compared with treatments lacking MRSA activity. ### objective To determine whether <b style='color:Tomato;'><i>cephalexin</i></b> plus <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b> yields a higher clinical cure rate of uncomplicated cellulitis than <b style='color:Tomato;'><i>cephalexin</i></b> alone. ### Design Setting And Participants Multicenter, double-blind, randomized superiority trial in 5 US emergency departments among outpatients older than 12 years with cellulitis and no wound, purulent drainage, or abscess enrolled from April 2009 through June 2012. All participants had soft tissue ultrasound performed at the time of enrollment to exclude abscess. Final follow-up was August 2012. ### interventions <b style='color:MediumOrchid;'><i>Cephalexin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>times</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>trimethoprim-sulfamethoxazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>320</i></b> <b style='color:DodgerBlue;'><i>mg/1600</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>248</i></b> <b style='color:DodgerBlue;'><i>participants</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>cephalexin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>248</i></b> <b style='color:DodgerBlue;'><i>participants</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Main Outcomes And Measures The primary outcome determined a priori in the per-protocol group was clinical cure, defined as absence of these clinical failure criteria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21). A clinically significant difference was defined as greater than 10%. ### results Among 500 randomized participants, 496 (99%) were included in the modified intention-to-treat analysis and 411 (82.2%) in the per-protocol analysis (median age, 40 years [range, 15-78 years]; 58.4% male; 10.9% had diabetes). Median length and width of erythema were 13.0 cm and 10.0 cm. In the per-protocol population, clinical cure occurred in 182 (83.5%) of 218 participants in the <b style='color:Tomato;'><i>cephalexin</i></b> plus <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b> group vs 165 (85.5%) of 193 in the <b style='color:Tomato;'><i>cephalexin</i></b> group (difference, -2.0%; 95% CI, -9.7% to 5.7%; P = .50). In the modified intention-to-treat population, clinical cure occurred in 189 (76.2%) of 248 participants in the <b style='color:Tomato;'><i>cephalexin</i></b> plus <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b> group vs 171 (69.0%) of 248 in the <b style='color:Tomato;'><i>cephalexin</i></b> group (difference, 7.3%; 95% CI, -1.0% to 15.5%; P = .07). Between-group adverse event rates and secondary outcomes through 7 to 9 weeks, including overnight hospitalization, recurrent skin infections, and similar infection in household contacts, did not differ significantly. ### Conclusions And Relevance Among patients with uncomplicated cellulitis, the use of <b style='color:Tomato;'><i>cephalexin</i></b> plus <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b> compared to <b style='color:Tomato;'><i>cephalexin</i></b> alone did not result in higher rates of clinical resolution of cellulitis in the per-protocol analysis. However, because imprecision around the findings in the modified intention-to-treat analysis included a clinically important difference favoring <b style='color:Tomato;'><i>cephalexin</i></b> plus <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b>, further research may be needed. ### Trial Registration clinicaltrials.gov Identifier: NCT00729937.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  In the NALA trial ,  <span class="marker" data-anno-id="0" data-anno-label="P1">neratinib</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  led to increased PFS and time to intervention for central nervous system disease over the standard regimen of  <span class="marker" data-anno-id="2" data-anno-label="P2">lapatinib</span>  plus  <span class="marker" data-anno-id="3" data-anno-label="P2">capecitabine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.</u></h4>Several agents are being developed for advanced HER2-positive breast cancer, such as potent tyrosine kinase inhibitors (TKI) targeting ErbB family receptors, novel antibody-drug conjugates, higher affinity anti-HER2 antibodies, among others. <b style='color:Tomato;'><i>neratinib</i></b> is an irreversible pan-HER (EGFR, ERBB2, and ERBB4) TKI being tested in early and advanced HER2-positive breast cancer. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NALA</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>neratinib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>led</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>PFS</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intervention</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>central</i></b> <b style='color:DodgerBlue;'><i>nervous</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The main adverse event in the <b style='color:Tomato;'><i>neratinib</i></b> arm was diarrhea, which mandates for prophylactic treatment with <b style='color:Tomato;'><i>loperamide</i></b>. ### Areas Covered In this review, we analyze and discuss preclinical and clinical data with <b style='color:Tomato;'><i>neratinib</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. We summarize efficacy and safety results from phase I/II and III trials, and discuss this regimen within the landscape of treatment for patients with HER2-positive metastatic breast cancer progressing after two lines of HER2-directed treatment. ### Expert Opinion <b style='color:Tomato;'><i>neratinib</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> is a valid treatment option for patients with advanced HER2-positive breast cancer, after progression to at least two anti-HER2-based regimens. Given the multiple options that are being developed in this context, efforts should be employed to establish strong predictive biomarkers of efficacy to each drug and combination.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Since the patient had anemia ,  <span class="marker" data-anno-id="0" data-anno-label="N1">aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">cilostazol</span>  were discontinued after diagnosis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[A Case of Ascending Colon Cancer with Essential Thrombocythemia].</u></h4>Essential thrombocythemia(ET)is a rare myeloproliferative disorder characterized by thrombocytosis and a risk of thrombotic and hemorrhagic events. ET rarely occurs simultaneously with colorectal cancer. Including our case, only 5 cases of c o l orectal cancer with ET have been reported in Japan. Herein, we report a case of colon cancer in an ET patient who underwent laparoscopic right hemicolectomy. Our perioperative management avoided complications such as thrombosis or bleeding. An 81-year-old woman developed bloody stools. She was previously diagnosed with ET 9 years ago. <b style='color:Tomato;'><i>aspirin</i></b>, <b style='color:Tomato;'><i>cilostazol</i></b>, and <b style='color:Tomato;'><i>hydroxyurea</i></b>(HU)were prescribed. Colonoscopy revealed a tumor at the ascending colon. Histopathological examination showed a well-differentiated tubular adenocarcinoma. <b style='color:DodgerBlue;'><i>Since</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>anemia</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cilostazol</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> HU was discontinued from the day before surgery to 2 days after surgery. <b style='color:Tomato;'><i>enoxaparin</i></b> was subcutaneously administered for 1 to 3 days after surgery. <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> were resumed on the fourth day post-surgery. The patient could be discharged when her condition stabilizes with no thrombosis and bleeding after 8 days.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  This case report describes a patient with O-NHL which was possibly linked to the combination of  <span class="marker" data-anno-id="0" data-anno-label="N1">methotrexate</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">etanercept</span>  for the treatment of her rheumatoid arthritis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Oral non-Hodgkin's lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate.</u></h4>Oral non-Hodgkin's lymphomas (O-NHLs) are a rare group of diverse lymphoid tissue malignancies and represent less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer's-ring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. O-NHLs share the same risk factors. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>describes</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>O-NHL</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>possibly</i></b> <b style='color:DodgerBlue;'><i>linked</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etanercept</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>her</i></b> <b style='color:DodgerBlue;'><i>rheumatoid</i></b> <b style='color:DodgerBlue;'><i>arthritis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> To our knowledge this is probably among the first cases of O-NHL with possible relation to the use of a Tumor Necrosis Factor (TNF) antagonist biological agent (<b style='color:Tomato;'><i>etanercept</i></b>). This case could contribute to the sensitization of the dentists for the signs and symptoms of this rare malignancy. It also underlines the need for thorough medical history and medication recording for all the dental patients. Key words:Lymphoma (oral) <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  In a prospective , pragmatic , randomised , parallel group study , 170 patients of mean ( SD ) age 37 ( 12 ) years with acute asthma ( peak expiratory flow ( PEF ) 212 ( 80 ) l/min ) presenting to hospital received treatment with either high dose  <span class="marker" data-anno-id="0" data-anno-label="P1">prednisolone</span>  and continuous nebulised  <span class="marker" data-anno-id="1" data-anno-label="P1">salbutamol</span>  as recommended in the US or lower dose prednisolone and bolus nebulised salbutamol as recommended in the UK by the BTS . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital.</u></h4>Systemic corticosteroids and inhaled beta(2) agonists are accepted first line treatments for acute severe asthma, but there is no consensus on their optimum dosage and frequency of administration. American regimens include higher initial dosages of beta(2) agonists and corticosteroids than UK regimens. ### methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pragmatic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomised</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>parallel</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>170</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>37</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>asthma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>peak</i></b> <b style='color:DodgerBlue;'><i>expiratory</i></b> <b style='color:DodgerBlue;'><i>flow</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PEF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>212</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>l/min</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>presenting</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>hospital</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>nebulised</i></b> <b style='color:MediumOrchid;'><i>salbutamol</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>nebulised</i></b> <b style='color:MediumOrchid;'><i>salbutamol</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>UK</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>BTS</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Outcome measures were: deltaPEF at 1 hour (BTS 89 l/min, US 106 l/min, p=0.2, CI -8 to 41) and at 2 hours (BTS 49 l/min, US 101 l/min, p<0.0001, CI 28 to 77); time to discharge if admitted (BTS 4 days, US 4 days); rates of achieving discharge PEF (>60%) at 2 hours (BTS 64%, US 78%, p=0.04); time to regain control of asthma as measured by PEF >/=80% best with </=20% variability (BTS 3 days, US 4 days, p=0.6); PEF at 24 hours in patients admitted (BTS 293 l/min, US 288 l/min, p=0.8); and control of asthma in the subsequent month (no significant differences). ### conclusions Treatment with higher doses of continuous nebulised <b style='color:Tomato;'><i>salbutamol</i></b> leads to a greater immediate improvement in PEF but the degree of recovery at 24 hours and speed of recovery thereafter is achieved as effectively with lower corticosteroid doses as recommended in the British guidelines.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Following an intravitreal injection of  <span class="marker" data-anno-id="0" data-anno-label="P1">ranibizumab</span>  , off-label administration of intravitreal  <span class="marker" data-anno-id="1" data-anno-label="P1">dexamethasone</span>  was considered to reduce the edema . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of intravitreal dexamethasone on macular edema in von Hippel-Lindau disease assessed using swept-source optical coherence tomography: a case report.</u></h4>Von Hippel-Lindau disease is a rare hereditary syndrome caused by germinal mutations in a von Hippel-Lindau tumor-suppressing gene. Retinal hemangioblastoma is the ocular hallmark lesion of von Hippel-Lindau disease. ### Case Presentation A 20-year-old Caucasian woman presented to our institution with painless visual impairment in the right eye. A fundus ophthalmoscopic evaluation and swept-source optical coherence tomographic examination revealed a retinal hemangioblastoma associated with cystoid macular edema. On the basis of the clinical ocular findings and genetic analysis, von Hippel-Lindau disease was diagnosed. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:DodgerBlue;'><i>injection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ranibizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>off-label</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>reduce</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>edema</i></b> <b style='color:DodgerBlue;'><i>.</i></b> An almost complete resolution of the edema in the macular area was observed 1 week after the injection. Finally, laser photocoagulation and transconjunctival cryotherapy were performed; the patient developed "ablatio fugax" after cryotherapy. ### conclusions In our experience, intravitreal <b style='color:Tomato;'><i>dexamethasone</i></b> administration has proven to be a useful tool for reducing retinal hemangioblastoma-related macular edema in von Hippel-Lindau disease and may be considered a potentially valuable treatment that can be used in combination with other therapies.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We performed a prospective , preplanned , pooled analysis of six randomized , phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX ( fluorouracil , leucovorin , and oxaliplatin ) or CAPOX (  <span class="marker" data-anno-id="0" data-anno-label="P1">capecitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">oxaliplatin</span>  ) administered for 3 months , as compared with 6 months . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.</u></h4>Since 2004, a regimen of 6 months of treatment with <b style='color:Tomato;'><i>oxaliplatin</i></b> plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since <b style='color:Tomato;'><i>oxaliplatin</i></b> is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>preplanned</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pooled</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>concurrently</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>noninferiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>FOLFOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CAPOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was the rate of disease-free survival at 3 years. Noninferiority of 3 months versus 6 months of therapy could be claimed if the upper limit of the two-sided 95% confidence interval of the hazard ratio did not exceed 1.12. ### results After 3263 events of disease recurrence or death had been reported in 12,834 patients, the noninferiority of 3 months of treatment versus 6 months was not confirmed in the overall study population (hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15). Noninferiority of the shorter regimen was seen for CAPOX (hazard ratio, 0.95; 95% CI, 0.85 to 1.06) but not for FOLFOX (hazard ratio, 1.16; 95% CI, 1.06 to 1.26). In an exploratory analysis of the combined regimens, among the patients with T1, T2, or T3 and N1 cancers, 3 months of therapy was noninferior to 6 months, with a 3-year rate of disease-free survival of 83.1% and 83.3%, respectively (hazard ratio, 1.01; 95% CI, 0.90 to 1.12). Among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; P=0.01 for superiority). ### conclusions Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Growth inhibition and apoptosis were significantly ( P < 0.05 ) higher in BxPC-3 , HPAC , and PANC-1 cells treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">celecoxib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">erlotinib</span>  than cells treated with either celecoxib or erlotinib . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.</u></h4>The aims of this study were to determine the effects of (a) combining the epidermal growth factor receptor (EGFR) blocker (<b style='color:Tomato;'><i>erlotinib</i></b>) and the cyclooxygenase-2 inhibitor (<b style='color:Tomato;'><i>celecoxib</i></b>) on cell growth and apoptosis in human pancreatic cancer cell lines, (b) baseline EGFR expression on the potentiation of <b style='color:Tomato;'><i>erlotinib</i></b>-induced apoptosis by <b style='color:Tomato;'><i>celecoxib</i></b>, and (c) the effects of the combination on the expression of the COX-2, EGFR, HER-2/neu, and nuclear factor-kappaB (NF-kappaB). Baseline expression of EGFR was determined by Western blot analysis in five human pancreatic cancer cell lines. BxPC-3, PANC-1, and HPAC had high EGFR and MIAPaCa had low EGFR. Cells were grown in culture and treated with <b style='color:Tomato;'><i>erlotinib</i></b> (1 and 10 micromol/L), <b style='color:Tomato;'><i>celecoxib</i></b> (1 and 10 micromol/L), and the combination. Growth inhibition was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and apoptosis was assayed by ELISA. Reverse transcriptase-PCR was used to evaluate COX-2 and EGFR mRNA. EGFR, COX-2, and HER-2/neu expression was determined by Western immunoblotting. Electrophoretic mobility shift assay was used to evaluate NF-kappaB activation. <b style='color:DodgerBlue;'><i>Growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>BxPC-3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>HPAC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>PANC-1</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, no potentiation in growth inhibition or apoptosis was observed in the MIAPaCa cell line with low expression of the EGFR. Significant down-regulation of COX-2 and EGFR expression was observed in the BxPC-3 and HPAC cells treated with the combination of <b style='color:Tomato;'><i>erlotinib</i></b> (1 micromol/L) and <b style='color:Tomato;'><i>celecoxib</i></b> (10 micromol/L) compared with <b style='color:Tomato;'><i>celecoxib</i></b>- or <b style='color:Tomato;'><i>erlotinib</i></b>-treated cells. <b style='color:Tomato;'><i>celecoxib</i></b> significantly down-regulated HER-2/neu expression in BxPC-3 and HPAC cell lines. Significant inhibition of NF-kappaB activation was observed in BxPC-3 and HPAC cell lines treated with <b style='color:Tomato;'><i>erlotinib</i></b> and <b style='color:Tomato;'><i>celecoxib</i></b>. (a) <b style='color:Tomato;'><i>celecoxib</i></b> can potentiate <b style='color:Tomato;'><i>erlotinib</i></b>-induced growth inhibition and apoptosis in pancreatic cell lines, (b) high baseline EGFR expression is a predictor of this potentiation, and (c) the down-regulation of EGFR, COX-2, and HER-2/neu expression and NF-kappaB inactivation contributes to the potentiation of <b style='color:Tomato;'><i>erlotinib</i></b> by <b style='color:Tomato;'><i>celecoxib</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  These results indicate that low-dose 100 microg  <span class="marker" data-anno-id="0" data-anno-label="P1">levonorgestrel</span>  and 20 microg  <span class="marker" data-anno-id="1" data-anno-label="P1">ethinyl</span>  estradiol given for 21 days is effective in suppressing ovarian activity and they confirm the contraceptive efficacy observed in clinical trials ( Pearl index of 0.8 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol.</u></h4>An open-label, single-center, noncomparative study was conducted to determine the effects of a monophasic oral contraceptive containing 100 microg <b style='color:Tomato;'><i>levo<b style='color:Tomato;'><i>norgestrel</i></b></i></b> and 20 microg <b style='color:Tomato;'><i>ethinyl</i></b> estradiol on ovarian activity. The subjects were 26 healthy women 20 to 35 years of age who had normal ovulatory cycles and were not at risk for becoming pregnant. For 3 treatment cycles, they took 1 tablet of active drug daily for 21 days followed by placebo tablets for 7 days. Follicle diameters and serum progesterone and 17beta-estradiol levels were measured before, during, and after treatment. In 2 (2.7%) of 73 cycles, luteinized unruptured follicles were present and in another 2 (2.7%) cycles, ovulation was confirmed by the disappearance of the enlarged follicle. Ovarian activity, as reflected by mean serum progesterone levels, was restored after treatment. The results of this study are in agreement with those of other studies that showed suppression of ovarian activity in women treated with a monophasic oral contraceptive containing 100 microg <b style='color:Tomato;'><i>levo<b style='color:Tomato;'><i>norgestrel</i></b></i></b> and 20 microg <b style='color:Tomato;'><i>ethinyl</i></b> estradiol. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>indicate</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>levonorgestrel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>microg</i></b> <b style='color:MediumOrchid;'><i>ethinyl</i></b> <b style='color:DodgerBlue;'><i>estradiol</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suppressing</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>contraceptive</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pearl</i></b> <b style='color:DodgerBlue;'><i>index</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>0.8</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  The combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">ixabepilone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  in the phase II study resulted in an ORR of 23 % in triple-negative patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.</u></h4>Patients with ER/PR/HER2-negative (triple negative) breast cancer are not candidates for hormonal therapy or HER2-targeted agents. Ongoing research is aimed at identifying and understanding the benefit of established and emerging therapies in this disease setting. Triple-negative patients may achieve early responses to anthracyclines and taxanes, but novel strategies are also eagerly sought. The epothilone B analog <b style='color:Tomato;'><i>ixabepilone</i></b> acts to stabilize microtubules and demonstrates antitumor activity in recent breast cancer studies. Herein, we have analyzed efficacy and safety data of <b style='color:Tomato;'><i>ixabepilone</i></b> specifically for the treatment of women with triple-negative disease. A retrospective analysis was completed using activity and toxicity data in the triple-negative subsets from 5 phase II studies. In addition, a prospective pooled analysis of triple-negative patients from 2 phase III trials is also reviewed. Of 2,261 patients evaluated in these trials, 556 (24.5%) had triple-negative tumors. In the neoadjuvant setting, <b style='color:Tomato;'><i>ixabepilone</i></b> produced a pathologic complete response rate in the breast of 26% in triple-negative patients (vs. 15% in the non-triple-negative population). In patients with metastatic breast cancer whose pretreatment status ranged from no prior therapy to progression on several classes of agents, overall response rates (ORR) in the phase II <b style='color:Tomato;'><i>ixabepilone</i></b> monotherapy trials ranged from 6 to 55%, comparable to rates seen in patients with non-triple-negative tumors. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ixabepilone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>ORR</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>23</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>triple-negative</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A similar ORR (31%) was observed for a preplanned pooled analysis of triple-negative patients in the phase III trials of <b style='color:Tomato;'><i>ixabepilone</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. The median progression-free survival (PFS) was significantly longer for triple-negative patients treated with <b style='color:Tomato;'><i>ixabepilone</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> (4.2 months) compared with treatment with <b style='color:Tomato;'><i>capecitabine</i></b> alone (1.7 months). No increase in toxicity was noted in the triple-negative subgroup compared with other patients. <b style='color:Tomato;'><i>ixabepilone</i></b> shows notable antitumor activity in patients with triple-negative breast cancer when used in a variety of settings. The addition of <b style='color:Tomato;'><i>ixabepilone</i></b> to <b style='color:Tomato;'><i>capecitabine</i></b> results in an approximately twofold increase in median PFS for triple-negative patients versus <b style='color:Tomato;'><i>capecitabine</i></b> alone and responses to <b style='color:Tomato;'><i>ixabepilone</i></b> in triple-negative disease are comparable to those seen in patients with non-triple-negative tumors.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that was marked by rapid tumor necrosis followed by massive hemorrhage shortly after  <span class="marker" data-anno-id="0" data-anno-label="N1">bevacizumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">paclitaxel</span>  administration . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.</u></h4><b style='color:Tomato;'><i>bevacizumab</i></b> when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rare</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>27-year-old</i></b> <b style='color:DodgerBlue;'><i>premenopausal</i></b> <b style='color:DodgerBlue;'><i>woman</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>marked</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>rapid</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>massive</i></b> <b style='color:DodgerBlue;'><i>hemorrhage</i></b> <b style='color:DodgerBlue;'><i>shortly</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>.</i></b> On the basis of histopathological examination of a biopsy specimen and computed tomography findings, she was diagnosed with stage IV estrogen and progesterone receptor-negative and human epidermal growth factor receptor type 2-positive breast cancer with multiple organ metastases when she had entered gestational week 24. <b style='color:Tomato;'><i>cyclophosphamide</i></b>, Adriamycin®, <b style='color:Tomato;'><i>fluorouracil</i></b> therapy was initiated, but multiple liver metastases continued to progress. A healthy fetus was delivered by induced delivery and <b style='color:Tomato;'><i>trastuzumab</i></b>-based treatment was initiated. Although the multiple liver metastases were controlled successfully by <b style='color:Tomato;'><i>trastuzumab</i></b> combined with <b style='color:Tomato;'><i>paclitaxel</i></b>, the primary tumor continued to expand even after subsequent administration of three other treatment regimens including anti-human epidermal growth factor receptor type 2 agents and cytotoxic drugs. To inhibit primary tumor growth, a combination therapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> was subsequently initiated. Following therapy initiation, however, the large tumor occupying the patient's entire left breast became necrotic and ulcerated rapidly. Furthermore, massive hemorrhage from the tumor occurred 5 weeks after <b style='color:Tomato;'><i>bevacizumab</i></b>-based therapy initiation. Although hemostasis was achieved by manual compression, the patient required blood transfusion for the massive blood loss. She eventually succumbed to respiratory failure. This case report demonstrates that primary breast cancer lesions with skin involvement have the potential to cause massive hemorrhage after <b style='color:Tomato;'><i>bevacizumab</i></b>-based treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  More recently ,  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  also has been evaluated in previously untreated patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Current status of chemotherapy for ovarian cancer.</u></h4>Standard treatment for patients with advanced ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Until recently, platinum-based chemotherapy was considered optimal and patients were treated with regimens built around either cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b>. Recently, <b style='color:Tomato;'><i>paclitaxel</i></b> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be a highly active agent in refractory ovarian cancer patients. Subsequently, the Gynecologic Oncology Group performed a prospective randomized trial of <b style='color:Tomato;'><i>paclitaxel</i></b> plus cisplatin compared with cisplatin plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> in suboptimal stage III and IV ovarian cancer patients. Based on higher response rates, longer time to progression, and marked improvement in median survival (37.5 months compared with 24.4 months), the Gynecologic Oncology Group currently considers <b style='color:Tomato;'><i>paclitaxel</i></b> plus cisplatin to be the new standard regimen for patients with advanced disease. <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using area under the curve dosing for <b style='color:Tomato;'><i>carboplatin</i></b>, it was demonstrated that this agent could be combined with <b style='color:Tomato;'><i>paclitaxel</i></b> (175 mg/m2 in a 3-hour infusion) with acceptable toxicity. All current Gynecologic Oncology Group protocols for untreated patients with ovarian cancer use a <b style='color:Tomato;'><i>paclitaxel</i></b>-based regimen. These clinical trials are evaluating the relative efficacy of <b style='color:Tomato;'><i>carboplatin</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> versus cisplatin plus <b style='color:Tomato;'><i>paclitaxel</i></b> as well as differences in dose and schedule and number of cycles of treatment. Investigational studies are continuing with high-dose chemotherapy that requires hematologic support as well as with intraperitoneal therapy (cisplatin or <b style='color:Tomato;'><i>paclitaxel</i></b>).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Mitoxantrone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  in advanced breast cancer : a pilot study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>A trial of combination chemotherapy using <b style='color:Tomato;'><i>mitoxantrone</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received <b style='color:Tomato;'><i>mitoxantrone</i></b>, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by <b style='color:Tomato;'><i>cyclophosphamide</i></b>, 200 mg/m2 by mouth (PO) daily in divided doses on days 3 to 6. It is too early to evaluate four patients at present. The remaining 12 received three or more courses of treatment, and three of these patients achieved a complete response. Another four patients went into partial remission, amounting to an overall response rate of 58%. The other evaluable patients showed stable disease with improved symptoms. Hematologic toxicity was mainly granulocytopenia, but thrombocytopenia occurred in two patients. Alopecia, nausea, and vomiting were attributed to the <b style='color:Tomato;'><i>cyclophosphamide</i></b> component of the therapy. <b style='color:Tomato;'><i>mitoxantrone</i></b> appeared to have no cardiac toxicity. It was concluded that <b style='color:Tomato;'><i>mitoxantrone</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> is an effective chemotherapeutic combination with minimal toxicity and should be further studied in larger controlled trials.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We retrospectively analyzed the data of 37 patients who had postprandial hyperglycemia ( ≥10.0 mmol/L ) with BOT ( long-acting insulin plus glimepiride ) with their insulin titrated enough to keep preprandial glycemia < 7.2 mmol/L , and who had their treatment changed to  <span class="marker" data-anno-id="0" data-anno-label="P1">liraglutide</span>  monotherapy , with the subsequent addition of  <span class="marker" data-anno-id="1" data-anno-label="P1">glimepiride</span>  , when required . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy.</u></h4>(J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00223.x, 2012) Aims/Introduction:  We assessed the efficacy of <b style='color:Tomato;'><i>liraglutide</i></b> therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy (BOT). ### Materials And Methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>retrospectively</i></b> <b style='color:DodgerBlue;'><i>analyzed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>37</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>postprandial</i></b> <b style='color:DodgerBlue;'><i>hyperglycemia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>≥10.0</i></b> <b style='color:DodgerBlue;'><i>mmol/L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>BOT</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>long-acting</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>titrated</i></b> <b style='color:DodgerBlue;'><i>enough</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>keep</i></b> <b style='color:DodgerBlue;'><i>preprandial</i></b> <b style='color:DodgerBlue;'><i>glycemia</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>7.2</i></b> <b style='color:DodgerBlue;'><i>mmol/L</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>changed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>liraglutide</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>subsequent</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>required</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Those who achieved the glycemic target at all points (preprandial glycemia <7.2 mmol/L and postprandial glycemia <10.0 mmol/L) were regarded as responders and the efficacy of <b style='color:Tomato;'><i>liraglutide</i></b> therapy was assessed. We also explored the predictive clinical characteristics associated with its efficacy. ### results Daily doses of insulin and <b style='color:Tomato;'><i>glimepiride</i></b> with BOT were 14 ± 9 units and 1.5 ± 0.9 mg, respectively. After the change to <b style='color:Tomato;'><i>liraglutide</i></b> therapy, 37% of the patients appeared to be responders to the therapy, whereas 12% had their glycemic control rather deteriorated. Efficacy of <b style='color:Tomato;'><i>liraglutide</i></b> therapy was significantly associated with baseline insulin dosage and post-breakfast glycemia with BOT. The C-statistic of the model was calculated to be 0.90. ### conclusions There were responders and non-responders to <b style='color:Tomato;'><i>liraglutide</i></b> therapy in Japanese BOT failures. It is likely that baseline insulin dosage and post-breakfast glycemia with BOT are clinically useful indicators for the efficacy of <b style='color:Tomato;'><i>liraglutide</i></b> therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We report here on a case of successful treatment of a patient suffering with severe liver dysfunction and metastatic gastric cancer ; the patient was treated with a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">capecitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">oxaliplatin</span>  ( XELOX ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.</u></h4>Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both <b style='color:Tomato;'><i>capecitabine</i></b> and <b style='color:Tomato;'><i>oxaliplatin</i></b> have been well tolerated as single agents for patients with severe hepatic dysfunction, the combination of these drugs has not been investigated. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>here</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>suffering</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>XELOX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The initial bilirubin level of the patient was 10.9 mg/dL. After two cycles of treatment, his bilirubin level decreased to 2.1 mg/dL. He has experienced an excellent radiological response and he has received six cycles of XELOX chemotherapy. XELOX chemotherapy is feasible and it can be associated with positive outcomes for the patients suffering with metastatic gastric cancer and severe liver dysfunction.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Cetuximab</span>  , 400 mg/m2 intravenously , was administered initially followed by  <span class="marker" data-anno-id="1" data-anno-label="C1">cetuximab</span>  , 250 mg/m2 intravenously weekly . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.</u></h4>On November 7, 2011, the U.S. Food and Drug Administration approved <b style='color:Tomato;'><i>cetuximab</i></b> in combination with cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b> and 5-<b style='color:Tomato;'><i>fluorouracil</i></b> for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized study of 442 patients conducted outside the U.S. Cisplatin (100 mg/m2 intravenously) or <b style='color:Tomato;'><i>carboplatin</i></b> (area under the curve 5 intravenously) on day 1 with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (1,000 mg/m2/day continuous intravenous infusion days 1-4) were administered every 3 weeks. <b style='color:MediumOrchid;'><i>Cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After completion of six planned treatment courses, <b style='color:Tomato;'><i>cetuximab</i></b> patients without progression continued <b style='color:Tomato;'><i>cetuximab</i></b> 250 mg/m2 weekly. The study used European Union (EU)-approved <b style='color:Tomato;'><i>cetuximab</i></b> rather than U.S.-approved <b style='color:Tomato;'><i>cetuximab</i></b>. U.S.-approved <b style='color:Tomato;'><i>cetuximab</i></b> provides approximately 28% higher exposure relative to EU-approved <b style='color:Tomato;'><i>cetuximab</i></b> in a pharmacokinetic comparability study in monkeys. Overall survival, the primary efficacy endpoint, was significantly improved in <b style='color:Tomato;'><i>cetuximab</i></b>-treated patients (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.64-0.98; p = .034, stratified log-rank test). Median survival times were 10.1 and 7.4 months, respectively. Progression-free survival (PFS) was also significantly improved in patients receiving <b style='color:Tomato;'><i>cetuximab</i></b> (HR: 0.57; 95% CI: 0.46-0.72; p < .0001). Median PFS times were 5.5 and 3.3 months, respectively. Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001). Adverse reactions (≥25%) from <b style='color:Tomato;'><i>cetuximab</i></b> plus chemotherapy treatment included nausea, anemia, vomiting, neutropenia, rash, asthenia, diarrhea, and anorexia. Conjunctivitis occurred in 10% of <b style='color:Tomato;'><i>cetuximab</i></b> patients. Other adverse reactions, sometimes severe, included infusion reactions, hypomagnesemia, hypocalcemia, and hypokalemia.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  From 1987 to 1991 , 194 previously untreated patients received vincristine and  <span class="marker" data-anno-id="0" data-anno-label="N1/N2">ifosfamide</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="N1">dactinomycin</span>  or  <span class="marker" data-anno-id="2" data-anno-label="N2">etoposide</span>  for 1 - 2 years . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.</u></h4>The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with <b style='color:Tomato;'><i>ifosfamide</i></b>-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma. ### Patients And Methods <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>1987</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>1991</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>194</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>dactinomycin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>ifosfamide</i></b> was given at 1.8 g/m2/day for 5 days with sodium mercaptoethane sulfonate, or 9 g/m2 of <b style='color:Tomato;'><i>ifosfamide</i></b> per course. The three-drug regimen was repeated every 3-4 weeks. ### results Twenty-eight patients (14%) developed renal toxicity: 19 had renal tubular dysfunction (RTD) characterized by low serum phosphate (< or = 3 mg/dl) or bicarbonate (< 20 or = mEq/L) levels, five had decreased glomerular function (DGF), and four had both RTD and DGF. When nine or more courses of <b style='color:Tomato;'><i>ifosfamide</i></b> (> 72 g/m2) were given, children < 3 years of age had a higher incidence of RTD than did children > or = 3 years of age (34% versus 6%; p < 0.001). A similar age difference was observed even when eight or fewer courses (< or = 72 g/m2) were given (p = 0.03). A matched case-control comparison showed that renal abnormalities at diagnosis, chiefly hydronephrosis, also increased the risk of renal tubular injury by <b style='color:Tomato;'><i>ifosfamide</i></b> by a factor of 13 (p < 0.001). Patients with DGF tended to be older than those with RTD, and all but one received > 72 g/m2 of <b style='color:Tomato;'><i>ifosfamide</i></b>. ### conclusions Patients who are < 3 years of age who receive more than eight courses (> 72 g/m2) of <b style='color:Tomato;'><i>ifosfamide</i></b> and who have a preexisting renal abnormality have an increased risk of RTD and DGF. The renal function of patients being considered for <b style='color:Tomato;'><i>ifosfamide</i></b> treatment must be carefully monitored. <b style='color:Tomato;'><i>ifosfamide</i></b> should be avoided in patients with renal abnormalities at diagnosis unless the potential benefit clearly exceeds the risk of further renal impairment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  This nested substudy of the AVALON trial assessed the effects of coadministered  <span class="marker" data-anno-id="0" data-anno-label="P1">amlodipine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">atorvastatin</span>  vs. either therapy alone or placebo on arterial compliance , to evaluate the vascular benefits of coadministered therapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.</u></h4>Combining statins with antihypertensive therapy has been demonstrated to provide an early reduction in cardiovascular events. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>nested</i></b> <b style='color:DodgerBlue;'><i>substudy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>AVALON</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>assessed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>coadministered</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>atorvastatin</i></b> <b style='color:DodgerBlue;'><i>vs.</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>arterial</i></b> <b style='color:DodgerBlue;'><i>compliance</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>benefits</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>coadministered</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods During an initial 8-week, double-blind phase, patients with concomitant hypertension and dyslipidemia were randomized into four treatment groups (placebo, <b style='color:Tomato;'><i>amlodipine</i></b> 5 mg, <b style='color:Tomato;'><i>atorvastatin</i></b> 10 mg, or coadministered <b style='color:Tomato;'><i>amlodipine</i></b> 5 mg and <b style='color:Tomato;'><i>atorvastatin</i></b> 10 mg). The sustained effect of combined therapy was evaluated during subsequent 8-week, single-blind, and 12-week, open-label periods. In the single-blind phase, all patients were coadministered <b style='color:Tomato;'><i>amlodipine</i></b> 5 mg and <b style='color:Tomato;'><i>atorvastatin</i></b> 10 mg, which were then titrated to optimize blood pressure and low-density lipoprotein cholesterol control during the open-label phase. Arterial compliance was assessed every 4 weeks using the HDI/Pulsewave CR-2000. ### results Overall, 668 patients (61% male, mean age 55 years) were randomized to treatment. A 19% improvement in small artery compliance (C2) was observed with coadministered <b style='color:Tomato;'><i>amlodipine</i></b> and <b style='color:Tomato;'><i>atorvastatin</i></b> from baseline to week 8, which was significantly greater than with either treatment alone or with placebo (P = 0.03 to 0.0001). After 28 weeks, C2 was increased from baseline in all groups, but the overall improvement was greatest in the group receiving coadministered drugs for the entire study period (P < 0.05). ### conclusions Early and sustained improvement in small artery compliance was observed following coadministration of <b style='color:Tomato;'><i>amlodipine</i></b> and <b style='color:Tomato;'><i>atorvastatin</i></b>, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We analysed the serial dermatoscopic photographs of atypical melanocytic lesions taken from patients with advanced metastatic melanoma on four different systemic therapies ( selective BRAF-inhibitor monotherapy ,  <span class="marker" data-anno-id="0" data-anno-label="C1">dabrafenib</span>  combined with  <span class="marker" data-anno-id="1" data-anno-label="C1">trametinib</span>  [ D&T ] , anti-programmed cell death protein 1 [ anti-PD1 ] therapies , and  <span class="marker" data-anno-id="2" data-anno-label="C2">anti-PD1</span>  combined with  <span class="marker" data-anno-id="3" data-anno-label="C2">ipilimumab</span>  ) seen from February 2013 to May 2016 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.</u></h4>Various cutaneous side-effects have been reported with anti-melanoma systemic therapies. This study investigated the changes in melanocytic lesion pigmentation in patients on four different therapies. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>analysed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>serial</i></b> <b style='color:DodgerBlue;'><i>dermatoscopic</i></b> <b style='color:DodgerBlue;'><i>photographs</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>atypical</i></b> <b style='color:DodgerBlue;'><i>melanocytic</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>taken</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>BRAF-inhibitor</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dabrafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>trametinib</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>D&T</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>anti-programmed</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>anti-PD1</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anti-PD1</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>February</i></b> <b style='color:DodgerBlue;'><i>2013</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>2016</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We compared these changes with the melanocytic lesions of 10 control patients. ### results In the control group, 19% of naevi lightened, 64% did not change and 17% darkened. Only the BRAF inhibitor group showed more darkened lesions than controls (37%, P < 0.001). Meanwhile, there were more lightened naevi in the D&T therapy group (86%, P < 0.001) as well as the anti-PD1 and <b style='color:Tomato;'><i>ipilimumab</i></b> groups (59%, P < 0.001) than controls. Patients on anti-PD1 monotherapy had more lightened (49%) and fewer darkened naevi (9%) than controls, but differences were not significant. ### conclusions Our study showed that different anti-melanoma systemic therapies have different effects on the pigmentation of melanocytic lesions. BRAF inhibitor may have the propensity to cause darkening while D&T therapy and anti-PD1 caused lightening compared with controls. The findings emphasise the importance of regular dermatological monitoring in specialised clinics for patients on anti-melanoma systemic therapy. Clinicians should expect changes in the global pigmentation of melanocytic lesions but be suspicious of lesions with structural changes.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Frontline  <span class="marker" data-anno-id="0" data-anno-label="P1">bortezomib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rituximab</span>  for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma : a multicentre phase II study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Frontline</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>newly</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>burden</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicentre</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>There is a lack of published data examining non-cytotoxic options for the frontline treatment of patients with high-tumour burden (HTB) indolent non-Hodgkin lymphoma (iNHL). We completed a multicentre phase II study for patients with untreated HTB iNHL (NCT00369707) consisting of three induction cycles of weekly <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> followed by an abbreviated consolidation. Forty-two patients were treated and all were evaluable; the most common histology was follicular lymphoma (FL) (n = 33, 79%). Patient characteristics included median age 62 years (40-86); 38% bulky disease; 19% malignant effusions; 91% advanced-stage disease; and median FL International Prognostic Index (FLIPI) score was 3. Therapy was well tolerated with few grade 3/4 toxicities including minimal neurotoxicity. On intent-to-treat, the overall response rate (ORR) at end of therapy was 70% with a complete remission (CR) rate of 40% (FL: ORR 76%, CR 44%). With 50-month median follow-up, 4-year progression-free survival (PFS) was 44% with 4-year overall survival (OS) of 87% (FL: 44% and 97%, respectively). Four-year PFS for FLIPI 0-2 vs. 3-5 was 60% vs. 26% respectively (P = 0·02), with corresponding OS rates of 92% and 81% respectively (P = 0·16). Collectively, <b style='color:Tomato;'><i>bortezomib</i></b>/<b style='color:Tomato;'><i>rituximab</i></b> is a non-cytotoxic therapeutic regimen that was well tolerated and resulted in long-term survival rates approximating prior <b style='color:Tomato;'><i>rituximab</i></b>/cytotoxic chemotherapy series for untreated HTB FL.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Effect of sequential treatments with  <span class="marker" data-anno-id="0" data-anno-label="C1">alendronate</span>  , parathyroid hormone ( 1 - 34 ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">raloxifene</span>  on cortical bone mass and strength in ovariectomized rats . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>alendronate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>parathyroid</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>34</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>raloxifene</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cortical</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>mass</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>strength</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ovariectomized</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Anti-resorptive and anabolic agents are often prescribed for the treatment of osteoporosis continuously or sequentially for many years. However their impact on cortical bone quality and bone strength is not clear. ### methods Six-month old female rats were either sham operated or ovariectomized (OVX). OVX rats were left untreated for two months and then were treated with vehicle (Veh), hPTH (1-34) (PTH), <b style='color:Tomato;'><i>alendronate</i></b> (Aln), or <b style='color:Tomato;'><i>raloxifene</i></b> (Ral) sequentially for three month intervals, for a total of three periods. Mid-tibial cortical bone architecture, mass, mineralization, and strength were measured on necropsy samples obtained after each period. Bone indentation properties were measured on proximal femur necropsy samples. ### results Eight or more months of estrogen deficiency in rats resulted in decreased cortical bone area and thickness. Treatment with PTH for 3months caused the deposition of endocortical lamellar bone that increased cortical bone area, thickness, and strength. These improvements were lost when PTH was withdrawn without followup treatment, but were maintained for the maximum times tested, six months with Ral and three months with Aln. Pre-treatment with anti-resorptives was also somewhat successful in ultimately preserving the additional endocortical lamellar bone formed under PTH treatment. These treatments did not affect bone indentation properties. ### summary Sequential therapy that involved both PTH and anti-resorptive agents was required to achieve lasting improvements in cortical area, thickness, and strength in OVX rats. Anti-resorptive therapy, either prior to or following PTH, was required to preserve gains attributable to an anabolic agent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Atorvastatin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">metformin</span>  both have pleiotropic effects . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.</u></h4> <b style='color:MediumOrchid;'><i>Atorvastatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metformin</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>pleiotropic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Whether <b style='color:Tomato;'><i>atorvastatin</i></b> combined with <b style='color:Tomato;'><i>metformin</i></b> could provide additive benefits on subjects with dyslipidemia and overweight/obese is unknown. And the mechanism is also not fully clear yet. ### methods A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of <b style='color:Tomato;'><i>atorvastatin</i></b> daily plus 500 mg of <b style='color:Tomato;'><i>metformin</i></b> twice daily) and control group (20 mg of <b style='color:Tomato;'><i>atorvastatin</i></b> daily). At baseline and 8 weeks later, parameters of interest were recorded and fasting venous blood was drawn for laboratory examination. ### results The rates of overweight (76.9% vs. 73.8%) and obese (23.1% vs. 26.2%) in both group were comparable. Dyslipidemia in both groups were featured by increased serum levels of triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). Serum level of high sensitivity C-reactive protein (Hs-CRP) was comparably elevated in both groups at baseline, and leukocyte rho-associated kinase 2 (ROCK2) and serum nitric oxide (NO) concentrations were also comparable. Generally, the baseline characteristics between these 2 groups were no significant differences. 8 weeks later, compared to baseline, body mass index (BMI), the rates of overweight and obese, daily exercise time, smoking status, lipid profiles, Hs-CRP level, leukocyte ROCK2 and serum NO concentrations in both groups were improved. Notably, compared to control group, the rate of obese, Hs-CRP level, leukocyte ROCK2 and serum NO concentrations were improved more profoundly in the combined group (p<0.05). After adjusted for age, gender, BMI, TG, LDL-C, Hs-CRP and exercise time, <b style='color:Tomato;'><i>atorvastatin</i></b> plus <b style='color:Tomato;'><i>metformin</i></b> was positively associated with serum NO concentration, with odds ratio (OR) of 1.146 (95% confidence interval (CI) 1.089-1.164, combined group vs. control group, p<0.05), and inversely associated with leukocyte ROCK2 concentration, with OR of 0.853 (95% CI 0.834-0.872, combined group vs. control group, p<0.05). ### conclusion In subjects with dyslipidemia and overweight/obese, <b style='color:Tomato;'><i>atorvastatin</i></b> plus <b style='color:Tomato;'><i>metformin</i></b> may confer additive benefits through reducing leukocyte ROCK2 concentration.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Between Oct 24 , 2016 , and Jan 24 , 2018 , 861 patients were randomly assigned to receive  <span class="marker" data-anno-id="0" data-anno-label="P1">pembrolizumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">axitinib</span>  ( n=432 ) or sunitinib monotherapy ( n=429 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.</u></h4>The first interim analysis of the KEYNOTE-426 study showed superior efficacy of <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> over <b style='color:Tomato;'><i>sunitinib</i></b> monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> monotherapy in patients with advanced renal cell carcinoma. ### methods In the ongoing, randomised, open-label, phase 3 KEYNOTE-426 study, adults (≥18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospitals and cancer centres) across 16 countries. Patients were randomly assigned (1:1) to receive 200 mg <b style='color:Tomato;'><i>pembrolizumab</i></b> intravenously every 3 weeks for up to 35 cycles plus 5 mg <b style='color:Tomato;'><i>axitinib</i></b> orally twice daily or 50 mg <b style='color:Tomato;'><i>sunitinib</i></b> monotherapy orally once daily for 4 weeks per 6-week cycle. Randomisation was done using an interactive voice response system or integrated web response system, and was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographical region. Primary endpoints were overall survival and progression-free survival in the intention-to-treat population. Since the primary endpoints were met at the first interim analysis, updated data are reported with nominal p values. This study is registered with ClinicalTrials.gov, NCT02853331. ### findings <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>Oct</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2016</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Jan</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2018</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>861</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>axitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=432</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=429</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With a median follow-up of 30·6 months (IQR 27·2-34·2), continued clinical benefit was observed with <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> over <b style='color:Tomato;'><i>sunitinib</i></b> in terms of overall survival (median not reached with <b style='color:Tomato;'><i>pembrolizumab</i></b> and <b style='color:Tomato;'><i>axitinib</i></b> vs 35·7 months [95% CI 33·3-not reached] with <b style='color:Tomato;'><i>sunitinib</i></b>); hazard ratio [HR] 0·68 [95% CI 0·55-0·85], p=0·0003) and progression-free survival (median 15·4 months [12·7-18·9] vs 11·1 months [9·1-12·5]; 0·71 [0·60-0·84], p<0·0001). The most frequent (≥10% patients in either group) treatment-related grade 3 or worse adverse events were hypertension (95 [22%] of 429 patients in the <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> group vs 84 [20%] of 425 patients in the <b style='color:Tomato;'><i>sunitinib</i></b> group), alanine aminotransferase increase (54 [13%] vs 11 [3%]), and diarrhoea (46 [11%] vs 23 [5%]). No new treatment-related deaths were reported since the first interim analysis. ### interpretation With extended study follow-up, results from KEYNOTE-426 show that <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> continues to have superior clinical outcomes over <b style='color:Tomato;'><i>sunitinib</i></b>. These results continue to support the first-line treatment with <b style='color:Tomato;'><i>pembrolizumab</i></b> plus <b style='color:Tomato;'><i>axitinib</i></b> as the standard of care of advanced renal cell carcinoma. ### funding Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Patients received 175 mg/m of  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  over a 3 h infusion , followed by  <span class="marker" data-anno-id="1" data-anno-label="P1">nedaplatin</span>  80 mg/m in a 1 h infusion on day 1 every 3 weeks for up to 6 treatment cycles . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.</u></h4>The aim of this study was to evaluate the efficacy and tolerability of the combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>nedaplatin</i></b> in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in this study. All patients had bidimensionally measurable disease. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>nedaplatin</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg/m</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The overall response rate was 47.7%, with complete and partial response rates of 6.1 and 41.7%, respectively. The median time to progression for all patients was 6.8 months (95% confidence interval, 6.2-7.4 months) and the 3-year disease-free survival probability was 3 (15.8%). The major toxicity observed was cumulative neutropenia, with 29% patients developing grade 4 toxicity. There was no treatment-related death. The most common nonhematologic toxicity encountered with this regimen was pain and cumulative peripheral neuropathy, with 26% patients experiencing grade 2 or 3 toxicity. The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>nedaplatin</i></b> shows significant antitumor activity and a favorable toxicity profile in patients with metastatic carcinoma of esophageal cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  After a median follow-up of 9.5 years , 10-year OS rates in the bolus/infusional  <span class="marker" data-anno-id="0" data-anno-label="P1">fluorouracil</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1/C1">leucovorin</span>  ( LV5FU2 ) and LV5FU2 plus  <span class="marker" data-anno-id="2" data-anno-label="C1">oxaliplatin</span>  ( FOLFOX4 ) arms were 67.1 % versus 71.7 % ( hazard ratio [ HR ] , 0.85 ; P = .043 ) in the whole population , 79.5 % versus 78.4 % for stage II ( HR , 1.00 ; P = .980 ) , and 59.0 % versus 67.1 % for stage III ( HR , 0.80 ; P = .016 ) disease . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.</u></h4>The MOSAIC (Multicenter International Study of <b style='color:Tomato;'><i>oxaliplatin</i></b>/<b style='color:Tomato;'><i>fluorouracil</i></b>/<b style='color:Tomato;'><i>leucovorin</i></b> in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant <b style='color:Tomato;'><i>oxaliplatin</i></b> in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. ### methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. ### results <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>9.5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10-year</i></b> <b style='color:DodgerBlue;'><i>OS</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bolus/infusional</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LV5FU2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>LV5FU2</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FOLFOX4</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>arms</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>67.1</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>71.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>hazard</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>HR</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.85</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>.043</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>whole</i></b> <b style='color:DodgerBlue;'><i>population</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>79.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>78.4</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1.00</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>.980</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>59.0</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>67.1</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.80</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>.016</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. ### conclusion The OS benefit of <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  [ Effects of combined use of  <span class="marker" data-anno-id="0" data-anno-label="C1">dofetilide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">verapamil</span>  on the action potential of papillary muscles in guinea pigs ] . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dofetilide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>papillary</i></b> <b style='color:DodgerBlue;'><i>muscles</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>guinea</i></b> <b style='color:DodgerBlue;'><i>pigs</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To test the effects of combined use of <b style='color:Tomato;'><i>dofetilide</i></b> and <b style='color:Tomato;'><i>verapamil</i></b> on the action potential of papillary muscles in guinea pigs. ### methods Under the stimulation of different frequencies (0.2, 0.5, 1.0, 1.25 or 2.0 Hz), the action potential of papillary muscles in guinea pigs was recorded with the standard microelectrode techniques. The impacts of different concentrations of <b style='color:Tomato;'><i>amiodarone</i></b> (1, 5 or 10 micromol/L), <b style='color:Tomato;'><i>dofetilide</i></b> (10, 50, 100 nmol/L), and a combination of 100 nmol/L <b style='color:Tomato;'><i>dofetilide</i></b> and 1 micromol/L <b style='color:Tomato;'><i>verapamil</i></b> on the action potential were tested. ### results <b style='color:Tomato;'><i>amiodarone</i></b> prolonged the action potential duration (APD) significantly, measured both at 50% (APD50) and 90% (APD90) of repolarization, in a concentration-dependent manner independent from stimulation frequencies. <b style='color:Tomato;'><i>dofetilide</i></b> prolonged APD in a concentration-dependent manner, which was negatively dependent on stimulation frequencies. The frequency-dependent effect was ameliorated by adding 1 micromol/L <b style='color:Tomato;'><i>verapamil</i></b> to <b style='color:Tomato;'><i>dofetilide</i></b>. ### conclusion Both <b style='color:Tomato;'><i>amiodarone</i></b> and <b style='color:Tomato;'><i>dofetilide</i></b> prolong APD in a concentration-dependent manner. The class III antiarrhythmic compounds, <b style='color:Tomato;'><i>amiodarone</i></b>, has less frequency-dependent effect than the pure class III antiarrhythmic drug. A combined use of potassium and calcium antagonists may reduce the frequency-dependence of the pure class III antiarrhythmic drug.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Patients with pancreatic adenocarcinoma , pre-treated with gemcitabine-based chemotherapy , were treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">capecitabine</span>  ( 800 mg/m(2 ) orally , twice a day for 14 days ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">docetaxel</span>  ( 75 mg/m(2 ) i.v , on day 1 ) , every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.</u></h4>To investigate the efficacy and toxicity of the <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>capecitabine</i></b> combination in patients with previously treated, unresectable adenocarcinoma of the pancreas. ### Patients And Methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>adenocarcinoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pre-treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gemcitabine-based</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was overall response rate (RR). ### results Thirty-one patients were enrolled in the study; 93.6% of them had a performance status (PS) of 0-1 and 96.8% had stage IV disease. Patients received a median of 4 cycles/patient, and the main reason for treatment discontinuation was disease progression. Partial response was observed in three (9.7%) patients, stable disease in seven (22.6%) (disease control rate: 32.3%, 95% CI: 15.80-48.71%) and disease progression in 21 (67.6%). The median progression-free survival (PFS) was 2.4 months (95% CI: 1.6-3.13) and the median overall survival (OS) was 6.3 months (95% CI: 3.38-9.23); the estimated 1-year survival rate was 14.7%. Grade III/IV neutropenia occurred in 10 (32.2%) patients and febrile neutropenia in one patient. Other severe non-hematologic toxicities were mild and manageable. After 2 chemotherapy cycles, pain control occurred in 20% of patients and stabilization of body weight in 40%. ### conclusion The combination of <b style='color:Tomato;'><i>docetaxel</i></b>/<b style='color:Tomato;'><i>capecitabine</i></b> may confer good disease control associated with improvement of quality of life as second-line chemotherapy in patients with metastatic pancreatic cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Comparative study of dose escalation versus interval reduction to obtain dose-intensification of  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  with granulocyte colony-stimulating factor in advanced breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Comparative</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>interval</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>obtain</i></b> <b style='color:DodgerBlue;'><i>dose-intensification</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>granulocyte</i></b> <b style='color:DodgerBlue;'><i>colony-stimulating</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>A potential application of hematopoietic growth factors is to obtain an increased dose-intensity. This can be achieved by either higher doses of chemotherapy with standard intervals, or by standard doses with shorter intervals. The potential of these approaches has not been investigated systematically. ### Patients And Methods In a randomized, multicenter study, 49 advanced breast cancer patients were treated with granulocyte colony-stimulating factor (G-CSF) and either increasing doses of <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with fixed intervals (arm one) or progressively shorter intervals with fixed doses of <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> (arm two). A cohort of at least six patients was studied at each interval/dose. A more intensified interval/dose was given if less than 50% of patients encountered a dose-intensity limiting criterium (DILC) in the first three courses. ### results In arm one, <b style='color:Tomato;'><i>epirubicin</i></b> 140 mg/m2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 800 mg/m2 every 21 days was too toxic. Subsequently, <b style='color:Tomato;'><i>epirubicin</i></b> 120 mg/m2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 700 mg/m2 was tested with two of 10 patients encountering a DILC. All initial DILCs consisted of febrile neutropenia. In arm two, <b style='color:Tomato;'><i>epirubicin</i></b> 75 mg/m2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 500 mg/m2 could be administered safely with 14- and 12-day intervals. In the 10-day interval, eight of 12 patients completed the first three cycles without a DILC. In the 8-day interval, seven of eight patients encountered a DILC. Incomplete neutrophil recovery, and to a lesser extent stomatitis, were dose-limiting. ### conclusion In combination with G-CSF, <b style='color:Tomato;'><i>epirubicin</i></b> 120 mg/m2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 700 mg/m2 every 21 days was feasible (projected dose-intensity, 40 mg/m2/wk and 233 mg/m2/wk, respectively). <b style='color:Tomato;'><i>epirubicin</i></b> 75 mg/m2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 500 mg/m2 could be administered safely every 10 days, allowing a projected dose-intensity of 52.5 mg/m2/wk and 350 mg/m2/wk, respectively.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The hearts were treated during the whole procedure either with vehicle , 0.5 μM  <span class="marker" data-anno-id="0" data-anno-label="C1">flecainide</span>  ( sodium channel blocker ) or 100 μM  <span class="marker" data-anno-id="1" data-anno-label="C1">streptomycin</span>  ( here used as stretch-activated ion-channel blocker ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Arrhythmogenic effects by local left ventricular stretch: effects of flecainide and streptomycin.</u></h4>Mechanical stretch has been shown to provoke arrhythmia. We wanted to analyze ventricular arrhythmia induced by local left ventricular stretch in order to find out, where arrhythmias originate and whether they can be prevented pharmacologically. Isolated rabbit hearts (Langendorff technique) were submitted to increased left ventricular stretch at the left wall by insertion of an additional intraventricular balloon and adjusting the end-diastolic pressure (EDP) to 25 mmHg for 10 min followed by 20 min recovery at normal EDP of 5-8 mmHg. Activation and repolarization processes were investigated by ventricular 256 electrode epicardial mapping. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>hearts</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>whole</i></b> <b style='color:DodgerBlue;'><i>procedure</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>vehicle</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>μM</i></b> <b style='color:MediumOrchid;'><i>flecainide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>channel</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>μM</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>here</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>stretch-activated</i></b> <b style='color:DodgerBlue;'><i>ion-channel</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In addition, we performed a series of experiments, in which we enhanced EDP to 30 mmHg (global stretch instead of local stretch) by inflating the left ventricular pressure balloon (strain, 0.148 ± 0.034). Each series was performed with n = 6. Stretch resulted in local strain of 25% at the left wall together with a local slowing of the activation process at the left wall, in a change in the activation pattern, and in ventricular arrhythmia. Coronary flow was not affected. Ventricular arrhythmias originated from the border between the stretched area and the non-stretched region. <b style='color:Tomato;'><i>flecainide</i></b> and <b style='color:Tomato;'><i>streptomycin</i></b> reduced the prolongation of the activation process at the stretched left wall and mitigated the difference in total activation time between left and front wall but only partially prevented arrhythmia. In the additional global stretch experiments relative coronary flow and the other parameters remained unchanged, in particular TAT. Thus, in contrast to the local stretch series, there was no difference in the change in TAT between left and front wall. Only rare single ventricular extrasystoles (<1/min; originating from LV (front and left wall) i.e. from within the stretched region) were seen during stretch (but not at the beginning) and during recovery. Local left ventricular stretch can elicit ventricular arrhythmias. Local slowing of electrical activation seems involved so that the difference in total activation time of the stretched free left wall and the non-stretched increased.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  In the APHINITY study ( NCT01358877 , BIG 4 - 11/BO25126/TOC4939 G ) ,  <span class="marker" data-anno-id="0" data-anno-label="P1">pertuzumab</span>  added to  <span class="marker" data-anno-id="1" data-anno-label="P1">trastuzumab</span>  and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.</u></h4> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>APHINITY</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NCT01358877</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>BIG</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>11/BO25126/TOC4939</i></b> <b style='color:DodgerBlue;'><i>G</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>invasive</i></b> <b style='color:DodgerBlue;'><i>disease-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>early</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The objective of this analysis was to assess the pharmacokinetics of <b style='color:Tomato;'><i>pertuzumab</i></b> in combination with <b style='color:Tomato;'><i>trastuzumab</i></b> in Chinese patients with early breast cancer. Samples for <b style='color:Tomato;'><i>pertuzumab</i></b> and <b style='color:Tomato;'><i>trastuzumab</i></b> pharmacokinetic analysis were taken from Chinese patients during cycle 1 of treatment and at steady-state in cycle 10. Noncompartmental analysis was used to estimate minimum and maximum serum concentrations (Cmax and Cmin), area under the concentration-time curve, clearance, and other pharmacokinetic parameters. In 15 patients, mean steady-state Cmax and Cmin <b style='color:Tomato;'><i>pertuzumab</i></b> serum concentrations (368 ± 177 μg/ml, and 122 ± 47 μg/ml, respectively) were numerically higher than observed previously in a pharmacokinetic analysis of the global population in APHINITY and in patients treated in the metastatic setting. The geometric mean ratio and corresponding 90% confidence interval for <b style='color:Tomato;'><i>trastuzumab</i></b> Cmax and Cmin in the presence (n = 15) or absence (n = 17) of <b style='color:Tomato;'><i>pertuzumab</i></b> were 104.6 (91.09-120) and 98.23 (84.58-114), respectively, indicating no apparent impact of <b style='color:Tomato;'><i>pertuzumab</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>trastuzumab</i></b>. Increases in <b style='color:Tomato;'><i>pertuzumab</i></b> Cmax and Cmin were not associated with an increase in adverse events. The APHINITY Chinese pharmacokinetic substudy analysis supports the dosing regimen for <b style='color:Tomato;'><i>pertuzumab</i></b> (840 mg loading dose followed by 420 mg maintenance doses every 3 weeks administered by intravenous infusion) in a Chinese HER2-positive early breast cancer patient population.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  In two trials , an anti-EGFR antibody (  <span class="marker" data-anno-id="0" data-anno-label="N1">panitumumab</span>  or  <span class="marker" data-anno-id="1" data-anno-label="N2">cetuximab</span>  ) reduced median survival when added to  <span class="marker" data-anno-id="2" data-anno-label="N1/N2">bevacizumab</span>  in previously untreated patients . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Chemotherapy of metastatic colorectal cancer.</u></h4>Without treatment, patients with inoperable or metastatic colorectal cancer have a median life expectancy of about 8 months. The following article is an update of our 2005 review of chemotherapy regimens used in metastatic colorectal cancer, based on the standard Prescrire methodology. In 2005, the de Gramont protocol, based on <b style='color:Tomato;'><i>fluorouracil</i></b> (always combined with folinic acid) plus either <b style='color:Tomato;'><i>oxaliplatin</i></b> (Folfox protocol) or <b style='color:Tomato;'><i>irinotecan</i></b> (Folfiri protocol), was the standard first-line chemotherapy in this setting. Four trials comparing monotherapy versus combination therapy in previously untreated patients showed that initial <b style='color:Tomato;'><i>fluorouracil</i></b> (or <b style='color:Tomato;'><i>fluorouracil</i></b> precursor) monotherapy, followed by the Folfox or Folfiri protocol in case of failure, was not associated with shorter overall survival. Two trials compared first-line treatment with the Folfiri regimen versus the Folfoxiri regimen (<b style='color:Tomato;'><i>fluorouracil</i></b> + <b style='color:Tomato;'><i>oxaliplatin</i></b> + <b style='color:Tomato;'><i>irinotecan</i></b>). One of these studies showed an increase in median survival with the Folfoxiri protocol (24 versus 17 months), but at a cost of greater neurotoxicity. The only tangible advantage of <b style='color:Tomato;'><i>capecitabine</i></b> and <b style='color:Tomato;'><i>tegafur</i></b>, two oral <b style='color:Tomato;'><i>fluorouracil</i></b> precursors, is their convenience of use. <b style='color:Tomato;'><i>pemetrexed</i></b> was less effective and more toxic than the Folfiri protocol in one trial. <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>panitumumab</i></b> have yielded disappointing results in previously untreated patients. Neither of these monoclonal antibodies has yet been shown to improve overall survival. Three trials have assessed the addition of <b style='color:Tomato;'><i>cetuximab</i></b> to combinations consisting of <b style='color:Tomato;'><i>fluorouracil</i></b> or <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>oxaliplatin</i></b> or <b style='color:Tomato;'><i>irinotecan</i></b>. In two of these trials, the median survival time of patients whose tumours carried the wild-type KRAS gene was about 3 months longer in the <b style='color:Tomato;'><i>cetuximab</i></b> arms, although the increase was statistically significant in only one trial. <b style='color:Tomato;'><i>cetuximab</i></b> had no impact on survival time in the third trial. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anti-EGFR</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> When progression occurs after treatment with the Folfiri protocol (or equivalent), a combination of the Folfox protocol and <b style='color:Tomato;'><i>bevacizumab</i></b> seems to increase median survival time by about 2 months versus Folfox alone, but it is also more toxic. In patients who progress after receiving the <b style='color:Tomato;'><i>fluorouracil</i></b> + <b style='color:Tomato;'><i>oxaliplatin</i></b> combination (Folfox) or the <b style='color:Tomato;'><i>fluorouracil</i></b>+ <b style='color:Tomato;'><i>irinotecan</i></b> combination (Folfiri), neither <b style='color:Tomato;'><i>panitumumab</i></b> nor <b style='color:Tomato;'><i>cetuximab</i></b> has been shown to provide a clinically meaningful increase in overall survival. It remains to be shown whether these drugs are more effective in patients with the wild-type KRAS gene than in patients with KRAS mutations. In early 2010, the standard cytotoxic drugs for treatment of metastatic colorectal cancer are <b style='color:Tomato;'><i>fluorouracil</i></b> (combined with folinic acid), <b style='color:Tomato;'><i>oxaliplatin</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>. Initial combination therapy may be beneficial when the metastases are borderline operable. When the metastases are inoperable and are unlikely to become operable after chemotherapy, it seems best to begin treatment with single-agent <b style='color:Tomato;'><i>fluorouracil</i></b> (+ folinic acid) or <b style='color:Tomato;'><i>capecitabine</i></b>. The use of monoclonal antibodies in first-line treatment of patients with colorectal cancer is not justified. Further trials of these drugs are warranted as second-line treatment for patients with KRAS wild-type tumours.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  The results of the APPEARANCE trial indicate that  <span class="marker" data-anno-id="0" data-anno-label="N2">adapalene</span>  does not prevent acne-like rash over placebo when added to topical moisturizer and oral  <span class="marker" data-anno-id="1" data-anno-label="N2">minocycline</span>  but instead may have a detrimental effect . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>APPEARANCE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>indicate</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>adapalene</i></b> <b style='color:DodgerBlue;'><i>does</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>acne-like</i></b> <b style='color:DodgerBlue;'><i>rash</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>topical</i></b> <b style='color:DodgerBlue;'><i>moisturizer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>minocycline</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>detrimental</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therefore, <b style='color:Tomato;'><i>adapalene</i></b> is not recommended as prophylaxis against acne-like rash induced by anti-epidermal growth factor receptor therapies.Given that acne-like rash was completely controlled with placebo in approximately half of patients, predictive measures to identify patients needing intensive prophylaxis are required. ### background Anti-epidermal growth factor receptor (EGFR) therapies are frequently associated with acne-like rash. To evaluate the prophylactic efficacy of <b style='color:Tomato;'><i>adapalene</i></b>, a topical retinoid used as first-line therapy for acne vulgaris, we conducted a randomized, placebo-controlled, evaluator-blinded, left-right comparative trial. ### methods Patients with non-small cell lung, colorectal, or head and neck cancer scheduled to receive anti-EGFR therapies were randomly assigned to once-daily <b style='color:Tomato;'><i>adapalene</i></b> application on one side of the face, with placebo on the other side. All patients had topical moisturizer coapplied to both sides of the face, and received oral <b style='color:Tomato;'><i>minocycline</i></b>. The primary endpoint was the difference in total facial lesion count of acne-like rash at 4 weeks. Secondary endpoints included complete control rate (CCR) of acne-like rash (≤5 facial lesions) and global skin assessment (Investigator's Global Assessment [IGA] scale, grade 0-4) at 4 weeks. Two blinded dermatologists independently evaluated the endpoints from photographs. ### results A total of 36 patients were enrolled, of whom 26 were evaluable. <b style='color:Tomato;'><i>adapalene</i></b> treatment was associated with a greater lesion count than placebo at 4 weeks, although the difference was not statistically significant (mean, 12.6 vs. 9.8, ### conclusion <b style='color:Tomato;'><i>adapalene</i></b> is not recommended as prophylaxis against acne-like rash induced by anti-EGFR therapies.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Both regimens included  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclophosphamide</span>  , methotrexate , 5-FU , prednisone , and  <span class="marker" data-anno-id="1" data-anno-label="P1">doxorubicin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.</u></h4>Ninety-six patients with metastatic breast cancer were entered in a prospectively randomized trial comparing a five-drug <b style='color:Tomato;'><i>doxorubicin</i></b> (Adriamycin)-containing regimen given in two different schedules. <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> On one schedule, referred to as "combination" treatment, <b style='color:Tomato;'><i>doxorubicin</i></b> was given every 21 days and <b style='color:Tomato;'><i>cyclophosphamide</i></b> was given daily. On the less intensive "fixed-rotation" schedule, <b style='color:Tomato;'><i>doxorubicin</i></b> was given on alternative cycles every 42 days and <b style='color:Tomato;'><i>cyclophosphamide</i></b> was given for 21 days of the 42-day cycle. Response frequency and survival were comparable among patients receiving either regimen. Significantly less (P < 0.05) nausea and leukopenia occurred on the fixed-rotation schedule. Therefore, similar therapeutic benefit along with decreased toxicity was obtained by use of combination chemotherapy involving <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> given in the less intensive schedule.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  A Randomized , Multicenter , Double-blind , Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of  <span class="marker" data-anno-id="0" data-anno-label="P1">Montelukast</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">Levocetirizine</span>  in Patients With Asthma and Allergic Rhinitis . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>Evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Allergic</i></b> <b style='color:DodgerBlue;'><i>Rhinitis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Montelukast</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Levocetirizine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>Asthma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Allergic</i></b> <b style='color:DodgerBlue;'><i>Rhinitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The aim of this study was to evaluate the efficacy and safety of a fixed-dose combination of <b style='color:Tomato;'><i>montelukast</i></b> and levo<b style='color:Tomato;'><i>cetirizine</i></b> in patients with perennial allergic rhinitis with mild to moderate asthma compared with the efficacy and safety of <b style='color:Tomato;'><i>montelukast</i></b> alone. ### methods This study was a 4-week, randomized, multicenter, double-blind, Phase III trial. After a 1-week placebo run-in period, the subjects were randomized to receive <b style='color:Tomato;'><i>montelukast</i></b> (10 mg/day, n = 112) or <b style='color:Tomato;'><i>montelukast</i></b> (10 mg/day)/levo<b style='color:Tomato;'><i>cetirizine</i></b> (5 mg/day) (n = 116) treatment for 4 weeks. The primary efficacy end point was mean daytime nasal symptom score. Other efficacy end points included mean nighttime nasal symptom score, mean composite symptom score, overall assessment of allergic rhinitis by both subjects and physicians, forced expiratory volume in 1 second (FEV ### findings Of 333 patients screened for this study, 228 eligible patients were randomized to treatment. The mean (SD) age of patients was 43.32 (15.02) years, and two thirds of subjects were female (66.67%). The demographic characteristics were similar between the treatment groups. Compared with the <b style='color:Tomato;'><i>montelukast</i></b> group, the <b style='color:Tomato;'><i>montelukast</i></b>/levo<b style='color:Tomato;'><i>cetirizine</i></b> group reported significant reductions in mean daytime nasal symptom score (least squares mean [SE] of combination vs <b style='color:Tomato;'><i>montelukast</i></b>, -0.98 [0.06] vs -0.81 [0.06]; P = 0.045). For all other allergic rhinitis efficacy end points, the <b style='color:Tomato;'><i>montelukast</i></b>/levo<b style='color:Tomato;'><i>cetirizine</i></b> group showed greater improvement than the <b style='color:Tomato;'><i>montelukast</i></b> group. Similar results were observed in overall assessment scores and in FEV ### implications The fixed-dose combination of <b style='color:Tomato;'><i>montelukast</i></b> and levo<b style='color:Tomato;'><i>cetirizine</i></b> was effective and safe in treating perennial allergic rhinitis in patients with asthma compared with <b style='color:Tomato;'><i>montelukast</i></b> alone. ClinicalTrials.gov identifier: NCT02552667.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Intravenous administration of  <span class="marker" data-anno-id="0" data-anno-label="C1">cefoperazone</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">sulbactam</span>  given as individual agents compared with the combination did not show pharmacokinetic differences that are likely to produce clinically relevant effects . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.</u></h4>The multiple-dose pharmacokinetics and toleration of <b style='color:Tomato;'><i>cefoperazone</i></b> (3 g every 12 h) and <b style='color:Tomato;'><i>sulbactam</i></b> (1.5 g every 12 h) were studied when these antimicrobial agents were administered continuously over 7 days as a 15-min infusion of individual agents and as a 3/1.5-g <b style='color:Tomato;'><i>cefoperazone</i></b>-<b style='color:Tomato;'><i>sulbactam</i></b> combination. Fourteen male volunteers participated in an open, three-way crossover study of Latin Square design with a 1-week washout period between phases. On days 1 and 7 of each phase, serial serum samples and urine were collected for drug assay over a 12-h period. Hematological and clinical chemistry determinations were made within 10 days before the first antibiotic dose and for each treatment phase just before the first dose, on day 4 of treatment, and within 24 h of the last dose. For <b style='color:Tomato;'><i>cefoperazone</i></b> as a single agent on days 1 and 7, the average maximal concentration in serum (Cmax) was approximately 430 micrograms/ml, the terminal elimination half-life (t1/2) was 1.8 h, and the average percentage of dose excreted unchanged in the urine (%Ur) was 30%. For <b style='color:Tomato;'><i>sulbactam</i></b> as a single agent, the Cmax was approximately 90 micrograms/ml, the t1/2 was 1 h, and the %Ur was 89% on days 1 and 7. When comparing individual versus simultaneous drug administration, the only pharmacokinetic alteration observed was a statistically significant but minor (about 10%) decrease in <b style='color:Tomato;'><i>sulbactam</i></b> renal clearance, on both days 1 and 7, resulting in a similar decrease in total body clearance (CL). The area under the curve, apparent volume of distribution by the area method (V), t1/2, and Cmax were not significantly altered. Although <b style='color:Tomato;'><i>cefoperazone</i></b> pharmacokinetic parameters were not significantly altered when comparing single-agent to combination drug administration, the area under the curve was slightly lower and CL, nonrenal clearance, and V were modestly higher from day 1 to day 7. Because Cmax and t1/2 were unaffected, these minor day effects would not be of clinical significance. <b style='color:DodgerBlue;'><i>Intravenous</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cefoperazone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sulbactam</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>individual</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>relevant</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>cefoperazone</i></b> and <b style='color:Tomato;'><i>sulbactam</i></b> was well tolerated, and the safety profile of the combination was similar to that either drug given alone under the conditions of this study.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  A recently reported phase II trial has demonstrated that  <span class="marker" data-anno-id="0" data-anno-label="P1">trastuzumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">vinorelbine</span>  is both effective ( overall response rate 75 % ) and well tolerated , with the major side effects being typical of single-agent vinorelbine . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>New combinations with Herceptin in metastatic breast cancer.</u></h4>Preclinical data indicate that <b style='color:Tomato;'><i>trastuzumab</i></b> (Herceptin) has the potential for synergistic or additive effects in combination with therapies including chemotherapy and hormonal agents, providing the rationale for a number of clinical trials in women with HER2-positive metastatic breast cancer. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>typical</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Other combinations of <b style='color:Tomato;'><i>trastuzumab</i></b> with a variety of other chemotherapeutic and hormonal agents are also being assessed. In an effort to overcome the cardiotoxicity observed with <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>doxorubicin</i></b> in the pivotal phase III trial, combination regimens involving potentially less toxic anthracyclines such as <b style='color:Tomato;'><i>epirubicin</i></b> and liposomal formulations of <b style='color:Tomato;'><i>doxorubicin</i></b> are ongoing. In addition, trials are investigating whether <b style='color:Tomato;'><i>trastuzumab</i></b> can reverse the resistance to hormonal therapy that develops in most women with metastatic breast cancer. These and other studies will identify the regimens that produce the best outcomes with the fewest possible side effects in women with HER2-positive breast cancer.</div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }
</script>
</body>

</html>